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Abstract 
Classical Hodgkin lymphoma (CHL) is a germinal centre B cell malignancy where the 
bulk of the tumour comprises a non-clonal immune infiltrate enriched for CD4+ T 
cells. The role of these cells in the pathophysiology of CHL is poorly understood. 
Biomarkers predictive of clinical outcome in CHL are limited. This thesis examines 
microenvironment biomarkers with the goal of identifying the 10-20% of patients who 
are not cured by conventional therapy, and also investigates the function of the CD4+ 
T cell in CHL.  
 
The prognostic power of FOXP3, a marker of regulatory T cells, CD68, a macrophage 
marker and CD20, a B cell marker, is validated in a new patient cohort and for the first 
time CD68 and FOXP3 are combined in a statistically robust scoring system. The data 
presented challenge the assumption that the microenvironment is Th2-polarised or 
senescent and demonstrates relative over-expression of T-BET, a Th1 marker and 
under-expression of PD1, a marker of senescence/exhaustion, with little evidence for 
Th2 marker expression. A cytokine-enriched in vitro culture system was developed 
demonstrating superior proliferation and longevity of CHL-derived T cells compared 
to non-malignant tissue-derived controls. These cells sustain expression of markers 
associated with proliferation and longevity (e.g. CD27, CD28) and remain functional 
(express cytokines) for many weeks. A panel of CD4+ T cell-specific markers was 
determined capable of differentiating CHL-derived from non-malignant or non-
Hodgkin lymphoma-derived CD4+ T cells, in which markers of central memory 
(CD62L and CCR7) and early activation (CD69) are over-represented and markers of 
senescence (CD57 and PD1) are under-represented. Cytokine profiles were found to 
resemble Th1 (expression of IL2, IFN-  and TNF  expression) rather than Th2 (IL4, 
IL13, IL21, IL10 and IL6) responses. 
 
The data presented confirm a new prognostic biomarker signature and show a Th1 
rather than Th2-dominated microenvironment enriched for cytokine-secreting 
functional effector CD4+ T cells and long-lived, proliferative cells resembling central 
memory cells rather than hypoproliferative, anergic, non-functional T cells.  
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1. Introduction & Objectives 
1.1 Classical Hodgkin Lymphoma: Clinical Background 
Classical Hodgkin lymphoma (CHL) is a cancer arising from the transformation of a 
germinal centre B (GCB) lymphocyte leading to a progressive accumulation of 
malignant cells (Hodgkin and Reed Sternberg - HRS cells) within a dense 
inflammatory and fibrotic microenvironment1. The disease often arises within a 
cervical lymph node, initially spreading through contiguous lymph nodes2 and 
eventually involving extranodal sites, commonly liver, lung and bone marrow, 
although presentation at advanced stage often occurs3. It is rare, occurring in 2/100,000 
population per year in Europe and the US4, rarer still in non-white ethnic groups and 
in the developing world5, but in ethnic and geographical areas of highest prevalence it 
is the second commonest cancer of young adults, with a second peak of incidence in 
the elderly6.  
 
Without treatment, progression is inevitable and death from bulky lymphadenopathy, 
cachexia, organ failure and infection follows within months or a few years7, 8. The 
disease carries an excellent prognosis for most patients, with long-term remission 
following conventional chemotherapy or radiotherapy-based protocols greater than 
80% but there remains a subset of patients whose disease is refractory to all 
conventional therapy9-12. Novel therapies with agents active in other haematological 
malignancies (targeted immunotherapy, immunomodulators, epigenetic 
manipulations and intracellular signalling pathway antagonists) have met with limited 
success in disease refractory to conventional treatment13, although novel therapeutics 
research is challenging for a disease which is in the most part curable and where 
conventional therapy-refractory patients are heavily pretreated. The curable nature of 
the disease has also generated a large cohort of long-term survivors many of whom 
suffer the late effects of treatments that were probably excessively toxic: 
cardiovascular, endocrine and secondary malignancies14, 15, providing further impetus 
for tailored therapy development: reducing toxicity for the ‘favourable risk’ patients, 
and maintaining treatment intensity in the ‘unfavourable risk’ patients. Identifying 
these patients early remains elusive, with current pre-treatment prognostic scoring 
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systems16 making little impact on therapeutic decisions beyond stratifying by early and 
advanced stage disease17. A better understand of the molecular biology of the disease is 
essential to identify clinically applicable predictive factors and in novel therapeutics 
development. 
 
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a histologically and 
clinically similar disease18 arising from a transformed GCB cell comprising the minority 
of tumour predominantly composed of reactive immune cells19. However despite 
superficial similarities, its distinct immunohistochemical and genetic signature, along 
with differences in natural history and epidemiology20 mean this distinct entity 
requires a separate functional analysis. 
1.2 The Malignant Cell in CHL 
1.2.1 The HRS cell is derived from a germinal centre B cell 
Microdissection of the histologically distinct HRS cell from primary tissue to a degree 
of purity sufficient for subsequent genetic analysis provided the first definitive 
evidence that the malignancy was derived from a germinal centre B cell (GCB)21. The 
cells possess clonal immunoglobulin gene rearrangements with evidence of somatic 
hypermutation, and some have undergone class switching confirming entry into a 
germinal centre (GC) reaction. However the cells do not express immunoglobulin due 
either to destructive somatic mutation (in around 25%) or modification of the B cell 
genetic22 or epigenetic program23 preventing expression of an otherwise functional 
gene. Loss of the normal B cell phenotype is a defining feature of this malignancy24. It 
remains unclear how this cell is then rescued from the normal stringent surface 
immunoglobulin expression-dependent, apoptosis-driven selection pressures of the 
GC. While anti-apoptotic factors may have been initiated within the malignant cell 
itself through genetic mutation, the malignant cell remains dependent upon its 
microenvironment: ex vivo maintenance of the disease has proved difficult (see below) 
and the malignant cell is always found in vivo to be embedded in a characteristic 
microenvironment. Hence, the malignant cell’s survival is at least as dependent on 
extracellular signals as from endogenous signals arising from its own mutated genome. 
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1.2.2 Survival Pathways in CHL and the role of EBV 
 
CHL, a GCB-cell derived malignancy, shares survival mechanisms common to normal 
B cells and other B cell-derived malignancies, despite loss of much of its B cell-defining 
phenotype. Many of these pathways require T cell help.  
 
Apoptosis pathway regulators frequently dysregulated in other haematological 
malignancies, such as FAS, caspase 8, caspase 10, FADD, BAD, ATM and BCL2, are 
rarely seen in CHL (reviewed in Kuppers 200925), although MDM2 gains may be 
present in 60%26 and TP53 mutated in 10%27, 28. However, components of the paradigm 
antiapoptotic pathways of normal lymphocyte physiology and lymphoid malignancy: 
nuclear factor- light chain enhancer of activated B cells (NF- B) and Janus-associated 
kinase / signal transducer and activator of transcription (JAK/STAT), are frequently 
dysregulated in HRS cells. REL (the core NF- B subunit) shows genetic gains and 
amplifications in half of CHL cases29, and abnormalities of NF- B IA30, NF- B IE31, 
TNFAIP and BCL332 are seen in 10-40%.  Jak233 and SOCS134, central components of 
JAK/STAT signalling are mutated in around 40% of cases. None are pathognomonic or 
even seen in the majority of cases. Clearly many survival pathways are at work. 
 
The commonest of the known viral immortalisers of B cells is Epstein Barr Virus (EBV) 
which has a well-established association with CHL and is a prime candidate for the 
initial cellular rescue mechanism. Only a limited selection of EBV gene products are 
expressed including EBNA1 (Epstein Barr Nuclear Antigen 1), LMP1 (Latent Membrane 
Protein 1) and LMP2a. LMP1 appears to be the most potent B cell survival factor of 
those expressed in the HRS cell. The mechanism of LMP1-mediated growth was 
elucidated in parallel with a physiological B cell survival mechanism: CD40/CD40-
ligand (CD40-L) in a tetracycline-conditional LMP-1 gene expression system35. 
Tetracycline-activated LMP1 and CD40-L stimulated pathways showed mutual 
redundancy but no synergism in supporting B cell proliferation. Activation of either 
pathway leads to increased NF- B to DNA-binding activity. However EBV is only 
found in 40% of CHL cases, predominantly HIV-associated disease and in the 
developing world and so cannot be the key survival factor in most cases of CHL.   
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1.3 Cancer and Immunity 
 
The immune system has an integral role in tumour suppression and development. 
Systemic immunodeficiency and localised chronic inflammation both predispose to 
malignancy. The tumour immune surveillance model has now gained wide acceptance 
and current work focuses not only on mechanisms by which the tumour escapes 
detection and effective destruction, but also means by which a tumour may subvert 
the immune infiltrate to provide a supportive environment rich in growth factors and 
survival signals, and insulated from an effective immune response. Despite being 
derived from self, tumours aberrantly express antigen thus providing targets for 
immune cell recognition, first demonstrated in mouse sarcoma models where 
suppression of a sarcoma’s growth was facilitated by exposing the mouse before 
transplant to syngeneic sarcoma cells36. Identity of the effector mechanism responsible 
was demonstrated to be largely T cell-mediated when it was found that lymph node 
isolates but not serum could suppress in vitro growth of similar explanted cells37, and 
antigen-specific38, with the first tumour-associated antigen recognised by cytotoxic T 
cells identified in a human melanoma cell line39.  
 
Since a T cell-mediated immune response is integral to suppressing early malignancy, 
any clinically progressive tumour must escape immune control. Many mechanisms by 
which this is achieved have been proposed, both tumour-mediated (such as reduced 
immunogenic antigen presentation), or host immune response suppression-mediated 
(reviewed in Dunn 200240). A T cell-mediated immunity defect has been observed in 
CHL for 50 years41, 42, which may persist beyond treatment43 but the mechanistic basis 
for this remains obscure and the relationship between tumour-infiltrating T 
lymphocytes (TILs) and the HRS cell is poorly understood. A growing body of evidence 
in solid malignancy has implicated subversion of another key immune effector – the 
macrophage – changing its phenotype such that its ability to eradicate malignant cells 
is suppressed while it develops tumour supportive functions, through mechanisms of 
stromal augmentation aiding malignancy growth, stromal disruption facilitating 
metastasis, and angiogenesis promotion44. Understanding the relationship between 
lymphoid tumours and the immune system is complicated by the fact that the 
malignant cell itself represents a subverted component of that immune system. 
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1.4 CD4+ T cells in CHL 
1.4.1 The unique inflammatory microenvironment of CHL 
CHL is unique amongst the lymphomas in that the bulk of the infiltrate comprises not 
the malignant cell, a morphologically distinct, large, complex, multinucleated cell 
known as the Hodgkin-Reed-Sternberg cell but also inflammatory cells including 
macrophages, neutrophils, eosinophils, fibroblasts, plasma cells, mast cells, and 
lymphocytes1 the most dominant component of which are T cells. These cells are not 
antigen restricted or tumour specific45. The T cells in the tumour microenvironment 
probably have an essential role in supporting the malignant cell’s growth.  
1.4.2 The complex role of the CD4+ T cell in the CHL microenvironment 
Most nucleated cells in the HRS microenvironment are CD4+, showing upregulation of 
early markers of activation including co-stimulatory CD28, (Poppema 1995, 
unpublished observation, personal communication) lymphoid tissue homing CD62L46, 
and the 'effector' isotype of CD45: CD45RO47. It is likely that these 
microenvironmental T cells are playing disparate roles in tumour suppression and 
progression, some representing the remnants and ongoing subversion of the initial GC 
reaction that enabled an antigen experienced B cell to thrive despite failure of its 
immunoglobulin-expressing apparatus. Others will have been attracted passively 
through expression of chemokine receptors or adhesion molecules and trapped by 
chemotactic stimuli, perhaps not providing any direct support or anti-tumour activity, 
but only tumour bulk or displacement of appropriate anti-tumour response. Other 
cells, including macrophages and CD8+ cytotoxic T cells along with activated 
proinflammatory Th1 cells may have appropriately recognised the malignant cell as a 
viable target, and been rendered incompetent by being crowded out by passively 
accumulated and HRS-supporting cells, or with their active function immobilised by 
immunosuppressive cytokines or lymphocytes. Other CD4+ cells may have recognised 
an inappropriate immune response and be discharging their regulatory function (again 
ineffectively) in an attempt to inactivate it. The remainder of the microenvironment: 
macrophage, dendritic cell, eosinophil, plasma cell, neutrophil, lymphoid and stromal 
form part of this interactive network, with tumour supportive, inflammatory, 
immunomodulatory, structural and passive roles. 
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1.4.3 CD4+ Cytokines and Chemokines in CHL 
There is evidence to suggest that IL4 stimulates the growth of HRS derived cell lines48  
with some IL4-encoding mRNA expressed in the reactive tumour microenvironment of 
biopsy material49, and HRS-derived cell lines strongly express IL-4 receptor50, although 
contradictory evidence exists51-53 and there are limitations to analysis of cytokine 
function in non-vital fixed tissue. IL13 is more widely expressed in primary samples and 
HRS cell lines54-56 and seems to be a distinctive property of CHL compared to NLPHL 
and another histologically similar malignancy T cell-rich B cell lymphoma (TCRBCL)54 
with IL13R expressed in most CHL cell lines and primary tissue55, 56. Exogenous IL13 
fails to augment cell line growth, but growth is inhibited by antibody-mediated IL13 
receptor blockade54-56. This highlights a Th2-like autocrine growth pathway (see 1.6.4) 
which may well be important in vivo, but cell line based models will always be limited 
by their absolute independence of the microenvironment, and hence underestimate 
the importance of microenvironment-derived supportive factors. IL5 and IL6, two 
further Th2-associated B cell-augmenting cytokines failed to show biological activity 
on HRS derived cell lines54, although both cytokines and their receptors have been 
found in some cell lines and primary material51, 57-59.  
 
Whether as passive bystanders, ineffective antagonists, or essential promoters of HRS 
cell growth and survival, T cells must be attracted into the malignant 
microenvironment. HRS cells secrete abundant cytokines and chemokines, integral as 
autocrine survival signals and in forming the distinctive microenvironment (reviewed 
in Skinnider 2002)60. Serial gene expression analysis identified TARC/CCL17 (thymus 
activation-regulated chemokine) mRNA in a CHL cell line (L428) at strikingly high 
frequency61 but not in NLPHL, NHL and EBV-transformed B cell lines, and confirmed 
its expression in a number of other CHL derived cell lines and patient derived material. 
Binding assays had already established the receptor for this chemokine: CCR462. 
TARC/CCR4 interactions may be central to recruiting specific functional T cell subsets 
in CHL. The importance of soluble TARC, and specificity for Hodgkin disease is 
becoming more apparent since it is almost universally present at increased levels in 
the serum newly diagnosed patients, rapidly reduces following chemotherapy and may 
be an early prognostic marker of tumour sensitivity63 and a tumour-specific target for 
chemo-immunotherapy64. MDC/CCL22 (macrophage-derived cytokine), a second 
ligand for CCR4 is also expressed in CHL tissue65 along with other functional subset-
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specific T cell-recruiting chemokines. These include RANTES/CCL566 (Regulated on 
Activation, Normal T cell Expressed and Secreted) whose receptor CCR3 is over-
expressed on Th2 cells67 and eosinophils68, MIP3A/CCL2069 (macrophage inflammatory 
protein-3) and its receptor CCR6, over-expressed in memory and regulatory T cells70, 
and MIP1A/CCL371 and its receptors CCR1&5, over-expressed in Th1-biased responses72. 
It is possible that reciprocal attraction of HRS cell towards the T cell zone occurs in 
addition to T cell attraction towards HRS. As will be described in the discussion of 
normal germinal centre B cell / T cell interactions, upregulation of CCR7 by activated 
follicular B cells leads to movement towards the T cell zone and hence encounter with 
cognate T cells for support. CCR7 is up-regulated in CHL cell lines and strongly 
expressed by the malignant cell in CHL, but not in NLPHL.73 
1.5 Normal B cells require T cell help for survival 
It has long been established that normal B lymphocyte survival requires interactions 
with the morphologically similar yet functionally and phenotypically distinct T 
lymphocyte. Seminal work showed that thoracic duct-derived cells synergise with bone 
marrow-derived cells to augment antibody production following infusion into 
irradiated syngeneic recipients74. A combination of secreted and cell surface mediated 
factors are required. Murine antigen-specific responses were found to be augmented 
by supplementing with activated T cell-derived soluble factors75 although only with 
large excess of antigen, otherwise the T cell itself or at least T cell-derived cell 
membrane76 needed to be available. In fact, the T cell could itself entirely replace 
antigen as activating stimulus77. The T and B cells require a ‘priming’ step to allow this 
interaction: naïve T cells were found to be ineffective and only activated T cells capable 
of delivering the necessary signals to allow in vitro antibody production78, 79 while in 
vitro stimulation of B cells using surface Ig cross linking at concentrations too low to 
induce proliferation, leads to upregulation of cell-surface expressed factors essential to 
B cell function: IL4 receptor80, IL2 receptor81, Major Histocompatibility Complex 
(MHC) class II82, and other co-stimulatory molecules such as B7 (CD80/86)83 and 
adhesion molecules84. Priming lowers the threshold for mutual interaction. T cells in 
the CHL microenvironment show evidence of priming, while the HRS cell expresses 
many markers of primed B cells, despite loss of most B cell defining features. 
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1.5.1 Cognate and non-cognate T/B cell interactions 
Normal B/T interactions require mutual activation by antigen presented in the context 
of compatible MHC complexes: early studies demonstrated superior T cell help in 
syngeneic over allogeneic systems74 and, following characterisation of the MHC85 
dependence of this help on the MHC86-88. T cell activation requires antigen presented 
in the context of the MHC89 while B cells encounter their cognate antibody via surface 
expressed immunoglobulin (B cell receptor). Immunoglobulin (IG)-bound antigen is 
internalised, degraded, assembled with MHC class II molecules, and presented as 
multiple epitopes capable of interacting with various cognate T cell receptors (TCR) 
thus facilitating cooperative action.  These epitope-specific T cells then go on to 
provide the reciprocally activating signal to the B cell. The requirements of such a 
model are of extreme specificity: colocalisation of B and T cells recognising the same 
antigen, the former primed and demonstrating APC function, the latter primed to 
discharge helper functions, and both primed to migrate to optimize chance of 
encounter.  
 
In vitro models have shown that such cognate antigen dependency may not be 
absolute since cocktails of activated T cell derived cytokines are able to stimulate some 
short-lived B cell proliferation without any antigen or B cell receptor engagement90. 
Activated murine T cell lines characterised as Th1 or Th2 (see also 1.6.4) by their 
particular cytokine expression profiles91 promote allogeneic B cell activation92, with 
Th2 cell lines providing the most efficacious support. Finally, MHC class II knock out 
mouse B cells still respond to activated T cell lines, as measured by DNA synthesis, 
immunoglobulin secretion, intracellular calcium flux and PI3-kinase signalling 
pathway activation93. Hence appropriately activated T cells producing sufficient 
survival factors may provide ‘bystander’ help: a physiological mechanism of recruiting 
additional T cells into an inflammatory reaction, and a mechanism which may be 
subverted by the HRS cell to promote its own survival. 
 
1.5.2 Molecular Mechanisms of T cell help 
CD40 was recognised as an early candidate for T cell derived B cell help. Initially 
discovered as an activation-associated B cell surface specific molecule, designated 
Bp5084, a monoclonal antibody was developed which was found to augment B cell 
proliferation94, and its ligand (CD154, CD40-L) was confirmed in the T cell 
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transcriptional repertoire by several groups: Armitage et al 199295 cloned the ligand 
from a cDNA library derived from a murine thymoma cell line with high soluble CD40 
binding capacity while Noelle et al 199296 confirmed function in B cell proliferation 
and IgE class switch by transfecting a cell line with the same clone. It was subsequently 
demonstrated in humans97. 
 
CD28 (Tp44) was discovered during screening for B/T cell discriminating proteins, and 
found to be involved in TCR independent activation in antibody binding 
experiments98. Its ligands are structural homologes of the immunoglobulin 
superfamily, known collectively as ‘B7’. B7-1/BB-1/CD80 was first discovered as a B cell 
activation marker99, 100, later as the ligand of CD28 through cell-adhesion experiments 
using a CD28 over-expressing CHO line101, and finally as the costimulator of anti-CD3 
activated T cells, in which it induces IL2 secretion and proliferation102. A further CD28 
binding, B cell expressed molecule, B7-2/CD86 was identified later103, 104 and a potent 
and essential co-stimulatory mechanism defining one interaction between B and T cell 
became clear. Other immune cells, particularly activated, antigen presenting DCs and 
macrophages express these co-stimulatory molecules, further strengthening the 
evidence for their role in immune activation.  
 
The confirmation of a pro-survival role for CD28 and CD40 implicated other 
structurally related molecules of the immunoglobulin (IGSF) and TNF receptor 
superfamilies (TNFRSF) respectively. Once primed by cognate antigen the T cell up-
regulates numerous cell surface molecules capable of delivering necessary survival, 
proliferation and differentiation signals to the B cell, and the B cell provides signals in 
return. Exploration of the unique surface repertoire of activated T cells revealed a 
structural homologue of CD28 with apparent potent stimulatory activity (ICOS) 105. Its 
ligand, CD275 (B7-H2), was discovered through homology with B7-1, B7-2 and B7-H1, 
and found expressed on DCs106 and B cells107. Its essential role in B/T interaction, 
particularly in the GC was revealed by failure of affinity maturation, class switching 
and GC formation in deficient mice108, 109. 
 
The spectrum of known TNFRSF members and ligand pairs with key stimulatory roles 
has grown and includes CD40 and its ligand (CD40-L/CD154), CD30 (first discovered 
in CHL derived cell lines) and its ligand (CD30-L/CD153), OX40 (CD134) and its ligand 
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(OX40-L/gp34), CD27 and its ligand (CD27-L/CD70) and 4-1BB (CD137) and its ligand 
(CD137-L). Immunoglobulin superfamily members include CD28 and its ligands B7-
1/B7-2 (CD80/86) and ICOS (CD278) and its ligand (ICOS-L/ B7-H2/CD275). Related, 
but potentially suppressive molecule pairs have also been discovered. Many of these 
cell surface factors are found expressed in the HRS cell and their ligands within the T 
cell-dominated immune microenvironment (Table 1.1). Hence, despite lacking BCR 
and down-regulation of MHC class II, the B cell derived HRS expresses a range of 
activated B cell-associated surface molecules, with surrounding cells possessing 
appropriate molecules capable of ligating and hence signalling downstream to survival 
pathways.  
 
MOLECULE CD Family R/L Expression Evidence Ref 
4-1BB 137 TNF R N/A N/A N/A 
B7-H4 276 IG L N/A N/A N/A 
B7.1 80 IG L HRS Prot 
110
 
B7.2 86 IG L HRS Prot 
110
 
BTLA 272 IG R N/A N/A N/A 
CD27 27 TNF R N/A N/A N/A 
CD27-L/Ki-24 70 TNF L HRS Prot 
111
 
CD28 28 IG R T Prot * 
CD30 30 TNF R HRS Prot 
112
 
CD30L CD153 153 TNF L N/A N/A N/A 
CD40 40 TNF R HRS Prot 
113
 
CD40L CD154 154 TNF L N/A N/A N/A 
CD95-L/FAS-L 178 TNF L N/A N/A N/A 
CTLA4 152 IG R T RNA 
114
 
FAS 95 TNF R HRS Protein 
115
 
HVEM 258 IG L N/A DNA 
116
 
ICOS 278 IG R T RNA 
114
 
ICOS-L/B7-H2 275 IG L N/A N/A N/A 
OX40 134 TNF R T RNA 
114
 
OX40L 252 TNF L HRS Protein 
117
 
PD-L1/B7-H1 274 IG L HRS Protein 
118
 
PD-L2/B7-DC 273 IG L HRS Protein 
118
 
PD1 279 IG R T Protein 
118
 
RANK 265 TNF R HRS Protein 
119
 
RANK-L 254 TNF L HRS Protein 
119
 
 
Table 1.1: Expression of selected TNFRSF and IGRSF with their ligands important in B/T cell 
interactions and evidence for their expression in CHL. Bold: expression data exists, Italics: 
theoretical only or no evidence of expression; Key: CD: cluster of differentiation designation; 
IG: Immunoglobulin Receptor Superfamily and ligands; TNF: TNFRSF and ligands; HRS: 
Expressed in HRS of primary CHL tissue or cell line; R: Receptor; L: Ligand; T: Expressed in 
microenvironment T cells of primary CHL tissue; DNA: CGH evidence of mutation in 
responsible genes only; RNA: PCR-based mRNA over-expression data only; Protein: Protein 
up-regulated by Western blot, IHC or Flow cytometry. *Sibrand Poppema et al; Unpublished: 
personal communication. 
Chapter 1: Introduction & Objectives 
25 
1.5.3 T cell / B cell interactions in the lymph node 
 
1.5.3.1 The lymph node is a lymphocyte and antigen concentrator 
As sophistication of microscopic imaging techniques has improved, so too has the 
understanding of the anatomy of B/T cell interactions. Lymph node architecture may 
be defined in terms of clearly distinct B and T cell zones. B cells form discrete 
aggregates - primary follicles, within which can sometimes be found further B cell 
aggregates with interspersed T cells - GCs (GCs), comprising a peripheral dark zone of 
tight packed cells, and a central light zone.  The follicles are embedded in a cortex 
dominated by T cells and the structure circumscribed by a capsule penetrated by 
endothelium lined organs - the sinuses. Macrophages, dendritic cells (DCs), follicular 
dendritic cells (FDCs), and terminally differentiated plasma cells are found distributed 
in these various compartments. Assumptions of function can be surmised from this 
structural arrangement: antigen delivered through the sinuses in tissue fluid draining 
the regional anatomy, both free and contained within phagocytes (macrophages and 
dendritic cells) or complexed with antibody, passing through the nodal structure and 
encountering B and T cells. B and T cells are themselves in constant circulation 
throughout the body, homing preferentially to lymph nodes in which foreign antigens 
are being processed. This is achieved by regulation of adhesion molecules, chemokines 
and cytokines. For T cells, CD62L and CCR7 are essential, preferentially expressed by 
antigen-naïve T cells or by rapidly responding central memory cells. Their ligands are 
expressed by the high endothelial vessels permitting entry to the lymph nodes, and the 
stromal cells of the paracortical T cell zones respectively, ensuring a concentration of 
lymphocytes and antigen to maximise opportunity for cognate encounter120. 
 
1.5.3.2 B cell/T cell interactions in the paracortex and the germinal centre 
Interaction between B and T cells was proposed to originate in the T cell zones. 
However more sophisticated work has shown the junction of B and T cell zones is a 
more likely candidate for initial T cell dependent B cell activity121.  Garside and 
colleagues (1998)122 infused BALB/c mice with syngeneic T cells receptor-restricted to 
recognise a chicken ovalbumin peptide (cOVA), along with B cells restricted to 
recognise hen egg white lysosome (HEL). The mice were then challenged with a 
peptide construct consisting of cOVA fused with HEL (cOVA-HEL) and lymph nodes 
examined at various time points, stained to show localisation of cOVA specific T cells 
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and HEL specific B cells. B and T cell populations initially migrated to primary follicles 
and cortex T cell zone respectively. Following cOVA-HEL challenge T cells clustered 
and proliferated within the paracortex, and B cells migrated towards the T cell zone-
abutting periphery of their follicles. Subsequently, T cells approached and formed 
close associations with B cells, which had proliferated. The cognate T cell dependence 
of B cell proliferation was confirmed by the fact that challenging with turkey 
ovalbumin (tOVA)-HEL conjugate peptide in combination with unconjugated cOVA 
antigen led to T cell proliferation and clustering (response to cOVA antigen), with 
HEL-specific B cells present in the node. However, since these were only capable of 
presenting tOVA and unable to interact with non-cognate cOVA-specific T cells, they 
failed to migrate or proliferate. This finding confirmed that the initial T cell 
engagement with antibody and activation can occur independently of a B cell: initial 
antibody presentation to T cell was by some other cell existing within the T cell zone. 
It also confirmed the necessity of cognate interaction with T cell for subsequent B cell 
proliferation and confirmed the location for initial T/B interaction. B cell expansion 
was blocked with anti-CD40-ligand, confirming this molecule’s key role in the initial 
interaction. Further evidence for the cognate nature of this interaction was inferred 
from the fact that most B cells in the cOVA-conjugate challenged mouse lymph nodes 
were engaged with cOVA specific T cells, while with non-cognate challenge with 
tOVA-HEL and cOVA antigen showed far less T/B engagement. Time-course IHC has 
revealed some molecular mechanisms behind these migration findings. Antigen 
engaged B cells up-regulate CCR7123, receptor for T zone expressed CCL19 and CCL21124, 
while downregulating CXCR5, responsible for follicle localization via CXCL13 
interactions125. CCL19/21 knock out models show impaired migration, CCR7 over-
expression (by retroviral gene transfer) will induce antigen-unexposed B cells to 
migrate to the T zone, while CXCL13 over-expression traps B cells within their primary 
follicles123.  
 
1.5.3.3 The T cell confers a GC selection pressure by selective B cell help  
Affinity of antibody increases with time of exposure to antigen126. The mechanism 
behind this phenomenon emerged when sequencing of the B cell immunoglobulin 
gene revealed a physiological process of mutation was at work, termed somatic 
hypermutation127. The lymph node compartment in which this phenomenon arises was 
confirmed by demonstrating that plasma cells in extra-follicular foci show less 
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hypermutation than in GCB cells128, with overrepresentation of amino acid replacing, 
rather than silent mutations implying a selection bias towards mutations conferring B 
cell receptor conformation and hence antigen affinity changes. A mechanism favouring 
B cells synthesizing antibody with greater affinity for antigen with deletion of those 
with lesser affinity suggests a mechanism requiring constant exposure to a selection 
pressure, namely competition for antigen129. Selection pressure and cell cycling 
probably occurs continuously as the B cell traffics around the GC until eventually 
triggering a terminal differentiation program and GC exit to migrate elsewhere as 
plasma cell or memory B cell130. The selection pressure was presumed initially to be a 
function of competition for immune complex derived from soluble antigen, displayed 
on FDC and determined by strength of association and hence signalling through the B 
cell receptor (Reviewed in MacLennan 1994131). This has been contested by data 
showing that soluble immunoglobulin deficient mice are still able to form GCs132 and 
that long-lived associations with FDCs have not been seen in real-time imaging 
studies: B cells seem to traffic freely between compartments133. Another selection 
pressure is being exerted, and this appears to arise from competition for T cell help in 
the GC. Fixed tissue analysis shows the GC light zone is rich in T cells122, 134 with 
dynamic fluorescence microscopic studies showing constant, brief interactions 
between T and B cells. Notably, in contrast to the interaction at initial activation 
between B and T cells in the paracortical zone, where B cells synapse so robustly that 
they are able to migrate with T cell in tow135, most interactions in the light zone appear 
to be brief: less than five minutes, too brief for a productive conjugate in which help-
conferring cell-cell signalling can occur136. CD40 signalling is essential for B cell 
survival in the GC137, but T cells available to provide this CD40-L-mediated help are 
outnumbered up to twenty to one in the GC and only a small proportion of GCB cells 
show evidence of CD40 signalling as evidenced by downstream cREL expression138. 
Hence for a B cell to receive help from T cells it must out-compete the surrounding 
cells: presumably through differential strength of binding cognate antigen. The GC T 
cells themselves may be relatively hyporesponsive to activation with altered expression 
of help-conferring molecules. The GC T cell may even be a phenotypically distinct 
subtype in itself.  
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1.6 The nature of the CD4+ T cell in the CHL microenvironment 
Most conclusions regarding the nature of the T cell infiltrate in CHL are based on 
limited evidence and oversimplification, while functionally defining a human CD4+ T 
cell is challenging and often artificial being based on in vitro and murine in vivo 
experimental models. 
1.6.1 Heterogeneity of CD4+ T cells: Phenotype and Function 
The heterogeneity of T cells has become clear as scientific methods have become more 
sophisticated; however while there is little controversy that they represent a 
morphological homogenous, long-lived, proliferative, mobile population of cells, each 
possessing a unique surface receptor (TCR) with stringent specificity for a limited 
number of amino acid sequences presented within the MHC, the eventual outcome of 
interaction of the activated cell with its targets is enormously diverse. This complexity 
distinguishes it from a morphologically similar cell (the naïve B cell) with similarly 
fastidious receptor/ligand demands but whose terminally differentiated function, 
whether immediately following activation and expansion, or after a long period of 
'primed' senescence (memory) is quite simply to secrete vast quantities of antibody. 
Non-phagocytic cell-mediated cytotoxicity was determined to be the key effector 
function of another group of apparently similar cells which express CD8, the cytotoxic 
T cell139. The function of CD4+ T cells have been based on studies of artificially 
discriminated populations of cells. The immunoglobulin synthesis-helping, but not 
secretory capacity which originally discriminated T helper cells from B cells is only one 
of many roles for this cell defined by expression of TCR, CD3 and CD4.  
1.6.2 Methodological problems in determining a functional CD4+ T cell subset 
The mechanism of polarisation and relative flexibility of CD4+ T cell phenotype 
commitment has yet to be fully understood and requires multiple layers of regulation, 
from microenvironmental and APC presented cytokines, TCR stimulation strength140 
and TCR-independent ‘alternative pathway’ activation mechanisms141, to differential 
activation of intracellular signalling pathways, such as Notch142 as well as epigenetic 
changes of gene accessibility. Interspecies as well as in vivo/in vitro differences have 
demonstrated the complexity of these mechanisms and the need for caution in 
interpreting and taking forward these findings. Studies of cellular function, preferably 
in vivo are the most robust and practical method of defining a T cell subset and should 
always remain the gold standard of phenotype definition. 
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Chromosomal packaging and accessibility (epigenetics), gene and consequent protein 
expression with attendant layers of regulatory mechanisms (genetics), signalling 
pathways and intra/extracellular communication (proteomics) influence the nature of 
a cell, and the consequence of these interactions leads to functional physiology and 
dysfunctional pathology. Scientific reductionism is increasingly accessible. An 
individual cell or cell population may be defined genetically by its nucleic acid 
sequence, epigenome, composition of transcribed and translated products, through 
high resolution whole genome sequencing, chip-based gene expression, RNA 
expression and methylation/acetylation profiling. Interdependently activated and 
inactivated intracellular and surface expressed proteins may be determined through 
techniques ranging from Western blotting to mass spectroscopic proteomics, 
phosphoproteomics and single cell multi-parameter flow cytometry. However 
emergent function can often only be inferred. Even with contemporary computational 
network analysis the significance of vast arrays of data and application to physiological 
models can be overwhelmingly complex, leading to inappropriate post-hoc analysis, 
selectivity of data interpretation and erroneous conclusions. Data generated from 
inevitably heterogeneous populations of cells may swamp the detail of functionally 
more important cells concealed in a mass of less important cells. Even studies based on 
samples highly enriched for the cells of interest rely on over-simplistic, surrogate 
markers for that cell. Functional assays of these purported subsets are considered a 
gold standard in understanding any biological system. But functional validation can 
only be performed using a model system amenable to interrogation by the scientific 
technology available. In the case of modelling human biological systems, ethical 
necessity means that ex vivo and animal models must be resorted to. The validity of 
these systems can only be inferred by successful applications of pharmacological 
experiments in man, with the further complexity of enormous interpersonal 
physiological variability.  
1.6.3 Effector T cell and Memory T cells 
The capacity to recognise antigen with a greater efficiency and discharge function with 
greater potency on subsequent exposure is the cornerstone of adaptive immunity. This 
depends upon the existence of a long lived memory component of the adaptive 
immune system with fine-tuned antigen specificity and capacity to more efficiently 
proliferate and function in response to a subsequent pathogenic challenge than their 
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naïve equivalent (reviewed in Berard & Tough 2002143) while being maintained at a low 
level for many years, up to the lifetime of the organism. In contrast, effector cells tend 
to devote their entire replicative and synthetic apparatus to the discharge of their 
pathogen-destroying function, with the majority arising in response to antigen 
challenge rapidly dying144. Hence the ‘memory’ compartment is functionally and 
phenotypically distinct. Memory compartments exist for each component of adaptive 
immunity: B cell, cytotoxic T cell and ‘helper’ T cell. The latter, with its widely varied 
and poorly understood repertoire of potential effector function is likely the most 
complex.  
 
Models of the memory compartment have largely arisen from observations in the 
CD8+ compartment.  Memory compartments are defined by expression of CD45 
isotype (with CD45RA being truncated predominantly to CD45RO in the effector and 
effector memory cell compartments and re-expressed as CD45RA in some long-lived 
memory cells) along with tissue homing molecules particularly node-homing CD62L, 
paracortical T cell zone-homing CCR7145 and survival-promoting cytokine receptors 
particularly CD127 – the IL7 receptor. The accumulated evidence supports a model 
whereby a naïve T cell although committed to either CD8 or CD4 lineage, is 
uncommitted to memory or effector fate until after antigen exposure146. The functional 
bias of the memory T cell component towards priming for future encounter rather 
than discharge of immediate function makes it a less feasible candidate for a HRS/T 
cell interacting subset. However, the cytokine rich microenvironment may well attract 
these cells passively into the involved lymph node tissue.  
1.6.4 The Paradigm Subsets: Th1 and Th2 
1.6.4.1 Functional Definitions of Th1 and Th2 
The earliest T helper dichotomies, defined as Th1 and Th2, were based on physical 
separation properties (degree of binding nylon wool) and relative ability to render B 
cell help in antibody synthesis147. These properties were entirely artificial and 
functionally unhelpful, arising from differential expression of MHC class II (then 
known as Ia antigen) by T cells, conferring possible antigen presenting function, a 
property that remains poorly understood today148. The most enduring and 
physiologically applicable discriminator of Th1 and Th2 function remains that 
described by Mosmann and Coffman in a more biologically applicable system149. The 
supernatant derived from the murine Th1-defined cell line LB2-1 was found to support 
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the growth of an IL2-dependent cell line HT2 more robustly than that from a murine 
Th2-defined cell line MB2-1. On addition of an IL2 blocking antibody, all of the 
supportive activity of the Th1 cell line was lost, while the Th2 cell line retained its 
activity, implying the existence of a less efficacious, but distinct Th2 growth factor 
(defined as T-cell growth factor 2: TCGF2). Conversely, MB2-1 ('Th2') preferentially 
supported the growth of a mast cell line (the activity being defined as mast cell growth 
factor 2: MCGF2). MB2-1 was also found to be superior to LB2-1 in enhancement of B 
cell line immunoglobulin secretion (B cell growth factor 1: BCGF1). Finally, IFN-  
suppressed the growth of the NFS60 cell line: a cytokine  known to be synthesized by 
LB2-1 ('Th1'), and not by MB2-1.  
 
These bioassays were applied to an extended panel of cell lines. Fortuitously, and by a 
mechanism still not understood, the biological function-discrimination coincided with 
the relative nylon wool adherence capacity of the Th subtypes. Western blotting 
confirmed that the ‘Th1’ cell lines produced IFN- , unlike Th2, and on SDS-PAGE 
fluorography the Th2 cells showed a distinctive band in the 16kd region, absent in Th1 
cells: a candidate for the mysterious TCGF2/BCGF1. These fundamental experiments, 
while purely in vitro assays, generated a robust basis for the Th1/2 dichotomy. The 
identity of the key secreted effectors of Th1 and Th2 function had been discovered: 
IFN-  and IL2 defining the Th1 subtype, and Th2 being defined by secretion of 
TCGF2/MCGF2/BCGF1-secretion, now known to be the same factor, IL4150. While huge 
advances in understanding the mechanism of differentiation into these subsets from 
naïve T cell have been made in the 25 years since these observations, these defining 
features remain the functional readout of Th1 vs Th2 activity: IFN- /IL2 vs IL4/B cell 
help. In vitro polarisation protocols were established for Th2151-153 and, with the 
identification and cloning of IL12154, 155 for Th1153. These experiments confirmed this 
polarisation was true in man as well as mouse. An in vivo model already existed that 
replicated this in vitro dichotomy. It had been observed that susceptibility to 
Leishmaniasis varied greatly between inbred mouse strains, in that some strains (e.g. 
C57BL/6) cleared infection effectively whereas others (e.g. BALB/c) invariably 
succumbed156. Athymic mice rapidly developed fulminant infection despite the 
mechanism of pathogen clearance being confined to macrophages, of non-thymic 
origin. A cooperation between T-cells and macrophages was proposed that was 
effective in some immunocompetent mouse strains, but ineffective in others. The 
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model was supported by lymphocyte transfer experiments from both allogeneic 
Leishmania-'healer' mice, and syngeneic 'non-healer' mice whose lymphocytes had 
been pre-activated using concanavalin-A. Under these conditions, recipient 
macrophages were effective in pathogen clearance. These differences implied a 
heterogeneity of T cell helper activity, and building on their in vitro work Coffman's 
group went on to demonstrate increased IFN-  and reduced IL4-coding mRNA in 
lymph nodes and spleen in C57BL/6 compared to BALB/c mice157. The fact that the 
difference arose from the differential T cell populations was confirmed when Th1 or 
Th2 cell lines were derived from otherwise susceptible BALB/c mice by limiting 
dilution and mice reconstituted with one or other158. Th1 reconstituted mice were now 
able to clear the infection. Th2 reconstituted mice succumbed more rapidly than the 
unmanipulated BALB/c mouse. Not only was the in vitro differential shown 
functionally but mutual inhibition confirmed, as well as demonstration of the capacity 
for one population to dominate an immune response in a genetically identical animal. 
 
1.6.4.2 Th1/Th2 defined by intracellular protein expression 
Advances in intracellular signal transduction studies revealed several receptor 
mediated protein phosphorylation cascades as candidate molecular mediators of 
lymphocyte polarization. STAT3 and 4 were found associated with Th1 polarisation159 
while STAT5 associated with Th2160, and their necessity was proven with knockout 
mouse models161, 162. A ‘master transcription factor (TF)’ lying behind more global gene, 
protein, signal transduction and effector mechanism expression is an attractive 
proposition for subset discrimination. Differential gene expression profiling comparing 
Th1 with Th2 based on cDNA library representational difference analysis (cDNA RDA) 
and subsequent functional antisense gene expression knockdown experiments 
revealed Gata3 as a fundamental Th2 TF163, with T-bet required for a Th1 response164. 
However, specificity of these TFs, murine/human physiological differences as well as 
stability of expression and plasticity of phenotype continues to limit their application 
in functional subset definition. 
 
1.6.4.3 Th1/Th2 defined by surface protein expression 
Cellular function is defined by the spectrum of cytokines, chemokines, and surface 
molecule interactions exercised by the functional cell, and phenotypic discrimination 
may be defined by this spectrum. Cell-surface molecules unique to a functional 
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subtype carry the advantage of enabling live cell purification using flow cytometry: 
intracellular markers generally require fixation and permeablisation, which while 
quantifying a population, also results in cell death. Bonecchi and colleagues (1998) 
addressed this72, attempting to discriminate Th1 and Th2 cells by surface cytokine 
receptor profiling. This required a ‘gold standard’ reference population of Th1 or Th2 to 
ensure validity. Polyclonal ‘Th2’ cells were generated by stimulating density gradient 
separated human PBMC TCR-independently with phytohaemagluttinin (PHA), 
polarising with recombinant IL4 and IL2 along with neutralising anti-IL12 antibodies 
for two weeks, and confirming phenotype using FACS analysis of intracellular cytokine 
staining with IL4. This has the advantage of enabling identification of individual cells, 
rather than broad populations of cells, expressing particular cytokine combinations165. 
Cells were purified using physical methods: plate-binding monocytes and nylon wool 
binding-out MHC-II (predominantly non-T) expressing cells. Using this 
polarisation/purification method, 25% of the resulting T cells expressed IL4 (and 2% 
IFN- ), compared to 2% of similarly prepared, Th1 polarised cells (of which 60% 
produced IFN- ).  A number of antigen-specific T cell clones known to be cytokine 
profile polarised were also used, generated from Lolium perenne P1-allergic subject T 
cells by limiting dilution. Greater than 90% of the Th2 cells in these cultures produced 
IL4. With these stringent definitions of Th2 phenotype, RNA was extracted from 
purified T cells and probed using northern blot analysis for a variety of cytokines.  
 
CCR4 was over-expressed in Th2 clones and polarisation cultures as well as in 
unpolarised, PHA-stimulated, purified T cells (T+PHA) compared to Th1, and 
expressed CCR3 weakly, but more than in Th1. CXCR3 was up-regulated in Th1 and 
T+PHA compared to Th2, and CCR5 in Th1 and monocytes compared to Th2.  CCR1 
was expressed at very low levels in Th1 and Th2. The functional significance of these 
receptors was confirmed using a migration assay with known ligand for CCR4. 
Migration in response to CCR4 ligand (MDC, now CCL22) and CCR3 ligand (eotaxin, 
now CCL24) was superior in Th2 cells, whereas Th1 cells migrated preferentially 
towards CCR5 and CXCR3 ligands (MIP-1 , now CCL4 and IP-10, now CXCL10).  
 
This study established a functional chemokine receptor profile differential 
discriminating Th1 from Th2 in a relatively robust (using polarised antigen-specific 
clones) but nonetheless in vitro system. However, while relative expression of mRNA 
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and relative migrational capacity to their appropriate ligands had been shown, what 
could not be inferred was stability of expression of these receptors, importance in vivo, 
and uniqueness to Th2 or Th1 lymphoid cells. PBMCs, magnetic bead purified based on 
CCR4 expression alone166 overexpress IL4 when stimulated compared to the 
unenriched fraction, with few expressing IFN-  as measured by intracellular cytokine 
FACS, however, the majority of cells remain uncommitted to IL4. The specificity of 
CCR4 (or indeed any alleged subset-defining ‘signature’ molecule) draws its usefulness 
as a functionally-defining marker into question. CCR4 is strongly up-regulated on 
regulatory T cells (Tregs)167, a functionally and otherwise phenotypically quite distinct 
T cell subset. Indeed, a growing murine literature exploring CCR4 function has failed 
to define it as either necessary or specific for Th2-like function. Undoubtedly, other 
surface molecules will emerge associating with various T cell subsets, most with key 
functional roles in target cell support or destruction, and tissue specific localisation. 
CRTH2, a prostaglandin receptor is one with a growing evidence base for Th2 
specificity168, 169. However using surrogate markers without functional correlates is 
problematic. 
1.6.5 A controversial subset: The regulatory T cell (Treg) 
 
1.6.5.1 Defining the Treg as a distinct phenotypic cell type 
The necessary potency and potential destructiveness of the immune response makes 
tolerance to self a vital capability. Tolerance arises partly through ‘central’ 
programming of the adaptive immune cells to ensure those reactive to self antigen are 
removed early in cell development: thymic and bone marrow mechanisms which 
delete immature T and B cells if they become activated within these central organs of 
production. Autoreactive cells that survive this and enter the secondary lymphoid 
organs are subject to peripheral mechanisms of tolerance: encounter of antigen in a 
‘benign’ context implying no pathogen presence and hence without inflammatory 
triggering of co-stimulatory molecules provided by the innate and antigen presenting 
components of the immune system leads to inactivation of the cell: anergy. However, 
auto-reactive clones remain and may become pathological, such as in autoimmune 
disease or perhaps maintenance of lymphoid malignancies through ongoing antigen 
receptor signal-mediated survival170. A further layer of ‘peripheral’ protection has 
emerged more recently, arising from the longstanding knowledge that T cells not only 
promote, but also suppress the immune response. 
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The first evidence that T cells were essential not only in enhancing immunoglobulin 
production but also in immune tolerance was shown at a time when evidence 
demonstrating the T and B cell dichotomy was still in its infancy171. Irradiated, 
thymectomised mice rescued with syngeneic bone marrow then exposed to massive 
doses of foreign antigen (sheep red blood cells: SRBC) become tolerant to that antigen  
- unable to mount an immunoglobulin-secreting response to subsequent antigen 
challenge. Combining the antigen challenge with a thymocyte infusion could restore 
this response. However if the initial ‘tolerising’ event was preceded by an infusion of 
thymocytes, the animal’s response to subsequent antigen challenge with thymocyte 
support was suppressed. Hence T cells tolerised by the initial antigen exposure 
appeared to be suppressing subsequent T cell help. While rudimentary in terms of 
purity of cell populations and using immunoglobulin synthesis as the sole measure of 
immune function, this provided first demonstration of a tolerance mechanism arising 
from the thymic component of the immune system. Discovery that mouse 
thymectomy could lead to autoimmunity as well as immunodeficiency if performed at 
particular stages of development in particular mouse strains172 along with rescue from 
autoimmunity by reconstitution with spleen-derived lymphocytes173, specifically 
populations enriched for the Lyt-1 (CD5) antigen174, with reciprocal induction of 
autoimmunity by repopulation of Lyt-1 depleted splenocyte provided further evidence 
that there was a specific suppressive T cell subset. The early discovery of Lyt-1 as a 
lymphoid subset marker is particularly fortuitous for these experiments’ findings: it 
happens to be highly expressed in the robustly investigated and widely accepted 
‘professional’ suppressor T cell of contemporary studies – the regulatory T cell (Treg)175 
and may in fact be integral to these cells’ survival and function176. However, failure to 
define effector mechanisms or unique phenotypic features for this proposed 
suppressor subset as had been robustly demonstrated for the Th1/Th2 paradigm with 
their distinct cytokine and TF profiles, led to years of scepticism in this field177, 178.   
 
This scepticism was convincingly overcome following the discovery that a subset of 
murine CD4+ cells constitutively expressing high levels of the IL-2R  chain (CD25) 
specifically possessed suppressive activity179, then confirmed in humans180. A master TF 
(Forkhead Box Protein 3: FOXP3) was demonstrated first in mice, in which there was a 
mutation-associated disease phenotype: Scurfy181-183, then humans184, in which a disease 
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equivalent had already been described185, 186. This subset is generated in the thymic 
medulla, demonstrated by IHC thymus examination and functional studies of FACS-
purified thymus-derived CD25hi CD4+ cells187. The TCR affinity of this subset to self 
antigen is high, shown by the fact that protection against spontaneous EAE 
(experimental autoimmune encephalitis) requires the presence of MBP (myelin basic 
protein)-specific TCR /  expressing CD4+ cells (but not B, CD8+, NK or /  T cells)188 
as well as evidence for thymic positive selection, rather than the expected deletion of 
CD4+CD25+ cells possessing high affinity for this same self peptide189.  
 
1.6.5.2 Tregs defined by FOXP3 
Although constitutive FOXP3 expression delineates a population of naïve T cells with 
self-antigen specificity and particularly potent suppressive activity (natural Tregs: 
nTregs), selected in the thymus and activated peripherally on recognizing 
autoimmunity promoting immunological cells, this TF is also expressed in other 
populations. Induced Tregs (iTregs), produced through activation of naïve T cells in 
the presence of TGF 190 may have some role in immunosuppression, perhaps 
potentiating the immunosuppressive capacity of nTregs, but their repertoire and 
potency of immunosuppression is likely much reduced, and in humans they may not 
possess immunosuppressive function at all191.  Stability of FOXP3 expression of nTregs 
is superior to that seen in iTregs, and even expressed transiently following 
proinflammatory activation192, perhaps through differential chromatin modelling and 
DNA methylation193. Even nTregs show some plasticity of function and gene 
expression, perhaps explaining one mechanism of immune tolerance breakdown 
during dysfunctional, chronic inflammatory states194. This is a fundamental 
observation, a further illustration of the pitfalls of applying mouse models of immunity 
to humans, and in drawing conclusions about the significance of FOXP3 in the context 
of an active inflammatory or TGF  rich microenvironment such as CHL. 
 
1.6.5.3 Tregs defined by surface protein expression 
A functional assay of any T cell subset requires a purification technique that is not 
destructive to the cell, as discussed for Th2 above. No single surface-expressed nTreg 
marker has been determined, and the strategy of CD4+CD25-hi enriching human T 
cells does not yield equivalent cell purities as seen in the mouse, largely because of 
contamination by activated T cells, which also up-regulate CD25. A balance between 
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inadequate yield by over-stringent selection based on CD25 brightness, and impurity 
of the derived population must be struck. Combinations of markers have been 
investigated which eliminate these contaminating non-regulatory T cells while 
sustaining a reasonable yield, including IL7-receptor (CD127)195,  chain of 4 1-
integrin/VLA4 (CD49d)196, both activated effector T cell associated and hence showing 
low expression in Tregs, while LAG-3 (CD223)197 is associated with particularly high 
FOXP3 expression and suppressive capacity. None are entirely nTreg specific, and 
indeed there may not be any single unique marker of this, or any other subset. 
 
1.6.5.4 Mechanisms of Treg and immunosuppressive function 
The mechanism of Treg action is still a being explored, with many candidate soluble 
and surface expressed molecules specifically, constitutively or over-expressed in 
purified Tregs. Treg-specific IL-10 gene knock out models develop spontaneous colitis 
and inflammatory reactions in skin and lung198 while CTLA-4 knock out leads to 
fulminant lymphoproliferation, autoimmunity and death199. TGF-β (an inducer of 
FOXP3 expression in CD25- T cells which may confer an ‘induced’ Treg phenotype in 
previously effector cells), IL35, a novel IL12α-IL27β heterodimer with T cell 
antiproliferative effects200 and galectin-1, a known inhibitor of T cell function201 up-
regulated in human Tregs202 are synthesized by some subsets. Cytotoxic mechanisms 
through granzyme/perforin203 or CD95/CD95-ligand interactions204 are described. 
Other proposed mechanisms include suppression of ATP-mediated inflammatory 
signals through Treg expressed nucleotidase CD39205 and blockade of MHC-II 
expression through the CD4 homolog LAG-3206. Multicellular models of 
immunosuppression more complex than the paradigm in vitro Treg-Tsuppressor 
functional assays207, 208 have demonstrated the involvement of other immune cells in 
peripheral tolerance, such as antigen presentation by dendritic cells209 or direct 
suppression of B cells210, 211. The dominant mechanism of suppression, along with the 
relative contributions of soluble and cell contact-dependent factors have yet to be 
determined and may in fact be conferred by tissue, effector mechanism and target cell 
specific subsets of Tregs, such as the proposed, but not universally accepted Tr1 subset 
(IL10-producing T cells212) and Th3 subset (gut-specific FOXP3+ TFGF -expressing 
CD4+ T cells and hence perhaps a conglomerate of induced and natural Tregs213), and 
specific Th1 and Th2-type response-suppressing Tregs which coexpress Th subset-
defining signalling molecules and TFs T-BET/Th1214, IRF4/Th2215 and STAT3/Th17216. 
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Suppressor activity may lie in other non-CD4 expressing cells, including the CD8217 and 
B cell218 compartments, as well as in T cells not expressing FOXP3219.  
 
It is now clear that Tregs represent an important, phenotypically distinct and 
functionally specific subset of CD4+ T cells. There is accumulating evidence of their 
importance in the CHL microenvironment (see 1.7.2 and 1.9.2) but the relevance of this 
is not known: passive or induced bystander, suppressor of T cells, or direct suppressor 
of the B-cell derived HRS cells themselves. 
 
1.6.5.5 CTLA-4 and PD1: Immunosuppressive B/T interactions?  
CTLA-4 was discovered as a T cell specific IGSF protein with structural homology to 
CD28220, expressed only on activated T cells and which more potently binds B7-1 but 
confers immunosuppressive function221. Discovery of a further ligand for both CD28 
and CTLA4 arose when it was found that antibody blockade of the B7-1 pathways was 
insufficient to antagonise all of CTLA4’s activity: there was another binding site for 
CTLA4: B7-2104, now confirmed to be closely related in the CD28/CD80/CD86 co-
stimulatory system. Confirmation of its potent immunosuppressive role was found in 
murine gene knock-out experiments in which fatal lymphoproliferation occurred222. 
 
A further unique structural homologue was discovered in apoptotic T cell lines223 using 
subtractive hybridization during an analysis of the mechanisms of cell death, hence 
named Programmed Death 1 (PD1). Not a ligand for CD28 or CTLA4, its role as an 
immunosuppressive molecule was inferred from murine gene knock-out 
experiments224 in which splenic enlargement and hypergammaglobulinaemia were 
noted in one early model, and multisystemic autoimmune disease in another225, both 
apparently attenuated forms of the CTLA4 knockouts. Further evidence for the 
immunosuppressive role of PD1 emerged using blocking antibodies in mouse models 
of immune-mediated disease, in which EAE226, diabetes227 and graft-versus-host disease 
(GVHD)228 were exaggerated. Its ligands, structural homologues of the B7 group (B7-
H1/PD-L1/CD274 and B7-DC/PD-L2/CD273) were identified using structural 
homologue cloning techniques229 and subtractive complementary DNA library 
screening in mouse230 and found to possess suppressive activity via PD1 interactions , 
with a structural homologue in man231. Expression of PD-L1&2 is seen on a wide variety 
of immune cells: DCs, macrophages, T and B cells. The structural homology of receptor 
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and ligand, both possessing intracellular domains, suggests two-way interactions. The 
consequences of these remain to be fully elucidated. Evidence for alternative receptors 
for the ligands has been provided by experiments demonstrating that ligand exposure 
can also enhance T cell activity232. Overall the evidence suggests that cells expressing 
PD-L1&2, widespread amongst inflammatory tissue suppress the function of PD1-
expressing T cells. However the role of PD1/PD-L1&2 signalling in the GC may be more 
complex, and potentially two-way, with T cells providing survival signals through PD1 
back to the PD-L1 expressing B cell. Molecules in this system are over-represented in 
the CHL microenvironment but their function in this context is obscure118.  
 
Further homology searches have gone on to reveal other members of the B7 family and 
respective receptors with probable inhibitory function. B7-H4/CD276233, 234 was 
investigated with murine in-vivo antibody-mediated blocking experiments showing 
exaggeration of murine EAE; the molecule BTLA235 may represent its receptor 
equivalent, although another IGSF candidate molecule, HVEM (herpes virus entry 
mediator) also binds BTLA with B/T cell functional consequences236. B7-H3237 was 
found in a human DC-derived cDNA library and possesses both enhanced T cell 
activity237 as well as inhibitory function238. Discrete definition of these molecules as co-
stimulators or co-inhibitors appears overly simplistic, emphasizing that function varies 
by tissue, interacting cells, and activation states.  
 
1.6.6 A professional GCB cell-helping T cell: T follicular helper 
The most phenotypically suited T subset for normal B cell and by extension perhaps 
malignant B cell support, even with the limitations of subset definition and plasticity 
of differentiation described above appears to be the Th2 cell. With B cell stimulating 
and maturation-promoting IL4, IL5 and IL13 secretory activity, expression of a range of 
B cell activating surface proteins, along with decades of functional in vitro and in vivo 
evidence, this cell is theoretically best suited for activated B cell promotion, and could 
perhaps be the prime candidate microenvironment T cell conferring the B cell 
malignancy equivalent, the HRS cell, with its survival signals. The CHL 
microenvironment was once thought to be dominated by Th2 polarised cells, but this 
model has been substantially challenged, as will be discussed below. Additionally, 
there is another recently, robustly defined subset of T cells that may fill the role of a 
professional GC-specific B helper cell: the T follicular helper cell (Tfh). Understanding 
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this cell’s function may provide candidate molecules of T cell-mediated HRS support. 
 
1.6.6.1 Evidence for a T follicular helper (Tfh) cell 
Bowen and colleagues (1991)239 first described the unique phenotype and localisation of 
a subset of T cells present in the GC, comprising around 10% of all cells. Their 
expression of the natural killer (NK) cell marker CD57 (Leu-7) and unique cytokine 
secreting profile240 differentiated them from peripheral T cells and those T cells 
inhabiting the lymph node cortex. Follicular T cells present in tonsil were found to up-
regulate membrane CD40-L more rapidly, suggesting that they possessed pre-
synthesised intracellular protein240, and this, together with the knowledge of B cell 
help requiring CD40 signalling, provided further evidence that the T cells in the GC 
were not mere bystanders, but the providers of B cell help, and of a distinct phenotype 
to other T cells. Th1, Th2 and Tregs have convincing evidence of distinct surface 
protein, TF, cytokine secretion and functional profiles, and these Tfh cells have 
acquired their own evidence to support them as a further distinct subset. CXCR5 is up-
regulated on their surface241, a receptor more characteristic of activated B cells and 
consistent with an ability to migrate into the CXCR5 ligand-rich (CXCL13) GC125. This 
surface factor is transiently expressed on most activated T cells, but appears to be 
retained on this subset242. Isolation based on CXCR5 expression enabled gene 
expression of this subset to be examined, revealing a distinct profile to those described 
for Th1, Th2, Th17 and Tregs243, and determining further characteristic surface proteins: 
CD200, PD1, ICOS, OX40 and Surface Lymphocyte Activated Molecule (SLAM) 
adaptor protein (SAP)243, 244. IL10 and IL21 secretion, along with expression of the GCB 
cell characteristic TF Bcl-6, unique in the context of T cells and distinct from other T 
cell subtypes244, 245 as well as the Th2 associated c-Maf have been described. Mouse 
models deficient in IL4 and STAT 6 (essential for Th2 function), IFN-  and STAT4 
(essential for Th1 function), IL17 and RORa/c (required for Th17 function) show 
evidence of an intact T follicular helper subset246. Hence, evidence supporting this 
CXCR5 expressing, GC localising T cell as a distinct entity is robust. 
 
The mechanism of migration to the GC, implied by CXCR5 expression, was confirmed 
in mouse CXCR5-/- T cell adoptive transfer experiments in which the GC response was 
much impaired and T cell-rich light zones did not form247. CXCR5 expression also 
seems to depend upon intact signalling through other Tfh surface proteins - OX40 and 
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CD30248 whose ligands are expressed in the T/B border zone in so-called lymphoid 
tissue inducer cells. These CD4+ CD3- cells may provide the survival and migration 
signals for Tfh entry into the GC249 by upregulation of CXCR5, overcoming the T cell 
characteristic CCR7 expression, which retains the cell in the cortex. Without sufficient 
expression of these Tfh over-expressed proteins, migration into the follicle is 
prevented, evidenced by the failure of CD30 and OX40 knockout mice to form robust 
GCs250. 
 
The origin of the Tfh cell is not clear. Expression in the Tfh of Th1, Th2 and Th17 
cytokines at low levels251 implies conversion of naïve T cells, activated in a polarising 
context, but then switched to a GC homing, B cell helping phenotype rather than an 
effector T cell destined for target antigen expressing tissue. Alternatively, the context 
of antigen presentation to a naive T cell may initially activate the Tfh program, which 
then acquires Th1, Th2 or Th17-like features, perhaps in order to bias the GCB cell 
response appropriately through influencing class switching. The location of this T cell's 
exposure to antigen also remains unclear. There is evidence for presence of these 
phenotypically similar cells in the interfollicular T zone, in close association with 
plasmablasts of extrafollicular primary B cell foci, as well as within the GC252, 253 hence 
the cells may arise within or migrate towards their region of eventual function. 
Polarisation towards the Tfh phenotype seems to depend upon the nature of the initial 
antigen encounter, perhaps through the strength of TCR signalling: Tfh lineage cells 
induced in a competitive environment of T cell cognate antigen exposure were found 
to have the greatest affinity for antigen254, while polyclonally activated Tfh cells have a 
more restricted TCR repertoire compared to other T cell subsets effectors activated 
similarly. In addition, the strength of TCR signalling was directly proportional to the 
amount of Tfh-characterising cytokine, IL21 production. A co-stimulatory environment 
of antigen exposure is particularly important to avoid autoreactivity. Pathogen 
associated molecular patterns (PAMPs) are recognised by APCs, through toll like 
receptors (TLRs) and the like, leading to upregulation of CD28's agonist ligand 
CD80/86 (B7). This, along with MHC class II upregulation and hence more potent 
antigen presentation, leads to induction of CXCR5 and OX40 expression in the 
associated Tfh cell255, a mechanism essential to prevent the disastrous potential of an 
auto-reactive Tfh cell being permitted entry to a GC and providing help to auto-
reactive B cell clones. 
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1.6.6.2 Tfh cell can be defined by BCL6 and C-MAF expression 
Expression of the Tfh phenotypic programme, as with the other well-defined T helper 
subsets, requires coordination through TFs. The unique combination of BCL-6 and C-
MAF expression is a candidate for this function. Over-expression of C-MAF is found in 
Tfh and is a dose-dependent enhancer of IL21245. Expression of C-MAF is impaired in 
ICOS null mice. Originally identified in B-cell lymphoma256 BCL-6 is a sequence 
specific transcriptional repressor gene257 expressed in GCB cells258 enabling 
proliferation, affinity maturation, class switching and maturation to plasma cells259, 260. 
In T cells BCL-6 over-expression leads to CXCR5, PD1, ICOS and IL21R upregulation 
with CCR7 down-regulation, while T cell-specific knockout prevents GC formation as 
well as maturation into the full Tfh phenotype251, 261. Expression reciprocally inactivates 
expression of T-BET261, 262 and GATA3263, preventing classical Th1/Th2 differentiation, 
and down-regulates the expression of their characteristic cytokines. In human tonsil-
derived Tfh cells261, 262 BCL-6 binds the promoters of T-BET and ROR- t, implying 
suppression of Th1, Th2 and Th17 differentiation respectively. The mechanism of 
reprogramming the T cell phenotype may be through suppression of normal T cell 
microRNA signatures262, 264. Expression of BCL-6 may be induced through in vitro 
stimulation of naive T cells with supplementary IL21 and IL6246, although the 
physiological correlate of this in the initial activation context in vivo has yet to be 
confirmed. 
 
1.6.6.3 Cell surface mechanisms of Tfh cell function 
One mechanism by which the activated Tfh cell is able to enter the GC is through 
CD28-mediated ICOS expression. CD28-independent GC formation in response to 
antigen does not occur in CD28 knock-out mice255. However, if ICOS is aberrantly up-
regulated (as is seen in the sanroque mouse strain with a Roquin gene point mutation 
leading to multisystemic autoimmunity) GCs are able to form without CD28 
costimulation265. This was demonstrated in the Roquinsan/san Cd28 -/- mouse model, and 
could be blocked by genetic ablation of ICOS ligand signalling: the Roquinsan/san Cd28 -/- 
Icos-L-/- mouse. B cell specific ICOS-L knockout (via CD19-cre ICOS-L conditional flox 
allele-carrying mice) impaired GC formation but did not abrogate it, suggesting that 
this essential pathway for Tfh function may also be stimulated by non-B accessory 
cells246. Additionally, modulation of TCR signalling strength may occur through 
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SLAM/SAP signalling. Deficiencies in this pathway lead to reduced participation of the 
T cell in GC formation266, 267. SAP modulates TCR signalling strength through 
phosphorylation of proteins downstream of the receptor268. Hence the context of 
antigen encounter, with appropriate SLAM/SAP interactions with the antigen 
presenting cell, may induce Tfh polarisation and provide another regulator against 
autoimmunity by preventing further differentiation of a T cell encountering antigen 
outside the strict context of inflammatory stimulated APC or even cognate B cell in the 
T/B border. SLAM/SAP interactions appear essential for ‘follicular’ Tfh cell 
differentiation and function269, however knock-out models do show evidence of extra-
follicular B cell proliferation and plasmablast interactions with T cells phenotypically 
similar to intrafollicular Tfh cells. These ‘pre-follicular’ Tfh cells over-express ICOS and 
BCL6, but not CXCR5 and PD1 and are found to interact with plasmablasts. Whether 
this represents an alternative fate for a naïve T cell in the early stages of Tfh 
commitment, or an entirely distinct Tfh-like lineage has yet to be determined 
(reviewed in Fazilleau 2009270). 
 
The mechanism by which this T cell, following appropriate activation and polarisation 
and follicle entry, exerts its supportive function is beginning to be understood. Early 
expression of CD40-L and ICOS271, 272 confirms their capacity to confer classic B cell 
help. IL4 production is likely to be important, since IL4 receptor deficient mice mount 
poor follicular humoral immunity, and GC CD4+ cells expressing a Tfh phenotype are 
seen particularly in the context of a parasite challenge273-275 but this could also imply 
subtypes of the Tfh phenotype which are capable of skewing the eventual 
immunoglobulin isotype complement of the helped B cells. Tfh cells, through high 
FAS-L expression, may play a role in deleting suboptimal affinity or auto-reactive B cell 
clones. CD95 signalling is essential for this negative selection process, since B cell-
specific CD95 knock out results in lymphoproliferation and increased spontaneous GC 
formation. B cells possessing a receptor most potently binding antigen and hence 
attracting most T cell support are therefore favoured130 and the T cell reciprocates with 
survival signals. Further survival signals continue to emerge: IL21/IL21-R and, 
paradoxically, PD1/PD1-L, both of which may have functional importance in CHL.  
 
Chapter 1: Introduction & Objectives 
44 
1.6.6.4 IL21: A Professional B cell-helping Cytokine  
A relatively recently discovered cytokine, whose receptor was cloned before the ligand 
determined276 has proved to be central to T cell / B cell interactions in the GC. IL-21 is 
an in vitro growth factor for B and T lymphocytes277 acting via Blimp-1 and Bcl-6 
upregulation278. However, its role in vivo seems more specific to maintaining GC 
reaction, as evidenced by the disease resulting from homozygous IL21 receptor 
mutation leading to hypogammaglobulinaemia with excess IgE: a failure of ordered 
class switching and plasma cell maturation, as well as some demonstration of a failure 
of Tfh cell maturation and GC formation in IL21 deficient mice246, 279. Tfh cells and GCB 
cells possess IL21-receptors (IL21-R), while Tfh cells secrete IL21278 hence the 
contribution of this cytokine to GC survival may arise both through induction and 
autocrine maintenance of the Tfh cell, as well as promoting B cell survival. Further 
detail of the relative contributions of these pathways, as well as the precise 
contribution to the GC reaction came from work with chimeric mouse models 
possessing intact B cell complements, only their T cells being deficient in IL21-R or 
cytokine synthesis280. The IL21-/- or IL21-R-/- systems demonstrated impairment neither 
in Tfh cell differentiation nor initial GC establishment. However GC function was 
defective: plasma cells slower to form, reduced somatic hypermutation, reduced GC 
cell cycling, reduced affinity of eventual antibody production and premature 
termination of GC while relative contribution of memory cells to the B cell 
compartment was increased. The chimeric systems recapitulated these findings only 
when T cell synthesis of IL21 was impaired: T-cell specific loss of IL21-R led to only 
slight impairment in measures of GC function.  
 
Hence IL21 activity seems to be mediated predominantly through T cell secretion 
enabling B cell survival, proliferation, hypermutation and selection via the B cell IL21-
R. Mature memory B cells still manage to emerge from these systems, but with 
impaired antigen specificity and evidence of less rounds of proliferation. Clearly IL21 is 
an integral survival factor for the proliferating, maturing GCB cell. There is also 
evidence for its involvement in HRS survival. Both IL21 and IL21-R are expressed 
strongly by CHL cell lines and patient-derived samples, tumour infiltrating T cells 
express IL21, and IL21-treatment of CHL cell lines leads to activation of STAT5 
survival/proliferation pathways: associated with NF -  pathway activation69, 281. 
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1.6.6.5  PD1: A B Cell Promoting Role for a ‘Suppressive’ Molecule?  
PD1/PD-L1&2, a classic immunosuppressive or ‘exhausted’ lymphocyte pathway 
described above, appears to play a novel role in the GC. Expression of PD1 by the Tfh 
subset may be fundamental to GCB cell survival. B cells (amongst many other cells) 
express PD1 as well as PD-L1, and once activated also express PD-L2282, the ligand 
constitutively expressed by accessory cells such as dendritic cells and macrophages231. 
A combination of mouse knock out and bone marrow chimeric models investigating 
PD1 and PD-L1&2 signalling through expression in both GCB cells and Tfh found an 
unexpected pro-survival role for this cell in the mouse GC283. During primary antigen 
response an upregulation of PD1, PD-L1 and PD-L2 was found in emerging memory B 
cells284 which developed through the course of the GC reaction. Three mutant mice 
strains were developed, deficient either in PD-L2/PD1 signalling (by PD-L2 knock out), 
PD-L2 and PD-L1/PD1 signalling (by PD1 knock out), or deficient in PD-L1 and PD-L2 
(abrogating all interactions with both PD1 and the structurally similar costimulator 
CD28). All were able to form normal GCs containing PD1+ T cells as readily as wild 
type C57BL/6 and early antibody response (defined by IgM and IgG1 titres at day 12), 
was unimpaired. At three months however, the knock-out mice proved to be deficient 
in long lived plasma cells.  
 
Hence these signalling pathways appear to be important for a sustained GC reaction 
capable of generating an adequate complement of long-lived plasma cells. This was 
confirmed on analysis of antibody titres beyond day 15: PD1 pathway knockout mice 
were deficient. Analysis of the 'late' GCs (beyond day 12) revealed reduced B cell 
number and increased apoptosis, but numbers of emerging plasmablasts were 
equivalent. PD1 pathways were operating to maintain maturing germinal B cell survival 
during the affinity-maturing phase; 'escaped' plasmablasts no longer required the 
pathways for survival. Tfh numbers were not reduced: they were increased in number. 
However they were functionally abnormal: expressing less IL-4 and IL-21 mRNA. 
Generation of hybrid systems by either inter-organism transfer of lymphocytes, or 
mixed-bone marrow chimeras generated from lethally irradiated BALB/c recipients, 
enabling selective deletion of PD1 on either B or T cell only confirmed that the effect 
was as a result of B cell PD-L1 and PD-L2 interacting with PD1 on Tfh cells rather with 
PD1 on other B cells. Both signalling pathways (PD-L1&2) appeared to be important, 
with an additive role of loss of both pathways. This data highlights the complexity of 
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the PD1 system, a possible pro-survival role, and a T-to-B cell (PD1 to PD-L1/2) signal 
direction and identifies a further candidate cell contact mediated mechanism of T cell 
conferred B cell help. 
1.6.7 Conclusions: Defining a T helper cell subset 
Defining a T cell merely by its complement of expressed genes and proteins, rather 
than directly observing an effector function will always be an oversimplification, and 
even confirming specific effector function artificially implies a stability of phenotype 
that may be influenced by the system in which it is being studied as well as by the 
inherent plasticity of a cell to enter another functional state. Phenotype stability seems 
to be conferred by increasing numbers of generations of cell divisions following 
antigen encounter and activation285, 286 with chromatin modelling and epigenetic 
changes supporting this concept of progressive generational ‘imprinting’ of a 
phenotype287. Intracellular signalling pathways and TFs interact, mutually suppress or 
stimulate and are modulated by microenvironmental signals (chemokines, cytokines, 
growth factors and cell-cell interactions) with complex intracellular circuitry which 
‘settle’ into a state of effector function (reviewed in Murphy & Stockinger 2010)288. 
Hence, while subsets may be defined by ‘master’ TFs which are mutually inhibitory 
and self promoting, (e.g. the T-BET Th1 vs GATA-3 Th2 paradigm) associated with well 
defined intracellular signalling events (STAT1 in Th1, STAT4/6 in Th2, STAT3 in Th17) 
there remains no gold standard of determination of a cell’s in vivo contribution. 
Measurable effector function (IL4 production in Th2, IFN-  production in Th1, effector 
T cell suppression in Treg) remains the most robust definition, with the caveats of 
plasticity and in vitro changes always present. 
1.7 Current understanding of CD4+ T cells in the CHL microenvironment 
1.7.1 Evidence for a TH2-dominated infiltrate 
Burgeoning understanding of B cell/T cell cooperation led investigators to propose 
that the T cell infiltrate in CHL would likely represent a Th2 biased response. Evidence 
for this is largely based on one 1989 study in which Poppema’s group attempted to 
characterise the CHL-infiltrating T cells immunohistochemically47. They show that the 
majority of tumour-infiltrating cells are CD45RO+, CD45RA- and CD45RBlo. 
Understanding of CD45 isotypes at this stage was limited: the function of this surface 
protein remains fairly elusive even today, but apparently discriminates activated from 
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naive or memory T cells, and proliferative versus secretory/effector T cells (reviewed in 
Penninger 2001289). Poppema’s study was based on only 10 cases of CHL and yet 
remains the much-cited basis of the assertion that the infiltrate in CHL is 
predominantly Th2. Drawing a functional conclusion based on a very limited panel of 
surface markers is erroneous, particularly in such a small and potentially non-
representative sample of patients. Attributing Th2-like activity to CD4+ CD45RO+ 
CD45RA- CD45RB-low cells was itself based on a relatively primitive study by 
Morimoto290 predating the seminal functional work of Mosmann and Coffmann's 
group149. Morimoto’s work found that FACS-enriched human peripheral blood-derived 
CD45RA- cells were able to stimulate IgG production from autologous PWM 
(pokeweed mitogen)-stimulated B cells (hence termed T helper/inducer) whereas 
CD45RA+ cells suppressed IgG production (termed T suppressor/inducer).  Based on 
current understanding of CD45 isotypes, peripheral blood derived CD45RA+ T cells 
would be enriched for an antigen naive or central/memory population while CD45RA- 
would contain more antigen experienced effector or effector/memory populations: 
clearly differing in their B cell helping capacity and in no way conferring a uniquely 
Th2 phenotype to the CD45RAneg cells.  
 
More convincing functional work, favouring Poppema’s group’s definition of Th2 cells 
is available, but derived from a mouse model. In Leishmania exposed BALB/C mouse T 
cells, the CD45RBhi population secretes significant levels of IFN-  and little IL4 (hence 
perhaps Th1 enriched) while the CD45RBlo population is enriched for cells secreting 
significant IL4 and little IFN-  (hence perhaps Th2) on in vitro stimulation with 
Leishmania antigen and irradiated antigen-presenting cells (APCs)291. However, there 
was also significant IL10 secreting capacity in the CD45RBlo cells: a cytokine now 
attributed to Tregs rather than Th2. Congeneic lymphocyte transfer experiments into 
functional T cell deficient mice (C.B-17scid) themselves incapable of eradicating 
Leishmania, led to restoration of an inflammatory response only on transfer of the 
CD45RBhi population, not on transfer of the CD45RBlo population. This experiment 
can only be used to define CD45RBhi as Th1 and CD45RBlo as Th2 in the BALB/c 
mouse model. An alternative explanation could be that while the BALB/c mouse is 
capable of mounting both Th1 and Th2 type responses it is already genetically 
predisposed (without ex vivo lymphocyte manipulation) to a Th2-dominated 
reaction157. Hence the CD45RBlo, effector and effector/memory subset may be 
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enriched for Th2 committed effector cells capable of reciprocally suppressing any 
potential Th1 response, while the CD45RBhi antigen naive subset would still have the 
capacity, if manipulated ex vivo, to produce a Th1-type response: CD45 isotype does 
not define polarisation, but rather capacity to be polarised. Hence the conclusion to be 
drawn from Poppema's study is that the majority of the T cells in the CHL 
microenvironment are antigen experienced, or activated T cells. No further functional 
sub-classification can be inferred. 
 
Further immunohistological exploration of the T cell microenvironment has been 
carried out using expression of the ‘master’ transcription factors (TFs) for Th1 and Th2 
to define subset representation46. Even assuming preserved expression with tissue 
fixation and staining procedures, this is another very small and potentially 
unrepresentative study: 16 cases of CHL showed considerable variability of expression 
of each factor, with nothing to support the hypothesis that the microenvironment was 
dominated by a Th2 response. GATA3 was expressed in <25% of all infiltrating cells, 
with the Th2-associated TF c-MAF weakly expressed in a similar proportion of cells. T-
BET conversely was strongly expressed in over 50% of cells in more than half of cases. 
Little of functional significance can be concluded from this study except that these TFs 
are heterogeneously expressed from case to case, and certainly there is nothing to 
corroborate the assumption that the microenvironment is dominated by Th2 cells. 
NLPHL, not the subject of this discussion, conversely showed substantial expression of 
GATA3 and c-MAF in the microenvironment, with little T-BET expression, and more 
homogeneity between cases, further discriminating this as a quite distinct pathological 
entity. A further weakness of this study was the failure to correlate the Th1/Th2 TFs 
with EBV staining in the HRS. Substantial evidence exists that the immune infiltrate in 
EBV positive CHL is distinct to that in its EBV negative counterpart292, implying an 
ongoing active, if ineffective anti-EBV cytotoxic and perhaps Th1 dominated response, 
which might explain some of the heterogeneity of T-BET expression in this study. 
 
1.7.2 Evidence for an anergic, suppressive CD4+ T cell infiltrate 
Evidence for antigen experience and hence activation status of T cells in the CHL 
microenvironment was confirmed in early IHC work showing expression of CD38, 
CD69, HLA-class II and CD28: co-stimulatory and homing molecules essential for 
effector function (Poppema 1995; unpublished observation; personal communication). 
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However, some expected activation factors are not expressed, and the T cells are 
clearly dysfunctional: failing to eradicate the tumour. CD26 (Ta-1) is one such 
molecule remaining unexpressed by these otherwise ‘activated’ microenvironment T 
cells: a molecule expressed by normal activated T cells293, 294 now understood to be an 
adenosine deaminase-anchoring protein involved, in cooperation with CD45RO, in 
mediating effective TCR signalling295 perhaps more important in Th1-type responses296. 
This finding has led some to conclude that the T cell infiltrate is anergic, or regulatory 
in nature114. Isolated CD26- CHL-derived T cells were shown to have up-regulated 
genes typically associated with a regulatory phenotype – such as CTLA4 or CCR4, and 
failed on stimulation to up-regulate genes expected of an activated effector cell, such 
as IFN- , IL2, IL4 and T-BET. However the control for these experiments (equivalent 
CD26- cells derived from tonsil) merely demonstrated that the phenotype of cells 
defined by absent CD26 was different between tonsil and HL-infiltrated lymph node, 
not that CD26 negativity conferred an anergic phenotype. Certainly no functional 
demonstration of suppressor activity was demonstrated in these cells. 
 
NLPHL T cells show striking expression of CD57, a marker associated with clonal 
exhaustion: failure to respond to mitogenic stimuli despite preserved secretory 
capacity, with truncated telomeres, increased apoptosis susceptibility and down-
regulation of the effector T cell markers CCR7 and CD28297. However this senescence 
marker is not seen in CHL46, 298. Anergy may well be a feature of many of the 
infiltrating T cells in CHL, and is evidenced by a failure of the infiltrate to eradicate or 
control tumour growth. However robust confirmation of this is lacking in the 
literature. 
 
A functional attempt to demonstrate the anergic and suppressive nature of the 
lymphoid cell infiltrate was performed by Marshall’s group in 2004299. They found that 
tumour infiltrating lymphocytes (TILs) failed to proliferate or secrete IFN-  or IL4 in 
response to mitogen, and suppressed proliferation of autologous lymphocytes in an IL-
10 dependent manner (blocked by anti-IL10 antibody). The use of 3H-thymidine in 
their suppression assay (hence failing to account for the comparative hypo-
proliferation of an anergic, but not frankly suppressive population of TILs), the use of 
unpurified node-derived cells rather than purified T cells (obtained by simple 
mechanical dissociation of lymph nodes) and inclusion of two ‘control’ nodes which 
Chapter 1: Introduction & Objectives 
50 
themselves containing malignant cells (breast and anaplastic lymphoma), along with a 
failure to examine for the more Treg-associated FOXP3 expression (instead using 
CTLA4 and CD25 as markers of Tregs - both up-regulated fairly non-selectively by 
activated T cells300, 301) limits the interpretation of these results and certainly does not 
convincingly demonstrate that the suppressive component of the tumour-derived cell 
preparation arose from the T cells. Regulatory T cells may well have a role to play in 
disease biology as evidenced by FOXP3 expression in the microenvironment: discussed 
further below and in my own data. However there is little robust functional data of 
suppression in the CHL microenvironment.  
1.8 Challenges in studying the function of the microenvironment in CHL 
1.8.1 Functional Studies 
To study the interaction between T cells and HRS usefully, in as robust an 
experimental way as that in which physiological B/T cell interactions have been 
studied, a representative model must be developed from which observations can be 
made and manipulations applied. The further such a model is from the in vivo 
pathophysiological state, the less valid any conclusions will be. CHL presents 
particular challenges in this respect. 
1.8.2 In vitro culture systems 
Continuous cell lines are available, derived from patients with CHL, which can be 
maintained cheaply and simply in culture, and applied to standard in vitro assays. An 
extensive literature exists characterizing the most well recognized CHL derived cell 
lines, from gene expression and proteomics to pharmacological susceptibility302-315. The 
overwhelming disadvantage of continuous cell line use is the biological distance from 
the tumour of origin. Most patient-derived cancer cells will not reproduce in vitro for 
extended periods of time. This is particularly true of CHL, for which a continuous cell 
line was not established until 1980316 compared to the first human tumour cell line 
established in 1951 (HeLa, by Gey317) and made more difficult by the rarity of the 
malignant cell compared to non-tumour infiltrate. The cells which sustain any long-
term and continuous cell culture (the progenitor or stem cells) are likely a rare 
subpopulation of the malignant clone, with the bulk of the tumour comprised of 
terminally differentiated cells without the capacity to further reproduce. In addition, 
maintenance even of this progenitor cell will likely require interaction with the tumour 
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microenvironment: immune or stromal. In other haematological malignancies these 
problems are overcome by selecting for putative progenitor/stem populations using 
cell surface markers, enabling purification using immunological techniques (e.g. FACS 
or magnetic beads), and by developing coculture systems including supportive cells 
derived from a comparable niche to the cancer cell: such as autologous bone marrow-
derived stroma or allogeneic continuous cell line equivalents. These confer the support 
required for growth without requiring up-front knowledge of the molecular basis for it. 
Once the molecular nature of support has been elucidated experimentally then 
supportive cells may be replaced by soluble or immobilized factors (as shown for B/T 
cell model systems described above), either plate-bound or (perhaps more 
physiologically) cell-sized bead-bound as has been achieved for antigen-presenting 
cell-free expansion of T cells using anti-CD3 and anti-CD28 antibodies318. However 
there will always be unknown in vivo factors that are absent from an in vitro culture 
system.  
 
In CHL, while the terminally differentiated malignant cell is clearly identifiable 
histologically (the huge, multinucleate HRS) and hence fit for micro-dissection from 
fixed or frozen tissue for further study21 and has a fairly unique signature of surface 
proteins (aberrant myeloid CD15+ and activated lymphoid TNFRSF member CD30+ in 
the absence of other B and T cell markers) enabling flow sorting of HRS319, it is well 
established that these cells have minimal proliferative capacity320 to enable in vitro 
culture. The precursor cell remains a hypothetical concept which likely arises within 
the GCB cell compartment21, but being derived from a relatively mature cell unlike the 
acute leukaemias, may not express established markers of stem or progenitor cell. 
Expression of B cell markers has been found in some CHL cell lines which when flow 
sorted and cultured are capable of recapitulating the entire population with greater 
efficiency than culture of unsorted cells321, 322 and with the capacity to persist over 
several replatings (a stem cell-like property). This, along with limited evidence that B 
cell marker positive cells with clonal relationship to the malignant cell can be isolated 
from the peripheral blood of patients lends weight to this argument322 but remains 
methodologically flawed323. Definitive high-resolution genetic evidence of clonal 
relatedness, and subculture of these primary cells with generation of terminal HRS has 
yet to be achieved. 
Chapter 1: Introduction & Objectives 
52 
1.8.3 In vivo culture systems 
The animal model (usually murine) is an attempt to provide the ‘unknown’ systemic 
survival signals as well as a model more closely resembling that of the tumour in situ. 
Two approaches are possible. The first is really no more than using the mouse as a 
culture dish with accessory tissues: primary patient or continuous cell-line derived 
malignant cells are engrafted into the mouse. In order to prevent graft rejection the 
recipient must be profoundly immunocompromised (non-obese diabetic severe 
combined immunodeficient (NOD-SCID) or similar324) which intrinsically prohibits 
the study of any interaction of tumour with immune cells. Co-transfer of human 
immune cells is possible, but T cells in particular will often outcompete tumour cells 
and rapidly cause GVHD, engrafting in the bone marrow and leading to fatal 
haematopoietic failure325, 326 with few conclusions possible regarding their interaction 
with tumour. Engraftment has relatively recently been achieved using CHL cell lines, 
showing contiguous lymphoid dissemination and subsequent multi-organ involvement 
resembling an accelerated form of human CHL327, but lacking the microenvironment 
of an immunocompetent host.  In fact, a requirement of reliable engraftment is the use 
of the NOD/SCID/ cnull (NOG) mouse lacking B and T cells and possessing 
dysfunctional NK cells, macrophages and dendritic cells328. While essential in 
preventing graft destruction by innate immune system, the tumour is consequently 
devoid of the majority of the characteristic CHL microenvironment. Primary CHL 
samples tend to engraft poorly, or be rapidly overwhelmed by bystander EBV-
immortalised B cell growth, a problem also encountered in early attempts to develop 
CHL cell lines329.  
 
The second type of animal model exploits the technology of inducing targeted genetic 
lesions which lead to spontaneous (but autologous and hence species-specific) tumour 
development comparable to human disease, such as the E -myc mouse model of 
Burkitt lymphoma330 or the E -TCL1 mouse model of CLL331 where proteins known to 
be over-expressed or pathogenic in lymphoid malignancies are artificially up-regulated 
in murine B cells using the immunoglobulin promoter gene. This can be studied in the 
mouse of origin or following transfer into a syngeneic mouse lacking the mutation. 
Hence a malignancy can be observed in the presence of an intact immune system: 
integral to any study of immune/tumour interaction. However it is limited by the fact 
that the tumour is non-human derived, an oversimplification of most tumours arising 
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in man, being initiated by only a single or a few transforming events, and probably far 
more aggressive: itself a necessary function of finite experimental observation 
duration. In CHL, while recurrent genetic abnormalities have been observed now that 
purification of such a rare cell has been achieved to the extent that genetic 
interrogation can be performed, from the level of fluorescence hybridization-enhanced 
karyotyping332 to that of comparative genomic hybridization (CGH)116, 333 and whole 
transcriptome sequencing334, the highly aberrant multinucleated malignant cell 
possesses countless candidate mutations only a few of which are recurrent and none 
alone likely to recapitulate the disease if altered in an otherwise immunologically 
intact mouse model. 
1.9 Descriptive and Correlative Studies of the CHL microenvironment 
1.9.1 The function / prognosis fallacy 
The importance of the immune infiltrate in defining prognosis and aggressiveness of a 
malignancy has long been recognized, with benefit apparently conferred by lymphoid 
cell infiltrate335 and adverse outcome conferred by macrophage infiltrate336.  However, 
prognostic markers have rarely led to a coherent explanation of molecular mechanisms 
of microenvironment interactions and functional models are lacking. Characterisation 
of the CHL microenvironment using biomarkers in an attempt to better understand 
the pathophysiology of the disease, and measuring patient to patient heterogeneity of 
biomarkers in an attempt to predict outcome are quite different approaches. While 
finding a favourable prognostic factor may provide some indication as to its 
importance in disease natural history, this is not robust confirmation of a biological 
mechanism. For example, correlating a high infiltrate of FOXP3 in the tumour 
microenvironment with a favourable clinical outcome (as will be shown) may lead to 
the conclusion that Tregs have a role in suppressing the tumour directly or through 
interactions with other microenvironment cells. However, even making the 
assumption that FOXP3 expression is indicative of an increased infiltrate of functional 
Tregs (rather than representative of transient FOXP3 expression following T cell 
activation induction of Treg from naïve T cell due to secretion of TGF  by the tumour, 
passive chemotactic attraction of circulating natural Tregs, or a combination of these 
factors, as described above), there is no direct evidence that these cells are suppressing 
tumour growth. The presence of malignancy indicates failure of a successful tumour-
suppressing immune response and CHL inevitably progresses without treatment. 
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Hence this ‘favourable Treg response’ could never have successfully eradicated the 
tumour. More importantly, anti-CHL therapy (cytotoxic chemotherapy or 
radiotherapy) eradicates the lymphoid microenvironment as much as the malignant 
cell itself and hence treatment success is unlikely a direct function of Treg presence. 
More likely, FOXP3 expression is a surrogate marker of an intrinsic property of the 
malignant cell itself (for example increased TGF  secretion, for which there has been 
no investigation of association with outcome) or of the host immune response (for 
example a marker of more robust anti-tumour immunity hence able to clear any 
residual disease failing to be removed by treatment). Both of these alternative 
explanations are entirely hypothetical with no evidence basis, however they highlight 
the limitations of any purely correlative, descriptive observations in drawing functional 
conclusions.  
 
Despite the obvious logical fallacy of drawing mechanistic conclusions from such data, 
overzealous explanations of similar data are rife in the literature. Robust conclusions 
on disease mechanisms can only be drawn from functional experiments. Descriptive 
data may contribute, or stimulate hypothesis generation for functional work, but are 
not themselves a test of function. This is not to say that such biomarker data cannot be 
used in prognostic models or if validated for clinical decision-making: this is quite 
distinct from understanding the biology of a disease process. Prognostic and 
descriptive studies of the CHL microenvironment remain relatively primitive and are 
often crudely interpreted with inappropriate statistical methods and erroneous 
conclusions. Contradictory results between groups and failure to validate in 
independent datasets explains why few biomarkers translate into clinical practice. 
Without prospective studies and standardised methodology and statistical techniques, 
these studies will remain only hypothesis-generating.  
1.9.2 Immunohistochemical Profiling of T cells in the CHL Microenvironment 
1.9.2.1 CD4+ Subset Markers 
One small study of Th1/Th2 representation in the microenvironment has already been 
discussed46. A variety of other T cell-associated immunohistochemically-assessable 
markers have been applied in further studies. One used FOXP3, T-BET, C-MAF and 
Granzyme B (GrB) as markers of Treg, Th1, Th2 and activated cytotoxic T cells 
respectively337. Validation of these markers as representative of T cell subsets (rather 
than expression in tumour or other infiltrating cell) was performed by co-staining a 
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small number of patient samples: FOXP3, C-MAF and GrB were confined to the T cell 
compartment but the analysis was complicated by T-BET expression in B cells and 
HRS cells in some cases. 87 CHL cases were examined, scored across entire sections 
using image analysis software and corrected to represent a 1mm2 area. It was noted 
that FOXP3 and C-MAF were represented in ‘high numbers’ and GrB and T-BET were 
‘rare’ (contrast Atayar 2007 above46), this time consistent with the accepted model of a 
microenvironment being rich in Th2/suppressor phenotype T cells. However, 
variability of expression was considerable from patient to patient:  range of FOXP3 
expression 40-1600 per mm2, C-MAF 100-1600: wide standard deviations. Mean values  
(the focus of discussion in this study) are a meaningless descriptor in the context of 
such wide variability, certainly when the aim of a study is to relate heterogeneity of 
outcome with heterogeneity of expression. Kaplan-Meier assessments of the data were 
performed which demonstrated an impact of GrB expression and C-MAF on survival 
outcomes, as well as a score based on C-MAF:FOXP3 ratio. However different survival 
outcomes measures were used for each score, a method of ‘optimal cut-point’ between 
‘adverse’ and ‘good’ outcome groups was applied, and an artificially derived measure 
(C-MAF/FOXP3 ratio) used. All of this post-hoc analysis weakens any interpretation. 
 
Optimal or multiple cut-point analysis is a commonly encountered pitfall of statistical 
analysis of novel biomarkers where normal ranges are unknown338. The availability of 
software that will determine by multiple comparisons the point at which statistically 
significant differences between groups is found (e.g. Xtile339) makes this statistical 
error more accessible. The consequence is a failure of many apparently significant 
biomarkers to be replicated by other investigators, and more important to find their 
way into clinical practice. Predetermination of cut-points or validation in independent 
datasets is the only robust method of confirming such findings: this is rarely done in 
the literature. Another significant problem lies in the method of data interpretation 
and generation of these raw data. Scoring by histopathologists (‘manual scoring’) was 
the original methodology, still used currently, tried and tested for decades, but long 
known to be hindered by interobserver (and day to day intraobserver) variability. In 
scoring large numbers of cells (a standard high powered field (HPF) of densely packed 
lymphoid cells comprises over 2,000 cells in a standard FFPE section) human error will 
invariably occur, and the limitations of human attention and perception will clearly 
render scoring large numbers of cases impossible. Even the introduction of 
Chapter 1: Introduction & Objectives 
56 
sophisticated image scanning and analysis software (‘automated scoring’) carries the 
limitation of interobserver variability where an initial training step is required to 
program the software to recognise ‘positive’ and ‘negative’ or varying degrees of 
intensity of staining. These problems only address the limitations of ‘reading’ the data: 
variability can occur at any point in data generation: acquisition of biopsy, quality of 
initial tissue preservation technique, selection of tissue area to analyse, staining 
technique and optimisation, and choice of image digitisation and analysis package. 
 
The paper does confirm the wide variability of C-MAF and FOXP3 expression and 
suggests sparse representation of T-BET (contrary to Atayar 200746) and GrB. Its 
shortcomings are reflected in much of this field’s literature. 
 
1.9.2.2 Cytotoxic T cell markers 
A number of groups have looked at markers of the cell-mediated immune response to 
CHL and how they might be represented in the microenvironment. CD8 has not 
proved a prognostic marker, although the CD8+ component of the CHL 
microenvironment is considered to be sizably less than its CD4+ counterpart. Hence 
other markers of CD8 activation and activity have been investigated. GrB is required 
for some of the cytotoxic activity of T lymphocytes340 while TIA-1 is a protein expressed 
in a subset of cytotoxic T cells, which may form part of their cytolytic function341. The 
earliest study in CHL, by Oudejans and colleagues (1997)342 looked at CD8, GrB and 
TIA-1 in the microenvironment of CHL (n=80) and found that an infiltrate of GrB+ 
cells greater than 15% of total lymphoid cells (determined manually and 
morphologically rather than by dual marker staining) was associated with adverse 
prognosis. However this was not significant on multivariate analysis, and the 
univariate analysis was performed using optimal cut-point analysis with its attendant 
statistical error. An association between GrB expression and EBV status was found. No 
survival associations were found with TIA1 or CD8 expression. Schreck (2009)337, as 
discussed above, confirmed this finding as well as the rarity of these cells also using an 
optimal cut-point technique but with different cut-point values. Alvaro (2005)343 
examined GrB and TIA-1 in a larger retrospective of 257 patients using TMA, found 
that high expression of TIA-1 was an adverse features, but found no impact of GrB. 
Cut-points were validly defined as quartiles with no ‘optimal cut-point’ strategy. Kelley 
(2007)344 stained for GrB and FOXP3 in a TMA comprising 98 patients with CHL, 
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counting 5 HPF manually and showed no impact on GrB expression unless combined 
with FOXP3 as a ratio, where it improved the FOXP3 only model (which had been 
significant for FFTF and OS). Cut-points were derived using an optimal cut-point 
strategy (recursive partitioning) hence limiting validity particular with a post-hoc 
derived score such as FOXP3:GrB ratio. Additionally, the absolute numbers of cells 
expressed per HPF were difficult to reconcile with other studies (possibly implying a 
different definition of HPF). Montalban (2004)345 examined a very heterogeneous 
range of markers in a manually scored TMA, based on previously published IHC and 
GEP findings and found an association between TIA-1 and EFS (but no other outcome 
measure) in univariate analysis. The scoring system was oversimplified (as a simple 
‘positive’ versus ‘negative’) leading to significant data loss (rather than reporting a 
continuous variable: the main problem of manual versus automated scoring) and no 
values for case-to-case variability of expression was reported. Canioni (2009)346 found 
increased numbers of TIA-1 expressing cells in patients with refractory and early 
relapsed disease compared to long term responders (n=59) but performed no 
regression analysis using Kaplan Meier or multivariate which may have revealed 
confounding factors. Additionally scoring was manual, in limited numbers of fields, 
and the absolute numbers of cells was extremely small (42 vs 21 cells for the two 
prognostic groups amongst the thousands of cells in each HPF).  
 
Taken together these studies, although flawed, perhaps show a correlation between 
increased infiltrate of GrB or TIA-1 and adverse outcome, but methods of scoring, cut-
point and endpoint analysis and inconsistent use of multivariate analysis limits these 
findings and renders conclusions tenuous. It is clear that cytotoxic T cells as defined by 
these markers of activation represent a very minor component of the 
microenvironment; indeed any variability in such small numbers of cells may simply 
represent predominance of other cells. That such a small population is playing any 
functional part at all seems unlikely, unless these proteins are up and down-regulated 
throughout the course of the immune response in a manner that cannot be captured 
by assessment of this fixed non-vital tissue. The validity of these markers as indicators 
of T cell function is drawn into question by the fact that a significant proportion of the 
microenvironment is comprised of CD8+ cells, with no explanation as to what role 
they are playing and why they do not express effector proteins. It remains to be 
demonstrated whether these cells are suppressed and anergic, or active but ineffective.  
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1.9.2.3 Regulatory T cell markers 
A number of TMA based IHC studies have found an association between expression of 
FOXP3 and outcome. Studies in solid tumours have predominantly found an 
association between increased FOXP3 infiltrate and adverse outcome347 suggesting that 
their presence reflects an impaired immune response to tumour348, 349, and there is 
extensive mouse-model evidence that Treg depletion can lead to tumour regression 
(reviewed in Zou 2006350). However, in follicular lymphoma the converse has been 
found with increased infiltrate being associated with improved outcome351-353 and as 
discussed this has also been shown in CHL343. This counterintuitive finding highlights 
the limitations of drawing mechanistic conclusions from descriptive data: suppression 
by large numbers of Tregs may be expected to reduce the antitumour immunity. 
However, interaction of FOXP3 expression with treatment and primary tumour cell 
biology is likely far more complex. Evidence that FOXP3 expression confers a superior 
prognosis in lymphoid malignancy has accumulated, with Kelley (2007)344 finding an 
interaction with GrB in defining a favourable subgroup, IHC validation of GEP work by 
Chetaille 2009 (and see GEP discussion below)292 confirming a beneficial impact of 
high FOXP3 expression, although Schreck (2009)337 failed to find an association. The 
considerable limitations of these studies have already been discussed. The most 
comprehensive IHC investigation of FOXP3 in lymphoid malignancy was by Tzankov 
(2008)354, which including the largest CHL cohort (n=249) assessed with a manually 
scored TMA. Increased FOXP3 infiltrate was associated with favourable prognosis: 
statistically significant using Kaplan-Meier survival analysis but applying a flawed 
optimal cut-point method (ROC curve analysis) and applying different cut-points to 
different outcome measures (statistically invalid). More of concern, numbers of 
FOXP3+ cells reported did not tally with our own experience, nor that in the wider 
literature, using ‘27.5’ cells per mm2 as a cut-point. Without a standard transparently 
reported measure of cell density, comparing data is difficult. To illustrate: a 1mm2 core 
of a cell density suitable for immune microenvironment analysis contains 20-30,000 
lymphoid sized cells, and between a few hundred and several thousand of these 
express FOXP3 when counted using automated image analysis software.  
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1.9.3 Gene Expression Profiling of the CHL Microenvironment  
Gene expression profiling (GEP) has provided one means by which candidate markers 
for prognosis can be generated and validated in alternative datasets or using different 
techniques, for example IHC on ‘discovered’ proteins. Techniques in nucleic acid 
extraction have improved such that even FFPE tissue can be used to generate material 
of sufficient quality for analysis355 with the potential to develop high throughput 
simple and relatively inexpensive gene expression techniques applicable to the 
clinic356. 
 
GEP in lymphoma first gained prominence when it was shown that prognostic 
subgroups of DLBCL could be discriminated using the technique357. The importance of 
the microenvironment’s gene signature (rather than the tumour cell itself) in 
contributing to prognosis was demonstrated in a later study which selected the most 
discriminatory genes for both poor and good prognosis in a large cohort of patients 
with follicular lymphoma (n=191) and found that these were expressed in a FACS 
sorted CD19- component, not in the CD19+, malignant cell enriched component358. The 
‘good prognosis’ gene set was enriched for genes involved in T cell and some 
macrophage functional pathways, while the ‘poor prognosis’ gene set was enriched for 
pathways involved in dendritic cell and other macrophage functions. These were 
defined immune responses 1 and 2 and formed the basis of countless subsequent 
studies of the relative contribution of T cell and macrophage to tumour survival in 
lymphoma. While a substantial body of functional work strongly supports the concept 
of a tumour associated macrophage (TAM) conferring immunosuppressive and 
supportive roles in tumour progression (reviewed in Condeelis & Pollard 200644), many 
conclusions derived from GEP of primary tissue: a merely descriptive and correlative 
technique, lack any robust corroborative functional basis. Three major groups have 
published on gene expression profiles in the CHL microenvironment: French, Spanish 
and Canadian. 
 
1.9.3.1 The French Group 
The first French investigation359 was later expanded to involve GELA (Group d’Etude 
des Lymphomes de l’Adulte)292. The small initial study applied an in-house 1045 cDNA 
clone array to material derived from 21 patients with CHL. Using hierarchical cluster 
analysis360, CHL cases were found to segregate into two unsupervised clusters (n=6 and 
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n=15) in which the smaller cluster exclusively contained favourable outcome patients 
(however note the small numbers and the fact that 75% of the entire cohort had a 
favourable outcome). A second hierarchical analysis was then applied using only those 
genes that appeared to most successfully delineate these two unsupervised clusters in 
the first analysis, and three clusters were then discriminated. The poor outcome group 
remained distinct. This GEP (relative to the median expression across all samples) 
found 40 up-regulated genes and 19 down-regulated genes defining the favourable 
outcome group while the unfavourable group was distinguished by relative 
upregulation of the favourable group’s down-regulated genes, and down-regulation of 
a further distinct cluster of 15 genes. Clear limitations of this study are low genome-
representation of the microarray, very small patient numbers and failure to use gene 
set enrichment analysis (GSEA). GSEA in itself is a controversial methodology: a post-
hoc bioinformatics method of integrating large GEP datasets into interrelated 
functional pathways, potentially conferring artificial biological plausibility to what are 
independently measured gene expression events, especially artificial when applied to 
the very heterogeneous mix of cells present in the immune microenvironment. The 
conclusion drawn from survival analysis in this study: that the GEP was superior to 
conventional prognostic scores in predicting outcome, was erroneous since it did not 
apply the hypothesis generating set of genes to an independent patient cohort. The 
gene set was also extremely restricted and hence unrepresentative: only around 1,000 
of the 40-60,000 genes thought to be expressed in the human genome. 
 
A similar method was applied to an expand pan-GELA cohort (n=63)292 this time using 
a more comprehensive commercial platform (Affymatrix U133 A2.0) representing over 
18,000 transcripts. Unsupervised hierarchical analysis successfully discriminated most 
(but not all) CHL cases from control samples of reactive lymph nodes and TCR/DLBCL 
(T cell-rich diffuse large B cell lymphoma, a histologically similar but clinically distinct 
disease) generating two clusters of patients in which unfavourable outcome patients 
were relatively overrepresented in one cluster. Supervised clustering (a statistically less 
robust post-hoc methodology) produced models with reasonable predictive value of 
EBV positivity and CHL histological subtype (although clearly the domination of EBV 
positivity in the mixed cellularity histological subtype known to have an 
overrepresentation of EBV positive cases will account for much of this difference) as 
well as a signature discriminating adverse from favourable outcomes. A number of 
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these genes were validated in an independent set of patients (n=146) by IHC read by 
histopathologists rather than automated image analysis. However, statistical 
robustness is again limited by the use of optimal cut-point analysis, and a categorizing, 
rather than continuous method of scoring (often the only feasible method when 
scoring manually). IHC was also performed on previously described prognostic 
markers including FOXP3, TIA1 and CD20 all of which had failed to emerge as 
differentially expressed from the GEP data. Much of the IHC ‘validation’ was based on 
surrogate markers of biological pathways enriched for quite different genes (for 
example CD20, not differentially expressed in the GEP, justified on the basis of 
overrepresentation of other ‘B cell pathway genes’ such as BCL11A and CCL21) hence 
possibly not validation at all. FOXP3 retained significance only in the EFS analysis, not 
in OS, while TIA1 was significant for EFS and OS but not in the multivariate analysis 
(MVA), which incorporated numerous IHC markers and clinical features. The only 
microenvironment marker retaining significance on MVA was CD20 in the OS, but not 
EFS analysis. MVA using so many independent variables may be inappropriate in a  
cohort of this size, reducing the applicability of its findings361. 
 
1.9.3.2 The Spanish Group 
The Spanish Hodgkin Lymphoma Study Group applied this technique to its extensive 
tissue bank with a view to finding markers of poor risk disease362. An initial test set of 
30 patients was determined, 50% with poor outcome (defined as first line treatment-
refractory disease or relapse within 12 months of initial therapy) and 50% with good 
outcome. GEP was performed on this group using a commercial microarray chip 
representing over 9000 malignancy-associated genes (OncoChip v2) with a view to 
identifying candidate genes differentially expressed between the two groups. 
Unsupervised clustering failed to discriminate the groups, whereas a supervised 
approach dividing them by known good versus poor outcome revealed 145 
differentially expressed genes, which clustered into 4 apparent signatures. The 
investigators chose to label these clusters based on over-representation of genes 
involved in various biological pathways: ‘microenvironment’ (T cell, macrophage, 
plasmacytoid dendritic cell), ‘adhesion/remodelling’ (fibroblast, matrix, antigen 
presenting cell), ‘apoptosis regulation’ and ‘cell-cycle regulatory’. This is a potentially 
misleading and artificial interpretation: post-hoc labelling of gene clusters based on a 
few convenient coincidences of expression, using labels as non-specific and unhelpful 
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as ‘apoptosis/remodelling’. Why should extracellular matrix and APC be grouped 
together, while the antigen-presenting ‘plasmacytoid dendritic cell’ is segregated into a 
separate group with T cells and macrophages (as is done in this paper)? The 
‘adhesion/remodelling’ signature was over-expressed in the favourable outcome group, 
while the other 3 signatures were over-expressed in the unfavourable group. Eight 
markers were selected for IHC on an independent series of 235 patients and analysed 
using tissue microarray and automated image analysis. Levels of expression were 
divided into quartiles and the patient cohort split in two, between the ‘top’ quartile 
and the rest. Using disease specific survival (DSS) as an endpoint a significant 
difference emerged between the groups using Kaplan-Meier and log-rank statistical 
tests. Cut-points were valid since quartiles, rather than optimal cut-points were used.  
 
As already addressed, the major concern in GEP of material comprised of multiple 
tissue types: malignant cell, inflammatory cell, vasculature and stroma, is that 
interpretation will be rendered impossible without knowledge of the cell of origin, and 
that substantial data will be lost arising from biologically important cells that only 
comprise only a small amount of the tissue and hence contribute relatively little 
nucleic acid despite fundamental functional importance. The Spanish Group began to 
address this by categorising the candidate gene set generated in their first study into 
‘tumour-derived’ and ‘microenvironment-derived’363. They applied the same 9,000 
gene chip as in their earlier study362 to 5 CHL-derived cell lines and applied 
hierarchical clustering to examine differential gene expression between cell line 
(entirely tumour derived) and primary material (predominantly microenvironment). 
Unsupervised clustering failed to discriminate the groups, but supervised clustering 
identified cell-line over-expression in around half of differentially expressed genes, and 
primary sample over-expressed in the other half of differentially expressed genes. The 
limitations of this technique lie in using the cell line as representative of tumour cell 
since continuous cell lines are biologically extremely different to primary tumour cells, 
which are still embedded in their microenvironment. However, some validation of this 
technique came through IHC of a small subset of gene products in which 
microenvironment or tumour cell-specific expression was confirmed.  
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Another limitation is the use of ‘over-expression’ as the only discriminatory marker 
without normal control tissue as a comparator. If a gene is down-regulated 
pathologically, then apparent ‘up-regulation’ may simply represent expression at 
physiological levels. However, for the purposes of developing a set of prognostic 
markers (the primary aim of the paper) it is a reasonable, pragmatic approach.  
 
With so many differentially expressed genes, and with the aim of producing a shortlist 
capable of being tested on a large scale for prognostic validation and potential clinical 
application, a number of statistical methods were applied which by their nature make 
very large assumptions about the data. Gene set enrichment analysis (GSEA) was 
performed on the ‘poor prognosis’ genes in each of the tumour and microenvironment 
gene lists, to identify genes clustering into purported biological pathways. This would 
have led to loss of data on ‘isolated’ genes that did not cluster into pathways on the 
GSEA database, but were nonetheless differentially expressed, as well as important  
‘good prognosis’ genes, and assumes the validity of the method of 
tumour/microenvironment discrimination. The finding that ‘tumour’ pathways 
identified included ‘drug resistance’, ‘cell cycling’, ‘MAP-kinase’ and ‘mitochondrial 
signalling’ and that ‘microenvironment’ pathway included T cell subsets and 
macrophages is based on considerable post-hoc assumptions. Clearly other functional 
pathways will have been represented which are not reported in the paper since the 
microenvironment is full of cells actively dividing and intracellularly signalling (hence 
expressing genes in what might be considered the ‘tumour’ pathways) without 
themselves being malignant. From this short list, the investigators reduced the 
candidate gene list further to include only those genes best discriminating outcome 
(reasonable for a study aiming to predict outcome, and with a separate validation set 
available) and those with the greatest ‘biological relevance’ (another artificial criteria 
given the problems of GEP in heterogeneous cell populations). The final list contained 
56 genes: 46 ‘tumour’ and 10 ‘microenvironment’-specific. RT-PCR was applied to a 
validation set of 52 patients using a TaqMan low-density array (TLDA) to develop an 
‘integrative risk score’ based on expression of all genes. The unfavourable group 
showed a significantly increased score, as expected by the methodology of gene 
selection. To further simplify the model and improve predictive capacity, genes with 
the best predictive capacity on ROC analysis were selected, giving a final shortlist of 14 
genes.  
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Further enhancement of the score356 was performed using another independent set of 
262 patients , divided themselves into a test set (n=183) and a validation set (n=79) in 
which a ‘modified’ shortlist from the previous study (of 30 genes) was assessed by 
TLDA on the test set, a shortlist of 11 genes with best discrimination ability chosen, and 
logistic regression of overall expression scores for the various biological pathway gene 
clusters used to generate a model (the ‘molecular risk score’: MRS). Cutoffs were again 
defined using ROC analysis, and the resultant score applied to the validation set. 
Kaplan-Meir log-rank was significant with the outcome of FFTF. Except for stage IV 
disease, the MRS proved the only significant factor on a backward stepwise 
multivariate Cox proportional hazards model including each individual component of 
the IPSS, with FFTF as the dependent variable. Including both MRS and stage IV 
disease as criteria for patient stratification generated a cohort of patients of ‘extremely 
poor risk’ with median FFTF less than 6 months and 20% five year FFTF.  
 
While an impressive prognostic model, even accounting for the potential limitations of 
GSEA and the subsequent statistical and biological assumptions in drawing up a 
shortlist of clinically applicable candidate genes, the model has virtually no capacity to 
indicate underlying disease mechanisms despite the assertions of the authors in their 
conclusions in the paper. The inclusion of IRF4 (MUM1) in the final 11 gene model 
gives one example of limitations: this gene was not picked out through shortlisting, 
but included due on prior studies showing its significance364. Similarly, FOXP3 
expression on the level of gene expression did not emerge as important, despite 
growing IHC evidence. 
 
1.9.3.3 The Canadian Group 
The largest scale and most genome-representative GEP looking for prognostic factors 
was performed by a Canadian group116. GEP was carried out on 130 fresh frozen (not 
FFPE) specimens obtained at diagnosis using the GeneChip Human Genome U133 Plus 
2.0 array (over 34,000 genes represented) and validated with IHC on an independent 
cohort of 166 patients. No discrimination of tumour versus microenvironment derived 
genetic material was attempted. A shortlist of candidate genes was determined 
following analysis of GEP data using sparse multinomial logistic regression (SMLR) 
and relative importance determined by cross-validation using a leave-one-out 
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regression technique. Classification accuracy of adverse versus favourable prognosis 
was measured using ROC curve analysis. Unsupervised clustering, as with previous 
studies, failed to identify the poor prognosis group. A shortlist of 271 differentially 
expressed genes were found in a supervised analysis to discriminate two clusters, and 
Ingenuity pathway analysis (one commercially available bioinformatics methodology) 
showed overrepresentation of ‘cell-cell signalling’, ‘macrophage IL12-pathway 
signalling’ and ‘apoptosis’ in the adverse outcome group, with underrepresentation of 
CTLA4 and G-protein coupled signalling. Globaltest (another commercial package) 
identified ‘tumour-associated macrophage (TAM)’, ‘monocyte’, ‘angiogenesis’, 
‘adipocyte’ and ‘HRS gene signature’ over-expression, and ‘GCB cell’ signature under-
expression. Further selection based on prognostic discriminability between the groups 
identified 27 genes superior in predictive ability to patient age, a well-documented 
clinical prognostic classifier, over-expressed in the adverse outcome group.  
 
These genes were incorporated into a risk model. IHC confirmed one of these gene 
products: MMP11 (expressed in many elements of tumour and microenvironment 
including HRS, macrophages and endothelium) to be a prognostic marker on Kaplan 
Meier survival analysis (using manual, categorical scoring by histopathologists on 
duplicate cores in a TMA in the independent dataset, with cut-point determination 
method not clear from the paper). As a further validation and potential mechanistic 
correlate for this finding, staining for CD68 was carried out, which was also of 
prognostic significance (for DSS, PFS and outcome from secondary therapy). While 
providing further substantiation to the IHC data on the adverse impact of TAM in the 
microenvironment, the true mechanism of MMP11 over-expression conferring adverse 
outcome is not determined by this study: CD68 staining does not provide validation 
that macrophages’ contribution to survival is represented by MMP11 gene over-
expression. 
 
1.9.3.4 Conclusions: GEP in the CHL microenvironment 
Overall, these studies have demonstrated that adverse risk disease can be 
discriminated from favourable risk using GEP and a real clinical benefit may indeed 
result from this work as long as cost effective, simple, reproducible techniques can be 
developed and prospective, independent dataset validity confirmed.  
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However the various studies have identified different candidate genes with few, if any 
commonalities (summarised in Table 1.2) This is unsurprising given the volume of data 
generated by such studies, different genome coverage in the initial analyses, and the 
attendant attrition arising from stripping huge datasets down to small numbers of 
manageable factors. The variety of statistical methods used, post-hoc and intrinsically 
biased gene selection methods based on ‘interesting pathway’ analysis, and variable 
patient cohorts and cohort size all contribute to these discrepancies. What these 
studies have not demonstrated, apart from the heterogeneity of the disease and the 
importance of the microenvironment, is the mechanisms by which this heterogeneity 
exerts its biological effect.  
 
GEP has also failed to identify key mediators of prognosis that have been determined 
through IHC (such as FOXP3) highlighting another weakness. Finally, and perhaps 
most fundamentally, conclusions drawn from this technique which analyses the 
nucleic acid composition of a heterogeneous mixture of tissue and cell types without 
any prior purification steps, makes massive assumptions: that mRNA content 
correlates with functional protein content, and that simple snapshot expression levels 
relate to the magnitude of a biological response in vivo despite vast differences in 
relative potency and cascading consequences of such proteins. 
Chapter 1: Introduction & Objectives 
67 
 
 
 
Table 1.2: Genes up-regulated in unfavourable outcome CHL using methods applied 
by French (Devillard359 and Chetaille292), Spanish (Sanchez-Esperidion356, 363) and 
Canadian (Steidl116) groups. Genes showing differential expression (up or down-
regulation) in other prognostic subgroups are omitted. Key for the Spanish group 
(Sanchez-Esperidion356, 363) demonstrates lack of concordance even within the same 
group (although a different patient cohort): black: unique to the genelist 
demonstrated in the particular study shown, blue: common to both 2009 and 2010 
studies, red: ‘additional’ genes not found through GEP but included due to pre-
existing predominantly IHC data. 
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1.10 Aims and Objectives 
 
Using patient-derived material available from the tissue bank of Barts Cancer Institute, 
applying immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) 
samples, flow cytometry (FACS) on frozen single cell suspensions (SCS) and in vitro 
cell culture models from fresh and frozen tissue I aimed to determine the key 
functional molecular markers represented on the CD4+ T cells in the CHL 
microenvironment. In determining the molecular markers discriminating CHL-derived 
CD4+ T cells from those present in non-malignant reactive and quiescent nodal tissue, 
along with those of tissue derived from other B cell malignancies, it may be possible to 
develop strategies to modify the interaction between HRS and CD4+ T cells. This 
strategy will be investigated using an in vitro culture system derived from primary 
diagnostic tissue. Further, this approach will be used to investigate the impact of such 
markers on clinical outcome. The outline of this approach is as follows: 
 
1. Construct a tissue microarray (TMA) of patients with known clinical outcome 
and adequate follow up.  
 
2. Determine the heterogeneity of immunophenotype in CHL-infiltrating CD4+ T 
cells based on normal and malignant B cell interactions and identify prognostic 
markers with potential for clinical translation by application of IHC and automated 
image analysis to a large extent of tissue, validation of markers correlated with patient 
outcomes established in the literature, and identification of new markers.  
 
3. Develop in vitro culture strategies to determine the functional properties of 
malignancy-derived tissue, manipulating with selected growth factors known to 
influence T cell growth.  
 
4. Analyse markers of T cell function, phenotype and proposed molecular 
mediators of interactions with CHL using multi-parameter flow cytometry.
  
 
CHAPTER TWO: 
 
Materials and Methods 
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2. Materials and Methods 
2.1 Patient Samples  
2.1.1: Formalin-Fixed Paraffin-Embedded Tissue 
Immunohistochemical analysis was carried out on formalin-fixed paraffin-embedded 
tissue which had been stored in paraffin blocks. Available blocks were determined by 
correlation of databases of the pathology and haemato-oncology departments in order to 
identify tissue stored for which there was data on clinical follow up (see 3.3.1). All 
samples were taken with full informed consent and ethical permission for use granted by 
the local regional ethics board and in accordance with the Declaration of Helsinki. 
Suitable blocks were retrieved, with sections made for staining with H&E and 
subsequent marking for tissue microarray. 
2.1.2: Frozen Single Cell Suspensions (SCSs) 
Ethics approval was obtained from the local regional ethics committee. Patient-derived 
samples were obtained with informed consent documented on a standard form and 
stored under conditions compliant with the Human Tissue Act 2008. SCSs derived from 
CHL, NHL, tonsil and reactive enlarged nodes were retrieved from archived samples in 
cell storage and subsequently as they became available from consented patients. Table 
5.5 (in Chapter 5) shows the samples used in the subsequent immunophenotyping and 
cell culture experiments. 
 
2.1.2.1 Preparation of initial single cell suspensions for storage on liquid nitrogen 
Single cell suspensions were prepared from surplus material available after diagnostic 
biopsy or from tonsils removed for therapeutic purposes from which no diagnostic 
specimen was required. Surplus material was placed into a sterile specimen pot 
containing RPMI and transported to the cell storage suite. The specimens were disrupted 
using forceps and scalpel under sterile conditions on an ice-block and flushed using 
further RPMI injected via a needle and syringe. Resultant suspensions were filtered 
through a 70mcm mesh under gravity to exclude undisrupted tissue and cell clumps and 
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the resulting suspensions washed twice in RPMI by centrifugation at 1500rpm for 6 
minutes with the supernatant disposed of. The final suspension was assessed for cell 
concentration and viability using an automated cell counter by trypan blue exclusion 
(ViCell: Beckman Coulter) and resuspended at 5 x 106 – 5 x 107/ml in 1 - 1.5ml freeze 
storage mix (10% DMSO in FCS) in Cryovials (NUNC). Cryovials were slow-frozen in 
adapted containers (CoolCell: BioCision) with temperature reduction of 1˚C per minute 
in -80˚C freezers for two hours before transfer to liquid nitrogen and long-term storage.  
 
2.1.2.2 Thawing and initial preparation of frozen SCS for immunophenotyping and cell 
culture 
All SCS-derived culture systems and flow cytometry were performed on previously frozen 
and nitrogen stored samples in order to standardise all conditions since establishment of 
cultures and flow cytometric analysis of fresh SCSs would often not be feasible. SCSs 
were thawed in a water-bath at 37˚C for 60 seconds, resuspended and washed twice in 
PBS by centrifugation at 1500rpm for 6 minutes with the supernatant disposed of and 
finally filtered through a 70mcm mesh (BD Falcon) under gravity to exclude cell clumps. 
Viability and total cell count of the resulting suspension was estimated using manual 
haemocytometry.  
2.2 Immunohistochemistry 
Samples used are as described in 2.1.1. 
2.2.1 Tissue Microarray Construction 
Tissue microarray is a technology developed to enable immunohistochemical assessment 
of multiple markers across large patient cohorts365. The CHL microenvironment is widely 
heterogeneous, including areas of fibrosis and necrosis interspersed with dense 
infiltrates of malignant cells and immune infiltrate. As such careful selection of suitable 
representative areas containing sufficient cells to analyse microenvironment 
heterogeneity was necessary. Haemotoxylin and Eosin-stained (H&E) sections were 
examined with an expert histopathologist (MC), and regions marked for array. Cores of 
tissue of 1mm2 diameter were then using a sharpened steel tube from these selected 
regions of biopsy material from each ‘donor’ block (each derived from one patient) and 
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inserted into a defined array of ‘recipient’ paraffin blocks (Figure 2.1) interspersed with 
control samples (usually tonsil) as internal staining control and orientation controls 
(usually myocardium or gut) as a means of cross-checking the generated data. Several 
recipient blocks were necessary to accommodate each available patient in triplicate. The 
block was then sectioned and sections transferred onto microscope slides, enabling 
many cores to be represented on a single slide. Each slide was then available to be 
assessed for expression of the biomarker of interest (Figure 2.2).  
 
 
 
Figure 2.1: Tissue microarray construction365. Small tissue core biopsies are punched 
from selected regions of donor blocks using a thin‐wall stainless steel tube sharpened 
like a cork‐borer. HE‐stained sections overlayed on the surface of the donor blocks guide 
sampling from morphologically representative sites on the tumour (a). A solid stainless 
steel stylet transfers tissue cores into defined array coordinates in the recipient block (b). 
An adhesive-coated tape sectioning system assists in cutting the tissue microarray block 
(c).   
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Figure 2.2: Example microarray slide showing slide (a), core at x5 (top) and x20 
magnification stained for FOXP3 with high (c) and low (d) infiltration represented. 
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2.2.2 Principles of immunohistochemistry 
Antigen specific staining was carried out using commercial antibodies and optimised for 
the tissue under investigation, as described in experimental Chapters 3 & 4. All primary 
antibodies used are described in the experimental chapters, and were stained using the 
protocol detailed here. Modifications to this standard protocol, which was successful for 
the majority of stains, are detailed in the relevant chapter. 
 
Immunohistochemistry relies on the specific binding of antibody to the target antigen 
for detection. This signal is amplified locally by subsequent binding of a multimeric 
compound capable of binding many molecules of a protein with enzymatic activity. 
Finally, the presence of the antibody – enzyme complex is determined by addition of a 
substance that both binds to, and is chemically altered by the enzyme such that a 
detectable colour change is observed. Unless stated in the specific methods of an 
experimental chapter, the chromogenic substrate was diaminobenzidine (DAB), which 
produces a dark brown/black colour when acted upon by peroxidase enzyme. The 
binding of the multimer–enzyme complex is achieved by addition of a secondary 
antibody with species and isotype specificity to the antigen-specific antibody (e.g. goat 
anti-mouse IgG2, if the primary is IgG2 mouse-anti-antigen). Traditionally, the avidin-
biotin complex (ABC) system has been used. Avidin, a glycoprotein egg-protein extract 
has particular avidity for the vitamin B complex member biotin, and can itself be 
conjugated with peroxidase. The secondary antibody is biotinylated (usually done 
commercially) and when avidin added, it binds many conjugated peroxidase molecules 
to each biotinylated antibody, thus providing a local amplification of the antigen signal. 
The non-specific binding properties of avidin, and the presence of endogeneous biotin in 
the tissue can lead to non-specific background staining, and as such the ABC method is 
being replaced by the dextran polymer method (Biogenix Supersensitive Polymer HRP), 
which was used for the staining in these experiments. In this case the multimeric 
compound is not avidin-biotin but another polymer (undisclosed by manufacturer, 
known as SuperEnhancerTM and PolymerHRPTM: BioGenix) conjugated with peroxidase 
and a secondary species-specific antibody (Figure 2.3). 
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Figure 2.3: Primary Antibody (antigen-specific labelling) - Dextran polymer (signal 
amplification) – Horseradish peroxidase (enzymatic action) – DAB (staining readout) 
method of IHC (A) with more traditional Avidin-Biotin complex system for comparison 
(B) illustrating the non-specific signal that can result from avidin’s promiscuous binding, 
and endogenous tissue biotin expression. HRP: Horse radish peroxidase; DAB: 
diaminobenzidine. 
  
2.2.3 Batch Immunohistochemistry using the DAKO Autostainer System 
Staining was optimised for temperature, duration of reagent exposure and antibody 
concentration on a slide by slide basis, and subsequently larger numbers of slides were 
stained using an automatic staining system consisting of a slide rack, robot arm with 
nozzles to dispense reagents, pump system and reservoirs of bulk reagents and a 
dispensing rack for the various primary antibodies and secondary amplification / 
colourimetric reagents, controlled by an incorporated software package (Dako 
Autostainer Plus). As a counterstain, the potent arginine-rich-histone-binding 
blue/purple dye haemotoxylin is used (fairly nucleus-specific). Industrial methylated 
spirits (IMS) at three concentrations (95%, 70% and 50%) provide a dehydrating and part 
hydrophobic part hydrophilic intermediate between the potent hydrophobic solvent 
xylene and subsequent water soluble staining steps. Xylene removes paraffin and 
improves clarity of image by dissolving hydrophobic residues. DPX (p-xylene-bis-
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pyridinium promide) is a viscous mix of a polystyrene, plasticiser and xylene, which 
provides a durable mountant with refractive properties suitable for high-quality 
microscopy and photomicroscopy. 
2.2.4 Primary antibodies for immunohistochemistry 
Antigen specific staining was carried out using commercial antibodies and optimised for 
the tissue under investigation, as described in experimental Chapters 3 & 4. All primary 
antibodies used are described in the experimental chapters, and were stained using the 
protocol detailed here. Modifications to this standard protocol, which was successful for 
the majority of stains, are detailed in the relevant chapter. 
2.2.5 Protocol for Immunohistochemistry Staining using Autostainer 
2.2.5.1 Paraffin Removal and dehydration 
1. Place TMA slides in oven overnight at 60oC in plastic racks 
2. Prepare pots containing all reagents for dewaxing and dehydration as shown in 
Table 2.1 
3. Remove paraffin using xylene in two stages: suspend slides in xylene pot for 5 
minutes, shake off excess and transfer to second xylene pot 
4. Transfer to industrial methylated spirits for 2 minutes 
5. Transfer to hydrogen peroxide (2ml reagent grade) in 100ml IMS for 2 minutes. 
This further dehydrates tissue and increases specificity of the subsequent 
reaction which depends upon a colour change in a chromogenic chemical 
diaminobenzidine (DAB) following the action of antibody-conjugated horse 
radish peroxidase. Hence this step reduces non-specific staining arising from the 
action of endogeneous peroxidises on the chromogen. Transfer to a second 
IMS/H2O2 pot for 2 minutes. 
6. Transfer to a fresh IMS pot for 2 minutes (final dehydration step) 
 
2.2.5.2 Pressure Cooker Heat Antigen Retrieval366 
7. Heat 3000ml of a working solution of antigen unmasking solution (Vector Labs: 
See Table 2.1) in a pressure cooker on low heat setting (100-110˚C). 
8. Once solution is boiling immerse dewaxed, dehydrated slides in their plastic 
racks fully in the boiling solution. 
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9. Increase the heat setting to high setting (120-130˚C) and leave for 10-15 minutes. 
10. Remove from heat and cool pressure cooker under cold tap for 5-10 minutes. 
11. Retrieve slides and rinse in wash buffer. 
12. Ensure slides remain wet with wash buffer at all times during subsequent 
staining process. 
 
2.2.5.3 Antigen-specific staining using Dako Autostainer Plus 
13. Mark slides using hydrophobic marker pen around the edge of the array field: 
this is to ensure uniformity of solution deposited on slide and hence of staining. 
14. Program Autostainer control software specifying number of slides to be stained, 
reagents and incubation times, specifically the rinse steps, non-specific protein 
block steps (using casein-based commercial protein compound), primary 
antibodies to be used at optimal dilutions (in BSA/azide), polymer-conjugated 
secondary antibody (with species and antibody isotype specificity denoted by the 
primary antibody being used), and chromogenic substrate (DAB). The software 
package generates a reagent diagram illustrating the position in which all 
reagents are located within the automated stainer, and a slide map illustrating 
the position of all slides to be stained in the batch. 
15. Top up wash buffer reservoirs, empty waste reservoirs, and fill appropriate bottles 
with reagents as dictated by the reagent diagram. 
16. Start the Autostainer. The process takes 2-3 hours including incubation and wash 
steps. 
17. Replace all slides in plastic racks ready for counterstaining and and mounting. 
 
2.2.5.4 Counterstaining, rehydration and mounting slides 
18. Rinse in tap water for 5 minutes. 
19. Suspend in haemotoxylin solution for 5 minutes 
20. Rinse for 2 minutes in tap water 
21. Plunge into acid alcohol solution x5 quick plunges 
22. Immediately into tap water wash for 2 minutes 
23. Rehydrate tissue using three 2 minute suspensions in IMS. 
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24. Remove residue and clarify tissue by suspending in two xylene baths, then 
suspend in final bath prior to mounting. 
25. Using DPX mountant apply cover slip removing trapped air bubbles. Air dry and 
label slide appropriately. 
 
Reagent Working 
Concentration 
Supplier 
Antigen unmasking solution 10ml/1000ml ddH2O Vector Laboratories 
Reagent Grade H2O2 Stock VWR 
Wash Buffer 1:10 ddH2O DAKO 
Xylene Stock Sigma 
Industrial Methylated Spirits Stock VWR 
Haematoxylin Gill 2 100ml filtered Merck 
Scotts Alkaline Tap Water Substitute Stock VWR 
DPX Mountant Stock Sigma 
Stable DAB Buffer Ready to Use Biogenix SuperSensitive 
Polymer-HRP IHC 
Detection System 
Liquid DAB 1 drop (38 mcl) in 1ml 
DAB Buffer 
SS Label Polymer HRP Ready to Use 
SuperEnhancer Ready to Use 
Table 2.1: Reagents used for the Polymer/HRP method of IHC. 
 
2.2.6 Slide analysis, immunohistochemistry scoring and cell counting 
For IHC analysis, arrays can be scored either manually by histopathologists, or using 
automated image analysis software. The following details the general methodology used 
to enumerate infiltration with cells expressing markers investigated in experimental 
Chapters 3&4. Variations in methodology are presented where appropriate within these 
chapters. 
 
2.2.6.1 Automated Method for Cell Counting using the Ariol system 
The specimens were scanned using an Olympus BX 61 microscope with an automated 
platform (Prior). Absolute numbers of positive cells were counted across all intact cores 
by automated image analysis system (Ariol).  
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The image analysis system was trained to discriminate stained and unstained cells by 
colour and shape. Selected representative regions of tissue were used to determine 
specific hue, saturation and intensity, which were deemed to be positive (usually the 
brown/black resulting from DAB colour change) requiring sufficient contrast to 
background and counterstaining. This was achieved by the operator selecting individual 
pixels from positive events, which were then displayed by the Ariol software as a pixel 
mask. Once the resulting pixel mask obscured only positive events, with minimal pixel 
masking of negative events and non-specific staining, the algorithm generated by the 
software was saved. Finally, the algorithm was refined by limiting the size and shape of 
the areas deemed to be positive by the colour algorithm, which was particularly useful 
for staining of discrete and homogeneous sized events such as lymphoid nuclei.  
 
Image analysis, while in itself automated, requires this extensive training step to define 
the algorithm, which introduces the possibility of inter-observer error. It arises from a 
need to compromise between sensitivity and specificity, with substantial signal/noise 
ratio due to variability of background staining. Automated image analysis has the major 
advantage of rapid assessment of very large numbers of events, consistency in 
application of predefined criteria defining events to be counted, and absence of fatigue, 
but is no better at discriminating positive or negative events than a human observer due 
to the need for a human-defined training step. It remains as influenced by technical 
variations in the quality and specificity of the stain applied. For these reasons results 
generated from nuclear staining of discrete cells such as FOXP3 or T-BET applied to 
lymphocytes are more reproducible than those generated from cytoplasmic or 
membrane stains applied to larger, more heterogeneous, interdigitating cells, such as 
CD68 or CD163 applied to macrophages. 
 
2.2.6.2 Manual Method for Cell Counting using the Hammamatsu system 
In order to provide a validation of the automated counting system and the potential for 
translation to clinical application, a manual validation step needed to be carried out. 
This was done using digitised images acquired using the Hammamatsu Virtual Slide 
Scanner NanoZoomer 2.0 (Hammamatsu, Japan), which could subsequently be viewed 
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using NDP.scan software. For the manual validation steps two observers accessed the 
digitised slidemaps using the NDP.scan software. A random selection of 40 cores were 
selected from all available cores using random number generating software 
(http://www.random.org/) and the two observers selected x20 objective-equivalent fields 
viewed using the NDP.scan software and exported the files as compressed image files 
(Joint Photographic Expert Group: JPEG) into Photoshop (Adobe) which enabled a grid 
to be superimposed on the image (Figure 2.4). Superimposition of this guidance grid and 
visualisation on a standard computer screen facilitated counting of larger numbers of 
cells more easily than direct visualisation through a microscope eyepiece, without loss of 
image resolution Total numbers of cells in the x20 exported image was then corrected to 
equivalent count across an entire 1mm2 field by a multiplication factor determined by the 
area of the JPEG image exported, which could be calculated by the NDP.scan software. 
 
 
Figure 2.4: Grid superimposed in Adobe Photoshop from selected x20 region of tissue 
exported as a JPEG from NDP.scan software, acquired as a digital image from the 
Hammamatsu NanoZoomer 2.0. The example shown is CHL stained for FOXP3 
representing an intermediate infiltrate of cells. 
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2.2.6.3 Method of Cut-point Determination and Survival Analysis 
Optimal or multiple cut-point analysis is a commonly encountered pitfall of statistical 
analysis of novel biomarkers where normal ranges are unknown338. The availability of 
software that will determine by multiple comparisons the point at which statistically 
significant differences between groups is found (e.g. Xtile339) makes this statistical error 
more accessible. The consequence has been the failure of many apparently significant 
biomarkers to be confirmed or validated by other investigators, and more important to 
find their way into clinical practice. Predetermination of cut-points or validation in 
independent datasets is the only robust method of confirming such findings: this is 
rarely performed in the literature. Xtile (Yale University School of Medicine: 
(http://medicine.yale.edu/labs/rimm/www/ xtilesoftware.html) is a software package 
providing a compromise method enabling novel marker cutpoints to be developed with 
statistical validity, by generating an optimal cut-point on only a subset of the cohort 
under investigation (the ‘test set’) and applying this as a ‘predetermined’ value to the 
remainder (the ‘validation set’). The disadvantage of this method is that the resultant 
cohorts are smaller, and hence the statistical power to demonstrate differences impaired. 
However, should a difference be detected, the robustness of that finding, being 
generated from a smaller cohort (as long as that cohort was representative of the whole 
and unbiased in its selection) may be greater. However, the chance of erroneously 
accepting the null hypothesis is by definition increased. 
 
The statistical significance of differences between groups segregated by these cut-points, 
according to outcome is assessed using the Kaplan Meier method367 where censorship 
occurred at the date of last known contact with the patient at which the event under 
consideration had not occurred, or date at which the event occurred, with time to that 
event calculated from a specified point, usually the date of diagnosis or commencement 
of first therapy. The logrank test368 was used to compare survival distributions. Xtile 
ranks the subjects in order of expression of the marker under investigation and divides 
into any number of groups using cut-points at every value generated for that marker. 
Using the Kaplan Meier method to generate variances for the estimated survival function 
and comparing functions using the logrank method, the probability of groups differing 
in terms of outcomes are generated for each of those cut-points. For one or two cut-
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points, the most simple and hence clinically translatable system, this is displayed in the 
form of a heatmap whereby a green pixel represents a favourable outcome for higher 
expression of that marker and a red pixel unfavourable, with intensity of colour 
reflecting the level of significance, and black representing a p value >0.05. For division 
into two groups, each potential individual cut-point is represented as a coloured pixel on 
a line. For division into three groups, each cut-point combination is represented as a 
pixel on a two dimensional grid (Figure 2.5) The corresponding Kaplan Meier survival 
curves are generated concurrently. Should the data demonstrate consistency in colour 
(green vs red) the inference of a biologically meaningful relationship may be made, 
assuming that there was not a bimodal or more complex association between survival 
and the variable under investigation in which, for example, extremes of values were both 
disadvantageous while intermediate values advantageous.  
2.3 Multicolour Flow Cytometry 
2.3.1 Principles 
Flow cytometry enables the simultaneous detection of different molecules present upon 
or within particles, in particular cells, using an integrated piece of equipment consisting 
of fluidic, optic, detector, computational and display components. The process depends 
on the particles being delivered as individually detected events in a uniform stream 
(fluidics), and requires the molecules to be tagged by different fluorescent markers 
(fluorochromes), whose emission spectra may be discriminated sufficiently from one 
another, by manipulation of incident laser wavelength and modulation of the emitted 
electromagnetic pulse through filters (optics), amplification of the wavelength-specific 
(‘colour’-specific) signal resulting from incidence of that filtered pulse on detection 
photomultiplier tubes (detector), and application of a mathematical transformation of 
the absolute value of emitted pulse intensity (compensation: performed by the 
integrated computational and display components usually within a single software 
package). Advancement of flow cytometric technology, in particular numbers of lasers, 
novel fluorochromes, computational power and software design means that over 20 
parameters can now be measured simultaneously. 
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Figure 2.5: Cut-point uncorrected probability distribution figures. Each pixel on the 
matrix and horizontal bar represents every possible division of the data by cut-point. The 
colour of the pixel represents the effect of that marker on the group expressing it at the 
highest value when the cut-point is applied as indicated, where red indicates an adverse 
effect and green advantageous. The intensity of the colour indicates chi square 
probability level of group differences, with black indicating p>0.05 and bright green/red 
p<0.0005. A: FOXP3: A beneficial prognostic effect at high levels, with most cut-points 
discriminating groups and indicating a probable dose-effect: the higher the expression, 
the better the outcome. B: CD68: Adverse prognostic effect at high levels, but fewer cut-
points discriminate groups and hence dose relationship less likely. C: CD8: Minority of 
cut-points discriminate groups with p<0.05. All plots are generated from the entire 
dataset, hence this visualisation represents optimal cut-point analysis and requires 
validation in an independent dataset. For A and B prognostic power was sustained in the 
validation set. This was not the case for CD8, although the consistency of the 
relationship (only green pixels, hence favourable prognosis with increased expression) 
suggests that there this marker should be explored in a larger, more highly powered 
dataset to detect differences. See Chapter 3 for further details. 
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Flow cytometry was carried out using a four laser LSR Fortessa (Becton Dickinson) with 
integrated fluidics and software package (BD FACSDivaTM). This uses a pressure driven 
fluidics system to force sample cells through a flow cell cuvette as individual events 
passing through the focal point of the integrated laser beam. Fixed alignment of this 
system improves reproducibility, which is confirmed on a daily basis by a specialist 
technician (GR) according to the manufacturer’s instructions.  
 
The optical system consists of four lasers (Red emitting at 640nm wavelength, 
Yellow/Green emitting at 561nm, Blue emitting at 488nm, and Violet emitting at 405nm) 
with beam shaping lenses and pinholes focusing the combined laser light as a single 
beam into the cuvette. Emitted light is delivered through fibreoptics to detector arrays 
arranged to maximise the signal detection, using reflecting mirrors. Photomultiplier 
tubes (PMT) lie beyond bandpass filters (for Red lasers: 670+/-14nm, 730+/-45nm, 780+/-
60nm, for Yellow/Green 585+/-15nm, 675+/-20nm and 780+/-60nm, for Blue 695+/-40nm 
and for violet 525+/-50nm and 450+/-50nm) enabling improved spectral resolution. 
These components were calibrated on a weekly basis using the FACS Comp software 
(BD) and Calibrite Beads (BD).  
 
PMT voltages are adjusted for the purposes of each experiment to ensure maximum 
signal : noise ratio and minimise interference (spectral overlap) in competing channels 
(PMT detectors) and recorded as a matrix for each individual event, which can then be 
displayed graphically (see below). Apart from the wavelength-specific, bandpass-filtered 
fluorescence intensity arising from each fluorochrome as detected at the PMTs, data on 
light forward scatter (related to particle size) and side scatter (relating to internal 
complexity of the particle, such as granularity) are additionally collected. 
 
Data acquired is interrogated using a number of software packages capable of 
transforming (compensating) the PMT-derived values and displaying them either as one 
dimensional histograms showing frequency distributions of detected fluorescence 
intensity, or as two and three dimensional scatter plots, displaying multiple parameter 
intensities with each particle/event represented by the appropriately positioned dot. 
Multiple superimposed dots may be visualised by false colour or contour plots (e.g. 
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Figure 2.11) Definition of an event with which the fluorescing molecule in question is 
associated depends upon signal/noise ratio (including non-specific fluorescence and 
background signal as well as interference from other fluorochromes present) and 
requires careful determination of thresholds, known as gating, described below. 
2.3.2 Fluorochromes and Staining Protocols 
Tagging of markers is usually achieved through conjugation of specific monoclonal 
antibodies to fluorochromes. For the experiments described here all such molecules were 
purchased from commercial laboratories which had themselves performed extensive 
quality control to ensure specificity and optimal dilutions. However, for each 
experiment, optimisation steps were carried out to determine the most appropriate 
concentrations of reagent for the samples under investigation. Fluorochrome 
combinations were also optimised for these experiments, as detailed in the experimental 
chapters, to maximise numbers of simultaneously assessable parameters while 
minimising spectral overlap or at least allowing for compensation of any overlap that 
occurred.  
 
Markers capable of detection by specific monoclonal antibodies may be present in any 
cellular compartment (membrane, intracytoplasmic, intranuclear, etc.) with varying 
degrees of resistance of access to them. Flow cytometry is usually carried out on fresh or 
thawed, vital tissue in which lipid barriers are intact and hence the 
compartmentalisation of the cell remains, in contrast to work using fixed tissue. Most 
staining protocols documented here are modifications of those provided with 
commercially available reagents. Most staining procedures were not carried out in 
individual 5ml sample tubes, but in a 96 well round bottomed plate (Figure 2.6), in order 
to increase efficiency of protocols and reduce sample preparation time. The flow 
cytometer requires a 5ml tube from which samples are aspirated, and as such each well’s 
contents were aspirated and transferred into 1ml polypropylene adaptor tubes which 
could be inserted consecutively into a standard tube for use on the flow cytometer 
(Figure 2.7). In the following staining protocols, in order to minimise sample to sample 
variations in staining when large numbers of conditions are being applied, cocktails of 
cytokines were pre-made and applied in batches using a multichannel pipette. 
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 Figure 2.6: Illustration of 96 well plate staining technique 
 
 
 
 
 
Figure 2.7: Final stage of 96 well plate staining technique: well contents harvested into 
receiver tubes arranged in pipette tip box; each tube analysed within standard 5ml FACS 
tube. 
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2.3.3 Surface Marker Staining 
Molecules present at the cell surface may be stained without any cellular disruption, 
following simple washing steps. This has the advantage of enabling cell viability to be 
maintained, as long as the preparation process is undertaken with care and in 
appropriate staining buffer. Subsequent functional studies may be carried out if the cells 
are analysed in strict sterile conditions and collected as they emerge in the waste stream 
from the flow cytometer.  
2.3.4 Intracellular Marker Staining 
Molecules present within the cytoplasm may be stained following a chemical disruption 
step usually with a strong alcohol or aldehyde, which covalently bonds proteins, in 
particular cytoskeletal elements, physically immobilising them. Usually denaturation is 
minimal, however in some cases antibody-specific epitope is lost leading to alteration in 
binding of fluorochrome conjugates, and hence optimisation of any protocols is 
necessary. In some cases there is little alteration in binding properties, and surface and 
intracellular markers may be stained simultaneously. In other cases, an initial surface 
staining step is carried out prior to intracellular staining. In the experiments requiring 
fixation described within (cytokine staining), only well-characterised optimised surface 
antigens (CD3, CD4 and CD69) were stained for and their properties were such that only 
a single staining step was necessary, which is described in the protocol below. Some 
fixation reagents (e.g. methanol, 95% ethanol) are also capable of permeabilising the 
cells. Others (e.g. paraformaldehyde, formalin) require addition of a cell membrane 
permeabilising agent. This is usually a hydrophobic ‘soap’ such as triton or saponin. A 
standard commercially available fixation and permeabilisation kit was used (Ebioscience 
one-step fix/perm kit), which was found to be optimal for the cytokine staining 
experiments described in Chapter 6, which is described in the subsequent protocol. 
2.3.5 Cytokine and secreted protein staining 
Some molecules, particularly those identifying functional pathways of cellular 
metabolism may only be released from cellular compartments, or fully assembled, 
following a stimulation step, and may subsequently be lost to the supernatant following 
secretion. As such, specific stimulation and protein secretion-blocking steps are required 
in order to artificially concentrate those molecules within the cytoplasm prior to 
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subsequent staining. While any such stimulation/secretion blocking step in itself 
represents a highly artificial system, careful control and optimisation of protocol enables 
at least between sample comparisons, even if conclusions regarding the in vivo 
equivalence of these markers should be drawn with caution. Various stimulants 
including phorbol-mysterate acetate (PMA) and inomycin, phytohaemagglutinin (PHA), 
concanavalin (CCA), staphylococcal enterotoxin B (SEB) and bead-bound stimulatory 
anti-CD3 and anti-CD28 antibodies were used with various incubation times. The 
cytokines under investigation had differing ‘optimal’ stimulation times. Following 
optimisation, PMA/Inomycin with a standardised time of 8 hours stimulation was 
decided upon. This enabled detection of the majority of cytokines with retained cellular 
viability. This incubation time was kept constant between experiments and within each 
batch between samples thus enabling comparisons to be made. Limitations of this 
relatively prolonged incubation (in particular for detecting cytokines associated with Th1 
reactions) mean that comparisons with the literature are made more difficult. However 
the experiment compared various experimental and control sample groups exposed to 
the same conditions and as such it was deemed valid. 
2.3.6 Viability 
Dying cells and debris have particularly high autofluorescent and non-specific binding 
properties and contribute to substantial noise in flow cytometry. As such, exclusion of 
these events using specific fluorescent markers improves the resolution of an assay. Most 
viability dyes depend upon the ability of live cells with intact cell membranes to actively 
exclude such a dye from their cytoplasm. These experiments used DAPI (4’6-diamidino-
2-phenylindole), which is relatively excluded from live cells with intact cell membranes, 
compared to dying and dead cells with compromised membranes. Hence dead cells may 
be excluded by their fluorecensce due to presence of DAPI. DAPI remains stably bound 
within the cell to Adenine/Thiamine-rich regions of DNA, absorbing in the UV and 
violet spectrum and emitting in the blue/violet spectrum. DAPI is also used for DNA 
quantification experiments, however staining and analysis protocols are different. Once 
plasma membrane integrity has been compromised by fixation or permeabilisation, the 
dye is no longer useful as a discriminant since all cells will take it up. New commercially 
available dyes are available which are actively excluded from live cells during the initial 
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staining step, and taken up by dead cells, but which remain excluded following cell 
permeabilisation steps, which is not the case with DAPI even if applied prior to a fixation 
/ permeabilisation step. These dyes also have the advantage of being available with 
fluorescence properties across the detectable spectrum. The dye chosen for the cytokine 
staining experiments was compatible with the fluorochrome combinations already in use 
(Ebioscience Viability Dye). 
2.3.7 Non-specific fluorochrome-conjugate binding-blocking step 
Non-specific binding of fluorochrome conjugates in particular to immunoglobulin Fc 
receptors, can interfere with signal/noise ratio within an experiment. Non-specific mixed 
protein suspensions (e.g. milk powder, serum, etc) can occupy immunoglobulin Fc 
receptors within an experimental system in preference to the subsequently added 
fluorochrome. However, the additional incubation and wash step required for this was 
found to lead to excess cell loss with the small numbers of cells used in these 
experiments, and did not contribute to determining thresholds and gating strategy 
described in Chapter 6, and as such no blocking step was performed. 
2.3.8 Protocol for Staining; (Chapters 6&7; 96 Well Plate Method) 
Batch to batch variation in flow cytometry may be considerable due to differences in cell 
preparation, staining, flow cytometer calibration and other factors and as such 
comparisons should be made with internal standards on each run, and batched with as 
many concurrently run samples as is feasible. For clarity and reproducibility, the 
protocol combining surface and intracellular cytokine staining is detailed below. The 
entire protocol takes approximately 12 hours assuming PMT voltages pre-programmed 
on BDFortessa: 3-4 hours harvest, cytokine stimulation and surface staining, 4-5 hours 
surface stain data acquisition (assuming 120 tubes, 20 samples with 6 surface staining 
cocktails plus staining controls), 2 hours harvest, fix, permeabilise and stain stimulation 
step, 2 hours intracellular stain data acquisition (assuming 40+ tubes: 20 samples with 2 
intracellular staining cocktails plus unstimulated and staining controls). Reagents used 
are shown in Table 2.2. For justification of reagents and controls used see 2.2.9. For 
details of fluorochromes used, and PMT voltages on BDFortessa see relevant 
experimental chapters (6 and 7). For compensation strategy see 2.2.10. 
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Reagent Supplied 
Conc. 
Stock Conc. Experimental 
Conc. 
Experimental 
Dilution 
Supplier 
DAPI 10mg dried 5mg/ml (dH2O) 2.5mcg/ml 1:2000 Invitrogen 
Fix/Perm 
Concentrate 
(formaldehyde 
base) 
4X AS 
MANUFACTURER 
AS 
MANUFACTURER 
1:4 ddH2O Ebioscience 
Perm Buffer 
(Saponin base) 
10X - - 1:10 ddH2O Ebioscience 
Fixable 
Viability Dye 
eFluor
TM 
780 
USE AS 
SUPPLIED 
USE AS SUPPLIED DILUTED AS 
PROTOCOL 
1mcl per 
condition in 
1ml 
Ebioscience 
Ionomycin 1mg dried 1mg/ml DMSO 500ng/ml 1:2000 Sigma-
Aldrich 
Monensin 0.7ml - - 1:1000 BD 
Phorbol- 12-
mysterate 
acetate (PMA) 
1mg dried 50mcg/ml DMSO  50ng/ml 1:1000 Sigma-
Aldrich 
Table 2.2 Reagents Used for Staining Protocol 
 
2.3.8.1 Experimental Set up (to be done on day prior to main experiment) 
1. Prepare staining cocktails (cocktails 1-8 as described in chapter 6) with adequate 
stain for the number of experimental and control conditions to be stained (+10% 
for pipetting errors) in advance, using optimised dilutions of fluorochrome 
conjugates. Ensure each cocktail is made up to equal total volumes with PBS to 
enable eventual dispensing of equal volumes across all samples using a 
multichannel pipette. For example, if the largest volume cocktail for each of 20 
samples totals 60mcl, there will be a total of 60 x 20mcl = 1200mcl. All cocktails 
with a lesser volume should be ‘topped up’ to 1200mcl. The cocktails are stored at 
4-8˚C in opaque containers until use (<72 hours storage once made up). The 
cocktail is then dispensed for convenience into a 96 well ‘dispensing’ plate to 
enable the multichannel staining to proceed (Figure 2.6) 
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2. Identify the samples for analysis in the experiment and design a surface staining 
plate map where rows represent each of the six surface staining cocktails and 
columns each sample. Up to 20 samples in two 96 well plates may be run in one 
batch using this method and a single operator. Allocation of samples to each 
column should be randomised to prevent systematic errors of sample 
preparation, data acquisition and interpretation arising from unequal cell loss, 
staining cocktail dispensing or flow cytometry errors. Make a separate plate map 
for the 2 cytokine staining steps including ‘stimulated’ and ‘unstimulated’ 
controls, with randomised order of samples as for the surface staining.  
3. Prepare ‘stimulation mix’ from thawed aliquots before each experiments: 
5ng/ml phorbol-mysterate-acetate (PMA) (1:1000 stock), inomycin (1:2000 stock) 
and Monensin (1:1000 stock) (Table 2.2). 
 
2.3.8.2 Harvest and Plate Samples for analysis: 
4. Harvest cells and count using manual hemocytometry. Harvest may be from 
fresh growing cells within a 96 well plate, harvested from the plate using a 
multichannel pipette and into a petri dish and resuspended in tubes, or from 
frozen samples, thawed and washed as described, and filtered through a 70mcm 
mesh filter if necessary. Fresh growing cells do not require the mesh filtration 
which removes dead cell clumps resulting from the freeze/thaw process. 
5. Resuspend the cells at >1x106/ml LCM during the final wash step which will 
enable an eight-cocktail staining experiment as described in chapter 6. Ten 
aliquots of each condition will be required: 6 surface stain, and 2 intracellular 
cytokine staining, for each of which a ‘stimulated’ and ‘unstimulated’ control is 
required. The unstimulated condition may be omitted in some cases to preserve 
cells / reagents but at least one unstimulated cytokine control is required for 
each experiment. 50-100,000 cells per aliquot are required optimally. This step 
should provide a cell suspension of around 1ml for each of the experimental and 
control conditions, containing at least 100,000 cells for each condition. Analysis is 
possible with fewer cells if a total of 1,000,000 cells are not available. 
Chapter 2: Materials and Methods 
Page 92 
6. Divide the 1ml of each suspension into ten 100mcl aliquots using a multichannel 
pipette across a 96 well plate according to the plate maps described in 2: six for 
surface staining and four for intracellular cytokine staining (a stimulated and 
unstimulated control for each of the two staining cocktails) 
7. Split available cells into two aliquots: one for ‘stimulated’ condition and one for 
‘unstimulated’ control. If insufficient cells are available a ‘stimulated’ only 
condition is adequate as long as there is an unstimulated control available from 
another experimental condition (one unstimulated condition per experiment).  
8. Centrifuge ‘Surface Stimulation’ plate/s at 3000g in centrifuge for 5 minutes at 
room temperature. While centrifuging proceed with cytokine stimulation step: 
 
2.3.8.3 Cytokine Stimulation: 
9. Take ‘Cytokine Stimulation’ plate. Add 100mcl of ‘stimulation mix’ (See Step 3 
of protocol) to each well according to plate map (resulting in 1:2 dilution). 
10. Place Cytokine Stimulation plate in incubator at 37˚C with 5% CO2 for 8 hours, 
during which time staining and analysis of the surface markers is performed. 
 
2.3.8.4 Surface Staining: 
11. WASH: Flick off supernatant; resuspend all wells in 200mcl PBS. Centrifuge at 
3000g in centrifuge for 3 minutes at room temperature. Flick off supernatant. 
12. STAIN: Apply staining cocktails (according to final total volumes calculated in 2., 
in this example 60mcl per sample) simultaneously using multichannel pipette. 
Ensure on dispensing each 60mcl aliquot, the cell pellet resulting from the 
previous centrifuge step is entirely resuspended with a partial volume 
aspirate/flush technique that itself does not introduce air bubbles into the 
sample. Air bubbles impair uniformity of staining and surface tension leads to 
problems with the ‘flick’ supernatant disposal technique. 
13. INCUBATE: Place plates in dark for 30 minutes at room temperature. 
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14. Prepare single stain control samples using beads for all flurochromes except 
DAPI and Horizon V500 conjugated-CD4, for which excess cell suspension from 
any condition (all of which assumed to contain CD4+ cells and CD4- controls 
both viable and dead) may be used to provide internal controls. 
15. Compensation Beads: Agitate all positive and negative control beads dispenser 
bottles; as described, each fluorochrome, but not each antigen, is represented in 
the control panel. Bead controls should be matched to the isotype specificity of 
the fluorochrome selected as the control (i.e. anti-mouse IgG or anti rat-IgG).  
16. Label one FACS tube for each fluorochrome for compensation.  
17. Dispense one drop each of positive and negative, or an aliquot of 100mcl 
containing cells at 1x106/ml (DAPI and Horizon V500) into each tube. 
18. Add preoptimised volume of selected fluorochrome/antibody conjugate to each 
tube. 
19. Incubate for 15 minutes at room temperature (this is adequate for bead and CD4 
controls). For the DAPI control, the DAPI may be added during the final step 
when DAPI is added to the experimental samples. 
 
2.3.8.5 Final Wash and Transfer to FACS Adaptor Tubes 
20. Retrieve surface staining plates from dark. 
21. Add 200mcl PBS to each well as first wash and centrifuge as for (11) 
22. WASH: Perform two further wash steps as per (11) using PBS.  
23. During centrifuge steps label appropriate number of adaptor tubes to correspond 
with plate maps, one tube to receive the contents of one well. Load adaptor tubes 
into suitable racks as for the plate map (empty 1000mcl pipette tip dispenser is 
ideal: see Figure 2.7). 
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24. Resuspend final cell pellets in 200mcl 1:2000 DAPI in PBS solution, and transfer 
in DAPI solution using multichannel pipette. 
25. Top up receiver tubes with further 200mcl PBS such that each contains 400mcl 
stained cell suspension ready for analysis. 
26. Ensure single stained control samples are exposed to similar washes, in 96 well 
plates or individual FACS tubes. 
 
2.3.8.6 Data Acquisition I using Fortessa 
27. Acquire data using BDFortessa flow cytometer with pre-optimised settings as 
described in Table 2.3. Ensure data is acquired uncompensated, for subsequent 
compensation using beads.  
28. Acquire optimally 5000 target events (in this case CD4+ cells) gating on viable 
cells and CD3+ CD4+ cells (this is possible even prior to compensation). If 5000 
CD3+CD4+ events are acquired, the next sample may be run. If few cells are 
present, run until the sample is fully acquired. At least 500 CD3+CD4+ cells 
should be acquired for subsequent inclusion in the anlaysis. 
 
2.3.8.7 Intracellular Cytokine staining 
The acquisition of all samples (60-120 tubes plus compensation tubes) will take 4-6 
hours, during which time cytokine stimulation will be completed. 
29. Retrieve cytokine stimulation plate from incubator. 
30. Remove viability staining dye from freezer and allow to equilibrate to room 
temperature. 
31. WASH: Perform three wash steps as per (11) using PBS to ensure all stimulatory 
and Golgi-inhibiting reagents are removed. 
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32. Harvest stimulated and stimulated cells for each sample into 5ml tubes 
(‘viability tubes’). There will be two tubes generated for each sample. Harvest in 
200mcl PBS and pool both ‘cocktail 4’ and ‘cocktail 8’ samples for each sample 
and each of stimulated and unsimulated, giving a total of 400mcl cell suspension 
x2 for each sample. Hence if there are 20 samples, there will be 40 resultant tubes 
each containing 400mcl cell suspension, half stimulated, half unstimulated, 
requiring a total of 40mcl of viability dye. 
33. Add 1mcl viability dye to each viability tube and resuspend fully using 1ml 
pipette. 
34. Incubate in fridge (2-8˚C) in dark for 30 minutes 
35. Prepare fresh Fix/Perm working solution and Perm buffer as described in Table 
5.2. There needs to be 100mcl Fix/Perm working solution and 500mcl Perm buffer 
per well (+10% for pipetting loss). 
36. Harvest cells from viability dye tubes and replate into a 96 well plate as per the 
plate map, this time into two wells per sample, one well for ‘Cocktail 4’ and one 
well for ‘Cocktail 8’. Hence if there are 20 samples there will be 40 wells, half 
stained with each of the cocktails. 
37. WASH: Perform two wash steps as per (11) using PBS to ensure all viability dye is 
removed. 
38. Resuspend all wells in 100mcl Fix/Perm working solution. Incubate at room 
temperature for 45 minutes. 
39. Spin Fix/Perm working solution-suspended cells at 3000g for 3 minutes. 
40. WASH: Perform two wash steps as per (11) using Permeabilisation buffer working 
solution. 
41. STAIN: Apply staining cocktails (according to final total volumes calculated in 2., 
in this example 60mcl per sample) simultaneously using multichannel pipette. 
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Ensure on dispensing each 60mcl aliquot, the cell pellet resulting from the 
previous centrifuge step is entirely resuspended with a partial volume 
aspirate/flush technique that itself does not introduce air bubbles into the 
sample. Air bubbles impair uniformity of staining and surface tension leads to 
problems with the ‘flick’ supernatant disposal technique. 
42. INCUBATE: Place plates in dark for 30 minutes at room temperature. 
 
2.3.8.8 Final Wash and Transfer to FACS Adaptor Tubes 
43. WASH: Perform one further wash steps as per (11) using Permeabilisation buffer.  
44. During centrifuge steps label appropriate number of adaptor tubes to correspond 
with plate maps, one tube to receive the contents of one well. Load adaptor tubes 
into suitable racks as for the plate map (empty 1000mcl pipette tip dispenser is 
ideal: Figure 2.7). 
45. Resuspend final cell pellets in 200mcl 1:2000 PBS, and transfer into receiver 
tubes. 
46. Top up receiver tubes with further 200mcl PBS such that each contains 400mcl 
stained cell suspension ready for analysis. 
 
2.3.8.9 Data Acquisition II using Fortessa 
47. Acquire data using BDFortessa flow cytometer with pre-optimised settings as 
described in Table 2.3. Ensure data is acquired uncompensated, for subsequent 
compensation using beads.  
48. Acquire optimally 5000 target events (in this case CD4+ cells) gating on viable 
cells and CD3+ CD4+ cells (this is possible even prior to compensation). If 5000 
CD3+CD4+ events are acquired, the next sample may be run. If few cells are 
present, run until the sample is fully acquired. At least 500 CD3+CD4+ cells 
should be acquired for subsequent inclusion in the analysis. 
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2.3.9 Threshold Gating Strategy: Selection of Control Populations 
2.3.9.1 Unstained Controls  
All particles possess intrinsic autofluoresce, biological particles such as cells particularly, 
and active or dying cells tend to autofluoresce more readily, in some wavelengths more 
than others. Hence to determine fluorescence of biological particles conferred by 
binding of a fluorochrome over and above the autofluorescent ‘noise’, unstained similar 
cells should have their fluorescence measured in all channels prior to acquiring stained 
cells in order to determine the difference. However, there will be non-specific binding of 
any fluorochrome-conjugated antibody in a system. This will lead to increased 
fluorescence of a cell without it possessing the cognate antigen (Figure 2.8).  
 
 
 
 
Figure 2.8: Threshold determination for gating: The problem of compensation. This 
figure is to illustrate the difficulty of determining gating thresholds in a multicolour 
system in which substantial compensation is required. On the left, a mixed cell 
population is stained with a 10 colour cocktail of antigens. It is known that a substantial 
proportion of the cells are CD95+ (the antibody conjugated to PECy5, read from the YG-
675/20 channel. However an unknown portion are stained with OX40+ PerCP-Cy5.5 
(read from B695/50). Right: Setting the threshold as shown by the dotted line would be 
erroneous since for the single stained bead population shown here, only stained with 
PECy5, the positive populations shows considerable overspill into the PerCP-Cy5.5 
channel. Hence true expression of OX40 is difficult to establish in this population and 
FMO controls would be useful. 
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2.3.9.2 Isotype Controls 
A simple control for this non-specific fluorescence present even in unstained cells is the 
isotype control. An isotype control possesses the immunoglobulin portion appropriate 
for the fluorochrome conjugate of interest, and as such the same non-specific binding 
properties, conjugated to that same fluorochrome, but without specificity for antigen 
within the sample under investigation. However, variability between isotypes, which are 
manufactured from a variety of hybridomas, may be considerable. Additionally, the non-
specific binding and fluorescence conferred by isotype controls is often quite different to 
that encountered when a population negative for a particular antigen is exposed to a 
fluorochrome-antibody conjugate specific for that antigen. Additionally, compensation 
algorithms often distort negative populations with significant spectral overlap: a feature 
that cannot be accounted for by isotype fluorescence (Figure 2.9). Hence the isotype 
control is entirely inappropriate for definition of the negative/positive threshold in 
complex multicolour flow cytometry369, 370. 
 
  
 
Figure 2.9: Compensation step 1: using beads. PE-Cy5 stained beads (read by the YG-
675/20 output channel) with internal negative control beads shown as example, plotted 
against the PerCP-Cy5.5 output channel (B-695/40-A). LEFT: Prior to compensation, the 
beads stained only with PE-Cy5 appear brightly positive in the PerCP-Cy5.5 output 
channel due to spectral overlap. Applying a correction algorithm to the read-out in the 
YG-675-20 channel improves the discrimination. However this combination proved the 
most challenging to compensate, and it should be highlighted that fluorescence up to 
the 4th log decade is still apparent, despite the population being unstained for this 
fluorochrome, and substantial expansion of the y axis into negative log decades is 
necessary to illustrate the resulting mathematical distortion. These factors must be taken 
into account before attributing expression of antigen to a population apparently 
fluorescing in the channel in which there is this degree of interference and my require 
validation with alternative fluorochrome combinations. 
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2.3.9.3 Fluorescence minus one (FMO) and blocking techniques  
In order to discriminate non-specific fluorescence and apparent fluorescence arising 
from spectral overlap an antigen-specific blocking step could be carried out, or the 
fluorochrome conjugate for that antigen excluded in a control sample, with the 
difference in profile resulting from omission or blocking enabling a positive threshold to 
be set: the fluorescence uniquely conferred by addition of that fluorochrome. The major 
drawback of this technique is that in order to remove a single probe one at a time from a 
multicolour system, the number of resultant replicates required is multiplied 
enormously, and there will usually be insufficient sample for this, while reagent costs 
and data to be analysed also increase enormously. FMO is also unable to account for the 
combined contribution of a number of antibody/fluorochrome conjugates to the 
fluorescence detected in a channel, and would require fluorescence-minus-two, three 
and more for full exploration. This is unfeasible. 
 
2.3.9.4 The internal negative and positive controls (Figure 2.10) 
The ideal control in a system will be a cell with similar biological properties of size, 
shape, internal complexity and viability, present within the same analysed sample or 
batch, but lacking any of the antigens under investigation (negative control), along with 
other cells in the same sample possessing one or more of the antigens (positive control), 
and discriminable from one another by staining for another known antigen (e.g. CD3 or 
CD20). The advantage of the panel of antigens analysed in this experiment is that they 
are all well described and in many cases differentially expressed by T and non-T 
populations in various activation states. A pilot experiment was performed to determine 
a ‘common control’ tube that could be run as part of every experimental batch in which 
populations of T and non-T cells both expressing and not expressing the antigens of 
interest were represented as comparator to the ‘unknown’ experiment samples. This 
optimisation experiment included tonsil, peripheral blood and CHL under resting and 
stimulated conditions. The stimulated condition was exposure to staphylococcal 
enterotoxin B for 72 hours since this stimulus was found to induce proliferation without 
significant apoptosis (unlike phytohaemagglutinin which induced significant apoptosis) 
in unfractionated lymphoid populations. It was found that unstimulated tonsil and 
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lymph node comprised the most diverse population of cells suitable for an internal 
negative/positive control for the greatest range of antigens of interest.  
 
This method has been cited as the preferred threshold gating strategy by several 
groups369. 
 
Any antigens whose expression remained ambiguous due to compensation problems or 
the absence of internal controls could then be analysed in separate experiments using 
alternative fluorochrome combinations containing less parameters, or validated using 
alternative methods of protein expression analysis. 
 
Figure 2.10: Threshold determination for gating: The internal control; The CD3 negative 
population should predominantly not express CD28, a T cell specific marker, which 
enables threshold to be set for this marker as shown. No isotype is necessary since the 
CD3neg fraction has been exposed to all other antibodies/flurochromes.  
 
2.3.10 Data Acquisition and Analysis 
Multicolour flow cytometry requires a methodical strategy in order to robustly and 
reproducibly ensure maximum discrimination of populations expressing and not 
expressing the target antigen, expressed as a percentage of a defined parent population, 
and if possible discriminate degrees to which different populations express an antigen, 
by measuring median fluorescence intensity (MFI), which bears a non-linear relationship 
to actual number of molecules expressed on each cell. In order to examine CD4+ T cell-
specific expression of each marker of interest, a common gating strategy was applied to 
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all samples as shown in Figure 2.11a&b.  Each marker was reported as percentage of total 
viable CD3+ CD4+ cells which were positive, or in the case of ICOS and CD95, 
percentage positive and percentage bright, where clear defined populations could be 
discriminated.  
 
In order to improve validity of comparisons of reported marker expression between 
samples derived from tissues of differing total cell viability and composition of the 
CD3+CD4+ cell of interest, sample data was rejected if the total number of analysed 
viable events was less than 1000 or the number of cells of interest (CD3+CD4+) less than 
500. Figure 5.5 in Chapter 5 demonstrates the heterogeneity of viability by DAPI 
exclusion as determined using a uniform FSc/SSc gate across samples, where the 
limitations of this technique as an assessment of between sample viability is discussed. 
 
2.3.10.1 Data Acquisition using BD LSR Fortessa 
Fluorescence data was acquired using the four laser BD LSR Fortessa (488 nm blue laser, 
561 nm yellow green laser, 641 nm red laser, 405 nm violet laser). Voltages enabling 
maximal signal/noise discrimination with minimal spectral overlap using the 
fluorochrome conjugates and samples described in Chapters 6&7 are shown in Table 2.3. 
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Fluorochrome/Parameter Excitation Laser Filter PMT Voltage 
Forward Scatter/ Size FSc  250 
Side Scatter / Complexity SSc  300 
FITC 
(Fluoroscein Isothiocyanate) 
Blue (488nm) 530/30 450 
PerCP-Cy 5.5 
(Peridin-Chlorophyll A-
Cyanine 5.5) 
Blue (488nm) 695/40 576 
Alexafluor 647 Red (641nm) 670/14 550 
APC (Allophycocyanin) Red (641nm) 670/14 550 
Alexafluor 700 Red (641nm) 730/45 530 
PerCP-Efluor710 Red (641nm) 730/45 530 
APC-Cy 7 and Viability Dye 
Efluor 780 
Red (641nm) 780/60 550 
DAPI 
(4’-6-4'-6-Diamidino-2-
phenylindole) 
Violet (405nm) 450/50 400 
Horizon V500 Violet (405nm) 525/50 475 
PE (Phycoerythrin) Yellow/Green 
(561nm) 
585/15 415 
PE-Cy5 Yellow/Green 
(561nm) 
675/20 530 
PE-Cy7 Yellow/Green 
(561nm) 
780/60 550 
 
Table 2.3:  Final laser / filter and PMT voltages used for acquisition of data on 
LSRFortessa flow cytometer. 
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Figure 2.11: Gating strategy for analysis of SCS at baseline. A: SCS from CHL. Populations 
reported in subsequent analysis defined by gates as shown: Viable, CD3+, CD20+, NBNT, 
CD8+, CD4+. B (overleaf): SCS from tonsil. Validation of the multicolour compensation 
strategy and gating strategy is provided as indicated by the open circle – CD20+ gate are 
all CD40+ while CD3+ gate contains no CD40+ cells, as expected for this activated B cell-
specific marker. CD95 expression analysis will be described in Chapters 6&7.  
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Figure 2.11: Gating strategy for analysis of SCS at baseline. A (previous page): SCS from 
CHL. Populations reported in subsequent analysis defined by gates as shown: Viable, 
CD3+, CD20+, NBNT, CD8+, CD4+. B: SCS from tonsil. Validation of the multicolour 
compensation strategy and gating strategy is provided as indicated by the open circle – 
CD20+ gate are all CD40+ while CD3+ gate contains no CD40+ cells, as expected for this 
activated B cell-specific marker. CD95 expression analysis will be described in Chapters 
6&7.  
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2.3.10.2 Compensation Strategy 
 
Compensation was carried out in two stages. No compensation was carried out at the 
time of data acquisition: this was all performed using the FacsDiva software after 
acquisition. Pre-optimisation experiments had been performed to determine the 
concentration of fluorochrome required to maximize signal to noise ratio without excess 
non-specific binding, and to determine the voltages required for amplification of signal 
in the photomultiplier tubes (shown in Table 2.3). 
 
For the first stage, in order to guarantee maximum and uniform fluorescence and 
preserve cells within the ‘unknown’ experimental samples, in which expression of the 
corresponding antigen could not be guaranteed, beads coated with antibody recognizing 
the appropriate isotype for each fluorochrome represented in the panel were used in 
combination with uncoated beads as the internal negative control. These compensation 
tubes were run for each fluorochrome (6-10), but not for every conjugated antibody in 
order to reduce total number of tubes to be analysed and preserve reagent. Optimisation 
experiments had determined that for this stage of compensation, approximations for the 
algorithms required to correct for spectral overlap could be made using a representative 
fluorochrome and did not need to be replicated for every antibody in every tube. 
Scattergraphs were produced using FACSDiva software which plotted the appropriate 
output channel on the x axis, against all other output channels under investigation in 
turn on the y axis (‘Compensation plots’: Figures 2.12 and 2.13). Compensation was 
adjusted until the ‘positive’ stained beads aligned horizontally with the ‘negative’ stained 
beads by eye, and the final adjustment was made by calculating the MFI in the 
‘competing’ channel (y axis) for positive and negative populations, and adjusting until 
these were equal. The two exceptions to using beads for the first compensation step were 
DAPI, for which a cellular population was used, and CD4-Horizon V500 since the beads 
themselves have substantial autofluorescence properties on exposure to the violet laser, 
and as such a T cell rich population was used to provide positive and negative controls: 
any frozen aliquot of the proliferating sample generated in Chapter 5 could be used. 
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Figure 2.12 A&B shows a composite of all such ‘compensation plots’ before (A) and after 
(B) applying the algorithm.  
 
 
 
 
 
Figure 2.12a: Compensation step 1: using beads, pre-compensation. Composite of 
contour plots enabling all combinations of detector channel outputs (as summarised in 
Table 2.3) to be visualised. Gated on all bead F/SSc events. PE-Cy5 stained beads with 
internal negative control beads shown as example. Fluorochrome-equivalent channel 
outputs (log fluorescence intensity) are indicated by row headings (y axis) and column 
headings (x axis). Spectral overlap can be seen by detection of PE-Cy5 in inappropriate 
channels, either as a ‘false double positive’ population, or as a ‘false positive’ population. 
Two examples of each false population are shown, but many are present in this figure. 
V500 and DAPI are excluded from this plot since beads are unsuitable for single stained 
controls and cellular controls are necessary. 
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Figure 2.12b: Compensation step 1: using beads, post-compensation. Composite of 
contour plots enabling all combinations of detector channel outputs (as summarised in 
Table 2.3) to be visualised. Gated on all bead F/SSc events. PE-Cy5 stained beads with 
internal negative control beads shown as example. The compensation algorithm 
summarised in Table 2.4 has been applied resulting in the above fluorescence profile. 
Fluorochrome-equivalent channel outputs (log fluorescence intensity) are indicated by 
row headings (y axis) and column headings (x axis). V500 and DAPI are excluded from 
this plot since beads are unsuitable for single stained controls and cellular controls are 
necessary. 
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The second stage was to further augment these algorithms specifically for the cell 
populations being analysed, whose intrinsic spectral properties would interfere with 
fluorescence generated by attached markers and thus alter the compensation necessary. 
The bead-determined algorithm was applied to approximate the final algorithm. A 
cellular control was run in the same batch, in which positive and negative expression of 
the majority of antigens was known (see ‘gating strategy’ below). A figure was devised 
within FacsDiva plotting each samples’ fluorescence in every channel for this sample, 
and the algorithm adjusted within FacsDiva until plots appeared appropriately 
compensated. Hence any inadequately or overcompensated sample could be readily 
visualised, and corrected, for each experimental tube, until the best compensation 
strategy had been applied for analysis. (Figures 2.13 A-C) 
 
The final stage was to check every sample, using the composite compensation plots, 
individually, since sample to sample variation in autofluorescence was observed based on 
variable expression of antigens, and final adjustment of the algorithm was applied until a 
compromise reached which gave the clearest plots for every sample. 
 
Table 2.4 shows the resultant algorithm used in the 10-colour experiment required for 
Cocktail 1 which would be modified slightly for each cocktail, but applied consistently 
across all samples within each cocktail’s resultant analysis. 
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Figure 2.13a: Compensation step 2: sample by sample (pre-compensation). Cocktail 1 
compensation, containing 9 colours, is used for illustration. Gated only on live cells (by 
DAPI exclusion). Substantial compensation required in many channels. 
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Figure 2.13b: Compensation step 2: sample by sample (post-compensation). Cocktail 1 
compensation, containing 9 colours, is used for illustration. Gated only on live cells (by 
DAPI exclusion). Most plots look well compensated; the internal negative/positive 
controls (CD3+ and CD3- differential expression of T cell specific or T cell over-expressed 
antigens: ICOS, CD28 & CD95 indicated for illustration with small black circles) provide 
valid gate positioning guides. However, spectral overlap of PECy5 particularly into 
PerCP-Cy5.5 detecting channel (indicated by large blue circle) makes true OX40-PerCP-
Cy5.5 difficult to determine. Additionally ICOS(bright) PECy7 shows considerable 
overlap which cannot be compensated for into the APC-Cy7 detecting channel creating 
an artefact which is difficult to resolve (indicated by blue square). 
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Figure 2.13c: Compensation step 2: sample by sample (post-compensation). Cocktail 1 
compensation, containing 9 colours, is used for illustration. Importance of gating out 
DAPI positive events. Horizon V500 channel detects enormous spectral overlap from 
DAPI, hence all DAPI expressing events even at a low level must be excluded. DAPI-
positive event exclusion creates a much cleaner plot (compare Figure 2.13b) with more 
clearly differentiated populations, since dying and dead cells autofluoresce, particularly 
in the red and violet spectra. This technique also enables valid comparisons to be made 
between samples of differing total cell viability, although the influence of proportion of 
viable cells within a total population on the immunophenotype of live cells live cells 
remains a potential confounding factor in data interpretation.  
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  FITC PCP5.5 V500 APC A700 APCCY7 PE PECY5 PECY7 DAPI 
FITC X 2.3 9.25 0 0 0 0 0 0 X 
PCP5.5 0 X 0 2.5 6.55 5 0 10.92 40 X 
V500 2.6 1.45 X 2.9 0 0 0.5 0 1.55 X 
APC 0 2.9 0 X 112.5 28.7 0 38.9 3.74 X 
A700 0 3 0 0.5 X 23.2 0 0 5.1 X 
APCCY7 0 0 0 3.15 12.6 X 0 3.9 30.78 X 
PE 0.88 0 0 0 0 0.4 X 19.85 1.3 X 
PECY5 0 275 0 7.36 7.88 0 0.85 X 165.3 X 
PECY7 0.15 0.75 0 0 0 5.6 1.66 0.6 X X 
DAPI X X X X X X X X X X 
Table 2.4.  Compensation algorithm applied for Cocktail 1 analysis. The numerical values 
represent the percentage of fluorescence in competing channel (columns) which was 
accounted for by each fluorochrome (rows). Table 2.3 summarises the output channel 
(laser and filter applied) used for each fluorochrome. In yellow and red are values 
exceeding 20% and 50% compensation respectively. These values were achievable due to 
the presence of cross-beam compensation in the flow cytometer, enabling FACSDiva to 
calculate a ‘corrected’ fluorescence value based on spectral properties recorded in 
different output channels thus determining the likely contribution of the ‘appropriate’ 
fluorochrome to its own and competing channels. However in these cases, the resultant 
populations required careful definition of positive and negative gates, with an example of 
a difficult case shown in Figures 2.8 and 2.9. 
 
 
2.3.10.3 Gating Strategy 
Discrimination of positive and negative populations in flow cytometry requires the 
determination of arbitrary thresholds, which are specific for each experimental batch but 
must be applied consistency. When there are clearly defined populations, setting the 
threshold is not problematic. When there is a continuum of expression, this becomes 
more difficult, and the median or mean fluorescence intensity (MFI) may be reported as 
a surrogate for expression levels. However this value is more difficult to standardise from 
experiment to experiment, subject to more alteration by compensation algorithms, is 
non-linearly and non-predictably related to the actual underlying expression level of the 
antigen and as such is difficult to analyse particularly when applying comparative 
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statistics between groups. A statistically significant difference in MFI represents a 
difference in two values which have been considerably mathematically altered and hence 
abstracted from the underlying biological factor of concern. As such this statistical 
difference is difficult to robustly justify as a biologically relevant one, and is difficult to 
reproduce, being overall a relative term relevant just to that experimental batch. For this 
reason, MFI was not reported as a measure of expression for these experiments, but 
instead used to determine the gating thresholds for positive, negative, and in some cases 
‘bright’, ‘intermediate’ and ‘low/negative’ expression of an antigen within each 
experimental batch. Differences in proportions of specifically defined cells falling within 
each threshold were then subject to statistical analysis. The object was to determine 
predominance or absence of populations of cells expressing the functional antigens of 
interest within the CD4+ compartment of CHL-lymph nodes, with normal and other 
malignant nodes as the comparator. Where possible, experiments were performed in 
batches, but where replicates or new batches were performed, new thresholds were set 
based on a common control used in every batch. 
2.4 Other Statistical Analysis 
2.4.1 Comparison of Means and Medians of pooled samples 
For experiments in which the difference between means of pooled samples and various 
controls was to be determined, the distribution of the data was first analysed. If the data 
appeared Gaussian in distribution, an unpaired T test was performed. If the data were 
not Gaussian, the medians were compared using the technique of Mann and Whitney371. 
For groupwise comparisons, comparisons were made using ANOVA. Further discussion 
of the application of these tests appears in the relevant Experimental chapters. All 
calculations were carried out using the statistical software package Prism  (Graphpad 
Software Inc). 
2.4.2 Multivariate Analysis using the Cox Proportional Hazards Model 
Details of multivariate analysis applied to survival outcomes and predictive biomarkers is 
given within the relevant experimental chapters. 
 
  
 
 
CHAPTER THREE: 
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3. FOXP3, CD68 AND CD20 expression in the classical Hodgkin 
lymphoma microenvironment are predictive of prognosis 
3.1 Introduction 
As discussed in Chapter 1, classical Hodgkin lymphoma (CHL) is unique amongst the 
lymphomas in that the bulk of the infiltrate comprises not the malignant cells, Hodgkin 
and Reed Sternberg (HRS) cells, but inflammatory cells including macrophages, T cells, B 
cells, neutrophils, eosinophils, fibroblasts, plasma cells and mast cells1. Over 80% of 
patients are successfully treated to a long-term remission with conventional 
chemotherapy or radiotherapy-based protocols9-11 but in those who are refractory to 
initial therapy or who relapse treatment is usually unsuccessful372, 373. In contrast, many 
long-term survivors suffer late effects of excessively toxic treatments, predominantly 
secondary malignancies and cardiovascular disease374. Established clinical prognostic 
indices for advanced stage disease17, such as those derived from the International 
Prognostic Factors Project (IPS)16 are rarely used to modify treatment. Risk-adapted 
therapy would improve management of this disease, but this requires identification of 
reliable biomarkers for ‘favourable’ and ‘unfavourable’ risk patients. Such biomarkers 
could also provide insight into the molecular biology of the disease. 
 
The malignant cell is probably at least as dependent on extracellular signals as from 
endogenous signals arising from its own mutated genome25. The macrophage appears to 
play a major role in tumour support44 and previous studies have suggested an adverse 
effect of increased macrophage infiltration116, 336, 375, 376. As discussed in Chapter 1, the 
tumour-dominating CD4+ T cells are also important in pathophysiology, but functional 
data are lacking1. Studies of solid tumour immune infiltrates have found an association 
between adverse outcome and increased expression of FOXP3347, the marker of Tregs 
(Tregs), a subset responsible for suppression of aberrant immune responses. In vivo Treg 
depletion leads to tumour regression350, suggesting that their presence suppresses 
effective immune response to tumour348, 349. However, in follicular lymphoma and CHL 
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the converse is found, with increased infiltrate associated with improved outcome292, 343, 
344, 351-354, 377. The role of ‘bystander’ B cells and other T cell subsets is more controversial, 
although there is evidence suggesting microenvironmental markers of B cell function are 
associated with favourable outcome292. The role of Epstein Barr virus (EBV) is poorly 
understood despite a clear association with this disease. EBV is present in the malignant 
cell in 20-30% of cases, associated with the mixed-cellularity subtype and disease 
presenting in immunosuppression and certain ethnic and age groups378. IHC and gene-
expression profiling (GEP) data suggest that EBV may influence the 
microenvironment292, 378. 
 
Translation of tissue microarray/immunohistochemistry (TMA/IHC) based studies to the 
clinic has been limited by experimental reproducibility and validity. This includes failure 
to apply consistent methodology, limited cohort sizes, inappropriate statistical methods 
(particularly optimal cut-point analysis), failure to validate findings in independent 
patient cohorts and the intrinsic fallibility of even expert histopathologists to count large 
numbers of cells across areas sufficiently large to draw conclusions regarding a 
heterogeneous microenvironment. Categorisation of the extent of infiltration as high, 
intermediate or low leads to substantial data loss and inter-observer discordance. Image 
analysis software can overcome some of these problems by counting huge numbers of 
events across larger regions, but has its own limitations. 
3.2 Objectives 
This study set out examine the immune microenvironment in CHL and in particular to 
validate three CHL microenvironment-expressed biomarkers with demonstrated 
prognostic significance in recent studies: the macrophage marker CD68116, the regulatory 
T cell marker FOXP3292, 343, 344, 354 and the B cell marker CD20292. CD3, CD4 and CD8 - 
non-specific T, T helper and cytotoxic T cell markers - were also assessed. 10-20 HPF 
equivalents (2-3mm2) were assessed using image analysis software and reported as 
continuous variables. This approach addresses major limitations of previous IHC work, 
namely limited regions of tumour assessment, categorisation data loss, and inter-
observer variability. 
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3.3 Methods 
3.3.1 Patients 
The patients for whom tissue and clinical data were available for array and subsequent 
analysis were identified from the St Bartholomew’s Hospital (Bart’s) database. This 
system was established in 1967 and documents clinical details of all patients presenting 
initially to, or referred from local hospitals to Bart’s for treatment of haematological 
malignancy. Data on the extended follow up of patients presenting with Stage IIIA CHL 
has been published previously379, 380. This database is linked to a second database 
detailing stored tissue samples provided for research. First, patients were identified who 
had been treated for CHL at Bart’s (n=1076). 219 patients were then excluded as having 
been treated initially at another centre and only subsequently referred for further 
treatment at Bart’s. The database of FFPE tissue was then consulted and patients 
excluded if there was no record of stored tissue, or if this stored tissue could not be 
located (n=595). For the remaining 262 eligible patients FFPE tissue sections were cut, 
H&E-stained and examined by expert histopathologists (MC and HR) to confirm the 
diagnosis of CHL. A further 140 cases were identified as being non-CHL, laparotomy 
specimens containing only uninvolved splenic and nodal tissue, samples derived from 
patients following relapse or samples with inadequate tissue for TMA. This left 122 cases 
suitable for array. Outcome for patients comparing the initial Bart’s treated cohort 
(n=857) and the cohort suitable for TMA and analysis (n=122) is presented for OS in 
Figure 3.1 and for freedom from first-line treatment failure (FFTF) in Figure 3.2, stratified 
by age and stage. 
 
For the final analysis using all three biomarkers (CD20, CD68 and FOXP3) data from 
only 90 patients was available due to tissue loss and technical difficulties (see 3.3.2) 
however this final cohort had similar characteristics to the original 122. Characteristics of 
these patients are summarized in Table 3.1. Median follow up was 16.5 years (range 2-40 
years). The final TMA cohort of 122, and the 90 analyzable for three biomarkers was 
found to be significantly enriched for advanced stage disease patients, with no 
representation by lymphocyte-rich disease, compared to the initial cohort of 857 
(Fisher’s exact test). This perhaps reflects the bulkier disease of advanced CHL providing 
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more tissue suitable for TMA. Enrichment for advanced stage disease, with its attendant 
poorer prognosis may increase the predictive power of the TMA given the increased 
numbers of events to then be applied to survival analysis. This technique of enrichment 
for advanced stage disease patients has been applied by other groups to improve the 
statistical power of a cohort in identifying new prognostic biomarkers116. 
 
 
% of TMA 
cohort 
(n=122) 
% of patients 
analysed for 
all 3 
biomarkers 
(n=90) 
% initial 
cohort 
(n=857) 
P (difference 
in TMA 
composition); 
Fisher 
Male 65 66 62 0.66 
Age>45 22 20 24 0.72 
Advanced (Stage 
IIB-IV) 
71 71 59 0.019* 
Anthracycline-
based 
chemotherapy 
46 42 45 0.922 
Alkylator-based 
chemotherapy 
43 46 40 0.491 
Radiotherapy only 11 12 15 0.454 
Combined 
modality 
39 34 35 0.364 
Histological 
Subtype 
    
Nodular 
Sclerosis 
78 71 63 0.0011** 
Mixed Cellularity 20 27 21 0.897 
Classical 
Lymphocyte 
Rich 
- - 12 <0.0001*** 
Lymphocyte 
Deplete 
2 2 3 0.56 
EBV+ (EBER-ISH) 31 36 n/k n/k 
 
Table 3.1: Patient characteristics for the entire arrayed cohort (n=122) compared to those 
for which data on all biomarkers was available (n=90) and the original treated cohort of 
857. The final TMAs were significantly enriched for advanced stage disease and NS 
subtype, at the expense of CLR compared to the total treated cohort, as determined 
using Fisher’s exact test and highlighted in bold. 
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Figure 3.1: Kaplan Meier curves showing overall survival of all patients treated at Bart’s 
(left) and those eligible for inclusion in the TMA analysis (right) stratified by age (top, 
according to international prognostic score cut-point of 45 years of age) or stage 
(bottom, early (stage group 1) versus advanced (stage group 2), with early stage disease 
being defined as stage I or IIA and advanced being defined as stage IIB, III or IV). 
Differences between groups were determined using the chi square method with 
significance defined as p<0.05. 
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Figure 3.2: Kaplan Meier curves showing freedom from treatment failure of all patients 
treated at Bart’s (left) and those eligible for inclusion in the TMA analysis (right) 
stratified by age (top, according to international prognostic score cut-point of 45 years of 
age) or stage (bottom, early (stage group 1) versus advanced (stage group 2), with early 
stage disease being defined as stage I or IIA and advanced being defined as IIB, III or IV). 
Differences between groups were determined using the chi square method with 
significance defined as p<0.05. 
 
3.3.2 TMA/IHC and IHC 
Triplicate 1mm2 cores were taken from regions of biopsy material identified by an expert 
histopathologist (MC) on haemotoxylin and eosin-stained sections, as being of high 
cellularity, containing malignant cells, avoiding fibrotic or acellular portions and 
confirmed to represent CHL. Sample collection followed informed, written consent in 
accordance with the Declaration of Helsinki. Ethical approval for this study was obtained 
from the local regional ethics board. Cores were arrayed into a recipient paraffin block, 
sectioned and transferred onto glass slides as described in 2.2.1. Staining for CD3, CD4, 
CD8, CD68 and FOXP3 following dewaxing and pressure-cooker antigen retrieval366 as 
described in 2.2.5 was performed using primary antibodies and dilutions detailed in 
Table 3.2. 
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Table 3.2: Primary Antibodies or in-situ hybridization probes used for the experiment 
 
To discriminate intact lymphoid follicle resident CD20+ cells from those in the 
malignant microenvironment (non-follicular CD20+ cells) dual-colour staining was 
employed, co-staining for CD21, a follicular dendritic cell-specific marker. Intact follicles 
were identified and with a dual-colour staining method, using a follicular dendritic cell-
specific marker (CD21). Following antigen retrieval CD21 was stained using primary anti-
CD21 antibody for 40 minutes, then gray SG peroxidase substrate (Vector Labs) for 10 
minutes, Super-enhancer (Biogenix) for 20 minutes and SS-Label (Biogenix) for 20 
minutes. After treatment with Mouse-on-mouse (MOM) block (Vector Labs) for 60 
minutes, primary anti-CD20 antibody was added for 40 minutes and stained orange with 
AEC (3-amino-9-ethylcarbazole) peroxidase substrate (Vector Labs) for 20 minutes. 
Super-enhancer and SS-Label were added as for CD21. No counterstaining was applied to 
enhance contrast and image analysis. (Figure 3.3) 
 
EBV status was determined using in-situ hybridization using a standard kit (Novocastra 
Laboratories). 
Antigen Clone Dilution Supplier 
CD3 SP7 1/500 Labvision 
CD4  368  1/500  Novocastra Ltd 
CD8 C8/144B 1/400 Dako 
CD20 L26 1/2,000 Dako 
CD21  2G9 1/130 Novocastra Ltd 
CD68  KP1 1/8,000 Dako 
FOXP3 263A/E7 1/100 Abcam 
EBER ISH Commercial kit AS DIRECTED Novocastra Labs 
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3.3.3 Microscope slide scanning, Image Analysis and Cell Counting 
 
The specimens were scanned and analysed using the Ariol automated system as 
described in 2.2.6. For lymphoid markers, due to the homogeneous and discrete 
morphology of the cells, total number of positive cells was counted across each intact 
core. For the macrophage marker CD68 total area stained positive was determined using 
Ariol and expressed as a percentage of the total core area. This is due to the 
interdigitating, heterogeneous morphology of the cell and the fact that CD68 is a 
cytoplasmic marker. For CD20, images were initially ‘censored’ by excluding follicular 
regions with an intact FDC network (stained grey, as above) from the image analysis 
counting step, and total cell numbers in the remaining regions outside intact follicles 
defined as ‘non-follicular’. The final counts for both total and non-follicular CD20 were 
then corrected for an equivalent area of 1mm2. Results were also reported per HPF 
enabling translation to manual histopathological techniques. Microscope technical 
variation means that there is no universal definition of HPF, however here it is defined as 
x400 (assuming x10 objective) with an area of 0.143mm2. The Ariol imaging system381 
(Genetix, San Jose, CA) was used to quantify antibody staining of the TMAs as described 
in 2.2.6. To standardize tumour area cellularity and enable valid comparisons, all cores 
were reviewed manually and the cell count accepted only if the core was intact, with 
<10% total area fibrotic or acellular (Figure 3.4) Each case was entered into the 
subsequent analysis only if there were two or three high quality cores representing a 
total of 2-3mm2 or 10-20 HPF. A mean count per 1mm2 core for lymphoid markers and 
mean percentage area for CD68 was then calculated. From the original cohort there was 
further attrition of cases based on these quality criteria, but for all markers the total 
number of cases available was 90 or greater. 
 
Manual validation of all counts was performed by two independent observers (RC and 
PG) using the method described in 2.2.6.2. 
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Figure 3.3: A: In order to discriminate follicular and non-follicular CD20+ cells, cores 
were co-stained for CD21 (grey) and CD20 (red) without haemotoxylin counterstaining 
to improve contrast. B: Adjacent tissue section demonstrating standard 
DAB/HRP/Polymer method of staining for CD20 with haemotoxylin counterstaining 
applied but without co-staining for CD21 preventing identification of intact follicular 
structures. 
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Figure 3.4: Example TMA cores to demonstrate quality control of samples. Only high 
quality, cellular cores containing HRS cells were included in analysis. Core A was 
deemed of acceptable quality, while core B was rejected due to excess representation of 
fibrous tissue. 
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3.3.4 Statistical Analysis 
To increase the robustness of statistical inferences, two independent analyses were 
performed; categorical and continuous data analysis. The first was a clinically applicable 
method, dividing patients categorically according to expression of each biomarker into 
cohorts based on levels of expression (high and low, or high, intermediate and low). The 
continuous data analysis analysed the prognostic effect of each of these biomarkers 
treated as continuous variables using Cox regression analysis. Outcomes, measured from 
date of diagnosis to occurrence of event or date of last follow-up, were overall survival 
(OS), the event being death from any cause, disease specific survival (DSS), the event 
being death from disease or complications of treatment for active disease, and freedom 
from first-line treatment failure (FFTF), the event being first relapse or progression of 
disease on first-line therapy, or therapy changed due to refractory disease. 
 
3.3.4.1 Categorical (Cut-point) Data Analysis 
Data analysis was performed using the Xtile statistical package339 enabling cut-points to 
be determined for markers without validated ‘normal ranges’, as detailed in 2.2.6.3. 
 
3.3.4.2 Continuous Data Analysis 
Cox proportional hazards models were used for this analysis to obtain estimates of 
hazard ratios (HRs) along with 95% CIs for CD20, FOXP3, CD68 and for the clinical risk 
factors for each outcome. The aim was to develop a predictive prognostic score 
incorporating age for all patients and for patients with advanced stage disease; age, 
presence of stage IV disease at diagnosis, along with the clinical risk score (IPS) derived 
from the International Prognostic Project16 (presence of >3 risk factors considered to 
represent high risk disease). There is no universally accepted prognostic score for early 
stage disease, and insufficient clinical information available to establish one for this 
cohort.  
 
All patients with evaluable data were included. For the multivariate analysis the total 
number of cases with all biomarkers assessable was reduced to 90. We analysed the 
effect of all potential prognostic factors (biomarkers and clinical risk factors) for OS, 
FFTF and DSS using a Cox proportional hazards regression model.  For each outcome, 
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models were formulated using forward selection procedure starting from the most 
significant clinical prognostic variable in the univariate analysis and adding factors, 
retaining only significant variables at each step. We used the backward selection method 
starting from a full model, to check that the prognostic factors maintained their 
significance in the final model382. For all analyses statistical significance was set at 
p<0.05. For all patients, variables included in the backward and forward selection 
procedure comprised age, FOXP3, CD68 and CD20.  For patients with advanced stage 
disease, variables included in the backward and forward selection procedure comprised 
age, stage IV disease (present/absent), IPS, FOXP3, CD68 and CD20.  We assessed the 
interaction between FOXP3 and CD68 with respect to OS, FFTF or DSS. In this cohort 
there were 84/116 (72%) with advanced stage disease of which 77/84 (92%) had sufficient 
diagnostic clinical data to calculate an IPS. The proportional hazards assumption for 
each predictor in the final model was assessed by testing correlation between the ranked 
failure times and the scaled Schoenfeld residuals. The proportional hazards assumption 
was not rejected in any of the models.  We used the final Cox regression model to derive 
a new prognostic index (PI).  
 
The predictive performance of the final model was evaluated using measures of 
discrimination to distinguish patients with different prognostic factors. This was 
quantified using a Harrell’s c (concordance) index, (probability of agreement between 
predicted and observed survival based on pairs of individuals). A value of 0.5 relates to 
no predictive ability to discriminate while a value of 1.0 relates to perfect discrimination 
of patients with different prognostic factors382. All statistical analyses were performed in 
STATA version 11.  
 
3.3.4.3 Manual validation of Automated Image Analysis 
Comparisons of counts derived using the manual validation methods described in 
Chapter 2 (2.2.6.2), both between manual observers and between manual and automated 
methods, were carried out using the Spearman Rank correlation coefficient. 
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3.4 Results 
3.4.1 Categorical Data Analysis  
Heterogeneity of expression of all biomarkers between patients is summarised in Figures 
3.8 and 3.18. None of the biomarkers analysed were differentially expressed according to 
EBV status or histological subtype (Figure 3.5). 
 
 
 
Figure 3.5: Mean expression of CD68, CD20 and FOXP3 was not significantly different 
between EBV+ and EBV- cases.  
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3.4.1.1 Prognostic significance of CD68 expression 
Figure 3.6 shows the heterogeneity of expression of CD68 across the patient cohort for 
which 101 patients had adequate cores for assessment. Median expression of CD68 was 
6.6% (Range 0.2%-45.9%). Three prognostic groups with low, intermediate and high 
CD68 density were defined with cut-points of <5%, 5-15% and >15% using the Xtile 
software, the favourable group having the lowest CD68+ density. OS was significantly 
different for low, intermediate and high groups (p=0.02) with five year OS of 89%, 80% 
and 65% respectively. FFTF was also significantly different (p=0.001) (Figure 3.7).  The 
prognostic significance for FFTF was maintained in subgroups presenting with advanced 
(73%, 63% and 33%, p=0.03) and early stage disease (92%, 70% and 20%, p=0.01). 
 
Figure 3.6. Variability of expression of CD68 between patients as illustrated by A: 
showing low infiltrate (<5% total area) and B: showing high infiltrate (>15%). 
 
 
 
Figure 3.7. Level of expression of CD68 was associated with survival outcome, with 
increased expression associated with an adverse prognosis.  
Chapter 3: FOXP3, CD68 & CD20 expression 
Page 129 
3.4.1.2 Prognostic significance of CD3+, CD4+ or CD8+ infiltrate 
 
Expression levels of each of CD3, CD4 and CD8 varied considerably between patients as 
demonstrated for CD3 and CD8 in Figure 3.9. As expected, the median number of CD3+ 
cells (9080, range 1639-14136) approximated sums of the medians of CD4 (4105, range 
1941-6560) and CD8 positive cells (5300, range 874-11363). Of interest, and in contrast to 
the literature to suggest that CD4+ cells predominate, there was a suggestion that CD8+ 
cells were more numerous (Mann Whitney p=0.015), however while numbers of CD3+ 
cells were normally distributed, numbers of CD8+ cells were distributed bimodally and 
CD4+ positively skewed making valid statistical comparisons more difficult (Figure 3.8). 
Figure 3.10 shows optimal cut-point probability plots generated using the Xtile software 
for each of these markers (see 2.2.3.3 and Figure 2.5). It is apparent that very few cut-
points generate patient groups for which there are significant differences in survival. 
This was confirmed on application of the test/validation set method.  
 
 
Figure 3.8: Heterogeneity of T cell infiltration between patients. The median number of 
CD3+ cells (9080, range 1639-14136) approximated sums of the medians of CD4 (4105, 
range 1941-6560) and CD8 positive cells (5300, range 874-11363) taken as a whole, as 
expected. Of interest, and in contrast to the literature to suggest that CD4+ cells 
predominate, there was a suggestion that CD8+ cells were more numerous (Mann 
Whitney p=0.015), however while numbers of CD3+ cells was normally distributed, CD8+ 
cell numbers were bimodal in distribution and CD4+ positively skewed  
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Figure 3.9: Heterogeneity of CD3 (top) and CD 8 (bottom) expression in the CHL 
microenvironment. 
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Figure 3.10: CD3 (top left) and CD8 (top right) optimal cut-point probability matrices 
showing a failure of expression level to predict outcome. Contrast the plot for FOXP3 
(bottom), which has significant prognostic power. See also Figure 2.5. 
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3.4.1.3 Prognostic significance of FOXP3 expression 
As described above, no significant association of overall CD3+, CD4+ or CD8+ cell 
infiltrate on prognosis was found. However FOXP3 cell density discriminated prognostic 
groups. 113 patients had adequate cores for assessment. Median expression of FOXP3 was 
2346 cells/mm2 or 335/hpf (range 46/mm2 or 7/hpf to 11,540/mm2 or 1650/hpf). Using 
Xtile-defined cut-points of <125, 125-500 and >500 nuclei/hpf, the favourable prognosis 
group had the highest FOXP3+ density (Figure 3.11). OS (p=0.006) and FFTF (p=0.002) 
were significantly different for low, intermediate and high groups, with five year OS of 
68%, 80% and 94% respectively (Figure 3.12) The prognostic significance was maintained 
for both advanced (FFTF: 48%, 60% and 72%, p=0.04) and early stage disease (FFTF: 
57%, 67% and 100%, p=0.04). 
 
Figure 3.11: Variability of expression of FOXP3 between patients as illustrated by A: 
showing low infiltrate (<125 cells/mm2) and B: showing high infiltrate (>500 cells/mm2) 
 
 
Figure 3.12: Level of expression of FOXP3 was associated with survival outcome, with 
increased expression associated with a favourable prognosis. 
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3.4.1.4 Prognostic significance of CD20 expression 
No prognostic significance was found for total CD20 expression. Non-follicular CD20 
expression however was found to influence survival. 98 patients had adequate cores for 
assessment. Median expression of non-follicular CD20 was 3517 cells/mm2 or 520/hpf 
(range 66/mm2 or 9/hpf to 11,593/mm2 or 1660/hpf). Using Xtile software a cut-point of 
1700 cells/mm2 (250 cells/hpf) defined two prognostic groups with low and high non-
follicular CD20+ cell density (Figure 3.13). OS was improved for patients with high non-
follicular CD20 expression (p=0.003), 87% versus 70% at 5 years, 84% versus 52% at 10 
years and OS 76% versus 43% at 20 years (Figure 3.14). There was no significant 
difference by 5 year FFTF (64% vs 57%; p=0.27), or DSS (90% vs 74%; p= 0.09).  
 
Figure 3.13: Variability of expression of CD20 between patients as illustrated by A: 
showing low infiltrate (<1700 cells/mm2 / <250 cells/hpf) and B: showing high infiltrate 
(>1700 cells/mm2). Counting was carried out using the CD21/CD20 co-staining method 
but here DAB/HRP/polymer-stained samples are shown for clarity. 
 
 
Figure 3.14: Level of expression of CD20 was associated with survival outcome, with 
increased expression associated with a favourable prognosis: overall survival was 
significantly improved with a greater infiltrate of CD20+ cells. 
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3.4.1.5 A combined prognostic score comprising FOXP3 and CD68 
We next sought to determine whether expression of CD68, FOXP3 and non-follicular 
CD20 were related, or independent variables. There was significant correlation between 
expression of non-follicular CD20 and FOXP3 while there was no significant correlation 
between FOXP3 and CD68 (p=0.684) (Figure 3.15). We determined whether a combined 
score of these two markers provided additional prognostic information. Suitable cores 
were available for both FOXP3 and CD68 on 98 patients. Patients were allocated into a 
‘good’, ‘intermediate’ or ‘poor’ risk combined FOXP3/CD68 score (Fox/Mac) according to 
the risk group for each marker individually, as described in Figure 3.16. Outcomes based 
on categorisation by Fox/Mac for ‘good’, intermediate’ and ‘poor’ risk were significantly 
different for FFTF (p=0.0002), with five year FFTF of 93%, 62% and 47%, DSS (p=0.03), 
with 5 year DSS of 93%, 82% and 63% (data not shown) and OS (p=0.002), with 5 year OS 
of 93%, 82% and 59% respectively (Figure 3.17) The statistical significance was 
maintained for both early and advanced stage patients with five year FFTF for patients 
with advanced stage 92%, 62% and 50% (p=0.03) and early stage of 100%, 72% and 25% 
(p=0.03). 
 
 
Figure 3.15: FOXP3 and CD68 expression show no correlation in CHL. Correlation 
assessed assuming non-Gaussian distribution of variables, using the Spearman Rank 
coefficient with significance in correlation set at the 0.05 level. 
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Figure 3.16: Illustration of method of assigning a combined FOXP3/CD68 score for each 
patient (bottom), showing the resulting distribution of patients between groups (top).  
P = Poor risk FOX/Mac, Int = Intermediate risk FOX/Mac, G = Good risk FOX/Mac. 
 
 
Figure 3.17: The combined FOXP3/CD68 score discriminates prognostic groups for 
patients with either early or advanced stage disease at diagnosis. 
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3.4.2 Continuous Data Analysis  
 
The distribution of FOXP3, CD68 and CD20 was assessed using dot plot graphs and a 
transformation of each of the three markers using the log function was used to facilitate 
multivariate analysis (Figure 3.18). Summaries of probability levels for the univariate and 
multivariate analyses of the continuous data are summarized in Table 3.3.  
 
Figure 3.18: Applying a logarithmic transformation (B) to the raw data (A) for the three 
markers FOXP3, CD20 and CD68 generated a more Gaussian distribution of variables 
suitable for subsequent multivariate analysis. 
 
3.4.2.1 Overall Survival 
In univariate analysis incorporating the biomarkers as continuous variables, only age, 
CD68 and FOXP3 were significant prognostic factors for OS. Multivariate analysis using 
a Cox proportional hazards model (based on 113 patients with available data and 37 
observed deaths) included age and FOXP3. In this model there was no significant overall 
interaction term effect determined between FOXP3 and CD68 (p= 0.475).  There was a 
significantly greater risk of mortality associated with older age and lower levels of 
FOXP3. The repeated multivariate analysis including clinical factors16 in the model was 
based on 76 advanced-stage patients and 28 deaths. Only FOXP3 was an independent 
prognostic variable (p=0.005). The model best explaining data variation included age and 
FOXP3 (PI = 0.040*[Age] – 0.00017*[FOXP3 absolute]) where Harrell’s c-index was 0.709 
indicating that both covariates in the model explain the variation in OS reasonably well.  
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3.4.2.2 Disease Specific Survival 
In univariate analysis only age and FOXP3 were significant prognostic factors for DSS. 
Multivariate analysis (based on 113 patients with available data and 24 observed events) 
included age and FOXP3. There was no significant interaction between FOXP3 and CD68 
(p= 0.423). The repeated multivariate analysis including clinical factors was based on 76 
advanced-stage patients and 20 events. Only FOXP3 was an independent prognostic 
variable (p=0.015) and the model best explaining variation in the data included age and 
FOXP3 (PI = 0.0293*[Age>45:1/0] – 0.00028*[FOXP3 absolute]) where Harrell’s c-index 
was 0.719. 
 
 OS DSS FFTF 
Prognostic factor Uni-
variate 
 
Multi- 
variate 
 
Uni-
variate 
 
Multi- 
variate 
 
Uni-
variate 
 
Multi- 
variate 
 
FOXP3 
(Based on 113 patients and 
37 events) 
0.026 0.038 0.018 0.035 0.005 0.010 
CD68 percent 
(Based on 101 patients and 
34 events) 
0.022 NS 0.233 NA 0.005 NS 
CD20-non-follicular 
(Based on 93 patients and 
30 events) 
0.255 NA 0.998 NA 0.191 NA 
Age 
(Based on 116 patients and 
37 events) 
<0.005 <0.005 0.004 0.012 0.100 NA 
Advanced vs Early Stage 
(Based on 116 patients and 
37 events) 
0.074 NA 0.083 NA 0.540 NA 
Stage IV vs not Stage IV 
(Based on 116 patients and 
37 events) 
0.268 NA 0.272 NA 0.005 0.043 
IPS >3 
(Based on 77 patients and 
28 events) 
0.057 NA 0.309 NA 0.197 NA 
 
Table 3.3: Probability values generated from the Cox regression analysis for survival 
factors based on each biomarker incorporated into the analysis as a continuous variable. 
Only factors significant in the univariate (Uni) analysis were incorporated into the 
multivariate (Multi) analysis. Effect of the variable on outcome was deemed significant 
for p<0.05. These significant values are highlighted in bold in this table. 
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3.4.2.3 Freedom From Treatment Failure 
In univariate analysis only stage, CD68 and FOXP3 were significant prognostic factors for 
FFTF. Multivariate analysis (based on 113 patients with available data and 50 observed 
events) included presence of stage IV disease and FOXP3. There was no significant 
overall interaction effect between FOXP3 and CD68 (p=0.728). The repeated multivariate 
analysis using prognostic score was based on 76 advanced-stage patients and 35 events.  
Only FOXP3 was an independent prognostic variable (p=0.03) and the model best 
explaining variation in the data included FOXP3 and presence of stage IV disease (PI = 
0.635*[StageIV:1/0] – 0.00021*[FOXP3 absolute]) where Harrell’s c-index was 0.656. 
 
Hence for all outcomes, incorporating FOXP3 into the prognostic score improved the 
predictive value of the model above that derived from the significant clinical factor alone 
(Shown for age in Table 3.4). 
  
Model OS FFTF DSS 
Age only 0.646 0.531 0.629 
Age and FOXP3 0.709 0.624 0.719 
 
Table 3.4: Improvement in the predictive value of the prognostic model derived from 
regression analysis when incorporating FOXP3 infiltrate as a continuous variable, 
compared to that derived using age alone. 
3.5 Discussion 
A biomarker signature that is validated robustly, powerfully predictive, and cost-effective 
for clinical implementation remains elusive in CHL. Few biomarkers have translated into 
clinical practice, as a result of flawed statistical analyses and failure to validate findings. 
This study validates three recently proposed prognostic biomarkers in a new patient 
cohort, and for the first time incorporates an automated system of image analysis to 
generate continuous variables applied to a multivariate analysis, eliminating the 
potential data loss of categorisation of data, and examining dose-effects of expression of 
each biomarker. The study includes a separate analysis of categorical data, comparable to 
the studies it set out to validate, and more applicable to manual scoring and clinical 
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translation. For each of the biomarkers CD68, FOXP3 and CD20, the prognostic 
association suggested in previous studies is confirmed. 
 
Non-follicular CD20 expression was predictive of superior OS in the categorical analysis 
without retaining a dose-effect in the continuous data analysis. High CD68 expression 
predicted adverse outcome by all survival measures in the categorical analysis but only 
showed a dose-effect for OS in the continuous variable analysis and was not significant 
in the multivariate analysis. High FOXP3 expression emerged as the most robust 
predictor of superior outcome in both independent statistical analyses. As a continuous 
variable this marker showed a dose-effect significant in univariate and multivariate 
analyses. It retained predictive power as a categorised variable in a simplified scoring 
system applicable to manual scoring or clinical use (high, medium and low infiltration). 
A combined categorical score incorporating both FOXP3 and CD68 was able to 
discriminate patients with particularly poor and good risk, in both early and advanced 
stage disease. A prognostic index based on absolute number of FOXP3 infiltrating cells 
and the patient’s age as continuous variables was able to predict OS and DSS better than 
one incorporating clinical factors alone. 
3.6 Summary and Further Work 
TMAs stained for various biomarkers can be used to characterise the CHL 
microenvironment and better understand disease pathophysiology, as well as measure 
patient heterogeneity to predict outcome. Much published IHC work is limited by 
experimental and statistical methodology and hence inadequate for translation into 
clinical practice. Conclusions drawn from gene expression profiling (GEP) of the 
microenvironment in CHL are limited by the heterogeneity of the tissue represented, 
and different groups have proposed quite different prognostic GEP patterns arising from 
different experimental and statistical methodologies116, 292, 356. Large-scale validation or 
clinical application of these findings is made difficult by the expense of the technology 
and lack of consistent findings. Finding that a biomarker is predictive of prognosis is 
merely a description of correlation, and suggests, but does not robustly confirm, a 
biological mechanism of functional importance. For example, the benefit of FOXP3 
expression could indicate that Tregs directly suppress the malignant B cell in CHL, 
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suppress tumour-supporting T cells in the microenvironment, reflect another aspect of 
tumour biology or host immune response beneficial in eradicating residual disease after 
treatment, or simply represent a non-specific T cell activation marker. The favourable 
impact of CD20 expression may indicate that normal B cells are contributing to anti-
tumour response or represent malignant cell precursors that are more treatment 
responsive. Finding that CD20 expression confers an impact on OS but not FFTF 
suggests a complex role for normal B cells in CHL, including interactions with host 
immunity, therapeutic late effects, late relapse, salvage, and overall host fitness. The role 
of the macrophage in tumour promotion has been demonstrated far more robustly in 
biological models10,11, but further functional work is required to demonstrate the 
pathophysiological importance of individual biomarkers. The absence of representative 
in vivo or in vitro models of CHL remains problematic and is the focus of ongoing 
investigation. 
 
Notwithstanding these limitations, correlative IHC biomarker data, generated 
appropriately, examined with statistical rigor and validated extensively could contribute 
to clinical decision-making in CHL. Functional imaging has shown considerable promise 
as a prognostic tool by demonstrating early treatment responsiveness383, but pre-
treatment prognostic biomarkers are scarce, and none used routinely to guide treatment. 
This study has validated and confirmed recently proposed prognostic biomarkers by 
examining a greater extent of pre-treatment lymph node-derived tissue per patient than 
any published work in CHL to date, analysing using test/validation methodology for cut-
point determination, and independently as continuous variables in a multivariate 
analysis, to demonstrate dose-responsiveness and avoiding categorisation data loss. We 
propose that by using only the widely available immunohistochemical markers CD68 
and FOXP3, with cut-points as described, a simple prognostic score can be developed 
which may be clinically translatable. To further validate these findings, we have initiated 
an international collaborative effort in two further independent patient cohorts, using 
predefined cut-points and both automated and manual counting methods across three 
different laboratories. 
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4. T-BET, GATA3, PD1 and PD-L1 expression in the classical 
Hodgkin lymphoma microenvironment 
4.1 Introduction 
The majority of the cellular CHL immune infiltrate is comprised of CD4+ T cells, along 
with cytotoxic T cells, macrophages and non-malignant B cells, and cells of the innate 
immune system. The heterogeneity of function of CD4+ T cells has made determining 
their role in the microenvironment more challenging. Data presented in Chapter 3 has 
highlighted the importance of one particular functional subset: Tregs, as having a 
potential fundamental role, although the limitations of defining a subset using only a 
single marker (in this case FOXP3) have also been introduced. There is very little 
functional work investigating the mechanism of interaction of the various components of 
the immune system with each other and with the malignant cell, and as presented in 
Chapter 5, the development of an experimental model capable of investigating such 
interactions is challenging. The approach introduced in Chapter 3 correlating clinical 
outcomes with immunohistochemical markers of immune function, enables mechanistic 
hypothesis generation, and additionally provides potential biomarkers for future clinical 
validation and translation. 
 
The number of CD4+ T cells in the microenvironment shows no correlation with patient 
outcome. The number of FOXP3+ cells shows a substantial correlation with outcome, 
tested using cut-points with appropriate validation methods, and independently as 
continuous variable, maintaining significance in multivariate analysis. Of all the markers 
tested in Chapter 3, FOXP3 remains the most statistically robust, although clinical 
validation remains to be confirmed in an independent cohort. As such, and consistent 
with the heterogeneity of CD4+ T cell function, it appears that the functional 
composition of this immune compartment is more important than the total number of 
CD4+ cells. 
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Defining functional subsets in normal physiology has limitations, which have been 
outlined in the introduction. Defining them in pathological circumstances is even more 
challenging, particularly those in which a chronic inflammatory stimulus (in this case 
malignancy) fails to be resolved, and further complicated by the nature of the 
malignancy being a subversion of the normal immune response, B cell derived 
malignancy emulating many of the stimulatory, survival and suppressor mechanisms of 
normal B and T cell interactions. Some markers have proved more robust determinants 
of T cell function. Three subsets of CD4+ T cells have been proposed as important in 
CHL, and malignancy in general: Th1, Th2 and Tregs. Th17 represents a further 
functionally distinct subset whose contribution to anti-tumour immunity is  evident384 
but whose contribution to CHL has not yet been adequately investigated114.  
4.1.1 TH1 and TH2 in malignancy 
It has been proposed that a cell-mediated, macrophage and cytotoxic T cell effector 
response orchestrated by Th1-polarised inflammation is as important to the elimination 
of cancer by the immune system as it is to the elimination of intracellular pathogens. 
Th1-promoting cytokine administration has been associated with murine tumour 
regression385. Murine models of melanoma have demonstrated enhanced tumour control 
and generation of cytotoxic T cells after suppression of a Th2 or Treg response by Th2-
polarising signalling pathway knock-out386 or administration of neutralizing anti-IL4, 
IL10 or TGF-  antibodies387. Tumour-infiltrating or circulating lymphocytes derived from 
patients with progressive malignancy have demonstrated a Th2-biased phenotype388, 
while Th1-biased infiltrates are seen preferentially in regressing tumours389. Hence it is 
believed that a Th2 biased immune response is inferior in combating progressive tumour 
and may suppress the more potent Th1 response. However, there is evidence to suggest 
that a Th2 component to anti-tumour immunity is also important390, 391, and conflicting 
evidence on Th-polarisation in tumour-derived lymphocytes392. Evidence for a Th2 
response bias in haematological malignancy is sparse and predominantly correlative 
rather than functional393-397. A Th2 bias in CHL has been suggested, but as was discussed 
in 1.7.1 is based on inadequately interpreted data.   
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4.1.2 TH1 and T-BET 
There is a robust functional literature on the importance of T-BET in CD4+ T cells in 
producing a stable functional phenotype: a T cell which produces IFN-γ, TNFα and IL2, 
along with other pro-inflammatory cytokines. The presence of these Th1 cells stimulates 
the cell-mediated immune response: with activated macrophages and cytotoxic T cells 
providing the final effector mechanism, while Th1 cells predominantly augment their 
microenvironment to optimise the response. 
 
In haematological malignancies, the differential expression of T-BET by the malignant 
component in contrast to the immune infiltrate is difficult to discriminate. Flow 
cytometry or multi-colour / fluorescence IHC could be used to discriminate the T-BET 
expressed by individual components, but there is no published work in the literature 
applying this method. The expression of T-BET, despite its original description in Th1 
polarised T cells, is not restricted to T cells: B cells are known to express T-BET at the 
stage of class switching where it may have a role in augmenting the cell-mediated nature 
of an immune response by the production of the appropriate antibody class398 (IgG2 and 
3 rather than IgG1399). T-BET is expressed by cytotoxic T cells, with a possible role in 
promoting effector function rather than memory differentiation400 and promotion of 
survival with repression of mediators of immunosuppression and exhaustion401. T-BET is 
notably restricted to the interfollicular T cell zone of reactive lymph nodes and 
underrepresented within follicles and germinal centres402. T-BET is expressed in a subset 
of B cell malignancies, with evidence to suggest that expression is not seen in the 
malignant cell of germinal centre B cell, pre-germinal centre B cell or plasma cell-derived 
malignancies,  (mantle cell lymphoma, diffuse large B cell lymphoma (DLBCL), follicular 
lymphoma (FL), plasmacytoma) whereas it is highly expressed in some cases of post-
germinal centre B cell malignancies (small lymphocytic lymphoma (SLL)/ chronic 
lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), hairy cell leukaemia 
(HCL) and Burkitt lymphoma (BL)) and unexpectedly in pre-B ALL403. As expected it has 
been found to be expressed at high levels in many peripheral T cell lymphomas (being 
derived from mature T cells) but not immature T cell-derived acute T cell leukaemias402. 
These studies had the disadvantage of failing to co-stain for B and T cell markers for the 
counting of T-BET positive cells. As such, and given that much of the infiltrate of the 
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lymphomas comprises immune infiltrate as well as neoplastic cells, unless the neoplastic 
cell is morphologically quite distinct (as in high grade lymphomas and CHL, but less so 
in lymphomas with small lymphocyte morphology), the true expression of T-BET by the 
malignant cells is uncertain. Rather it seems that T-BET (including B cell and cytotoxic T 
cell-expressed T-BET) is indicative of a substantial cell-mediated immune response 
present within the malignant microenvironment, unable to effectively discharge its 
function. This same group confirmed previous work404 demonstrating that a subset of 
cases of CHL contained malignant cells (which can be easily discriminated from the 
immune microenvironment by their morphology) expressing T-BET at high levels. They 
similarly observed that a substantial component of the lymphoid infiltrate comprised T-
BET positive cells. Co-staining with CD3 or CD20 was not undertaken, and as such the 
identity of these microenvironment cells was not clear. Any conclusions drawn regarding 
the importance of T-BET expression in HRS cells are speculative: e.g. denoting maturity 
of the B cell of origin (germinal centre vs post germinal centre) or importance in 
mediating malignant cell survival or suppression of the B cell program of 
differentiation405 (e.g. Notch1 activation with Pax5 suppression406). Aberrant 
transcription factor expression may provide a marker for the putative precursors of 
terminally differentiated HRS cells present in the microenvironment, which are able to 
sustaining disease despite the poor proliferative capacity of HRS cells. However no such 
work has been carried out and these HRS progenitor cells remain only a theoretical 
concept with a limited evidence base323. 
 
No clinical correlates of T-BET expression, expressed in HRS cell or microenvironment, 
are reported, and although an association with EBV expression in the malignant cell, in 
terms of viral induction of a Th1 response has been reported in one study other aspects of 
this study are inconsistent and apply flawed methodology407. 
4.1.3 TH2 and GATA3 
The CHL microenvironment has classically been described as comprising a large 
proportion of Th2 polarised cells, however evidence is sparse and justification based on 
citation of an early paper in which there was flawed interpretation of data47 (See 1.7.1 and 
Chapter 6). In fact evidence is accumulating to indicate a relative absence of Th2-
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defining markers in the microenvironment, with the exception of some less specific 
markers such as CCR4, whose expression is shared by other functional subsets. GATA3 
and C-MAF have been described as the master regulators of Th2 polarisation. Th2 
function is characterised by promotion of B cell development, maturation and class 
switch towards the humoral, extracellular pathogen eradication response, via production 
of cytokines IL4, IL5 and IL13. This response is coordinated by engagement of 
transcription factor programmes of GATA3163 and C-MAF408, 409, through suppression of a 
Th1 response and differential activation of the intracellular pathways JAK1/JAK3 and 
STAT5410/STAT6411, 412. These factors have been robustly determined in functional mouse 
and human experiments and as such may be considered the best markers of such a 
response. However, as understanding of these pathways evolves it is clear that no marker 
has complete specificity for any cellular function, and as such can only provide 
supportive evidence as to the role of any expressing cell. A key example is the finding 
that GATA3 is essential in early T cell development413, before antigen encounter or 
lineage commitment, and may have a role in Treg function414. 
 
A shift towards a Th2 response is often cited as being responsible for the failure of an 
immune response to eradicate tumour by the more effective cell-mediated 
mechanisms415 with Th2-biased lymphocyte composition described in patients with a 
wide variety of cancers388, 416. Much of this literature has failed to explore the potential 
role of Tregs whose functional sub-classification has only relatively recently emerged. In 
these cells, functional markers including cytokines and chemokine receptors (e.g. IL10 
and CCR4) are often overlapping and whose importance in failure of the immune 
response in cancer is now widely accepted (Reviewed in Curiel 2007417). Evidence for a 
Th2 dominated infiltrate in CHL is unconvincing with low expression of C-MAF and 
GATA3 in the immune infiltrate, in stark contrast to that derived from NLPHL46. There is 
little other direct evidence supporting the assumption that Th2 cells dominate the CHL 
microenvironment, as has already been discussed in 1.7.1. 
4.1.4 Immunosuppression and PD1 
The importance of Tregs in cancer and immunosuppression has been discussed, 
although the molecular mechanisms mediating this are still being established, including 
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secreted factors such as IL10, IL35 and TGF-β, cell-surface associated proteins such as 
CTLA4, and competition for key inflammatory stimulators such as IL2. The PD1/PD-L1&2 
axis is another potent immunosuppressive mechanism which appears to be important in 
malignancy, as has already been discussed in 1.6.5.1. Its importance in CHL has been 
suggested by the finding of amplification of the PD-L1 and PD-L2 genes by copy number 
changes occurring at the chromosomal region containing their genes (9p24.1) in CHL cell 
lines and 38% of 16 NS-CHL-derived HRS cells, microdissected from tumour 
specimens418. Over-expression of PD-L1 was confirmed at the protein level by IHC, along 
with members of JAK/STAT signalling pathways associated with PD-L1 & 2 signalling in 
CHL-derived cell lines and primary tissue. Further evidence was provided by a whole-
transcriptome paired-end sequencing assay which for the first time showed evidence of a 
recurrent chromosomal translocation in CHL, in 15% of 55 cases analysed (along with 
38% of cases of the pathophysiologically similar but clinically more aggressive primary 
mediastinal B-cell lymphoma (PMBCL) in which expression was associated with a poorer 
clinical outcome), resulting in the apparent upregulation of CIITA expression334. Two 
fusion partners for this translocated gene were found to be PD-L1 and PD-L2, resulting in 
unmodified translational reading frames beginning at the original gene transcriptional 
start site, and corroboration by RT-PCR that in tumours harbouring CIITA translocations 
there were 400-4000-fold changes in PD-L1/2 mRNA expression. 
 
PD-L1 is expressed by a range of cell lines and tumours, which has been postulated as 
mediating part of the immuno-evasive strategy of cancer419, 420. However, it is a non-
specific marker, and is up-regulated by a broad range of activated immune cells421. PD1 
expression is similarly widely up-regulated by T cells following activation, on exposure to 
chronic inflammatory stimuli such as chronic viral infections or malignancy422. Signalling 
through the pathway, as has been discussed, may also be involved in augmenting the 
germinal centre reaction and conferring B cell help, although the mechanisms of this are 
only partly described. PD1 is highly expressed in the microenvironment of NLPHL, 
although its representation in the CHL microenvironment is at relatively low levels. One 
study has found it to confer adverse prognosis when expressed at higher levels in CHL423, 
contrary to a finding in FL353. Functional evidence for the importance of this axis in CHL 
is limited and contradictory to the IHC evidence of under-expression of PD1 in the 
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tumour infiltrating lymphocytes. Indeed the paper demonstrating adverse prognosis of 
PD1 used an upper cut-point of 23 PD1+ cells per mm2 tissue to confer adverse prognosis. 
As has been shown in Chapter 3, the dense immune infiltrate of CHL comprises around 
20,000 cells per mm2, and a dense FOXP3 infiltrate comprised over 2500 positive cells 
per mm2. Hence PD1 expressing cells are generally very sparse in CHL, consistent with 
the findings of other published work424-426. Although lymphocyte-rich CHL may itself 
contain a greater proportion of PD1-positive cells427 it is a rarely described entity 
representing <1% of all CHL, and often misclassified428.  
 
Yamamoto and colleagues reported a relatively high expression of PD1 in CD4+ T cells 
derived from CHL lymph nodes (54-76%), although this data was derived from only 
three patients, and the authors report this to be at similar levels to that seen in other 
non-Hodgkin lymphoma-derived tumour infiltrating lymphocytes118. Both of these 
findings are entirely at odds with published IHC data, and the limited number of 
samples examined fails to address any patient-to-patient heterogeneity of expression. 
Comparing expression of a marker by two contrasting techniques, such as IHC compared 
with flow cytometry, without well defined negative and positive internal controls (as 
reported in this paper), is open to misinterpretation. The functional experiment 
described in the paper, demonstrating PD1-dependent suppression of CD4+ T cell IFN-  
production, was limited by very small number of primary tumour samples tested (n=2), 
the simplicity of the in vitro model used (lymph node derived cells cultured with or 
without PD-L1&2 pathway blocking antibodies, and subsequently depleted of CD4, CD8 
and CD20-expressing cells respectively), and the limited number of measures of 
immunosuppression tested – performing only assays of IFN-γ production and SHP-2 
phosphorylation (a downstream mediator of PD1/PD-L1 signalling). Although there was 
clearly an effect of blocking antibodies, to conclude that this arose due to the 
overrepresentation of PD1 positive CD4+ cells interacting with the PD-L1 positive 
malignancy is as over-interpretation of rather minimal data. In fact, the addition of anti-
PD-L1 antibodies may instead have mediated upregulation of IFN-γ secretion directly, by 
acting on PD-L1 present on the surface of activated T cells themselves, not indirectly by 
removing inhibitory PD1/PD-L1 interactions. The authors remark that the IFN-γ 
production of the CHL-derived culture system was markedly greater than that in any 
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NHL-derived sample, and present contradictory data regarding the amount of IFN-γ 
produced with or without the blocking antibodies. Overall, the best conclusion that can 
be drawn from this data is that the CHL-microenvironment is more capable of producing 
IFN-γ than NHL (in the very few primary samples tested here), and that this can be 
augmented by adding PD-L1-blocking antibodies. This is consistent with the finding that 
CHL contains few PD1 expressing lymphocytes, particularly compared to NLHPL or 
NHL.  
 
The data are overall contradictory, and while it appears that the activation-induced 
molecule PD-L1 is indeed expressed by the malignant cell in CHL, there is no convincing 
IHC, flow cytometric or functional data that it exerts any effect through PD1 expressing T 
cells in the CHL microenvironment. 
4.2 Objectives 
This study set out to determine the heterogeneity of expression of the T cell subset 
defining markers GATA3 and T-BET in the CHL microenvironment and determine its 
relationship to clinical outcome, along with the potent immunosuppressive PD1/PD-L1 
axis, using IHC on the TMA described in Chapter 3. The markers were selected as being 
most representative of the subsets Th1 and Th2 (with FOXP3 already investigated for 
Tregs in Chapter 3), along with an immunosuppressive axis (PD1/PD-L1) whose 
importance in CHL has been suggested by functional and gene expression data but for 
which corroborative data is conflicting. 
4.3 Materials and Methods 
4.3.1 Patient samples, TMA construction and Staining Methodology 
This was as described in Chapter 3 using the same patient cohort. Antibodies used for 
this experiment along with optimal dilutions are shown in Table 4.1. It was observed that 
in most cases with T-BET expression in the HRS cells, the majority of HRS cells 
expressed the marker. Hence a simple manual scoring system was applied which 
classified HRS cells based on their intensity of staining (Figure 4.1) Counting of positive 
cells was otherwise performed by the automated system, using the scanning and training 
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system described in 2.2.6.1. T-BET being a nuclear stain, was expressed as mean number 
of cells per mm2, which facilitated correlation with expression of FOXP3 whose nuclear 
staining characteristics are similar. Strategies for the assessment of the other markers are 
addressed in the results section due to difficulties relating to non-specific staining and 
low levels of expression. 
 
Antibody Isotype Clone Dilution Supplier 
PD1 Mouse IgG1 NAT 1:100 Abcam 
PD-L1 Rabbit Polyclonal 1:5 Abcam 
GATA3 Rabbit Polyclonal 1:1000 Abcam 
T-BET Mouse IgG1 4B10 1:100 Santa Cruz 
Table 4.1: Optimal antibody dilutions and suppliers for the experiments reported in 
Chapter 4. 
 
4.3.2 Statistical Analysis 
Statistical methodology was restricted to univariate analysis using the Kaplan Meier 
method applied to the outcome measures as described in Chapter 3. A multivariate 
analysis was not applied because of difficulty enumerating PD-L1 and GATA3, and the 
very low expression of PD1 demonstrated for this patient cohort. T-BET expression was 
not applied to a multivariate analysis since correlation was significant for only one 
outcome measure, namely DSS. Expression levels appeared to correlate with FOXP3, and 
there was a bimodal distribution of outcomes (see results section). However, this would 
be an important future analysis once these findings have been validated in an expanded 
cohort as outlined in Chapter 3. Statistical significance of correlations between variables 
were assessed using Pearson’s R test following log transformation to improve normal 
distribution of the data.  
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Figure 4.1: HRS cells were positive for T-BET in the majority of cases but at varying 
levels of expression. A manual scoring system was developed allocating each core a score:  
A: ‘0’ = no expression, HRS marked with arrow (although note substantial expression in 
the microenvironment) 
B: ‘+’ = weak expression 
C: ‘++’ = intermediate expression 
D: ‘+++’ = strong expression. 
Mean levels were determined for each sample based on this score.  
4.4 Results 
4.4.1 T-BET expression in the microenvironment 
T-BET staining in the tonsil was consistent with the literature and was confined 
predominantly to the interfollicular T cell zone with little expression in the germinal 
centres or follicles (Figure 4.2) The distribution in tonsil was notably similar to that seen 
for FOXP3 (Figure 4.3) in keeping with the findings of Roncador et al429. T-BET 
expression was restricted to the nucleus, but was present in lymphoid cells in the 
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immune infiltrate as well as morphological HRS cells in a subset of patients. Staining 
appeared specific, with little non-cellular staining, with nuclear restriction and providing 
adequate contrast using the DAB chromogen to facilitate cell counting by manual or 
automated image analysis systems.  
 
 
 
Figure 4.2:  Expression of T-BET in TMA control tonsil: T-BET is represented in a 
substantial proportion of interfollicular T cells, far more so than in the germinal centre 
of the lymphoid follicle, in which expression is virtually absent in the light zone, and 
present at a lower level in the dark zone. 
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Figure 4.3: Expression of FOXP3 in TMA control tonsil: FOXP3 is represented in a 
substantial proportion of interfollicular T cells, far more so than in the follicular region.  
 
The level of expression of T-BET was widely heterogeneous between samples (expressed 
in 14-5406 cells, mean 1285, median 879) but present in all cases (Figure 4.4a-d). 
Frequency distributions comparing variability of expression of T-BET to that of FOXP3 
are shown in Figure 4.5. Distribution was positively skewed similarly to that of FOXP3, 
but was generally at lower levels than FOXP3. There was evidence of a statistically 
significant correlation between the two variables (Pearson’s R applied to log transformed 
values = 0.225; 95% CI: 0.03-0.39; p=0.021). The absolute counts of T-BET expressing 
cells, being generated using the Ariol automated image analysis software without 
counterstaining (e.g. CD4, CD8 or CD20), included all cells expressing the marker, 
discriminating neither immune cell type nor HRS cells expressing T-BET. Hence the total 
count is influenced in part by density of non-CD4+ cells in the tissue and expression of 
T-BET in the malignant cells. This further limits interpretation of the data. T-BET 
expression was found to be greater in cases which were EBV positive than in EBV 
negative CHL (Figure 4.6: mean expression 1750 vs 1055/mm2, p = 0.0027). 
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Figure 4.4a-d: Heterogeneity of expression of T-BET in the CHL microenvironment. 
Representative T-BET expressing HRS cells indicated with black arrowheads, T-BET 
negative HRS cells with blue arrowheads, and lymphoid microenvironment cells with 
black arrows. 
 
4.4a High microenvironment T-BET expression with HRS cells positive for T-BET. 
 
 
4.4b: Low microenvironment T-BET expression with HRS cells positive for T-BET. 
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4.4c: High microenvironment T-BET expression with HRS cells negative for T-BET. 
 
 
4.4d: Low microenvironment T-BET expression with HRS cells negative for T-BET. 
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Figure 4.5: T-BET expression was widely heterogeneous between patients, positively 
skewed as for FOXP3, and expressed at lower levels than FOXP3. However there was a 
positive correlation between expression levels of the two markers. 
 
 
 
Figure 4.6: T-BET expression was significantly greater in EBV+ cases compared to EBV- 
cases (mean number of cells per mm2 = 1750 vs 1055, p=0.0033 comparing raw values 
using non-parametric Mann-Whitney U test (left), and p=0.0046 using unpaired T test 
comparing log transformed values (right) where normal distribution is better 
approximated. 
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4.4.1.1 T-BET density may influence survival outcomes 
 
110 of the total 122 patient samples were deemed adequate for further analysis. Using the 
test/validation set methodology described in Chapter 3, the cohort could be divided into 
two groups (using a cut-point 1500 T-BET-expressing cells/mm2) or three groups (using 
cut-points of 500 and 1500 T-BET-expressing cells/mm2. Figure 4.7 shows Kaplan Meier 
survival curves for each of the outcome measures using these cut-points, with Table 4.2 
summarising these findings. Using optimal cut-point analysis enables the data to be 
analysed for trends for which larger datasets may be adequately powered to demonstrate 
differences, although this may not be statistically robust (See 2.2.6.3). When optimal cut-
point analysis fails to demonstrate a statistically significant difference, the test/validation 
method is not applied, since following this step levels of significance are invariably 
reduced. However if the ‘uncorrected p’ generated for optimal analysis falls below the 
0.05 level, further validation work may be warranted. Numbers of T-BET-expressing cells 
failed to discriminate the groups using the outcomes of FFTF or OS, even using optimal 
cut-point analysis. However, numbers of T-BET-expressing cells did significantly 
influence DSS, both by optimal cut-point analysis, with an increased infiltrate conferring 
a superior outcome, and correcting this p value by applying the test/validation method 
(corrected p=0.045 using either two or three prognostic groups).  
 
However, on dividing the cohort into three groups using two cutpoints, an intermediate-
outcome group emerged in which T-BET infiltrate was lowest (<500 cells/mm2) yet in 
which DSS was superior compared to the group with intermediate infiltrate (500-1500 
cells/mm2). The indication of a direct correlation of T-BET infiltrate with FOXP3 
infiltrate, along with the known biological interactions between cells expressing these 
transcription factors430 suggests that these findings need to be pursued using functional 
analysis. 
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Figure 4.7: Survival Curves generated by Kaplan Meier analysis with patients stratified 
by expression of T-BET using either one (left) or two (right) cut-points. Outcome 
measures of OS, DSS and FFTF are included with only DSS proving statistically 
significant, as summarised in Table 4.2 (below). 
 
Outcome 
measure 
Hi vs Low 5 year % 
event 
Hi/Med/Low 5 year % 
event 
P (null);  
one cut-point 
P (null);  
two cut-points 
OS 92%/76% 92%/70%/82% 0.13 0.16 
DSS 97%/77% 97%/68%/85% 0.045 0.045 
FFTF 69%/56% 69%/51%/64% 0.12 0.19 
 
Table 4.2: Summary of results of Kaplan Meier analysis based on T-BET expression using 
one cut-point (Hi=>1500/mm2, Low=<1500/mm2), or two cut-points (Hi=>1500/mm2, 
Med=500-1500/mm2, Low=<500/mm2) with p values reported for the uncorrected 
optimal cut-point analysis in the case of OS and FFTF (where no significant differences 
could be demonstrated in any analysis) and the corrected value (in bold) after 
test/validation set application for DSS. 
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4.4.1.2 T-BET is expressed in malignant cells in the majority of cases 
As has been previously reported, T-BET was found to be expressed in a majority of cases, 
with strong nuclear expression apparent. There was no apparent relationship between 
expression of T-BET in the HRS cell and degree of T-BET positive infiltrate, although in 
all cases T-BET was present in a substantial proportion of lymphoid microenvironment 
cells as reported above. Table 4.3 summarises the findings of T-BET expression in the 
HRS cells using the manual scoring system as described. Hence T-BET was expressed at 
any level in 82% of cases, strongly in 25%, and absent in only 18%. Stratifying by these 
groups did not reveal any survival differences by OS, DSS or FFTF (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
Table 4.3: Summary of differential expression of T-BET in HRS nuclei using the scoring 
system described in Figure 4.1 
 
 
 
 
Figure 4.8: Expression of T-BET in HRS cells, while heterogeneous, did not enable 
stratification of patients by prognosis. In these figures for FFTF (A), DSS (B) and OS (C), 
degree of HRS staining as determined by the manual scoring system described, is 
stratified as ‘-’=absent, ‘++’=present at high levels (+++ in the manual system) and the 
intermediate group ‘+’ (+ / ++ in the manual system).  
HRS T-BET 
score 
No cases % cases 
0 20 18.2 
+ 32 29.1 
++ 30 27.3 
+++ 28 25.5 
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4.4.2 GATA3 expression in the microenvironment 
 
GATA3 expression was difficult to analyse under the conditions applied for this study 
(Figure 4.9a-d) There was significant background staining in all cases, particularly dense 
in immunoglobulin-rich regions, consistent with non-specific binding, despite measures 
taken to attempt to reduce this. Strong expression was restricted to the cytoplasm, not 
the nucleus as was expected for a transcription factor. Those cells strongly taking up the 
marker included plasma cells and, consistent with the literature, morphological HRS 
cells in a proportion of cases, although this finding may also be an artefact. Due to the 
non-specificity of the staining, failure to stain the nuclei (unlike T-BET and FOXP3 for 
which potent and easily enumerable nuclear staining was apparent), no further analysis 
was carried out. Optimisation by alteration of the antibody concentration was carried 
out, but with no improvement in resolution, and no nuclear staining.  
 
Figure 4.9a-d: GATA3 staining difficulties and observations:  
 
 
4.9a: Substantial non-specific background staining.  
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4.9b: Predominant expression in cytoplasm and only infrequently in nucleus (Arrow). 
 
 
4.9c: Expression apparent in HRS cells including nuclear staining. 
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4.9d: Tonsil revealing differential non-specific uptake in follicle light zone compared to 
T cell zone and (inset) strong cytoplasmic staining apparently in plasma cells, indicative 
of nonspecific binding in immunoglobulin-rich regions. 
 
As a pilot to these experiments, an alternative marker of Th2 cells to GATA3 - C-MAF -
was also examined. However similar staining problems were encountered and this was 
not taken forward. The literature on IHC staining for GATA3 has demonstrated similar 
problems, and concurs with these findings that very little of this TF is present in the 
microenvironment of CHL. Notably, it is also absent from NLPHL which, in contrast, has 
a striking over-expression of C-MAF46, perhaps indicating an over-representation of a Tfh 
component in NLPHL, rather than the presence of Th2-polarised cells (see Introduction 
1.6.6.1). There is a limited literature on the assessment of GATA3 expression using IHC, 
likely due to the same staining problems as those encountered during this study. 
Staining is predominantly cytoplasmic, not nuclear, except in the case of HRS cell nuclei 
in a subset of patients, while non-specific staining remains problematic. The cytoplasmic 
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localisation of GATA3 using antibodies designed for IHC has been previously described 
but not been explained in the literature, leading to inconsistencies in reporting of 
‘GATA3-positive’ cells and immune infiltrates431. As such no further assessment using 
Th2-defining transcription factors was carried out, and a failure to find convincing 
evidence of Th2-defining cytokine profile cells using flow cytometry in subsequent 
experiments (Chapter 6) further justifies this. 
 
4.4.3 PD1 expression in the microenvironment 
PD1 expression was strikingly low or absent in the microenvironment of the majority of 
cases of CHL (Figure 4.10): <0.5% of cells in 80% of cases and <0.1% of cells in 42% 
(Median expression 0.14%, or 5 cells/hpf, 30 cells/mm2, range 0-8.9% (0-1700/mm2 or 
250/HPF: Figure 4.11) This was in stark contrast to tonsillar expression in which there 
was strong expression predominantly within the lymphoid follicles, as expected (Figure 
4.10). The pattern of staining in CHL was at a lower level than in the tonsillar follicles, 
and predominantly as a low-level background infiltrate with frequent clusters/nodules of 
PD1 positive lymphoid cells aggregating around HRS cells (Figure 4.12). Based on this 
apparent biological separation of cases: virtually absent expression contrasting with a 
few patients with relatively higher expression, patients were divided by quartiles, in 
which the upper quartile had infiltration >0.5% all cells (15/hpf or 120/mm2). The group 
expressing PD1 had poorer outcome (Figure 4.13) measured by DSS (63% vs 86% at five 
years; p=0.012) while FFTF and OS outcomes were not significantly inferior, with 5 year 
OS 63% vs 84% (p=0.18) and 5 year FFTF 44% vs 66% (p=0.051). There was no apparent 
association with EBV status, with 11% of the EBER+ cases expressing PD1 at a high level 
and 15% of the EBER- cases. 
Chapter 4: T-BET, GATA3, PD1 & PD-L1 expression 
Page 164 
 
 
Figure 4.10: PD1 expression virtually absent in most CHL cases (top) in contrast to the 
striking expression in germinal centre of reactive lymph node (bottom). 
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Figure 4.11: Heterogeneity of expression of PD1 showing predominance of extremely low 
levels (<0.5% level expanded to demonstrate clustering of the lower three quartiles and 
distinct nature of upper quartile) 
Chapter 4: T-BET, GATA3, PD1 & PD-L1 expression 
Page 166 
 
 
 
Figure 4.12: In most cases of CHL only a tiny minority of microenvironment cells weakly 
express PD1 (top). In cases expressing PD1 a nodular/clustering pattern of PD1+ lymphoid 
cell infiltration was apparent (bottom) but staining intensity was overall far weaker than 
in tonsillar follicles and germinal centres. 
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Figure 4.13: In the few patients in whom PD1 was expressed in >15 of cells/hpf 
(120/mm2), or 0.5% of all cells, DSS is inferior (at 5 years 63% vs 86%, p=0.012). 5 year OS 
was 63% vs 84%  (p=0.18), and 5 year FFTF 44% vs 66% (p=0.051). 
 
4.4.4 PD-L1 expression in the microenvironment 
Expression of PD-L1 was marked across all samples. However staining pattern, consistent 
with the membrane and cytoplasmic expression of the protein, rather than the easily 
defined nuclear localisation of transcription factors, meant that enumeration was 
difficult, and raises the possibility of the contribution of non-specific staining (Figure 
4.14). Intensity of staining varied from sample to sample, however the validity of IHC 
staining intensity as a reflection of biologically relevant relative amounts of antigen is 
questionable, with little validation against gold standards. Tonsillar staining was also 
relatively ubiquitous, but with denser staining apparent in the follicles (Figure 4.15) 
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Whether this was merely a reflection of cellular density and non-specific 
immunoglobulin binding, presence of a greater proportion of B cells, in which PD-L1 is 
more commonly expressed as an activation marker, or reflective of activated germinal 
centre reactions, in which PD-L1 plays a vital role, is not clear. However, difficulty in 
devising a consistent and reproducible enumeration strategy, despite apparent 
heterogeneity between samples, led this not to be pursued as a means of discriminating 
patient prognostic groups. PD-L1 clearly has importance in CHL as discussed, but IHC 
studies (and flow cytometry, as will be shown in Chapter 6), have not provided evidence 
that its expression is any different to that seen in other activated lymph nodes. 
 
 
Figure 4.14: PD-L1 staining is heterogeneous between samples but difficult to quantify. 
Chapter 4: T-BET, GATA3, PD1 & PD-L1 expression 
Page 169 
 
 
Figure 4.15: Tonsillar PD-L1 staining reveals apparent differential staining intensity 
between follicle and T-zone. 
4.5 Discussion 
4.5.1 Limitations of IHC 
Single colour IHC is limited by its inability to determine the cell in which a marker is 
expressed unless it is morphologically quite distinct, along with difficulty in 
interpretation and the technical challenge of an alternative method - multicolour or 
fluorescence IHC. The problems of antigenic alteration by preparation and storage 
technique are another limitation. However analysis of FFPE tissue has the advantage of 
preserving tissue architecture thus enabling analysis of the spatial organisation of tissue 
components without the need for tissue disruption and cryopreservation steps, which 
favour the survival of some cell subsets over others and potentially introduce 
contamination from peripheral blood cells. While flow cytometry is able to identify the 
Chapter 4: T-BET, GATA3, PD1 & PD-L1 expression 
Page 170 
cell subtype expressing an antigen of interest with a reproducible, robust and technically 
simple method, it requires tissue disruption and consequent loss of structural data. 
Therefore, these two approaches should be used in tandem. Discrepancies in 
interpretation of levels of expression arising from application of these two distinct 
techniques are well documented, and in the case of this study, comparing results in this 
chapter and Chapter 6, it is clear that for PD1 and PD-L1 results are inconsistent. 
4.5.2 Limitations of TMA 
Drawing conclusions about the nature of the microenvironment as a whole using only 
small, if apparently representative samples, may lead to significant interpretation bias, 
loss of data, and difficulty translating and validating the work of other laboratories. 
However, substantial work in solid tumour has established the validity of conclusions 
drawn using 1mm2 cores analysed in duplicate or triplicate compared to whole section 
analysis432-435. There is only one validation study in CHL. This concluded that duplicate 
cores were sufficient to draw valid conclusions about the tissue as a whole, at least for B 
cell markers and LMP165, 436. However problems arising from the fibrotic, heterogeneous 
nature of the disease remains, hence it is important to standardise optimal practice to 
determine regions representative of the overall microenvironment, hence suitable for 
reproducible, comparative analysis. Strategies could include standardisation by overall 
tissue cellularity, as has been described here, or standardising by numbers of HRS cells 
present. However, density of HRS cells varies widely between cases and may have 
independent effects on prognosis. This study adopted a pragmatic approach, selecting 
high quality regions of tissue with hypercellular infiltrate and presence of any number of 
HRS cells for array and analysis, with no further criteria of standardisation. This may well 
be a limitation, but has enabled a simple protocol to be developed and applied to 
validation cohorts in other laboratories. 
4.5.3 Th1 and Th2 
This study was not an exhaustive immunohistochemical study of Th1 and Th2-definining 
markers in the microenvironment. However, the markers were chosen for the robustness 
of their evidence base and the fact that they represent relatively specific determinants of 
function. T-BET showed consistent expression in the microenvironment at variable levels 
consistent with a Th1 polarised response, although the identity of the expressing cell was 
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not determined (CD4 vs CD8 vs CD20). GATA3 could not be demonstrated at any 
convincing level, although the staining was suboptimal as had already been encountered 
in the literature. Reporting of these findings is relatively neglected in reviews describing 
the CHL microenvironment. In fact, the major classical T subsets within the 
microenvironment based on this and preceding work, appear to be Tregs and Th1 cells. 
Co-staining with both factors would establish this more convincingly. Whether FOXP3 
represents functional Tregs and T-BET functional Th1 cells remains to be determined. 
This expression pattern is strikingly similar to that observed in the interfollicular T cell 
zones of normal lymph nodes, in contrast to follicles and germinal centres, from which 
T-BET+ cells in particular, and to a large extent FOXP3+ cells, are excluded (Figures 4.2 
and 4.3). It is also in contrast to the infiltrate of NLPHL in which the markers of Tfh 
cells: C-MAF46, BCL6, CD57437 and PD1425 in particular, have been described as over-
expressed.  
 
The infiltrate in CHL could be interpreted as a failed immune response, rich in Th1 cells 
but also in Tregs, which are always found accompanying any acute inflammatory 
reaction. It could alternatively be interpreted as a massive expansion of the normal 
interfollicular T cell zone initiated by the presence of the malignant cells, causing it to 
fill with non-specific T cells recruited from the circulation. Any cell residing in the 
normal T cell zone is primed to encounter antigen, yet will only fully activate to 
proliferate and discharge its function when a cognate antigen-specific encounter has 
occurred. HRS cells meanwhile will be insulated from specific anti-tumour immune 
responses by the overwhelming numbers of non-specific T cells enveloping them. This 
model of CHL has already been alluded to in the literature438. However, the explanation 
coexists with an ongoing description of a Th2-polarised infiltrate in which Tregs mediate 
further immunosuppression leading to failed tumour clearance. In fact, since the 
FOXP3+ cells are associated with favourable prognosis, expression of this marker may 
simply reflect the robustness of the host immune response. Any inflammatory infiltrate 
is rich in FOXP3+ cells, part of normal immune homeostasis, and not necessarily 
reflective of these cells being the major mediators of pathological immunosuppression. 
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4.5.4 PD1 and PD-L1 
This study confirmed that PD-L1 is ubiquitously expressed by tumour and 
microenvironment in CHL, but at levels indistinguishable from tonsil. While 
heterogeneity of expression between samples appears evident, IHC is inadequately 
sensitive to quantify this. PD1, on the other hand, is markedly underrepresented. The 
chapter introduction (4.1.3) has discussed some of the assertions made in the literature 
about the functional importance of the PD1/PD-L1 axis in mediating immunosuppression 
in CHL. However these studies have a weak functional basis. The profound absence of 
PD1 demonstrated here, and in previous studies suggests that this pathway is not 
important in the majority of cases, and cannot explain the failure of the immune 
response to eradicate tumour. Its apparently adverse prognostic significance in the small 
minority of cases in which it is expressed, along with its close association with the 
malignant cells in nodular configurations, suggests that perhaps it is important in these 
particular rare cases, but not in general. 
4.6 Summary and Further Work 
Chapters 3 and 4 have documented attempts to describe the heterogeneity of the CHL 
microenvironment based on the expression of non-specific immune cell markers 
(cytotoxic and helper T cells, B cells, macrophages), and T cell subset (Th1, Th2, Treg) 
and functional markers (PD1, PD-L1) already described in the literature, but examined 
for the first time here using automated image analysis. Clinically translatable prognostic 
models may emerge from this data as long as robust validation is carried out. However, 
associations of expression with patient outcome only allude to function and are in no 
way demonstrative of the importance of biological pathways in initiating, maintaining or 
suppressing the disease. This requires in vitro and in vivo model systems capable of 
manipulation. The development of these systems however, is problematic, as described 
in 1.8. An attempt to develop an in vitro co-culture system to specifically investigate the 
interaction between the HRS cell and CD4+ T cells will be described in Chapter 5. 
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5. A culture system to sustain primary tissue-derived HRS cells 
and tumour-infiltrating CD4+ T cells 
5.1 Introduction  
5.1.1 Clinical Trials without in vitro or in vivo models 
CD4+ T cells are numerically dominant in CHL and correlative data are highly suggestive 
that these cells play a fundamental role in malignant cell survival comparable to the 
absolute dependence of B cell survival on CD4+ T cells in normal physiology. However as 
described in 1.8, development of a model system beyond CHL-derived continuous cell 
lines and simplistic murine tumour transplant models, has eluded investigators. Hence, 
conclusions regarding the functional importance of micro-environmental cells in tumour 
survival are often derived from the success of pharmacological manipulation of survival 
pathways in clinical trials, not from data derived from basic science. Examples include 
the success of the anti-CD20 antibody rituximab in inducing remissions in relapsed 
patients despite the absence of expression of CD20 by the malignant cell439, anti-CD40 
antibodies (SGN-40) administered for NHL and under investigation in CHL440 which may 
antagonise key T cell-mediated B cell survival signals (described in 1.5.2), and the use of 
the T cell depleting antibody anti-CD52 (alemtuzumab) to treat refractory CHL, under 
investigation in a number of Phase II clinical trials as part of conventional chemotherapy 
as a single agent, or to improve outcomes following allogeneic transplantation441. The use 
of immunomodulatory drugs such as lenalidomide in CHL also has a hypothetical basis 
of action by manipulating the T cell microenvironment in particular442. The actual 
mechanism of action of these ‘indirect’ therapies has little evidence base since clinical 
trials have been performed without the usual preceding in vitro or in vivo model 
demonstration of action required of novel pharmacological agents, and are justified 
ethically due to a context of failed of conventional therapies, and inevitability of tumour 
progression and death without treatment.  
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5.1.2 Maintaining the HRS cell indirectly using T cell supporting cytokines 
 
5.1.2.1 IL2 
IL2 is a T cell growth and survival factor that signals via a receptor comprising three 
subunits. One subunit, the common gamma chain (CGC/CD132) is constitutively 
expressed by many immune cells including B cells and monocytes443 and shared by a 
number of other interleukin receptors444. The receptor has two other cell type and 
activation status-specific components which determine affinity for ligand, namely 
IL2R (CD122), expressed preferentially by cytotoxic T cells and NK cells445, and 
IL2R (CD25) constitutively expressed by nTregs179 and up-regulated on activation of 
other lymphoid cells301. IL2 leads to activation, proliferation and enhanced function of 
lymphocytes446, but also induces apoptosis447 (activation induced cell death) unless other 
survival pathways are induced: notably in Tregs whose survival and expansion are 
dependent upon prolonged exposure to IL2448. While many CHL-derived cell lines and 
primary tissues express IL2Rα449, 450 there is little convincing evidence that CHL itself 
produces IL2451 nor that IL2 is a growth factor for the HRS cells themselves452 although its 
role in the T cell rich microenvironment is not clear. 
 
5.1.2.2 IL4 
IL4 signals through its receptor, comprising the common γ chain as well as a unique 
subunit CD124 (IL4R ), to stimulate growth and survival of B and T lymphocytes. In 
CD4+ T cells IL4 activates the Th2 differentiation pathway151 via the transcription factors 
GATA3, C-MAF and STAT6 inducing further IL4 production as well as other Th2-
defining cytokines such as IL5 and IL13453. IL2 and IL4 may act antagonistically, 
cooperatively or synergistically on T cell growth and activation depending upon the 
experimental conditions and responder cell populations454-458. There is evidence to 
suggest that IL4 is an autocrine stimulus of HRS derived cell line growth48. IL4-encoding 
mRNA is present in the reactive tumour microenvironment of biopsy material49, and 
HRS-derived cell lines strongly express the IL-4 receptor50, although contradictory 
evidence exists51-53 and there are clear limitations to analysis of cytokine function in non-
vital fixed tissue.  
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5.1.2.3 IL13 
IL13 is more widely expressed in primary samples and HRS cell lines54-56, distinguishing 
CHL from NLPHL and another histologically similar malignancy, T cell-rich B cell 
lymphoma (TCRBCL)54 with IL13R expressed in most CHL cell lines and primary CHL 
cases55, 56. While exogenous IL13 fails to augment cell line growth, some growth is 
inhibited by antibody-mediated IL13 receptor blockade54-56. 
5.2 Aims and Objectives 
A culture system was developed to test the hypothesis that the survival of the HRS cell in 
CHL is dependent upon signals derived from the microenvironment and that a 
significant contribution to these signals arises from CD4+ T cells. An attempt was made 
to prolong the survival of primary CHL-derived lymph node single cell suspensions (SCS) 
by enriching with cytokines known to sustain both T cell, specifically Th2, and HRS 
growth. Should survival of measurable cell populations be achieved, conditions of the 
culture system could be manipulated in order to determine the molecular mediators of 
survival and proliferation of HRS cells and tumour-sustaining T cells. Pathway and 
molecule-specific blocking methods could include monoclonal antibodies or gene 
knock-down. Candidate molecules participating in this interaction have been discussed 
in 1.5.2. In order to determine the effects of manipulating such a system the following 
conditions were required:  
1. Development of an optimised culture system including media composition and 
plating techniques. 
2. Identification of a technique to identify or isolate HRS cells within mixed cell 
populations at baseline and at subsequent time points in order to perform assays 
on this specific population. 
3. Selection of a method to conclusively demonstrate that any population being 
assayed was derived from clonal B cells, consistent with it representing the 
malignant cell.  
4. Selection of control cell populations, derived from benign and malignant nodal 
tissue. 
5. Selection of quantitative assays of proliferation and growth in this population 
6. Modifications of the system to identify mediators of proliferation and survival. 
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5.3 Materials and Methods 
5.3.1 Single cell suspensions 
Details on preparation of single cell suspensions is provided in Materials and Methods 
2.1.2. Table 5.1 shows the samples used in the following immunophenotyping and cell 
culture experiments. 
 
Sample Source 
Histology 
Immuno 
EBV status 
SCS 
Classes 
Biopsy 
Date 
Date 
plated 
% viable at 
baseline 
(Tryp Blue 
exclusion) 
Total 
cells 
plated 
Total 
no 
wells 
C1 
(501) 
Axillary 
LN 
CHL: NS 
EBV- CD30+ 
CD3-CD20- 
CHL/  
Malig 
19/06/09 11/05/2011 >90% 10x10
6 
120 
C2 
(302) 
Cervical 
LN 
CHL: NS 
EBV- CD30+ 
CD3- CD20- 
CHL/ 
Malig 
19/02/09 11/07/2011 >90% 5x10
6 
60 
C4 
(304) 
Cervical 
LN 
CHL: MC 
EBV+ CD30+ 
CHL/ 
Malig 
17/09/99 11/07/2011 >90% 5x10
6 
60 
C5 
(305) 
Cervical 
LN 
CHL: NS 
EBV+ CD30+ 
CHL/ 
Malig 
18/08/99 11/07/2011 >90% 5x10
6 
60 
C6 
(506) 
Cervical 
LN 
CHL: NS 
EBV- 
CD30+ 
CHL/ 
Malig 
21/02/02 11/05/2011 >90% 10x10
6
 120 
F1 
(603C) 
Cervical 
LN 
Grade 2 FL 
FL/ 
Malig 
05/07/11 05/07/2011 >90% 10x10
6 
120 
F2 
(802) 
Axillary 
LN 
Grade 2 FL 
FL/ 
Malig 
02/08/10 15/08/2011 <60% 5x10
6
 60 
F4 
(805) 
Cervical 
LN 
Grade 3A FL 
FL/ 
Malig 
01/02/08 15/08/2011 <60% 5x10
6
 60 
L1 
(801) 
Inguinal 
LN 
NLPHL 
NLPHL/ 
Malig 
11/09/06 11/7/2011 <60% 5x10
6
 60 
P1 
(605) 
Cervical 
LN 
PTGC EBV- 
Reactive
/ Benign 
22/08/11 22/08/2011 >90% 5x10
6
 60 
R2 
(808) 
Cervical 
LN 
Follicular 
hyperplasia 
EBV- 
Reactive
/ Benign 
29/03/10 12/10/2011 >90% 5x10
6
 60 
T1 
(804) 
Tonsil Tonsil 
Tonsil/ 
Benign 
- 15/08/2011 <60% 5x10
6
 60 
T2 
(806) 
Tonsil Tonsil 
Tonsil/ 
Benign 
- 15/08/2011 <60% 5x10
6
 60 
T3 
(T3203) 
Tonsil Tonsil 
Tonsil/ 
Benign 
- N/A <60% N/A N/A 
T4 
(T3121) 
Tonsil Tonsil 
Tonsil/ 
Benign 
- N/A <60% N/A N/A 
Table 5.1 Samples established in culture using the optimised cytokine enrichment 
systems. Note that T3 and T4 were not established in culture but instead used as control 
for subsequent immunophenotyping experiments. Key: NS: Nodular Sclerosis, MC: 
Mixed Cellularity. 
Chapter 5: A culture system to sustain primary tissue-derived cells 
Page 178 
5.3.2 Multicolour Flow Cytometry for identification of HRS cell population 
Details on staining technique and analysis for flow cytometry are provided in Materials 
and Methods 2.3. Details specific for this experiment are provided below. Flow cytometry 
was performed on thawed single cell suspensions prepared as described. 
 
5.3.2.1 Selection of fluorochromes and antibodies 
HRS can usually be identified not only by a unique immunophenotype distinct from 
other haematological, lymph node and bone marrow resident cells but also by their large 
size. They rarely express the characteristic cell surface markers of B cells (CD19 and 
CD20), T cells (CD3, 4 and 8) or cells of the monocyte/macrophage/dendritic cell lineage 
e.g. CD64319. They often express TNFRSF markers of activation such as CD40 and CD95 
and are characterised by expression of the B and T cell activation and co-stimulatory 
TNFRSF molecule CD30, which was first discovered when a novel antibody was raised to 
a CHL-derived cell line112. These features have been used to develop an antibody panel 
and gating strategy which can identify HRS cells within a CHL-derived lymph-node 
population319. These studies did not demonstrate clonality by investigating the genome 
of the immunophenotype-defined purported HRS cell, and were validated only by first 
demonstrating that this cell had forward and side scatter properties consistent with 
being larger and more intracellularly complex than surrounding cells, second by 
examining the morphology of cells flow-cytometrically sorted using this panel, and 
finally by confirming the panel’s ability to discriminate CHL from other lymph node-
derived malignant and non-malignant tissue459. As such it should be considered only a 
promising pilot strategy. Based on the panel proposed by this group the fluorochrome 
and antibody panel shown in Table 5.2 was proposed: 
 
 Eponym Fluorochrome Clone Isotype Supplier 
CD3 - PE-Cy7 UCHT1 Mouse IgG1-kappa Biolegend 
CD4 - Horizon V500 RPA-T4 Mouse IgG1-kappa BD 
CD8 - Alexafluor 700 HIT8A Mouse IgG1-kappa Biolegend 
CD20 - APC-H7 2H7 Mouse IgG2b-kappa BD 
CD30 TNFRSF8 PE BY88 Mouse IgG1-kappa Biolegend 
CD64 Fc-γ-R1 APC 10.1 Mouse IgG1-kappa Biolegend 
CD40 TNFRSF5 PerCP-Cy5.5 5C3 Mouse IgG1-kappa Biolegend 
CD95 FAS/TNFRSF6 Alexafluor 488 DX2 Mouse IgG1-kappa Biolegend 
Table 5.2: Antibody panel to examine T cell, B cell and monocyte/macrophage lineage 
within experimental lymph nodes, and attempt to identify HRS cells by surface markers. 
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5.3.3 Culture of single cell suspensions derived from lymphoid tissue 
 
5.3.3.1 Lymphocyte Culture Media (LCM) 
Enriched media, known as ‘lymphocyte culture media’ (LCM) was prepared as stock as 
described in Table 5.3 and discarded and replaced if unused within 28 days. This is based 
on the media used by various groups in order to proliferate and polarise human T cells191, 
460. 
 
Reagent Supplier Volume 
Final 
concentration 
RPMI with added glutamine PAA Laboratories 500ml - 
Heat-inactivated human AB serum Invitrogen 16ml 3% 
Penicillin/streptomycin Invitrogen 5.5ml 1% 
1M HEPES PAA Laboratories 5.5ml 10mM 
Non-essential amino acids PAA Laboratories 5.5ml 1% 
Sodium pyruvate PAA Laboratories 5.5ml 1% 
2-mercapto-ethanol 14.3mM stock (dilute 
14.3M stock 1:1000 in ddH2O) 
PAA Laboratories 2ml 50mcM 
Table 5.3: Lymphocyte culture media enrichment reagents 
 
5.3.3.2 Cytokine Enrichment and Culture Establishment 
Cytokines were added as required from frozen aliquots to LCM immediately prior to 
plating as shown in Table 5.4. 
 Supplier Aliquot  Culture condition Biological activity 
Dilute Concentration ED50 
(ng/ml) 
Specific 
Activity 
(units/ng) 
Responder 
Assay cells ng/ml U/ml 
rh-IL2 Milteyi 
Biotec 
50mcg in 
5ml 
1:1000 10 >50 <0.1 >5 HT-2
461
 
CTLL-2
462
 
rhIL-4 Gibco 25mcg in 
2.5ml  
1:1000 10 25 0.05-0.4 2.5 TF-1
463
 
rh-IL13 eBio 
Science 
200mcg 
in 2ml 
1:2000 100 20-
100 
1-5 0.2-1 TF-1
463
 
Table 5.4: Cytokines used for cell culture, supplied as freeze-dried concentrate, made up 
in 0.1% HuABS/PBS aliquots as in Table 5.3 stored at -80˚C. Specific activity was defined 
by the growth-stimulating activity of each cytokine on responder cells as indicated. 
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Thawed, washed SCS-derived cells were resupended at 0.25-0.4 x 106/l in a total volume 
of LCM enriched with cytokines at the concentrations shown in Table 5.4 as determined 
by the experimental condition (no cytokine, single cytokine enrichment with IL4, IL13 or 
IL2 alone, and dual enrichment with IL4&IL13 or IL4&IL2). Cytokine concentrations were 
based on the literature on T cell stimulation, proliferation and expansion460 and IL13 
stimulation of HRS-derived cell lines54. Cell culture was carried out in round-bottom 96 
well plates to maximise cell-cell contact and thereby emulate the close proximity of cells 
within the lymph node microenvironment. The number of wells established depended 
upon the availability of viable cells from the original SCS. No more than 60 wells were 
established for each sample and each culture condition. Based on a final LCM+/- 
cytokine suspension of 0.25-0.4 x 106 cells per ml each well was filled with 200mcl of cell 
suspension at plating, thus 50-80,000 cells per well. 96 well plates were placed into 
aprimary cell culture-designated incubator humidified at 35˚C with 5% CO2. 
 
At no point was any non-specific or specific activator of lymphoid cells nor any 
additional co-stimulatory factors added except the cytokines described and 2-
mercaptoethanol. These may have included anti-CD3, anti-CD28, phorbol-mysterate 
acetate (PMA), PHA (phytohaemagglutinin), concanavalin, or bacterial super-antigen. As 
such, for these experiments, any proliferative effects result only from the action of the 
LCM and supplementary cytokines on intrinsic properties of the cell suspensions derived 
from each lymph node. 
 
5.3.3.3 Refinement of Cytokine Enrichment Conditions 
In initial pilot experiments using tonsil and one CHL case exposed to media only, IL13 
only, IL4 only and IL4&IL13 colony/cluster formation was only apparent in IL4-enriched 
conditions, with no apparent superiority of colony formation on further addition of IL13, 
and culture death within 2 weeks with no or little evidence of culture/cluster formation 
in IL13-only or media-only conditions. Therefore subsequent culture systems were 
established using IL2 only and IL2 & IL4. Figure 5.1 shows the growth resulting from a 
subsequent pilot experiment in which SCS-derived cells from tonsil and one case of CHL 
(C1) were established using media only, IL2 or IL4 only or both cytokines. For this pilot, 
all wells were harvested weekly in the first instance and fortnightly subsequently, and 
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total cells estimated by haemocytometry on the resulting cell suspension. Cells were 
then replated across the appropriate number of wells. This experiment was abandoned 
after 10 weeks once a clear differential in growth had been established. Subsequently, 
culture systems were limited to IL2 and IL2&4 only given that only these conditions 
enabled persistence or expansion of the culture. Additionally, the method of harvest, 
resuspensions, cell counting and replating as described for this pilot was abandoned at 
this stage in favour of the technique described below (estimating growth by viable vs 
non-viable well counting, Table 5.5) which enabled a larger number of different tissue-
derived SCS to be cultured simultaneously with minimum disruption to the culture 
system at each assessment. 
 
 
 
Figure 5.1: Cytokine Optimisation Pilot: Relative growth rates and survival of culture 
systems according to cytokine augmentation. HRS: CHL lymph node-derived SCS (C1). 
Blue lines/Squares: estimated growth rate of HRS, Green lines/Circles: estimated growth 
rate of tonsil-derived SCS. Filled figures: IL2&4, open figures: Media only, Top filled: IL4 
only, Bottom filled: IL2 only. IL13 was rejected since no growth was seen when used alone 
and no apparent augmentation of growth when used in conjunction with IL4. 
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Only a single CHL-derived SCS and single control tonsil were used for this pilot 
experiment. Hence IL13 may have a role to play in augmenting further the growth of 
other CHL-derived SCS. However it was decided to focus only on IL2 and IL4 given the 
relative redundancy of IL13 and IL4 in Th2 cell polarisation and growth augmentation 
well documented in the literature464. Therefore the influence of IL13 on residual HRS 
cells in the system has not been pursued any further. 
 
5.3.3.4 Culture plate inspection and splitting 
Culture plate wells were examined every 3-5 days by the naked eye for media colour 
change indicating active cellular respiration and consequent pH change, and under an 
inverted microscope using a x5 and x10 objective (Figure 5.2). Using this technique, the 
majority of cells were a homogeneous lymphoid population and large HRS cells could 
not be identified. However, this was likely due to difficulty assessing cellular detail in 
cells in close contact or multiple layers within the round-bottom plate. However colonies 
and clusters of cells could be identified easily within and surrounding the main cell 
pellet and at the periphery of the pellet blastic cells and apoptotic debris were 
identifiable.  Potential bacterial or fungal contamination could also be identified using 
this method. Individual culture wells were abandoned, split or media replaced 
depending upon an assessment of proliferation and viability in that well, using the 
method described in 5.3.3.6. Photomicrographs were acquired using an inverted 
microscope using a x5 objective lens and digital imaging software. 
 
Figure 5.2: Cell number estimation by occupancy of x10 objective field on inverted 
microscope. The semi-transparent rings indicate the approximate extent of the x10 
objective field. Left: Well appropriate for SPLITTING. Proliferating colony containing 
innumberable cell clusters occupying greater than the total x10 field. Right: Well 
appropriate for MEDIA CHANGE. A viable well containing a dense central colony/cluster 
with multiple less distinct surrounding colony/clusters.  
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5.3.3.5 Initial LCM Change 
One week after initiation of culture some systems showed clear formation of cell 
colonies/clusters on inspection of wells as above, while others showed minimal growth 
or evidence of cell death. However there was little evidence of media colour change, nor 
increase in overall cell numbers assessed by haemocytometry or by estimation of cell 
pellet size. Two weeks after initiation, there was substantial growth in the majority of 
wells in some systems with media colour change and increase in pellet size. Subsequent 
to this time period, growth tended to be sustained, with media colour change and 
increase in pellet size every 5-10 days. As such it was decided that the first media change 
should be to remove 50% of the media from each well and replace with fresh LCM with 
appropriate cytokine enrichment. Aspiration of media was easily achieved using a 
200mcl pipette (either well by well or using a multichannel pipette), removing 90mcl of 
supernatant LCM (assuming some evaporation since the previous media change) without 
disruption of the cell pellet. Replacement was with 100mcl of appropriately cytokine 
enriched LCM dispensed similarly through a 200mcl pipette individually or using a 
multichannel pipette, the force of which led to a complete resuspension of all cells. 
Extreme care was taken on replacement of media that no well to well contamination 
occurred, by ejecting fresh LCM gently from a short distance above the plate. 
 
5.3.3.6 Assessment of Proliferation 
Pilot experiments counting cells by haemocytometry determined that the number of 
cells per well when the cell pellet occupied the entirety of a x10 objective field was 
between 100,000 and 150,000 (Figure 5.2) As such, in order to minimise time of culture 
systems spent outside the incubator due to multiple well sampling for haemocytometry, 
or the disruption of evacuating an entire plate into sample tubes in order to perform a 
cell count on total volumes followed by replating, a method to estimate overall culture 
system proliferation was devised. Each well was visually inspected under the inverted 
microscope and scored according to Table 5.5.  
 
Any well appearing senescent was classified as ‘dead’ for counting purposes. All other 
growth was classified simply as ‘live’ for counting purposes, and media changed 
according to Table 5.5. Classification as ‘live’ or ‘dead’ was taken to reflect successful 
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plating on the previous media change. Hence from this inspection and scoring, the total 
number of live and dead wells on each media change was recorded. A total cell count 
could be estimated from this assuming that wells plated on the previous media change 
contained 50-80,000 cells. This relies on an estimate of total cells occupying a x10 
objective field. However, applying this methodology consistently across all conditions 
and being blinded to the source of each culture system during the counting process 
enabled valid comparison between systems and conditions to be made. 
 
5.3.3.7 Subsequent media change 
Media was changed every 7-10 days according to the scoring system described in 5.3.3.6 
and with appropriate cytokine enrichment on each occasion. Weekly cytokine 
enrichment was chosen since this is consistent with standard T cell proliferation and 
polarisation protocols460. Cytokine-enriched LCM for each media cycle was made up 
fresh at double the concentration of cytokine required (see Table 5.4). Media change 
constituted removal of 90mcl supernatant and replacement with 100mcl fresh LCM as for 
the initial media change one week after first plating. Splitting 1:2 required initial 
resuspension of each cell pellet, followed by aspiration of 50% of the volume of the well 
(75-90mcl) and plating half in a fresh well, leaving half in the original well. Splitting 1:3 
required resuspension of each cell pellet, followed by aspiration of two aliquots of 50-
60mcl of cell suspension and plating into new wells, leaving approximately one third in 
the original well. Each resultant well was topped up with fresh media as for media 
change, ensuring that a total of 200mcl was present in each well. It is acknowledged that 
this strategy meant 1:3 splits led to a final concentration of fresh cytokine 150% that of 1:2 
splits and 50:50 media changes (assuming that all cytokine from the previous cycle had 
been exhausted or degraded). The assumption was made that since cytokines were being 
used at the upper limit of biological activity as defined in Table 5.4, this would not lead 
to additional advantages for the cells within that well. Should there be any advantage, 
however, this would be applied consistently across all culture systems and should 
therefore not influence an analysis of differences between systems. 
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Description Examples Media 
change 
Prolif++ 
 
SPLIT 1:3 
Prolif+ 
 
SPLIT 1:2 
Prolif+/- 
 
REPLACE 
MEDIA 
Senescent 
 
DISCARD 
Table 5.5: Scoring system for individual wells using visual inspection to determine media 
change technique. 
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5.3.3.8 Estimation of overall culture system proliferation 
Assessment of numbers of viable wells using the technique described above enabled an 
estimation of overall proliferation of the culture system across all wells over a period of 
many weeks. Continual expansion of the more proliferative systems would not be 
practical or economically feasible, requiring many hundreds of culture plates and large 
amounts of media and cytokine. Hence, at each media change in the more proliferative 
systems, only a proportion of total proliferating wells were subsequently split and 
replated. Total number of wells maintained at any one time for each proliferating culture 
system was typically between 60 and 300. Less proliferative systems were maintained at 
the maximum possible number of viable wells. 
 
At each media change, the number of viable wells and the proportion of viable wells in 
actively proliferating cultures that were then split was recorded, and an estimate 
calculated of the ‘theoretical potential maximum’ number of viable wells that could have 
been populated in the ideal situation of all viable wells having split at each cycle. This 
was documented as a ‘corrected’ number of total wells, using the equation overleaf 
applied using an Excel spreadsheet (Figure 5.3). 
  
 
Figure 5.3: Portion of Excel spreadsheet demonstrating documentation of viable wells at 
each media change and application of formula to estimate theoretical maximum / 
corrected number of total wells at each point (CW). Estimated overall proliferation in 
each of the systems are highlighted in green. Cultures in which all cells have died are 
highlighted in red. 
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Equation to calculate proliferation in cell culture system: 
 
CWT0 = AWT0 (CWT-1/AWT-1) 
        F 
Where: 
CWT0 = Theoretical (corrected) number of viable wells at current media change 
AWT-1 = Actual number of viable wells present at current media change 
CWT-1 = Corrected number of viable wells at previous media change 
AWT0 = Actual number of viable wells at previous media change   
F = Fraction of total number of viable wells replated at previous media change (where F 
is a decimal ≤1.0). 
 
And the overall proliferation (P) of the system at the time of the current media change 
was calculated thus:  
P = CWT0 
CWTW2 
Where CWT2 = Number of viable wells present at week 2. 
 
This value is a crude estimate, likely overestimating the proliferative potential of each 
culture system. However the method was applied across all culture systems in a standard 
manner, enabling comparisons between groups. Absolute values generated should not be 
taken as representative of the actual total number of cells that would have been 
generated had all viable, proliferating wells been split at every opportunity, but rather as 
a comparative indicator of the proliferative potential of each culture system. 
 
5.3.3.9 Freezing down of cells for subsequent analysis 
Cells were stored down once they had proliferated in sufficient numbers to occupy 
individual freezing vials (approximately 5-10x106 cells stored in 1-1.5ml of freeze mix.) 
Longevity of culture systems was longer than anticipated and in some cases exceeded 25 
media changes and 200 days of culture. It was decided to discontinue further expansion 
at day 200 to preserve reagents, reduce costs, and enable further SCSs to be assessed for 
proliferative capacity. There were insufficient excess cells expanded for cryopreservation 
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in any system until beyond 4 weeks of expansion. As such, and ideally, excess cells were 
frozen down at baseline, day 30, day 60, day 100, day 150 and day 200 where the culture 
system was declared ‘viable at day 200’ and discontinued. In cases where proliferation 
was inadequate, freezing was carried out once sufficient numbers had been acquired. In 
some cases freezing down of samples was not possible beyond baseline. Cells were 
subsequently analysed for extended CD4+ cell phenotype as described in Chapter 7. 
 
5.3.3.10 Senescence of culture systems 
Wells were declared senescent if after two media changes (and hence no splitting) there 
was no evidence of ongoing growth by the morphological criteria defined in Table 5.5. 
Culture systems were terminated if there were no viable wells remaining. However, even 
if a single viable well remained an attempt was made to support its growth using the 
media change technique described. A culture system was declared senescent if the 
theoretical maximum number of viable wells at any time point (CW) fell below 50% of 
the highest previous value of CW (CWmax). As explained, an attempt to maintain even a 
few remaining viable wells was made in any case. However, in no case did a culture 
system recover once there was such a reduction below CWmax, although in some cases 
the CW remained static or fell marginally before recovering again. 
 
5.3.4 Statistical Analysis 
 
5.3.4.1 Immunophenotyping 
Composition of each cell subtype defined by surface antigen expression was expressed as 
a percentage of a parent population or of all viable cells (Figure 5.4), as described in the 
results. Means were calculated for each class of SCS derived cells (malignant, non-
malignant, CHL, FL, Reactive and Tonsil) and medians compared between classes as 
non-Gaussian variables using the method of Mann & Whitney with significance values 
set at <0.05. 
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Figure 5.4: Gating strategy for analysis of SCS at baseline. SCS from CHL. Populations 
reported in subsequent analysis defined by gates as shown: Viable, CD3+, CD20+, NBNT, 
CD8+, CD4+.  
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5.3.4.2 Proliferation 
Survival of each culture system was determined by time to senescence as defined above. 
Data was pooled by class of SCS and survival duration compared between groups using 
Kaplan Meier analysis. Differences between survival of SCS classes was determined using 
the log rank method and deemed significant if the chi square value generated had an 
equivalent p value of <0.05. Proliferative capacity of each culture system was assessed at 
each media change point as described above, generating a CW value (See 5.3.3.8) at each 
time point. Differences in median proliferation (median CW) for each SCS class at each 
time point were compared assuming non-Gaussian distribution using the method of 
Mann and Whitney. 
5.4 Results 
5.4.1 Flow cytometry of single cell suspensions 
 
5.4.1.1 Viability heterogeneity between SCSs 
The viability of single cell suspensions as measured by DAPI exclusion in a population 
defined by FSc/SSc properties was highly variable between samples. There was no 
significant difference in total cellular viability comparing malignant with non-malignant 
conditions (Figure 5.5) although the numbers are small and influenced by the outliers 
which have been included. However, the suspensions with the highest viability (>70%) 
were all derived from malignant tissue and all but one of the non-malignant tissue 
samples (T1) had total cell viability <60%. This finding may influence the validity of 
subsequent immunophenotyping findings.  
 
5.4.1.2 B cell, T helper and cytotoxic T cell composition 
Representative plots for each sample type is shown in Figure 5.6. Tables 5.6 and 5.7,  and 
Figures 5.7 & 5.8 summarise the findings of immunophenotyping of the SCSs at the time 
of culture plating.  Only samples in which greater than 1000 viable events were recorded 
were analysed. With limited numbers of replicates this experiment was underpowered to 
demonstrate significant differences between the groups. The dominant lymphoid subset 
in all cases was CD3+ CD4+, or T helper cells (Figure 5.8). There was no significant 
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difference in composition of CD3+ subsets (CD4+, CD8+, DP and DN) between samples. 
CHL-derived SCS were comprised of a significantly greater proportion of CD3+ cells than 
tonsil or reactive node with corresponding reductions in CD20+ cell numbers. However, 
of those CD3+ cells there was no significant difference in relative composition defined by 
CD4 and CD8 expression (Figure 5.8). 
 
 
 
 
Figure 5.5: Viability of all SCS-derived cells at baseline. Left: Malignant-derived vs non-
malignant. Right: By histological or tissue subtype (FL (n=3): Follicular Lymphoma, CHL: 
Classical Hodgkin lymphoma (n=5), NLPHL (n=1): Nodular Lymphocyte Predominant 
Hodgkin Lymphoma, Reactive (n=2): Progressive transformation of germinal centre and 
follicular hyperplasia, Tonsil (n=3). 
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No 
viable 
cells 
% 
viable 
% 
CD20 
% 
CD3 
Of CD3% 
% 
NBNT 
% 
CD4 
% 
CD8 
% 
DP 
% 
DN 
C1 14732 29.1 53 34.6 63.1 25.4 4.1 4.4 7.7 
C2 42870 77 23.8 19.4 70.7 20.5 1.5 5.4 54.1 
C4 23941 72.1 30.4 60.7 32.9 50.1 5.1 2.2 3.1 
C5 20892 79.6 43.2 48.5 51 37.8 6.3 1.7 3.1 
C6 10368 69.1 33.9 59.1 85.9 7.4 2.7 1.7 2.2 
F1 42711 82.9 66.6 28.3 80.8 9.9 2.3 5.1 1.2 
F2 4361 47.6 77.5 6.4 45.1 9.2 4.9 34.5 9.7 
F4 70504 82.6 87.1 11.7 67.4 15.4 9.6 4.9 0.4 
L1 8626 51.2 31.1 64.5 80.3 3.1 14.6 12.1 2.3 
P1 6738 54.5 61 21.8 58.7 22.6 7.1 8 15 
R2 5335 50.8 65.5 27.9 62.9 21.4 2.3 9.8 5.2 
T1 39314 67.4 70.1 26.5 66.9 10.2 4.4 15.1 2.1 
T2 18295 51.4 68.8 23.4 58.8 15.4 1.9 20.2 5.6 
T3 68859 49.1 84.3 7.1 86.3 4.8 2.1 4.7 5.2 
T4 450 3 35.4 6.8 62.1 10.3 10.3 0 51.9 
 
Table 5.6: Composition of all viable cells at baseline in lymph node tissue derived frozen 
SCS. T4 was omitted from further analysis due to extremely poor viability and number of 
events recorded. DP = CD4+CD8+ (double positive), DN = double negative, NBNT = 
non-B non-T (CD3- CD20-). 
 
 CHL 
Mean (SEM) 
FL  
Mean (SEM) 
Reactive  
Mean (SEM) 
Tonsil  
Mean (SEM) 
CD20% 33.6 (5.1) 77.1 (5.9) 63.3 (2.3) 74.4 (4.9) 
CD3% 44.6 (7.8) 15.5 (6.6) 24.9 (3.1) 19.0 (6.0) 
CD4% 60.7 (9.0) 64.4 (10.4) 60.8 (2.1) 70.7 (8.2) 
CD8% 28.2 (7.3) 11.5 (2.0) 22.0 (0.6) 10.1 (3.1) 
CD4% of all 26.2 (6.4) 11.2 (6.0) 15.2 (2.4) 12.5 (3.4) 
Table 5.7: Summary of composition of viable cells at baseline by tissue of origin, as 
represented in Figure 5.8. SEM = Standard error of the mean. 
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Figure 5.6: Representative FACS plots derived from each sample type showing variation 
in composition of lymphoid cell subsets gating on the CD3+ population and as shown in 
figure 5.4. 
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Figure 5.7: Lymphoid subset composition of SCS at baseline. Left: CD3+ cells 
represented a significantly greater proportion of total viable cells in SCS derived from 
CHL compared to those derived from FL. Right: CD20+ represented a significantly lesser 
proportion of total viable cells in SCS derived from CHL compared to those derived from 
FL, reactive nodes or tonsil.  
 
Figure 5.8: Composition of SCS at baseline. Left: B and T cells, Right: T subsets by CD4 
and CD8 expression. Bars are subdivided by mean % of all viable cells with SEM 
indicated by bars, illustrating significant heterogeneity between samples obtained from 
each source. 
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5.4.1.3 Identification of HRS cell population: 
 
Using the gating strategy shown in Figure 5.9 (CD3-, CD20-, CD30, 40 & 95+) a small 
minority of cells fulfilling the immunophenotype criteria established by Fromm319 were 
present (Table 5.8). However, this population was not unique to the CHL-derived 
samples, also being present in tonsil and reactive cells, although not in the FL or NLPHL 
derived samples. The population was also at such a low level that validation of this 
strategy using flow sorting or other purification techniques would not be feasible. 
 
 
Sample Absolute number of 
cells in ‘HRS gate’ 
% of all 
viable cells 
C1 2 0.0001 
C2 1 0.00002 
C4 0 0 
C5 0 0 
C6 0 0 
F1 1 0.00002 
F2 0 0 
F4 0 0 
L1 1 0.0001 
P1 0 0 
R2 0 0 
T1 2 0.00005 
T2 2 0.0001 
T3 107 0.001 
 
Table 5.8: Using the strategy proposed by Fromm et al319 and illustrated in Figure 5.9, 
few cells, or none at all appeared in the proposed HRS gate for any sample, and this 
strategy was not specific for samples derived from CHL. 
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Figure 5.9: Gating strategy for analysis of identification of putative HRS population 
defined as CD3- CD20- CD30+ CD64- CD40+ CD95+. 
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5.4.2 Culture of SCS derived cells 
 
The results of initial pilot experiments to determine the optimal cytokine combination 
have been described in the methods. As such, all subsequent results are reported for IL2 
and IL2 & IL4 augmented conditions only. Viability and absolute numbers of cells plated 
at baseline is summarised in Table 5.1. Viability of cells derived from malignant and 
reactive conditions, particularly CHL was often superior at baseline to that of tonsil 
which may influence the validity of subsequent assessments of proliferation (Figure 5.5). 
 
5.4.2.1 Proliferation in culture systems 
Using only the optimised cytokine enrichment techniques, proliferation was seen in the 
majority of culture systems for the first four weeks. There was significant heterogeneity 
from sample to sample and by class of SCS source, particularly malignant vs non-
malignant.  
 
5.4.2.2 Identity of Proliferating Cells 
Immunophenotyping at day 30 and day 60 in two systems: one tonsil and one CHL-
derived, revealed that the majority of cell classes were no longer present in the system 
and that >99% of viable cells were now T cells. In CHL >95% of T cells were CD4+. In 
tonsil >80% of cells were CD8+ (Figure 5.10). Further immunophenotyping of expanding 
cell populations was performed in the experiment described in Chapter 6. However the 
absence of any CD3- or B cell population meant that there was no evidence in any CHL-
derived system of maintenance or expansion of a putative immunophenotypically-
defined HRS cell. The extended immunophenotype of the CD3+ CD4+ population at 
baseline is the subject of Chapter 6 while that of the expanded T cells is described in 
Chapter 7. 
 
Chapter 5: A culture system to sustain primary tissue-derived cells 
Page 198 
 
 
 
Figure 5.10: Composition of example cultures at day 60. Gating on all viable events there 
were no CD3 negative events at this stage. Tonsil derived cultures were comprised 
predominantly of CD8+ T cells, while CHL derived cultures comprised >97% CD4+ T 
cells, with almost complete absence of CD8+ T cells in the IL2 only condition. 
 
 
5.4.2.3 Time to Senescence 
IL2&IL4-enriched culture systems had superior survival compared to those enriched with 
IL2 alone. Pooling all malignant and benign SCS-derived culture systems, median 
survival of IL2-enriched systems was only three media changes (approximately 30 days) 
whereas 75% of IL2&IL4-enriched systems survived to 200 days or approximately 25 
media changes (Figure 5.11). The surviving IL2-only enriched systems were exclusively 
derived from CHL SCSs. No tonsil-derived cultures survived beyond 100 days or 10-12 
media changes. All CHL-derived culture systems survived beyond 200 days. Two of three 
FL-derived culture systems enriched with IL2 and IL4 survived to 200 days. Pooling all 
benign culture systems and comparing to FL and CHL-derived systems there was no 
significant difference by Kaplan Meier analysis but the number of replicates were not 
powered to detect less extreme differences between groups (Figure 5.12). 
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Figure 5.11: IL2&IL4-enriched culture conditions were longer lived than IL2-only 
enriched conditions; all samples pooled.  
 
 
 
 
Figure 5.12: Longevity of T cell cultures may have been influenced by node of origin, but 
sample size is too small to demonstrate significant differences. 
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5.4.2.4 Proliferative Capacity: IL2-only enrichment 
Proliferation was not sustained beyond 5 media changes or around 40-50 days in any IL2-
only enriched culture systems except those derived from CHL. Only two of five CHL-
derived samples enriched with IL2 only survived beyond 5 cycles (40%) but in these 
cases the proliferation was sustained beyond 200 days (Figure 5.13). Due to the poor 
survival of the IL2-only enriched conditions, subsequent analysis will only examine the 
IL2&IL4 enriched conditions. 
 
 
Figure 5.13: Graph to illustrate differences in proliferation in IL2-only and IL2&IL4-
enriched conditions for cultures derived from CHL-infiltrated lymph nodes. Since only 
two of five samples in the IL2-only condition survived beyond 5 split cycles, comparison 
of proliferation rates between the IL2-only and IL2&IL4 enriched systems could not be 
determined. However in those IL2 only-enriched samples surviving beyond 5 split cycles, 
proliferation was comparable to the IL2&4 conditions and sustained to 200 days.  
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Figure 5.14: Relative proliferation of IL2&4-enriched culture systems colour coded by 
tissue of origin and plotted for each individual sample, showing apparent superiority of 
growth of the CHL-derived systems. Note that a single non-malignant sample, derived 
from a node containing follicular hyperplasia, continued to proliferate comparably to 
malignant samples while all other non-malignant samples have senesced. 
 
5.4.2.5 Proliferative Capacity: IL2&IL4 enrichment 
Proliferation for each IL2&IL4-enriched culture system is shown in Figure 5.14, while 
Figure 5.15 shows mean proliferation for samples pooled by SCS class. Fold proliferation 
of pooled FL-derived samples compared to pooled CHL samples were 2.4 vs 16.6 at 5 
splits, 32.6 vs 228.1 at 10 splits and 250 vs 13,000 at 20 splits (Figure 5.14). However, 
statistically significant differences were not demonstrated, due to small numbers of 
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replicates and wide heterogeneity of proliferation between samples, using either a T test 
on log-transformed data for improved Gaussian distribution, or the Mann-Whitney non-
parametric test on the raw data. For similar reasons, a significant difference was not 
demonstrated between pooled malignant and pooled benign samples at 5 splits. 
However, only a single benign culture system continued to expand beyond 10 splits. This 
was derived from follicular hyperplasia (the granulomatous reactive node and PTGC 
were senescent within 5 splits) and proliferation of this sample was comparable to the 
expanding malignant culture systems (Figure 5.13). 
 
 
Figure 5.15: Mean relative proliferation of IL2&4-enriched culture systems by tissue of 
origin showing an apparent superior proliferation in CHL-derived systems compared to 
FL and non-malignant derived systems. This did not reach statistical significance owing 
to low replicate numbers and wide heterogeneity in proliferative capacity between 
samples. 
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5.5 Discussion 
In order to study the functional relationship between HRS cells and a major component 
of the inflammatory infiltrate – CD4+ T cells – in an in vitro co-culture system capable of 
further manipulation, an attempt was made to sustain lymph node-derived cells ex vivo. 
The B cell helping T cell phenotype, Th2 is proposed in the literature to represent the 
majority of the T cell infiltrate although the functional evidence for this is scarce, and as 
such Th2-polarising cytokines were used to supplement the system.  
 
Using a previously validated panel of antibodies in a flow cytometric assay, five frozen 
SCSs derived from CHL infiltrated lymph nodes were examined for the presence of the 
malignant HRS cell. However this strategy failed to identify a convincing population 
present at sufficiently high numbers, or which was absent in control lymph nodes. 
Additionally, there was no evidence for the presence of this population after 30 days in 
culture. However, there was significant proliferation in IL2&IL4 augmented media, 
which was sustained for many weeks, up to and beyond 200 days or 25 media changes for 
all CHL-derived cultures and the majority of FL-derived cultures. Benign lymph nodes 
did not show the same longevity or proliferative capacity with the exception of a single 
case of follicular hyperplasia. 
 
This culture system is unsuitable as a model system to manipulate trophic or 
antagonistic factors conferred by T cells on the malignant cell in CHL since no malignant 
cell population could be convincingly identified. The conflict with the results of Fromm’s 
group, and other groups which have successfully isolated PCR-defined clonal HRS cells 
using magnetic bead sorting based on surface antigen phenotype465 may be explained by 
differences in preparation technique, in particular the use of frozen samples in this case, 
in which only the most robust cells in the node survive the initial indeterminate period 
prior to SCS preparation, and then the subsequent freezing process. HRS cells in 
particular are known to be pre-apoptotic and replicatively senescent320 with the 
exception of cell lines unable to survive ex-vivo, while lymphocytes, particularly T 
lymphocytes, are known to have remarkable proliferative capacity ex-vivo. Activated 
lymph nodes, such as those in a malignancy-infiltrated process or reactive process, as 
opposed to predominantly quiescent nodal tissue such as tonsil, are likely to have greater 
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proportions of viable cells capable of surviving this preparation and this was evidenced 
by the predominantly low viability at baseline in tonsillar, compared to malignancy-
derived cells. 
 
Long-lived non-malignant T cells (predominantly CD4+) have been generated from 
malignant and non-malignant inflammatory tissue by another group, using inflamed 
skin specimens466. All culture systems in this case were established as in this experiment 
without stimulatory TCR agonist, plant lectin or super-antigen exposure. The resultant 
cell lines were IL2-dependent in all cases and IL2 and IL4-dependent in some cases, with 
the dependence on IL4 being lost in some cases, as has been observed in this experiment. 
7/12 atopic dermatitis derived T cell lines persisted beyond 40 to 50 population 
doublings, to 500 doublings in one case, retaining their requirement of cytokine 
augmentation. Details of culture conditions (e.g. culture plates and supplementation to 
the media) are not provided but it appears that doubling was occurring every 20-30 
hours in these systems, far exceeding anything in the experiments described in this 
chapter. Further work arising from this finding is not published and further 
characterisation of the resultant T cells in terms of clonality, function or surface 
phenotype not performed or documented. T cell proliferation and expansion is easily 
achieved in vitro but requires combined ‘signal one’ stimulation via the TCR, either 
specifically and directly (antigen/APC or peptide tetramer), non-specifically and directly 
(anti-CD3 with co-stimulatory anti-CD28) or non-specifically and indirectly (super-
antigen such as SEB, small molecules or plant lectins such as PMA, PHA and 
Concanavalin).  Cytokines provide augmentation of the so-called ‘signal two’ stimulation 
(such as IL2), and altered intracellular signalling may alter the eventual proliferative 
capacity and phenotype of resulting cells (polarising conditions including IL4 and anti-
IL12, or IL12 and anti-IL4 to produce Th2 or Th1 cells respectively). Supra-physiological 
doses of such cytokines can provide TCR-independent stimulus sufficient to induce 
activation and proliferation467 although this phenomenon is reported more in CD8+ T 
cells than CD4+, which may simply reflect a publication or investigator bias than a true 
physiological distinction between the cell subtypes. Most T cell expansion protocols 
suggest restimulation through the TCR every 7-10 days. However there is in vitro and in 
vivo468 evidence to suggest that once activated, a proliferating population of CD4+ T cells 
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can continue to expand without further antigen exposure, although augmentation of 
proliferation is achieved upon re-exposure to antigen. Conversely other studies have 
demonstrated a dependence on ongoing TCR stimulation469. IL2 is thought to be the 
major mediator of this process469 although believed not to be important in proliferation 
of naïve T cells. It seems unlikely in the culture systems described in this experiment 
that any antigen persists and hence TCR-independent proliferation must be occurring. 
IL2 dependence of ongoing survival is confirmed. However there is no further 
investigation of the mechanism of such cytokine-dependent TCR-independent expansion 
in the literature, nor of the contribution of IL4 to such a system. The culture systems 
established here are extremely artificial, in vitro and as such likely unrepresentative of 
any in vivo process. At best the superior proliferation seen in some systems, particularly 
malignant over non-malignant and possibly CHL-derived over any other system, may be 
a functional read-out of activation status of a minority of T cells in the tissue of origin. 
However, it may represent a functional class of T cells lying dormant and non-functional 
in the context of the lymph node, but which is ‘primed’ for proliferation and function. 
The mediators of its suppression are unclear, but apparently overcome by removal of 
these cells from the node environment and exposure to large excesses of IL2 and IL4. The 
importance of other non-T and CD4- constituents of the cell suspension at this time in 
stimulating or suppressing T cell growth is not clear.  
 
Further experiments to determine this would include purification of the CD4+ cells prior 
to plating and exposure to the same cytokine enriched media. Ongoing presence of a 
malignant cell providing antigen to be recognised by the proliferating CD4+ T cells is 
unlikely given the relative purity of the CD4+ component of the system after several 
weeks proliferation, and the virtual absence of HRS-phenotype cells at baseline. A HRS 
precursor, progenitor or stem cell of a different phenotype could be driving the process 
but there is no established phenotypic marker of this and it remains a hypothetical 
concept323. There is no evidence that the proliferating T cells are tumour antigen specific: 
priming or preactivation could in itself have been a result of exposure to the cytokine 
and chemokine products and cell-cell interactions within the malignant node, of tumour 
non-specific T cells that have been passively attracted into and retained within the node. 
Hence these cells could be derived from memory, rather than naïve T cell populations 
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whose TCR-independent, cytokine dependent proliferation and survival has been 
investigated previously468. Relatively slow overall proliferation compared to that achieved 
with TCR-stimulating expansion techniques implies that only a small minority of T cells 
are expanding even in the most proliferative system. 
 
There is little or no information in the literature investigating the molecular mediators, 
nor the functional, gene or protein expressing phenotype of the T cells participating in 
this in vitro phenomenon, despite its being well described. Further experiments to 
characterise the expanding T cell populations arising from each SCS class, along with 
markers present at baseline and predictive of the T cells possessing such capabilities will 
be described in Chapter 6 and 7. A better understanding of this in vitro phenomenon 
may provide insight into why this apparently activated and expansile population is 
suppressed within the tumour microenvironment and may enable in vivo activation by 
pharmacological means. 
5.6 Summary and Further Work 
Taken together, these data suggest that the immune microenvironment of CHL may be 
investigated using frozen SCS prepared as described, that HRS cells may not be detected 
using a previously proposed panel of antibodies in frozen samples, nor can any putative 
malignant population be sustained in culture. However, the CD4+ T cell component in 
CHL is not anergic or hypoproliferative as has been suggested and apparently 
demonstrated functionally299, but rather highly responsive to a cytokine-induced 
proliferation, most optimally with IL2 and IL4 augmentation. This phenomenon may 
also be a feature of other malignant and benign reactive tissue: certainly in some cases of 
FL and in one case of FH, but not in tonsil-derived tissue. The phenotype of this 
proliferating CD4+ population, although an artificial in vitro phenomenon, and 
differential expression of CD4+ markers at baseline should be assessed in order to 
determine the origin of this survival advantage, and potential implications for the 
pathophysiology of the disease. 
  
 
 
 
 
 
 
CHAPTER SIX: 
 
Fluorescence immunophenotyping to 
functionally characterise and 
discriminate CHL-infiltrating CD4+ T 
cells from other lymph node-infiltrating 
CD4+ T cells 
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6. Fluorescence immunophenotyping to functionally 
characterise and discriminate CHL-infiltrating CD4+ T cells 
from other lymph node-infiltrating CD4+ T cells 
6.1 Introduction 
The introduction to this thesis (1.5) has described the genes and proteins through which 
T cells exert their influence on the HRS cell in CHL. Pharmacological manipulation of 
these factors may result in improved treatments, however as discussed in Chapter 5, 
basic functional data is lacking. Studies investigating the entire microenvironment have 
the disadvantage of failing to discriminate the contribution of individual cells, leading to 
a loss of information. However, investigation only of individual cellular components may 
fail to recognise the importance of complex coordinated systems and networks at work 
in the CHL microenvironment. 
6.2 Aims and Objectives 
The aim of this study was to use multi-parameter flow cytometry to validate markers 
described in the literature as being important in CD4+ T cells in CHL, and in 
physiological B/T cell interactions, and use these to characterise the CD3+CD4+ infiltrate 
in CHL. By defining CHL-specific CD4+T cell-mediated functional pathways and 
contrasting them with those present in other haematological malignancies (using FL and 
NLPHL samples as controls), reactive nodes (PTGC, FH and bacterial reactive node), and 
tonsils potential mediators of the pathophysiology of the disease may be determined. In 
addition, identifying markers showing substantial heterogeneity of expression across 
CHL samples will allow application to a wider patient cohort using IHC in order to 
investigate for interactions with clinical factors, in particular prognosis. Hence an 
understanding of the disease-defining and pathophysiological heterogeneity-conferring 
molecular signature of the CD4+ T cell could be established for future functional 
experiments manipulating these factors. The drawbacks of analysis by IHC, or gene 
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expression profiling of unselected, heterogeneous cell populations have been discussed 
in the Introduction 1.9.2.2 and 1.9.2.3.  
6.2.1 Selection of antigens for T cell panel 
Flow cytometry is limited by the number of factors assessable simultaneously and the 
expense of the reagents per factor analysed, in contrast for example to gene expression 
profiling. Multicolour flow is usually performed with a panel of 4-8 markers, although 
using newer techniques 20 and more may be assessed simultaneously. However the 
technique has the advantage of analysing on an individual cell basis and therefore 
expression of proteins is not ‘averaged’ across heterogeneous cell populations but instead 
determined for specific subpopulations. This property also enables cells to be analysed at 
relatively low numbers with minimal disruption prior to analysis (single cell suspension 
preparation, wash, stain, analyse) compared, for example, to nucleic acid extraction and 
gene expression profiling, or formalin fixation, paraffin embedding and IHC. For these 
reasons, and due to the extremely limited amount of tissue available as frozen SCSs, flow 
cytometry was selected as the method to analyse the properties of the CD4+ T cells. 
Selection of this method meant that the number of function-defining antigens available 
for investigation was limited and as such stringent antigen-selection criteria were 
applied, as justified in the Introduction, and summarised in Table 6.1. 
6.3 Materials and Methods 
6.3.1 Single cell suspensions 
Single cell suspensions used for extended phenotype analysis of the CD3+ CD4+ 
population were as used in chapter 5 and detailed in Table 5.1. 
6.3.2 Selection of fluorochromes and antibodies 
The difficulty of attributing T cells to functional subsets, as well as the limited validity of 
subset-defining markers has been described. Therefore only antigens with a pre-existing 
evidence base for expression or functional importance in CHL were selected for further 
investigation. These have been described in detail in the introduction and are 
summarized in Table 6.1. 
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CD / 
Common 
name 
Eponym Class Justification for inclusion 
CD134 OX40 TNFRSF ?HRS promotion 
CD154 CD40-L TNFRSF ?HRS promotion 
CD254 RANK-L TNFRSF ?HRS promotion 
CD278 ICOS IGRSF ?HRS promotion 
CD30 - TNFRSF ?HRS promotion 
CD40 - TNFRSF ?HRS promotion 
IL13 - CK ?HRS promotion 
IL21 - CK ?HRS promotion 
IL6 - CK ?HRS promotion 
TNFα - CK ?HRS promotion 
CD69 - ? T cell activation 
CD27 - TNFRSF T cell activation 
CD28 - IGRSF T cell activation 
CD122 IL2-Rb CK receptor T cell activation 
CD124 IL4-Ra CK receptor T cell activation 
CD132 CGC CK receptor T cell activation 
CD25 IL2-Ra CK receptor T cell activation 
IL2  CK T cell activation 
CD127 IL7-Ra CKR SUBSET: Memory T cell 
CD197 CCR7 CKR SUBSET: Naïve T cell / lymphoid 
homing 
CD62L L-selectin Adhesion SUBSET: Naïve T cell / lymphoid 
homing 
CD45RO -  SUBSET: Memory T cell 
CD45RA -  SUBSET: Naïve T cell / Late memory T 
cell 
CD185 CXCR5 Chemokine receptor SUBSET: Tfh 
IFN-γ  CK SUBSET: Th1 
CD183 CXCR3 Chemokine receptor SUBSET: Th1 
IL4 - CK SUBSET: Th2 
CD193 CCR3 / RANTES-
receptor 
Chemokine receptor T CELL RECRUITMENT: Th2 
CD194 CCR4 / 
TARC-receptor 
Chemokine receptor T CELL RECRUITMENT: Th2/Treg 
CD195 CCR5 / 
MIP1a-receptor 
Chemokine receptor T CELL RECRUITMENT: Th1 
CD196 CCR6/ 
MIP3-receptor 
Chemokine receptor T CELL RECRUITMENT: Treg/Th17 
CD178 FAS-ligand TNFRSF Apoptosis/Activation 
CD95 FAS TNFRSF Apoptosis/Activation 
CD152 CTLA-4 IGRSF Immunosuppression 
CD274 PD-L1 IGRSF Immunosuppression 
CD279 PD1 IGRSF Immunosuppression 
CD57 - ? Senescence 
 
Table 6.1: Justification for selection of antigens for use in CD4+ characterising panel. 
Key: ?HRS Promoting: ligand for receptor expressed on Hodgkin-Reed-Sternberg cell 
with evidence for downstream pathway activation promoting survival, anti-apoptotic 
factors or proliferation. 
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Table 6.2: Details of fluorochromes for CD4+ T cell typing experiment 
 
CD / 
Common 
name 
Eponym Clone Isotype Source Fluoro-
chrome 
Tube 
CD4 - RPA-T4 Mouse IgG1-κ BD Horizon 
V500 
1-8 
CD69 Very Early 
Activation 
Antigen 
FN50 Mouse IgG1-κ Biolegend PE/Cy7 4&5 
CD3 - UCHT1 Mouse IgG1-κ BD FITC 1-5, 
7&8 
CD134 OX40 / 
TNFRSF4 
Ber-ACT35 Mouse IgG1-κ Biolegend 
 
PerCP/Cy5.
5 
1 
CD154 CD40-L 24-31 Mouse IgG1-κ Biolegend 
 
APC/Cy7 1 
CD178 FAS-ligand 
/  
CD95-L 
NOK-1 
 
Mouse IgG1-κ BioLegend 
 
PE 1 
CD278 ICOS C398.4A Armenian 
Hamster IgG 
Biolegend 
 
PE/Cy7 1 
CD28 T44/Tp44 CD28.2 
 
Mouse IgG1-κ BioLegend Alexa 
Fluor® 700 
1 
CD30 TNFRSF8 BY88 Mouse IgG1-κ Biolegend 
 
APC 1 
CD40 TNFRSF5 5C3 Mouse IgG1-κ Biolegend 
 
PerCP/Cy5.
5 
1 
CD95 FAS / 
TNFRSF6 
DX2 
 
Mouse IgG1-κ BioLegend 
 
PE/Cy5 1 
CD185 CXCR5 TG2/CXCR
5 
 
Mouse IgG2b-κ 
 
BioLegend 
 
PerCP/Cy5.
5 
2 
CD193 CCR3 / 
RANTES-
receptor 
5E8 
 
Mouse IgG2b-κ 
 
BioLegend 
 
PE 2 
CD194 CCR4 /  
TARC-
receptor 
TG6/CCR4 
 
Mouse IgG2b-κ 
 
BioLegend 
 
PE/Cy7 2 
CD195 CCR5 /  
MIP1a-
receptor / 
HIV-1 
fusion co-
receptor 
HEK/1/85a Rat IgG2a-κ BioLegend Alexa 
Fluor® 700 
2 
CD196 CCR6/  
MIP3-
receptor 
TG7/CCR6 Mouse IgG2b-κ 
 
BioLegend 
 
Alexa 
Fluor® 647 
2 
CD127 IL7-Ra A019D5 Mouse IgG1-κ BioLegend 
 
PerCP/Cy5.
5 
3 
CD152 CTLA-4 L3D10 Mouse IgG1-κ BioLegend 
 
PE 3 
CD183 CXCR3 1C6/CXCR3 Mouse IgG1-κ 
 
BD PE 3 
CD197 CCR7 3D12 Rat IgG2a-κ BD PE/Cy7 3 
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CD / 
Common 
name 
Eponym Clone Isotype Source Fluoro-
chrome 
Tube 
CD274 PD-L1 / B7-
H1 
29E.2A3 
 
Mouse IgG2b-κ 
 
BioLegend 
 
APC 3 
CD279 PD1 EH12.2H7 Mouse IgG1-κ BioLegend APC/Cy7 3 
CD62L L-selectin DREG-56 Mouse IgG1-κ 
 
BioLegend 
 
PE/Cy5 
 
3 
IFN-γ - 4S.B3 Mouse IgG1-κ BD PE 4 
IL2 TCGF MQ1-17H12 
 
Rat IgG2a, κ BioLegend 
 
Alexa 
Fluor® 700 
4 
IL6 - MQ2-13A5 Rat IgG1, κ 
 
Biolegend APC 4 
TNFα - MAb11 
 
Mouse IgG1-κ Biolegend PerCP/Cy5.
5 
4 
CD122 IL2-Rb 9A2-CD122 
 
Mouse IgG2a, κ Ebioscience PerCP-
eFluor 710 
5 
CD124 IL4-Ra hIL4R-M57 Mouse IgG1-κ BD PE 5 
CD132 CGC TUGh4 
 
Rat IgG2b-κ BioLegend 
  
APC 5 
CD25 IL2-Ra BC96 Mouse IgG1-κ BioLegend 
 
PE/Cy5 5 
CD27 S152/T14 O323 Mouse IgG1-κ Biolegend PerCP/Cy5.
5 
5 
CD20  2H7 Mouse IgG2b-κ BD APC-H7 6 
CD3  UCHT1 Mouse IgG1-κ Biolegend PE-Cy7 6 
CD30 TNFRSF8 BY88 Mouse IgG1-κ Biolegend PE 6 
CD40 TNFRSF5 5C3 Mouse IgG1-κ Biolegend PerCP-
Cy5.5 
6 
CD64 Fc-γ-R1 10.1 Mouse IgG1-κ Biolegend APC 6 
CD8 - HIT8A Mouse IgG1-κ Biolegend Alexafluor 
700 
6 
CD95 FAS / 
TNFRSF6 
DX2 Mouse IgG1-κ BD 
 
APC 6 
CD254 RANK-L / 
TRANCE 
MIH24 Mouse IgG1-κ Biolegend 
 
PE 7 
CD45RA - HI100 
 
Mouse IgG2b-κ 
 
BioLegend 
 
APC/Cy7 7 
CD45RO - UCHL1 Mouse IgG2a-κ 
 
BioLegend 
 
PE/Cy5 7 
CD57 NK-1, / Leu-
7 
HCD57 
 
Mouse IgM-κ 
 
BioLegend 
 
Alexa 
Fluor® 647 
7 
CD69 Very Early 
Activation 
Antigen 
FN50 Mouse IgG1-κ BD Alexa 
Fluor® 700 
8 
IL4 BSF-1 / 
TCGF-2 
8D4-8 
 
Mouse IgG1-κ BioLegend 
 
PE 8 
IL10 B-TCGF / 
TGIF 
JES3-9D7 Rat IgG1-κ 
 
BioLegend 
 
PE-Cy7 8 
IL13 - JES10-5A2 Rat IgG1-κ Biolegend 
 
APC 8 
IL21 - 3A3-N2 
 
Mouse IgG1-κ Biolegend PE 8 
Table 6.2: Details of fluorochromes for CD4+ T cell typing experiment 
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Final fluorochrome panels were based on optimisation experiments using combinations 
of fluorochromes with manageable spectral overlap, in order to minimise total number 
of tubes and hence cells used and enable processing of up to twenty samples in each 
batch. Combinations (cocktails) were based on availability of compatible conjugated 
antibodies and ‘class’ of target antigen as summarised in Table 6.3 with conjugate details 
in Table 6.2. 
 
Cocktail 
number 
Antigen Class 
1 TNFRSF/IGSF 
2 Chemokine receptor 
3 Suppressor/Memory (homing) 
4 CYTOKINE PANEL: Th1/proinflammatory 
5 Cytokine receptor 
6 Lymphocyte Subsets / TNFRSF 
7 Activation/Senescence/Memory (CD45) 
8 CYTOKINE PANEL: Th2/suppressor 
 
Table 6.3: Summary of cocktails and major antigen class for analysis within each cocktail 
6.3.3 Flow cytometric analysis, data acquisition, compensation and gating  
This has been described and justified in detail in Materials and Methods 2.3. 
6.3.4 Statistical Analysis 
6.3.4.1 Differences between sample classes / lymph node of origin 
Percentage expression of each marker within the CD3+ CD4+ population was pooled for 
each sample class and expressed as mean percentage for each sample class (CHL, FL, 
Reactive, Tonsil) and for a separate calculation of mean expression for all control 
samples (‘pooled controls’). Significance of differences of expression was compared 
between samples assuming non-Gaussian distribution of data using the Mann-Whitney 
U test with significance set at the <0.05 level. Only a single case of NLPHL was available 
for this experiment, the analysis of which is included in each figure for completeness.  
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6.3.4.2 Hierarchical Cluster Analysis 
Hierarchical cluster analysis was applied to these flow cytometry results in order to test 
the hypothesis that the composition of the CD4+ component in CHL was unique to the 
disease and able to discriminate it from all other sample classes, and also in order to 
better visualise the combined flow cytometry data. The data was log transformed to 
remove skew and each marker was expressed as the number of SDs from the mean across 
all samples. Hierarchical clustering derived from this data was applied using complete 
linkage and Pearson correlation for the distance metric, based on a method applied in 
previous published literature using cluster analysis to discriminate lymphoid subsets 
from flow cytometric data, which found that the most stable clustering based on 
multiple replicates of randomised samples was derived from these statistical 
algorithms470. Analysis was performed using the Cluster 3.0 software package 
(eisen@rana.lbl.gov; copyright Stanford University) and presented using the Java 
Treeview (V1.1.6r2) package (alokito@users.sourceforge.net). 
6.4 Results 
6.4.1 Raw Flow Cytometry Data 
Representative scatterplots from only four of the analysed cases are presented: in all 
cases for C1, C4, N4 and P1 representing two cases of CHL, one of FL and a PTGC. 
Comparative data for all markers are described below and shown in Tables 6.4-6.11 and 
Figures 6.1-6.9 grouped by functional class or staining cocktail from which they were 
derived. In all cases, the expression level of each marker is expressed as a percentage of 
all CD3+ CD4+ cells for each sample, and means derived from data pooled by sample 
class as described in 6.3.4.1 (lymph node of origin), or calculated from all control samples 
compared to mean expression in pooled CHL-derived samples, depicted in the figures 
with standard errors of the mean indicated. Any significant differences between mean 
expression is indicated on figures. 
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6.4.1.1 Cocktail 1: TNFRSF/IGSF (Table 6.4; Figures 6.1 & 6.2 a&b) 
Data for RANK-L and CD69 are included due to functional grouping with TNFRSF/IGSF 
members, but were acquired from Cocktails 5&7 due to fluorochrome combination 
considerations. CD154/CD40L was significantly under-expressed by CD3+CD4+ cells 
derived from CHL SCSs compared to tonsillar controls (mean = 6.0% vs 17.9%; p=0.036), 
but not pooled controls. No other marker was represented at a statistically significant 
differential level in CHL samples compared to controls, either individually or pooled, 
Both CD27 and CD28 were expressed at high levels in all samples (mean CD27 = 57.4% of 
CHL-derived CD3+ CD4+ cells vs 60.6% controls, CD28 = 43.5% of CHL-derived CD3+ 
CD4+ cells vs 31.9% controls). CD95 was expressed in a mean of 79% of CHL-derived 
CD3+CD4+ cells vs 96% pooled controls and 90% of FL-derived CD3+CD4+ cells. CD95 
was expressed in a mean of 79% of CHL-derived CD3+CD4+ cells vs 96% pooled controls 
and 90% of FL-derived CD3+CD4+ cells. OX40 was expressed in a mean of 34% of CHL-
derived CD3+CD4+ cells vs 30% pooled controls and 35% of FL-derived CD3+CD4+ cells. 
ICOS was expressed in a mean of 49% of CHL-derived CD3+CD4+ cells (range 28%-77%) 
vs 58% pooled controls, 60% of FL-derived and 79% tonsil-derived CD3+CD4+ cells. 
 
RANK-L was not expressed at a level exceeding 1.5% in any sample nor was there any 
appreciable difference for this marker between CHL-derived and any control SCS-
derived CD3+CD4+ cells. CD69 is significantly under-expressed in the CD3+CD4+ 
component of CHL (mean=51.5%) compared to tonsils (mean=81.9%; p=0.04) but not 
reactive nodes (mean=50.2%; p=0.23) or pooled controls (mean=63.7%; p=0.23).  
  
 
Figure 6.1a: Cocktail 1 Analysis: TNFRSF and IGSF member expression. Representative FACS plots for four samples showing variability 
of expression of markers in CD3+ CD4+ population. C2&C4: CHL; N4: FL; P1: PTGC. Results for all samples are summarised in Table 6.4. 
  
 
 
Figure 6.1b: Cocktail 1 Analysis: TNFRSF and IGSF member expression. : Summary of expression of cocktail 1 markers shown as a % of 
all viable CD3+CD4+ cells. Sample set is indicated on the x axis. ‘Controls’ indicates pooled control (not CHL) samples. Individual 
results are plotted, along with mean (horizontal line) and SEM (vertical bars). Medians were compared assuming non-Gaussian 
distribution of data using the Mann-Whitney U test. 
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Figure 6.2a: CD69 analysis: Representative FACS plots for four samples showing 
variability of expression of CD69 in CD3+ CD4+ population. C2&C4: CHL; N4: FL; P1: 
PTGC. Results for all samples are summarised in Table 6.4.  
 
 
 
Figure 6.2b: CD69 Analysis: CD69 is significantly under-expressed in the CD3+CD4+ 
component of CHL (mean=51.5%) compared to tonsils (mean=81.9%; p=0.04) but not 
reactive nodes (mean=50.2%; p=0.23) or pooled controls (mean=63.7%; p=0.23). 
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ID %CD3+ %CD4+ CD4 CD95+ CD95hi CD28+ CD134+ RANK-L 
C1 46.8 65.3 12314 78.4 26.3 45.5 24.9 2 
C2 19.1 48.4 11464 81.5 49.5 54.6 51.2 0.2 
C4 56.6 40.3 6307 54.8 21.8 28.4 27.5 0.7 
C5 54.8 54.4 5849 78.3 41.8 28 25.9 0.8 
C6 50 77.3 6073 90.8 47.6 61 43.3 0.5 
L1 65 75.2 748 99.6 68.4 41.8 17.8 0.5 
N1 31.4 83.4 12493 88.5 75.3 42.4 41 0.4 
N2 6.5 52.8 174 98.8 31 9.8 33.3 0 
N4 12.9 68.6 6734 88.2 57.6 26.4 27.4 0.4 
P1 21.1 62 1719 89.7 56.7 42.1 34.7 0.6 
R1 45 53.4 1033 76.2 18.8 28.8 16.8 0.7 
R2 27.9 69.7 1115 48 17.6 18.5 20.6 0.6 
T1 25.8 66.2 7282 95.5 45.8 49.8 25.8 0.5 
T2 18.8 62.4 2084 73.9 28.3 20.2 18.7 1.1 
T3 7.3 84 2304 96.6 68.9 39.3 34.3 1.4 
 
 
 
ID CD278+ CD278hi CD154+ CD178+ CD30+ CD69+ CD27+ 
C1 27.4 6.8 4 4.4 0.6 41.1 59.9 
C2 67.6 50.4 6 1.1 0.6 61.7 54.5 
C4 39 14.2 5 0.7 0.9 44.1 73.8 
C5 42 18.5 4.6 0.6 0.7 53.5 62.7 
C6 70.5 49 10.2 1.2 0.9 57 35.9 
L1 46.9 4.5 3.2 0.9 0.2 69.3 32.1 
N1 65.3 8.8 2.9 0.5 1.4 74.4 62.7 
N2 19 1.7 0.6 0 0.6 x x 
N4 48.7 13.2 7.5 1.8 0.8 66.3 73.7 
P1 61.1 20.6 10 1.8 0.9 74.4 60.2 
R1 14.6 4 3.4 1.4 0.7 31.7 28.8 
R2 25.2 7.4 4.1 0.5 0.6 44.5 73 
T1 82.7 60.1 17.8 2.9 0.3 85.8 69.3 
T2 58.2 30.1 10.5 0.9 0.4 71.9 72.4 
T3 85.9 43.7 25.4 8.7 0.7 88 74.3 
 
Table 6.4: Expression of Cocktail 1 markers (TNFRSF/IGSF) expressed as % of all 
CD3+CD4+ events. Total number of CD4+ events is shown to illustrate wide 
heterogeneity between samples. A minimum of 500 viable CD4+ events was required for 
inclusion in the statistical analysis. %CD3 is expressed as % total viable events. %CD4 is 
expressed as % total CD3+ events. 
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6.4.1.2 Cocktail 2: Chemokine Receptors (Table 6.5; Figures 6.3a&b) 
CXCR5 was under expressed in CHL CD4+ T cells compared to pooled controls 
(mean=25.8% vs 48.7%, p=0.099/ns), significantly lower than tonsil (mean=65.2%, 
p=0.037). CCR3 and CCR6 were expressed at relatively low levels in all samples (<10%) 
but relatively over expressed in CHL CD4+ T cells population compared to pooled 
controls (CCR3 mean=5.9% vs 2.2%, p=0.043; CCR6 mean=2.42% vs 0.85%, p=0.036). 
CCR4 and CCR5 were heterogeneously expressed across all samples without significant 
differences in mean expression levels. 
 
 
ID CD4 CCR3 CCR4+ CCR5+ CCR6+ CXCR5 
C1 5196 12.3 42.9 15.4 2.9 13.7 
C2 5411 2.9 66.2 33.5 1.2 6.8 
C4 6052 2 15.4 12 3.4 30.4 
C5 6131 7 22 24.2 2.7 30.5 
C6 6150 4.3 77.2 10.1 1.9 47.5 
L1 6478 1.9 33.4 29.2 0.3 53.2 
N1 6221 1.4 14.5 6.5 0.4 73.4 
N2 474 3 51 17.2 1.3 26.7 
N4 5580 1.6 50.1 13.8 0.3 43.8 
P1 2490 1.1 40.5 2.7 0.3 46.2 
R1 938 4.3 57.1 41 3.4 22.6 
R2 2157 1.2 16.7 1.1 0.2 25.2 
T1 6892 2 53.1 2.7 0.5 66 
T2 2567 1.2 25.7 5.2 0.2 56 
T3 5682 4.7 27.1 12.5 1.6 73.5 
 
Table 6.5: Expression of Cocktail 2 markers (Chemokine Receptors) expressed as % of all 
CD3+CD4+ events. Total number of CD4+ events is shown to illustrate wide 
heterogeneity between samples. A minimum of 500 viable CD4+ events was required for 
inclusion in the statistical analysis.  
  
 
Figure 6.3a: Cocktail 2 Analysis: Chemokine receptor expression. Representative FACS plots for four samples showing variability of 
expression of markers in CD3+ CD4+ population. C2&C4: CHL; N4: FL; P1: PTGC. Results for all samples are summarised in Table 6.5. 
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Figure 6.3b: Cocktail 2 Analysis: Chemokine receptor expression.  
Overview of expression of cocktail 2 markers shown as a % of all viable CD3+CD4+ cells. 
Sample set is indicated on the x axis. ‘Controls’ indicates pooled control (not CHL) 
samples. Individual results are plotted, along with mean (horizontal line) and SEM 
(vertical bars). Medians were compared assuming non-Gaussian distribution of data 
using the Mann-Whitney U test.  
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6.4.1.3 Cocktail 3a: Naïve T cell markers / Lymphoid tissue homing markers (Table 6.6 
and Figures 6.4a&b) 
 
CCR7 and CD62L were both over-expressed in CHL compared to pooled control, with 
double positive cells particularly discriminatory (Mean % total CD3+CD4+ cells 
CCR7+CD62L+ in CHL 16.6% vs 4.8% pooled controls (p=0.001), vs 4.3% tonsils 
(p=0.036) and vs 4.8% reactive (p=0.036). CD62L was expressed in 50.4% of CHL 
CD3+CD4+ T cells, compared to 18.2% pooled control (p=0.002) and 14.5% tonsil 
(p=0.036) CD3+CD4+ cells. CD127 was over-expressed in 23.3% CHL T cells, compared to 
11.1 % pooled controls (p=0.012) using the arbitrary CD127hi gate determined as defined 
in Figure 6.4a.  By MFI of all CD3+CD4+ cells there was also evidence of over-expression: 
MFI in CHL was 402 vs 248 in pooled control (p=0.05), although the limitations of 
application of comparative statistics on arbitrary, compensated logarithmic values 
generated using flow cytometry in terms of validity and translatability have been 
discussed in 2.3.10.3. 
 
ID CD4 CD62L+ CCR7+ 
CD62L+ 
CCR7+ CD127+ 
CD127 
MFI 
C1 4699 32.6 22.7 8.1 36.1 658 
C2 5419 71.2 13.2 10.7 16.5 195 
C4 5156 48.9 31.5 19.9 26.5 468 
C5 5315 58.5 42.5 31.9 24.6 413 
C6 5040 40.7 21.9 12.2 12.8 277 
L1 5114 4.5 4.8 1.8 6.4 239 
N1 4885 18.7 13.5 6.1 7.5 148 
N4 5399 27.3 17.2 7.5 14.1 187 
P1 558 19.2 8 4.1 11.6 267 
R1 1770 16.6 52.6 7.3 22.7 413 
R2 526 33.6 7.8 3 14.6 384 
T1 4766 15.8 11.8 3.7 8.5 245 
T2 573 21 17.8 7.7 11 237 
T3 4158 6.8 5.3 1.6 3.1 111 
 
Table 6.6: Expression of Cocktail 3 naïve / homing T cell markers expressed as % of all 
CD3+CD4+ events. Total number of CD4+ events is shown to illustrate wide 
heterogeneity between samples. A minimum of 500 viable CD4+ events was required for 
inclusion in the statistical analysis. %CD3 is expressed as % total viable events.  
  
 
Figure 6.4a: Cocktail 3a Analysis: Naïve T cell / T cell homing markers. Representative FACS plots for four samples showing variability 
of expression of markers in CD3+ CD4+ population. C2&C4: CHL; N4: FL; P1: PTGC. Results for all samples are summarised in Table 6.6. 
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Figure 6.4b: Cocktail 3a Analysis: Naïve T cell / T cell homing markers. ‘Controls’ 
indicates pooled control (not CHL) samples. Individual results are plotted, along with 
mean (horizontal line) and SEM (vertical bars). Medians were compared assuming non-
Gaussian distribution of data using the Mann-Whitney U test.  
  
 
Figure 6.5a: Cocktail 3b Analysis: Immunosuppressor markers. Representative FACS plots for four samples showing variability of 
expression of markers in CD3+ CD4+ population. C2&C4: CHL; N4: FL; P1: PTGC. Results for all samples are summarised in table 6.7. 
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ID CD4 PD1+ PD-L1+ PD-L1 MFI CTLA4+ CD57+ 
C1 4699 7.3 9.9 86 4.4 5.2 
C2 5419 16.2 17 85 10.9 3.1 
C4 5156 18.3 3.2 34 2.5 6.8 
C5 5315 16.9 5.9 50 4.6 4.7 
C6 5040 51.4 1.7 23 12.8 5.7 
L1 5114 86.9 3.2 14 3.9 54.5 
N1 4885 76.7 1.3 1 4.2 28.3 
N4 5399 54.1 1.6 12 2.6 32.6 
P1 558 54.6 2.2 25 4.1 8.2 
R1 1770 20.6 1.8 23 2.3 5.5 
R2 526 21.3 1.3 18 2.7 7.5 
T1 4766 79.4 5.4 21 5.8 21.1 
T2 573 53.9 3.5 16 4.7 36.7 
T3 4158 90.3 7.7 27 15.4 40.6 
 
Table 6.7: Expression of Cocktail 3b immunosuppressive/senescence T cell markers 
expressed as % of all CD3+CD4+ events. Total number of CD4+ events is shown to 
illustrate wide heterogeneity between samples. A minimum of 500 viable CD4+ events 
was required for inclusion in the statistical analysis.  
 
 
6.4.1.4 Cocktail 3b: Suppressive / Senescence markers (Table 6.7 & Figures 6.5 & 6.6a&b) 
 
Data for CD57 is included due to functional resemblance to suppressive markers, but was 
acquired from Cocktail 7 due to fluorochrome combination considerations. CTLA4 
showed significant heterogeneity of expression although was never expressed in more 
than 15% of CD3+CD4+ cells (2.3%-15.4% across all samples). PD-L1 was apparently 
significantly over-expressed (p=0.009) using MFI of all CD3+CD4+ cells in CHL 
(MFI=55.6) compared to pooled controls (MFI=17.4) although the limitations of 
application of comparative statistics on arbitrary, compensated logarithmic values 
generated using flow cytometry in terms of validity and translatability have been 
discussed and using this antibody/fluorochrome and data acquisition settings expression 
was not demonstrated at a high level despite contrasting IHC data (see chapter 4) There 
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was no significant over-expression by proportion of total CD3+CD4+ expressing PD-L1 at 
a level determined by the gating strategy shown in Figure 6.5a. CD57 is markedly 
suppressed in the CHL CD3+CD4+ population (mean expression: 5.1%) compared to 
pooled controls (mean expression: 26.1%; p=0.004), tonsil (mean expression: 32.8%) or 
FL (mean: 30.5%, inadequate replicates for comparison) CD3+CD4+ cells, but at similar 
levels to all reactive nodes (mean expression 7.1%). CD57 is expressed by >50% 
CD3+CD4+ cells from NLPHL. PD1 was significantly under-expressed in the CHL 
CD3+CD4+ population (mean=22%) compared to other groups (mean=59.8% in pooled 
controls; p=0.004, 74.5% in tonsil; p=0.036) but not compared to reactive benign nodes 
(mean=32.2%; p=0.14). PD1 was markedly over-expressed in NLPHL (86.9%). 
 
 
Figure 6.5b: Cocktail 3b Analysis: Immunosuppressor markers. ‘Controls’ indicates 
pooled control (not CHL) samples. Individual results are plotted, along with mean 
(horizontal line) and SEM (vertical bars). Medians were compared assuming non-
Gaussian distribution of data using the Mann-Whitney U test.  
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Figure 6.6a: CD57 expression. Representative FACS plots for four samples showing 
variability of expression of marker in CD3+ CD4+ population. C2&C4: CHL; N4: FL; P1: 
PTGC. Results for all samples are summarised in table 6.7. 
 
 
 
Figure 6.6b: CD57 Analysis: Summary of expression of cocktail 1 markers shown as a % 
of all viable CD3+CD4+ cells. Only markers expressed in at least one sample at a level of 
>10% of all CD3+CD4+ are shown. Sample set is indicated on the x axis. ‘Controls’ 
indicates pooled control (not CHL) samples. Individual results are plotted, along with 
mean (horizontal line) and SEM (vertical bars). Medians were compared assuming non-
Gaussian distribution of data using the Mann-Whitney U test.   
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6.4.1.5 Cocktail 5: IL2 and IL4 receptor components (Table 6.8 and Figures 6.7a&b) 
 
IL2R  was not appreciably expressed in CHL-derived samples and only rarely in control 
samples, with the exception of C1, an outlier whose expression was twenty-fold greater 
than other CHL-derived samples (11% vs 0.4-0.8%. As such no comparison with other 
groups was carried out. IL4R  was similarly expressed at a low level in all samples, with 
mean CHL-expression not significantly different from pooled controls (5.2% vs 3.3%) 
except for the same outlier, C1, with expression of 15.3%. CD25/IL2R  was 
heterogeneously expressed across CHL-derived samples (9.8-43.2% of all CD3+CD4+ 
cells), with mean expression significantly greater than pooled controls (23.9% vs 11.2%; 
p=0.045). Similarly CD132/CGC was heterogeneously expressed across CHL-derived 
samples (27.5-53.3%) with mean expression in CHL derived CD3+CD4+ cells (40.0%) 
significantly greater than in pooled controls (mean=24.7%; p=0.016) or tonsils 
(mean=22.6%; p=0.036). 
 
ID CD4 CD25+ CGC+ IL2R + IL4R + 
C1 7981 24.8 48.1 10.9 15.3 
C2 5754 43.2 53.3 0.6 2.5 
C4 6236 9.8 27.5 0.4 1.5 
C5 9975 24 40 0.9 2.1 
C6 4668 17.5 31.2 0.8 4.5 
L1 9036 7.6 17.3 0.6 0.7 
N1 5662 8.6 22.5 0.2 1.2 
N4 6520 18.4 32.7 0.8 1.7 
P1 1619 16 23.3 2 4.1 
R1 2871 11.1 32.7 5.1 5.1 
R2 1063 11.1 26.3 1.2 6 
T1 6647 10.3 25.9 1.5 1.5 
T2 1119 5.9 17.4 1.8 2.6 
T3 5385 12.2 24.6 7.3 7 
 
Table 6.8: Expression of Cocktail 5 IL2/IL4 receptor components expressed as % of all 
CD3+CD4+ events. Total number of CD4+ events is shown to illustrate wide 
heterogeneity between samples. A minimum of 500 viable CD4+ events was required  for 
inclusion in the statistical analysis.  
  
 
Figure 6.7a: Cocktail 5 Analysis: IL2 and IL4 receptor expression: Representative FACS plots for four samples showing variability of 
expression of markers in CD3+ CD4+ population. C2&C4: CHL; N4: FL; P1: PTGC. Results for all samples are summarised in table 6.8. 
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Figure 6.7b: Cocktail 5 Analysis: IL2 and IL4 receptor expression. Summary of 
expression of cocktail 5 markers shown as a % of all viable CD3+CD4+ cells. Sample set is 
indicated on the x axis. ‘Controls’ indicates pooled control (not CHL) samples. Individual 
results are plotted, along with mean (horizontal line) and SEM (vertical bars). Medians 
were compared assuming non-Gaussian distribution of data using the Mann-Whitney U 
test.  
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6.4.1.6 Cocktail 7: CD45 Isotype (Table 6.9 and Figures 6.8 a-c) 
 
CD45 isotype expression defined by CD45RO and CD45RA assumed a characteristic 
phenotype for the CHL-derived population, with a substantial CD45RA+ population, and 
an ‘intermediate’ population less pronounced in other samples (Figure 6.8a). Analysis of 
gated populations showed a trend towards a greater expression of CD45RA and lesser 
CD45RO with increased ‘intermediate’ population for the CHL component compared to 
FL or tonsil, but was indistinguishable from reactive CD3+CD4+ cells, and only 
significant comparing the intermediate population in CHL (mean=6.2%) with tonsil 
(mean=1.8%; p=0.036). 
 
ID %CD45RO+ %CD45RA+ %CD45RORA 
C1 59.8 28.1 9 
C2 75.6 11.9 9.1 
C4 58.2 25.2 4.8 
C5 65.3 22 5.1 
C6 89.2 5.8 3.2 
L1 93.9 1.8 1.2 
N1 80.1 10.9 5.6 
N4 82.6 10.4 4.2 
P1 88.8 7.5 1.8 
R1 71.4 16.6 4.3 
R2 57.1 32.6 7.8 
T1 88.1 9.5 1.4 
T2 83.3 13.4 1.5 
T3 88.9 6.1 2.4 
 
Table 6.9: Expression of Cocktail 5 CD45 isotype, expressed as % of all CD3+CD4+ 
events. A minimum of 500 viable CD4+ events was required for inclusion in the 
statistical analysis.  
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Figure 6.8a: Cocktail 7 analysis: CD45 isotype. Illustration of the distinctive 
CD45RO/RA isotype profile of the CD3+CD4+ component of the majority of CHL cases 
(left column) with a bias towards CD45RA and intermediate population, rather than the 
majority CD45RO expression seen in tonsil and PTGC (right column) or FL (central 
column).  
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Figure 6.8b: Cocktail 7 Analysis: CD45 isotype. Representative FACS plots for four 
samples showing variability of expression of markers in CD3+ CD4+ population. C2&C4: 
CHL; N4: FL; P1: PTGC. Results for all samples are summarised in table 6.9.  
 
 
 
Figure 6.8c Cocktail 7 Analysis: CD45 isotype. Summary of expression of cocktail 6 
markers shown as a % of all viable CD3+CD4+ cells. Sample set is indicated on the x axis. 
‘Controls’ indicates pooled control (not CHL) samples. Individual results are plotted, 
along with mean (horizontal line) and SEM (vertical bars).  
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6.4.1.7 Cocktail 4: Th1/inflammatory Cytokine Profile (Table 6.10 and Figures 6.9a & 6.10) 
Neither IL2 nor IL6 were expressed at any appreciable level. There was a wide 
heterogeneity of expression of both IFN-  (7.7%-89.8%) and TNF  expression (2.8%-
20.3%). Only malignant-derived T cells expressed IFN-  in greater than 40% of cells 
(three samples, 2 CHL, one FL), and CHL-derived T cell expression was never less than 
18%, while tonsillar samples expressed IFN-  in <18% of T cells in both samples. However 
there was no statistically significant difference between the means of any sample classes, 
nor between means of pooled malignant (35.1%) versus pooled benign (19.7%) samples 
(p=0.13). Note that NLPHL expressed IFN-  at extremely high levels (89% of all T cells) 
however was excluded from comparative statistics due to its being an outlier and the 
only representative of its histological class. TNFα similarly showed no statistically 
significant difference in mean expression between sample classes, however there was a 
significantly greater expression in pooled malignant node-derived T cells than those 
derived from benign lymph nodes (14.2% vs 7.1%; p=0.030). 
 
ID % viability CD4 IL2 IL6 IFN-  TNF  
IFN-  / 
TNF  
C1 69.6 1252 0 0.1 30.6 18.2 8.1 
C2 93.1 9211 0 0 21.7 7.6 5.5 
C4 86.9 1449 0 0.1 65.6 15.9 14.6 
C5 91.3 5184 0.1 0 58.2 20.3 17.8 
C6 79 619 0.5 0.3 18.3 12.2 4.5 
L1 73.4 2558 0.1 0.1 89.8 17.2 16.6 
N1 92.7 5828 0 0.1 25.7 8.5 4.2 
N2 94.4 1195 0.1 0 14.5 14.8 2.8 
N4 75.2 5562 0 0.1 45.8 16.1 11.6 
P1 81 1386 0 0.1 33 11.2 6.1 
R1 68.6 810 1.5 1.5 27 13.2 10.2 
R2 85.4 1923 0.1 0.1 7.7 3.8 1 
T1 83.7 2125 0 0 13.7 4.6 1.5 
T2 83.1 609 0 0 17.2 2.8 1 
 
Table 6.10: Expression of Cocktail 4 Th1/inflammatory cytokines, expressed as % of all 
CD3+CD4+ events. Total number of CD4+ events is shown to illustrate wide 
heterogeneity between samples. A minimum of 500 viable CD4+ events was required for 
inclusion in the statistical analysis.  
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6.4.1.8 Cocktail 8: Th2/suppressor Cytokine Profile (Table 6.11 and Figures 6.9b & 6.10) 
Neither IL10 nor IL13 were expressed at appreciable levels (<2.5% of CD3+ cells in all 
samples). There was an apparent over-expression of IL13 relative to pooled controls 
(1.62% vs 0.67%; p=0.0024), however the expression as measured by MFI was at a low 
level and hence the gating strategy may have lead to overestimation of the population of 
cells expressing it (prior experiments on stimulated population have showed a distinct 
IL13 population in Th2 polarised cultures which was absent from all samples in this 
experiment). IL4 and IL21 were only expressed in the reactive nodes (FH and PTGC but 
not the granulomatous lymph node), but not in CHL (mean expression for IL4 in CHL 
0.48% vs reactive 6.43%; p=ns, for IL21 CHL 1.6% vs reactive 7.57% of CD3+ cells; 
p=0.035). 
 
ID % viability CD4 IL13 IL21 IL10 IL4 
C1 69.6 1252 2.4 2.8 0.1 1.3 
C2 93.1 9211 1.9 0.6 0.9 0.2 
C4 86.9 1449 1 2.2 0.4 0.1 
C5 91.3 5184 1.6 2.2 1.3 0.2 
C6 79 619 1.2 0.6 0 0.6 
L1 73.4 2558 0.8 1.3 0.1 0.3 
N1 92.7 5828 0.6 0.7 0.1 0.9 
N2 94.4 1195 1.3 4 0.9 1.3 
N4 75.2 5562 0.8 0.3 0.2 0.5 
P1 81 1386 0.7 15.1 1.2 14.4 
R1 68.6 810 0.5 3.1 0 0.3 
R2 85.4 1923 0.3 4.5 1.2 4.6 
T1 83.7 2125 1.1 0.8 0.1 0.5 
T2 83.1 609 0.7 3 0.3 1.3 
 
Table 6.11: Expression of Cocktail 4 Th2/suppressor cytokines, expressed as % of all 
CD3+CD4+ events. Total number of CD4+ events is shown to illustrate wide 
heterogeneity between samples. A minimum of 500 viable CD4+ events was required for 
inclusion in the statistical analysis.  
 
  
 
Figure 6.9a: Cocktail 4 Analysis: Th1 / inflammatory cytokines. Representative FACS plots for four samples showing variability of 
expression of markers in CD3+ population.  
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Figure 6.9b: Cocktail 8 Analysis: Th2/T suppressor cytokines. Representative FACS plots 
for four samples showing variability of expression of markers in CD3+ population.  
Chapter 6: Immunophenotyping to characterise CHL-infiltrating T cells 
 
Page 240 
 
 
Figure 6.10: Overall Cytokine expression profile. Representative FACS plots for four 
samples showing variability of expression of markers in CD3+ population.  
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6.4.2 Summary of Flow Cytometry findings  
6.4.2.1 Cluster Analysis 
Figure 6.12 (overleaf) displays the result of unsupervised hierarchical clustering. Two 
main clusters emerge: one containing all CHL-derived T cell samples as well as one 
reactive node (granulomatous inflammation), the other segregating into two clusters: 
one containing both malignant samples with one of the tonsils, the other containing 
benign samples. Repeating the analysis without log transformation resulted in the same 
clustering. A second unsupervised hierarchical clustering analysis incorporating only 
those factors found to be most discriminatory in the marker by marker analysis 
described above (6.4.1) led to similar clustering despite the reduced number of available 
parameters to with which to form groups (Figure 6.11). 
 
 
Figure 6.11: See figure overleaf for initial clustering. A second unsupervised hierarchical 
clustering analysis incorporating only those factors found to be most discriminatory 
using the marker by marker analysis led to similar clustering despite a reduced number 
of available parameters with which to form groups. 
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Figure 6.12 Unsupervised hierarchical clustering using Pearson’s correlation coefficient 
and complete linkage derived two major clusters, one containing all the CHL-derived 
CD3+CD4+ phenotypes, and the other containing a mixture of benign and non-CHL-
derived tissue.  
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6.4.2.2 Heterogeneity of CD4+ T cell markers 
Figure 6.13 shows markers which are expressed in >5% of CHL-derived CD4+ T cells and 
with considerable variability of expression. This is summarised in Table 6.12. Those 
markers that are expressed as a discrete positive population (e.g. CCR4, CD278) and 
hence easily discriminated from a negative population are potentially applicable to 
assessment by IHC, as performed in Chapters 3 and 4. Those expressed as a continuum 
(e.g. CD25, CD28) would be more difficult to quantify using IHC since degrees of 
expression are less reproducible than in flow cytometry. Using IHC those markers 
expressed heterogeneously may be validated, and potentially applied to correlative 
studies of clinical outcome. 
 
CD Eponym 
 
Min % Max% SD Discrete or 
Continuous 
CCR5 - 9 35 12 D 
CCR4 - 15.4 77.2 26.9 D 
CCR3 - 2 12.3 4.2 D 
CXCR5 - 6.8 47.5 16.0 D 
CD45RA - 5.8 28.1 9.4 D 
CD127 IL7RA 12.8 36.1 9.1 C 
CD25 Il2RA 9.8 43.2 12.4 C 
CD132 CGC 27.5 53.3 10.9 C 
CD28 - 28 61 15.0 C 
CD134 OX40 24.9 51.2 11.0 D 
CD278 ICOS 27.4 70.5 18.9 D 
CD278hi ICOS 6.8 50.4 20.5 C 
IFN-  - 18.3 65.6 21.7 D 
TNF  - 7.6 20.3 5.0 D 
 
Table 6.12: Most heterogeneously expressed CD4+ T cell markers. Final column 
indicates the potential for validation and further investigation using IHC, with those 
markers expressed in a discrete manner (D), that is more easily segregated into a positive 
and negative population, being more likely to be interpretable using IHC than those with 
a range of expression levels (continuous/C) 
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Figure 6.13 Markers expressed in >5% of CHL-derived CD4+ T cells and with 
considerable variability of expression. This is summarised in Table 6.12.  
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6.4.2.3 Discriminatory Molecules 
Table 6.13 and Figure 6.14 a&b summarises those markers whose mean expression was 
significantly different in CHL-derived CD4+ T cells to those derived from other lymph 
nodes. 
 
Marker Eponym Control 
Population 
%CD4+ 
CHL 
% CD4+ 
Control 
P vs 
control 
CD154 CD40L Tonsil 3.0 17.9 0.036 
CCR3 - Pooled 5.9 2.2 0.043 
CCR6 - Pooled 2.4 0.9 0.036 
CXCR5 - Tonsil 25.8 65.2 0.037 
CXCR5 - Pooled 25.8 48.7 (ns=0.099) 
CD62L L-
selectin 
Pooled 50.4 18.2 0.002 
CD62L L-
selectin 
Tonsil 50.4 14.5 0.036 
CCR7 
CD62L 
- Pooled 16.6 4.8 0.001 
CCR7 
CD62L 
- Tonsil 16.6 4.3 0.036 
CCR7 
CD62L 
- Reactive 16.6 4.8 0.036 
CD127 IL7R Pooled 23.3 11.1 0.0.12 
PD1 - Pooled 22.0 59.8 0.004 
PD1 - Tonsil 22.0 74.5 0.036 
CD25 IL2Ra Pooled 23.9 11.2 0.045 
CD132 CGC Pooled 40.0 24.7 0.016 
CD132 CGC Tonsil 40.0 22.6 0.036 
CD45RORA - Tonsil 6.2 1.8 0.036 
CD45RO - Tonsil 69.6 86.8 (ns=0.07) 
CD57 - Pooled 5.1 26.1 0.004 
CD57 - Tonsil 5.1 32.8 0.004 
CD69 VEA Tonsil 51.5 81.9 0.04 
CD69 VEA Pooled 51.5 63.7 (ns=0.23) 
 
Table 6.13: Most discriminatory CD4+ T cell markers showing mean in CHL and 
indicated control and p value by Mann-Whitney test.  Those markers showing significant 
differences in expression level compared to the appropriate control as indicated, are 
highlighted in bold, non-significant trends are in italics 
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Figure 6.14a Markers whose mean expression was significantly different in CHL-derived 
CD4+ T cells compared to those derived from other lymph nodes. Summarised in Table 
6.13. See also Figure 6.16b. 
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Figure 6.14b Further markers whose mean expression was significantly different in CHL-
derived CD4+ T cells compared to those derived from other lymph nodes. Summarised 
in Table 6.13. See also Figure 6.16a. 
 
 
6.4.2.4 Homogeneity of CHL markers 
Figure 6.15 shows the CD4+ T cell-expressed markers demonstrating the least variability 
in CHL as well as some ability to discriminate from other lymphoid tissue CD4+ T cells. 
CD62L over-expression (in particular when co-expressed with CCR7) and CD57 under-
expression, are the most robust discriminators, with down-regulation of CD95 and CD69 
compared to FL and tonsil, and of CD154/CD40-L compared to tonsil. Of the control 
groups, that which most frequently ‘overlaps’ with CHL in terms of marker expression is 
derived from reactive nodes, although these in themselves are clinically and 
histopathologically heterogeneous, with some markers showing wide heterogeneity of 
expression between samples. An expanded reactive control group would be important to 
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further validate these findings. Failure to discriminate reactive nodes was a feature of the 
cluster analysis described above. If only these three most discriminatory markers are 
incorporated into a CHL-defining CD4+ T cell score as shown in Table 6.13, a ‘CHL score’ 
may be proposed. Scoring one point for each of the following features, defined as % of 
total viable CD3+ CD4+ cell populations the following is applied: 
 
CD3+CD4+ population:  
CD62L+ >30% - SCORE 1 
CCR7+CD62L+ >5% - SCORE 1 
CD57 <10% - SCORE 1 
 
A score of 3 defines CHL , 1/0 is unlikely to be CHL, and 2 an intermediate group which 
may represent reactive tissue. Table 6.14 shows the resulting score applying this method 
to all samples analysed for this experiment. 
 
 
 
Figure 6.15: CD4+ T cell-expressed markers demonstrating the least variability as well as 
an ability to discriminate beween other lymphoid tissue CD4+ T cells.  
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ID 
CD62L
+ 
CD57
+ 
CCR7+ 
CD62L+ 
>30% 
CD62L? 
>5% 
CD62L+
CCR7+? 
<10% 
CD57? 
‘CHL 
score’ 
C1 32.6 5.2 8.1 1 1 1 3 
C2 71.2 3.1 10.7 1 1 1 3 
C4 48.9 6.8 19.9 1 1 1 3 
C5 58.5 4.7 31.9 1 1 1 3 
C6 40.7 5.7 12.2 1 1 1 3 
L1 4.5 54.5 1.8 0 0 0 0 
N1 18.7 28.3 6.1 0 1 0 1 
N4 27.3 32.6 7.5 0 1 0 1 
P1 19.2 8.2 4.1 0 0 1 1 
R1 16.6 5.5 7.3 0 1 1 2 
R2 33.6 7.5 3 1 0 1 2 
T1 15.8 21.1 3.7 0 0 0 0 
T2 21 36.7 7.7 0 1 0 1 
T3 6.8 40.6 1.6 0 0 0 0 
 
Table 6.14: CHL score-defining markers demonstrating a classification system for 
further validation 
6.5 Discussion 
6.5.1 Limitations of interpretation 
6.5.1.1 Low replicate numbers and statistical underpowering 
The data here presented are based on limited numbers of replicates, and are intended as 
an exploratory pilot experiment. As such, any conclusions to be drawn remain 
predominantly speculative, but provide the grounds for further validation.  
 
Chapter 6: Immunophenotyping to characterise CHL-infiltrating T cells 
 
Page 250 
6.5.1.2 Limitations of using frozen tissue 
Ideal experiments would be performed on fresh samples, disrupted, resuspended, stained 
and analysed within hours of collection. Practicality, disease rarity, and batch processing 
prevent this. As such, the ‘standard method’ used samples frozen soon after collection 
and tissue disruption, analysed within hours of thawing. Controlling for conditions prior 
to cell storage is difficult and data must be interpreted with caution particularly when 
comparing with previous reported work using “fresh” samples. This will be more 
important for some antigens and functional assays than for others. 
 
6.5.1.3 Limitations of control tissue 
6.5.1.3.1. Peripheral Blood 
Peripheral blood has the advantage of being in plentiful supply from normal donors and 
affected patients. However, the nature of the lymphoid component of peripheral blood is 
quite different to that within the lymph node. The blood is merely an organ of 
conveyance for T cells for which the majority of antigen encounter, proliferation and 
effector functions occur within the confines of primary lymphoid organs and immune 
infiltrates at sites of inflammation, infection and malignancy. Only 2-5% of total body 
lymphocytes are circulating at any one time, while >40% is within lymph nodes. Hence 
the effector status of circulating T cells cannot be considered a valid comparator. 
 
Contrasting the characteristics of circulating T cells between unaffected controls and 
patients with active disease may be valid in determining the systemic impact of 
malignancy on immune status. However it is not a valid comparator for T cells derived 
from lymph nodes or malignancy-infiltrated tissues. Peripheral blood T cells are in an 
entirely different functional state from those arising within inflamed tissue or lymph 
nodes, expressing distinct complements of markers. Interpretation of data arising from 
peripheral blood T cells should hence be made with caution, bearing these factors in 
mind. For the purposes of this experiment specifically investigating the tumour-
infiltrating T cell, peripheral blood was deemed unsuitable as a control. 
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6.5.1.3.2. Tonsil 
Overall, it is clear that even within a supposedly homogeneous tissue like tonsil, there is 
wide heterogeneity in expression of many functional T cell markers. This may be a result 
of the extreme variation in initial tissue handling at the point of surgical excision, despite 
uniformity of sample preparation once received by the cell storage laboratory. Other 
variables that are difficult to control for or even to quantify accurately include the 
characteristics of the patient from whom the tonsil was excised, particularly age and 
immune status in terms of prior infectious challenge, and inflammatory state of the 
tonsils at the time of excision. Excised tonsils, while normally in a relatively quiescent 
state at the time of operation, are by their definition pathological, or there would be no 
indication for excision.  For these reasons it is erroneous for tonsillar control to be 
defined as ‘normal’ or ‘homogeneous’ in any way.  
 
Tonsillar tissue is different to other lymph nodes being mucosa-associated-lymphoid 
tissue (MALT), a distinct immune compartment with function and anatomy more 
comparable to the gut’s immune system, not that of other lymph nodes. Tonsils possess 
no afferent lymph vessel; antigen is encountered via direct contact through the epithelial 
surface which is essentially the only separation from the outside world. This is in 
contrast to lymph nodes existing in relatively sterile conditions within body cavities 
(tonsillar-derived culture systems frequently grow candida: a problem encountered 
during this project) and encountering antigen in a far more regulated way through 
delivery, as unaltered antigen, immune complex, or in association with migrating 
antigen-presenting cells entering via afferent vessels. As such immune cell trafficking is 
mediated by expression of a different spectrum of adhesion molecules and chemokines, 
and the immune response is biased in favour of a localised mucosal protective response 
(IgA-based) rather than systemic immune response (IgG-based). Hence, 
pathophysiological, physiological, donor characteristics and preparatory techniques 
make this a highly imperfect control for ‘normal lymph node tissue’. Use as a control is 
simply a function of availability, not suitability. 
 
Chapter 6: Immunophenotyping to characterise CHL-infiltrating T cells 
 
Page 252 
6.5.1.3.3. Reactive nodes 
Ideally, an experiment designed to define CHL-specific T cells, in contrast to those 
activated in a physiological antigen-specific immune response (likely a substantial 
component of T cells found within any malignant microenvironment) would ideally use 
reactive lymph nodes derived from age-matched controls. Uninvolved lymph nodes from 
the same donor may be ideal but to be a useful control without the influence of systemic 
effects of CHL they would need to be derived from the same patient in remission who 
develops a reactive lymph node suitable for biopsy. Incidence of such an event is too rare 
to be of use, and would be influenced further by any germline-derived immune defect 
that may predispose to the development of the disease and for which evidence is 
accumulating471-473. 
 
Approximately age-matched reactive lymph nodes are a more available control. Of 
clinical applicability, presentations resembling CHL in terms of patient characteristics 
and tissue of origin are Follicular Hyperplasia (FH) and Progressive Transformation of 
Germinal Centre (PTGC), as well as infection-reactive nodes with a clearly defined 
causative organism. PTGC is seen in around 10% of cases of FH, usually idiopathic in 
origin, with distinct histopathological characteristics474. The demographic and 
anatomical similarities of these conditions, as well as comparable immune-stimulating 
pathophysiology make these conditions the ideal benign correlates against which to 
compare the T cell constituent of lymphoid malignancies. Availability of this tissue is the 
major drawback. 
6.5.2 Condition-defining CD3+CD4+ T cell subsets 
This experiment focussed only on the CD3+CD4+ compartment, being a dominant and 
heterogeneous component in CHL, in which classical functional definitions have failed 
to satisfactorily describe or explain its role in CHL, and a compartment which even in 
normal physiology, unlike B cells or cytotoxic T cells (CD8+) with well-defined function, 
has diverse and largely poorly understood roles. 
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6.5.2.1 NLPHL contains an entirely distinct population of cells unlike PTGC or CHL 
Only a single case of NLPHL was available for this study. However the CD4+ T cell 
component of this sample proved particularly distinct from all other samples. The rarity 
of this condition, along with its resemblance of CHL by classical histopathology and a 
favourable clinical course has led it to be classified as a related lymphoma. However 
there is evidence with which this study is in concordance, that the disease is quite 
different, even at the level of the tumour-infiltrating T cell. CD95, CD57, PD1, CD45RO 
and IFN-γ were expressed at particularly high levels of CD4+ T cells, while IL2 receptor 
components were virtually absent. These markers are well-described in NLPHL, with 
‘rosetting’ CD57437 and PD1-expressing T cells425, 475 used to corroborate the diagnosis. 
High levels of the follicular-homing molecule CXCR5 along with under-expression of 
CCR7 in this sample were also found, additional characteristic features of Tfh cells. As 
seen in Chapter 5, T cells derived from this sample failed to proliferate in IL2 and IL4-
enriched culture systems, perhaps more markedly even than those derived from benign 
tonsillar or reactive lymph nodes. Further validation is essential to ensure that the 
sample was not unrepresentative of the disease. However, most of the phenotypic 
features observed in this experiment are entirely consistent with the established IHC 
literature, in which the relative novelty of this experiment is the use of flow cytometry, 
which has confirmed that these markers arise in the CD4+ T cell compartment. 
 
Over-expression of markers of activation and senescence, with potent Th1-defining 
effector activity (IFN- ), along with a failure to proliferate in vitro is suggestive of a 
terminally differentiated effector cell phenotype, existing alongside a Tfh-like 
immunophenotypic signature typical of germinal centre reactions. These two signatures 
may coexist within a single cell, since IFN-γ expressing ‘Th1-type’ Tfh cells are proposed 
to be a functional subset. Alternatively the finding may indicate two separate CD4+ T 
cell populations. However these results are interpreted, it would seem that the CD4+ T 
cell in NLPHL is entirely distinct from that in CHL – representing an apparent expansion 
of a germinal centre or proliferating follicle reaction, with Th1-like functional capacity. 
These findings are consistent with the documented histology of the disease, which 
comprises large germinal centres and expanded mantle zones474. There is some 
description in the literature and anecdotally of transformation from PTGC to NLPHL or 
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DLBCL, with the suggestion that PTGC represents a precursor lesion. Indeed there are 
cases of PTGC in which chromosomal lesions characteristic of B cell malignancy have 
been described476. However evidence is limited and patho-physiological mechanisms 
speculative. This experiment demonstrated some overlap with the single PTGC sample in 
terms of high expression of CD95, PD1, CD57, CXCR5 and CD45RO, although CCR7, the 
T cell zone marker, was present at higher levels in PTGC. Further replicates are essential 
to corroborate these distinctions. 
 
6.5.2.2 Is the dominant CHL-infiltrating CD4+ T Th1, Th2, Treg or Tfh? 
6.5.2.2.1 Treg 
Substantial IHC evidence, including that presented in Chapter 3 exists to demonstrate 
that FOXP3 is expressed by a significant proportion of T cells in the CHL 
microenvironment344. Expression is heterogeneous between patients, with 
pathophysiological implications evidenced by the impact of this heterogeneity on 
survival. However, there is no functional evidence that these CHL-derived T cells are in 
fact Tregs. The only published study to have isolated a Treg population (based on CD25 
and CD127 expression) from the immune infiltrate of a malignancy managed to 
demonstrate suppressive activity in a standard autologous T-responder cell / purported 
Treg coculture/stimulation assay377. The cells used in this suppressor assay were derived 
from colorectal carcinoma. This group demonstrated an equivalent CD25-hi, CD127-lo 
FOXP3-expressing population in CHL-derived lymph nodes, but could not isolate 
sufficient cells from these samples to perform functional suppressor assays (personal 
communication). Being the major interface between antigen, infectious organisms and 
the immune system of the body, the gastrointestinal tract requires particularly well-
developed mechanisms of effector/regulatory immune homeostasis comprising 
abundant and various regulatory T cells. Mouse models demonstrate this, in that colitis 
severity is used as the quantitative readout of regulatory T cell dysfunction182. Hence, 
functional conclusions regarding cells derived from GI tract tissue, malignant or benign, 
may not be applicable to other lymphoid tissue.  
 
The limited flow cytometric data presented in this chapter shows only a trend towards 
greater representation of CD4+CD25+ cells, with comparable heterogeneity of 
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representation to that seen for FOXP3 in the IHC experiment presented in Chapter 3 (10-
45% cells) although co-staining was not carried out to confirm that these represented the 
same cells. Moreover, CD127 is heterogeneously expressed in these CHL-derived CD4+ T 
cells at comparable levels to reactive nodes, and at significantly higher levels than tonsil 
or FL-derived tissue. CTLA4, one potent effector of Treg function222, is expressed at a 
higher level than in the reactive or FL-derived samples, but at comparable levels to that 
seen in tonsillar CD4+ cells. Expression was observed in less than 15% of cells in all cases. 
However, only surface CTLA4 was stained.  This molecule demonstrates rapid 
intracellular/extracellular trafficking, which is essential to its function477. As such 
evidence based only on surface, and not total cellular expression, should be interpreted 
with caution. This data is suggestive of a greater role for CTLA4 in CHL than in reactive 
nodes. It should also be noted, however, that CD25 and CTLA4 are non-specific markers 
of cell activation478 and not entirely specific to Tregs. 
 
IL10, a classically described immunosuppressive cytokine was not expressed at an 
appreciable level in any sample. 
 
Overall, although there is evidence suggesting an overrepresentation of Treg-associated 
markers such as CD25 and CTLA4 by CD4+ cells in CHL compared to non-CHL-derived 
nodal tissue, this study does not provide evidence favouring the Treg as the numerically 
dominant cell. The functional role of a Treg component however, may be more profound 
than its cellular frequency suggests - as the IHC FOXP3 expression levels’ correlation 
with survival implies.  
 
6.5.2.2.2 Th1 
As presented in Chapter 4 there is IHC evidence for substantial and heterogeneous 
expression of the transcription factor T-BET in the microenvironment, confirming 
previous reports46. However, co-staining with CD4 was not performed to confirm the 
identity of the cells expressing T-BET, important since this TF is also expressed by CD8+ 
T cells, B cells and malignant HRS cells. A proportion of samples showed expression of T-
BET in the morphologically distinct HRS cells as previously reported404. Some impact on 
survival was demonstrated based on heterogeneity of expression although expression of 
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T-BET by the malignant cells was not related to survival. The dominance of the 
microenvironment by cells expressing a TF associated with the promotion of a Th1-
skewed immune response is therefore likely to have functional significance. The cytokine 
flow immunophenotyping presented in this chapter has corroborated this evidence, with 
Th1-defining IFN-  (under the influence of pathways coordinated by T-BET) highly 
expressed in CHL, reactive, NLPHL and FL-derived CD4+ T cells, more so than in tonsil, 
along with TNF , another Th1 defining factor. IL2 was notably not detectable. There is 
already a suggestion in the literature that CHL-derived T cells can be stimulated in vitro 
to produce IFN-  and TNF  (again, and intriguingly, not IL2), but apparently also IL4 
(not demonstrated in these experiments479, 480). It has also been reported that the CHL-
derived lymphoid cells are capable of co-expressing IL4 and IFN-  at high levels when 
stimulated with IL2 and anti-CD28 (without TCR stimulation, similar to experiments 
reported in Chapters 5 and 7). However these reports are anecdotal, give little 
methodological detail, and there is no formal presentation of results except in 
unreferenced literature reviews.  
 
The Th1-associated cytokine CCR572 was expressed in a significant minority of CHL-
derived CD4+ T cells (10-30%), and to a greater extent than in tonsillar and reactive 
tissue with the exception of the granulomatous-reactive lymph node (which if bacterially 
reactive would be expected to have a significant Th1 bias in response), with FL expressing 
to a similar extent, and NLPHL a larger extent. While no significant differences could be 
confirmed comparing nodes of origin, expression is at a lower level than that of CCR4, 
and greater than CCR3 (a less subtype-specific Th2 marker) or CCR6 (a possible memory 
T cell marker, whose ligands CCL20 and CCL19 MIP3-  and  are over-expressed in the 
CHL microenvironment (See introduction). Hence, using chemokine receptors to define 
functional subsets, a CCR3 expression-defined Th1 response is well represented in the 
CHL microenvironment, although at a lower level than the CCR4-expressing population. 
 
Chemokine receptors, as discussed, are imperfect markers of functional phenotype of 
CD4+ T cells. The panel selected here included those whose expression has been 
detected at high levels in CHL-derived tissue or cell lines in previous experiments. 
Overall they were not found to be expressed at high levels in CHL-derived CD4+ T cells 
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with the exception of CCR4 and CCR5, whose ligands are the most well described CHL-
associated chemokines: TARC and RANTES. Expression levels as defined in this 
experiment could have been influenced by preparation techniques. Importantly, 
incorporating a variety of control tissues into the experiment has revealed that 
expression of all receptors appears to be universal in nodal tissue regardless of source. 
While this does not imply a lack of importance in CHL, there is no suggestion that 
pathways mediated through these receptors are any more important than in normal 
inflammatory processes, and are certainly not relatively suppressed. Probably more 
functionally relevant are the cytokines produced by these cells, of which IFN-γ and TNFα 
predominated for all tissues, although IL2 was absent. There was some evidence to 
suggest that expression of these Th1-associated cytokines was significantly greater in 
malignant tissues, particularly in NLPHL, compared to the benign controls. 
 
Overall, the evidence gathered on the samples assessed in this experiment is in favour of 
a Th1-bias in the microenvironment, but one which is no different to that seen in 
reactive nodes, FL-derived nodes, and one which is substantially less than in NLPHL.  
6.5.2.2.3 Th2 
As presented in Chapter 4 there was no evidence by IHC assessment of the transcription 
factor GATA3 for an increased representation of Th2 cells in the microenvironment, 
consistent with a limited IHC literature, but contrasting with many investigators’ current 
description of the CHL CD4+ T cell compartment.  As discussed this is based on flawed 
interpretation of the data. While intracellular cytokine staining based on stimulation 
with PMA/Inomycin has its own limitations by intrinsically altering the system with 
profound activating stimuli via massive calcium release and TCR-independent 
mechanisms, there is an established evidence base for the method’s validity165, and as will 
be described in chapter 7, it is capable of discriminating Th2 cytokine-producing cells in 
the expanded culture T cells. In this analysis there was no evidence of any Th2-defining 
cytokines (IL4, IL13 or IL21) except in the case of PTGC, and certainly not in the CHL-
derived CD4+ T cells. IL13 has been found by IHC in HRS cells and is expressed by a 
number of CHL-derived cell lines, and IL13 receptor inhibition leads to growth 
suppression in HRS cells. However, the major source of this cytokine would not appear 
to be microenvironment Th2-polarised CD4+ cells.  
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Two early studies investigated the expression of Th subset defining cytokine mRNA 
arising from CHL but arrived at contradictory results. The first demonstrated no IL4, 5 or 
9 mRNA expression in CHL-derived lymph node tissue, while IFN-γ and TNFα were 
expressed, much as suggested at the protein level by the flow cytometry data reported 
here481. However a subsequent study found IL4 and IL5 as well as IFN-γ mRNA transcript 
in all nodes tested (n=14) and at similar levels to reactive nodes482. This second study 
went on to culture T cell clones derived from CHL and predominantly derived cells 
expressing both IL4 and IFN-γ again resembling clones derived from reactive nodes. 
These results are in line with the cytokine expression profiles for expanded T cells 
described in Chapters 7, under culture conditions described in Chapter 5. However, 
unlike experiments described here, these early experiments expanded clones using a 
mixed lymphocyte reaction (co-culture with irradiated allogeneic PBMCs with IL2 
augmentation), and following separation of CD4+ cells using magnetic beads after lymph 
node dissociation and density gradient separation. To draw conclusions regarding the 
lineage-commitment of a founder clone, based on the cytokine mRNA profile of MLR-
stimulated and expanded colonies, appears to be an over-interpretation of the data. 
These results may instead be explained as arising due to the expansion of multipotent or 
phenotypically plastic initiating cells, themselves without Th1 or Th2 bias, which were 
then polarised under these in vitro culture conditions. The heterogeneity of the clones 
produced may represent the relatively stochastic nature of lineage commitment483 in 
vitro without robust Th1 or Th2 defining conditions (e.g. IL12, IFN-γ or exogenous IL4 
exposure). The presence of both IL4 and IFN-γ in the supernatant despite the apparent 
mutual inhibition of synthetic pathways may mean that the clonal colonies remained 
phenotypically plastic288, with some resulting cells going on to develop a Th1-cytokine 
secreting phenotype and others Th2.  
 
Alternatively, and in line with the results presented in Chapter 7, in which intracellular 
cytokine flow cytometry enables the origin of the cytokine production to be determined 
on a cellular basis, an intermediate phenotype may be present capable of producing both 
cytokines. This may be an in vitro artefact, or result from intracellular regulatory 
mechanisms not yet understood, which enable co-expression of Th1 and Th2-defining 
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cytokines by a single cell. However these results are interpreted, the contradiction in 
Th2-defining mRNA expression between studies, possibly arising from differential 
methodology, and limited by the small number of samples tested in this heterogeneous 
disease, cannot be explained. Level of mRNA transcript does not necessarily reflect 
eventual cytokine expression, for which no data is presented at baseline, and only for 
that derived from in vitro cloned, expanded and allogeneic PBMC-exposed cells. 
 
CCR4, a non-specific Th2 and Treg expressed molecule which is the receptor for TARC, a 
chemokine produced at high levels in CHL and purported to be the mechanism of T cell 
chemo-attraction to the microenvironment, was not expressed at significantly different 
levels to control samples, although it was expressed at substantial levels (15-80% of CD4+ 
T cells). However, as a Th2 defining marker its specificity is limited and without 
corroborating evidence at the cytokine or transcription factor level, should be 
interpreted carefully. Another Th2 defining chemokine receptor, CCR3 is expressed at 
significantly greater levels in CHL than in control samples, but at <5% in most samples 
and <15% in all samples. Its ligand RANTES is well described in CHL but a substantial 
contribution of CCR3/RANTES interactions to the composition of the microenvironment 
is not supported by these results. CCR3 expression in CHL assessed by IHC and flow 
cytometry has been performed for a number of lymphoid subsets in a previous small IHC 
and fluorescence immunophenotyping (n=5) experiment484. This confirmed a relative 
over-expression of CCR3 in CHL-derived CD4+ T cells and to a greater extent than found 
in the data presented in this chapter, although no cytokine-based functional work was 
performed. This discrepancy may be explained by the use of fresh tissue (in the cited 
experiment) rather than frozen (as in this experiment), although it is clear that inter-
patient heterogeneity exists, and sample numbers are small in both experiments. 
Additionally HRS-overexpressed RANTES is recognised by a number of other chemokine 
receptors, including Th1-expressed CCR1 and CCR5 and Treg/Th2-expressed CCR4, and 
hence an absence of CCR3 does not preclude a substantial role for RANTES in defining 
the microenvironment. 
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6.5.2.2.4 Tfh 
The Tfh-defining markers CXCR5, CD57 and PD1 are expressed at significantly lower 
levels in the CD4+ T cells of CHL compared to pooled controls, and while ICOS, another 
Tfh-characteristic cell surface marker is present at substantial levels, expression is 
heterogeneous and comparable to controls. This study does not support the hypothesis 
that the HRS is being sustained through a dominating infiltrate of these professional-B 
cell supportive cells. PD1 and CD57, while expressed strongly in normal germinal centres 
and expressed by Tfh cells, have also been defined as markers of immunosuppression, 
chronic activation and senescence whose relative under-expression in CHL derived CD4+ 
T cells is of interest particularly with respect to the longevity and proliferative capacity of 
these cells in vitro described in Chapter 5. 
 
6.5.2.3 Is the dominant CHL-infiltrating CD4+ T cell naïve, activated or memory? 
Notably, and consistent with the proliferation experiments described in Chapter 5, the 
senescence/immunosuppressor markers PD1 and CD57 were under-expressed in CHL-
derived CD4+ T cells compared to control samples, and starkly in contrast with the 
single NLPHL sample in which both markers were highly over-expressed. 
 
Homing to the T cell zone requires expression of CD62L, L-selectin, whose ligands 
include endothelial cell proteins such as CD34 and GlyCAM-1485 which enables entry to 
the node via the afferent high endothelial venules, and CCR7 which retains the T cell 
within the interfollicular T cell zone, within which it will encounter antigen-bearing APC 
and cognate B cell. CCR7 and CD62L are expressed preferentially by naïve and central 
memory cells145. These markers proved to be amongst the most discriminatory of CHL-
derived T cells from control samples, suggesting an overrepresentation of these subsets. 
However, CD27, a TNFRSF member associated with memory cells and prolonged survival 
and proliferative capacity486, was expressed at similarly high levels of CD4+ T cells in all 
samples. 
 
CD45 isotype is an indicator of maturity of the T cell – with CD45RA being expressed in 
naïve T cells, lost to become CD45RO following activation, and subsequently re-
expressed in a subset of memory cells which tend also to be hypoproliferative, 
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hyporesponsive and expressive of markers of senescence seen in chronic viral infections 
487, 488. CHL-derived CD4+ T cells appeared in this study to express CD45RO+ at lower 
levels, although CD45RA+ cells were not seen at significantly greater levels, perhaps due 
to a large proportion being in an intermediate CD45RORA+ state.  
 
CD28 is highly expressed in naïve T cells, and down-regulated in response to stimulation 
despite its expression being cited in the literature as evidence that the CHL-infiltrating T 
cell is activated47. High levels of expression are confirmed in all samples, with no 
significant difference according to tissue of origin. CD69, the early activation marker, is 
transiently and rapidly up-regulated following stimulation in lymphoid cells, particularly 
T cells489, persisting for around 30 hours following removal of the stimulus490 but whose 
function remains unclear since both proinflammatory491 and immunosuppressive492 
actions have been demonstrated. In this study it was expressed at relatively 
homogeneous levels across all CHL samples, and at a lower level than that seen in all but 
reactive nodes. The transient nature of this molecule’s expression means that this 
observation may either reflect an over-representation of naïve T cells in CHL, or instead 
chronically active cells in which CD69 has been down-regulated, and so is difficult to 
interpret. 
 
Expression of other activation markers in CHL was heterogeneous, and not significantly 
different to other lymphoid tissue derived cells. CD95, a non-specific marker of 
activation in T cells, which triggers apoptosis on encountering its ligand493, shows a 
trend towards under-expression in CHL compared to control samples. ICOS and OX40, 
whose ligands are expressed by the HRS cell, were not expressed at significantly different 
levels in CHL compared to control tissue across all samples, although heterogeneity of 
expression was greater in CHL than in other tissues, which may be of biological 
relevance. CD40 is expressed by HRS cells and signals through similar pathways to those 
triggered by LMP1, the EBV-encoded protein, and is key to normal B cell survival. 
However these data show relative under-expression of its ligand CD154/CD40L in the 
CHL-derived CD4+ T cells compared to tonsil, although CD40L was also 
underrepresented in other activated tissues. Expression of these activation markers in a 
snapshot experiment on frozen tissue may be unrepresentative of the situation in vivo, 
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where dynamic and transient changes in expression level may occur. However, overall 
there is no indication that CHL-derived CD4+ T cells express ligands for receptors 
involved in HRS survival at any greater level than non-malignant lymphoid tissue. 
CD30L was not included in the panel for technical reasons but would be an important 
inclusion in future experiments. CD30 is the HRS-defining marker112, signalling through 
which in lymphocytes can trigger cell proliferation and survival via the NF- B pathway, 
while reverse signalling from which can have diverse immunosuppressive or stimulatory 
effects494.  
  
Taken together, and considering the pooled CHL samples in contrast to the pooled 
controls, there is evidence to suggest that the CD4+ T cell compartment in CHL is 
comprised of fewer chronically stimulated, senescent cells (lower CD45RO, CD69, CD95, 
PD1 and CD57) particularly in contrast to those of FL and NLPHL. While activation 
markers such as CD95, ICOS and OX40 are confirmed to be expressed at a high level, 
this is only as much as seen in the control reactive nodes or tonsils, and is markedly 
heterogeneous between samples. The abundance of activated T cells is also evidenced by 
cytokine expression data presented here. The proliferative capacity of CHL-derived T 
cells demonstrated in Chapter 5 is a property to be expected of primed memory or naïve 
CD4+ T cells, but not chronically activated or terminally differentiated effector cells. 
This, along with overexpression of CD62L and CCR7 in the CHL-derived samples, 
provides further evidence that coexisting with the activated, cytokine-secreting cells in 
the microenvironment there is a substantial CD4+ T cell component, which is either 
naïve or derived from central memory cells.  
 
6.5.2.4 Does cytokine receptor expression explain the proliferative capacity of the T cells? 
There is evidence that IL2-receptor components CD25 and CD132 (although not CD122, 
more characteristic of cytotoxic T cells) were relatively over expressed in CHL-derived 
CD4+ T cells compared to control samples, providing some explanation for the superior 
IL2 responsiveness described in Chapter 5. However, there was no evidence for IL4-
specific receptor component expression in any sample. Hence levels of receptor 
expression cannot explain the augmentation of growth observed with dual cytokine 
enrichment. 
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6.5.2.5 Summary and Context 
To classify a T cell infiltrate as predominantly one subset or another is inherently flawed, 
particularly given the relative artificiality of those subsets in the first place. However a 
description of the overall complement of function-defining markers unique to or 
showing heterogeneity within a disease is likely to enable a better understanding of the 
contribution of any microenvironment cells possessing those marker to disease 
pathophysiology. These results have been interpreted only on CD4+ T cells in isolation. 
Their numerical dominance implies primary importance, but clearly other functional 
classes: cytotoxic T cells, B cells and macrophages in particular, also interact in a 
complex network with the malignant cell. This study provides some insight into this and 
by focusing on a single subclass has the advantage over an integrated study of the entire 
microenvironment, which cannot discriminate between the relative contributions of the 
different cell types. This is the problem of gene expression profiling, which has failed to 
generate any reproducible, functional or clinically translatable conclusions116, 292, 356. 
6.5.3 A CD3+CD4+ signature for CHL with potential clinical application 
A more clinically useful application of these findings, avoiding functional inferences, 
would be the capacity to discriminate a malignancy by its compliment of CD3+CD4+ 
cells. Since these cells provide the majority of infiltrate in reactive nodes, and a 
substantial minority in haematological malignancies, they may therefore be amenable to 
assessment using a minimally invasive strategy such as fine needle aspiration (FNA). 
Flow cytometric analysis of FNA samples has been shown to be sufficiently robust for use 
in diagnosis of many lymphoid malignancies, but due to the scarcity of the malignant 
cell has the technique has not been applied to CHL diagnosis. Although FNA has 
exceptional specificity in those rare cases in which HRS cells are detected by microscopy 
of the samples, it has poor sensitivity, and flow cytometry of the samples remains 
unsuitable at this stage for clinical diagnosis495-498. Whole fresh lymph node flow 
cytometry may be capable of discriminating phenotypic HRS cells459 but this remains 
relatively untested clinically, is no less invasive than conventional histopathology, 
requiring whole nodes and could not be reproduced using the SCSs and techniques 
documented in Chapter 5.  
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Using only the most differentially and consistently expressed markers – CD57, CCR7 and 
CD62L, and cut-points at levels that could be easily and reasonably assessed as long as 
valid internal negative and positive controls are available (peripheral blood provides T 
cells with high expression of CCR7 and CD62L, and tonsils T cells with high expression 
of PD1), the strategy detailed in 6.4.2.4 above could be applied.  Scoring 1 for each of the 
following expressed as a percentage of all CD3+CD4+ cells, CD57 < 5%, CD62L > 30%, 
CCR7+CD62L+ >10%, a score of 3 is proposed as a strong indicator of CHL being present, 
a score of 2 that the differential remains with a reactive node, and a score of <2 that the 
node is unlikely to be CHL. NLPHL may in itself have a far more unique profile, which 
needs to be taken forward into a larger scale validation exercise.  
6.6 Summary and Further Work 
The data presented here on the extended phenotype of CD4+ T cells may be interpreted 
as showing that CHL T cells represent an aberrant accumulation of naïve or memory 
cells attracted by the presence of malignant HRS (or precursor) cells arising within the 
lymph node, demonstrating under-expression of markers of senescence (PD1, CD57), 
over-expression of markers of priming prior to activation (CGC, CD28, both down-
regulated after activation) and a substantial admix of activated IFN-  secreting, T-BET 
expressing Th1 cells, and CD25, CCR4, CTLA4 and FOXP3 expressing Tregs. The 
naïve/central memory component is primed for activation by cytokines, lineage 
uncommitted and hence capable of Th1 and Th2 polarisation (see Chapter 7) as well as 
prolonged survival and substantial proliferation.  
 
In vivo, these cells are perhaps drawn into the microenvironment antigen non-
specifically by chemotaxis, through secretion of chemokines by the HRS, and retained by 
ongoing expression of CD62L and CCR7. Potential HRS-clearing Th1 cells, and their 
attendant Tregs (whose presence is always a feature of inflammatory tissue) are attracted 
and capable of discharging their function, but rendered unable to reach their target cells 
due to being embedded within a primed but not activated, antigen non-specific mass of 
naïve and memory T cells. The sequestration of this compartment within the malignant 
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lymph node may further lead to systemic immunosuppression, particular cellular 
immunity.  
 
These hypotheses are highly speculative. Further validation, with modified antibody 
combinations to demonstrate appropriate co-expression of markers, as well as increased 
sample and control numbers, is required to substantiate this hypothesis. The possibility 
of a clinical application of the HRS-infiltrating CD4+ T cell in the form of diagnostic flow 
cytometry is one that requires substantial ongoing validation and optimisation but 
certainly shows potential. 
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7. Fluorescence immunophenotyping to characterise CHL-
derived proliferative CD4+ T cells 
7.1 Introduction 
Chapter 5 described an attempt to develop an autologous co-culture system in which 
both microenvironment and malignant cells could be supported through addition of T 
cell supportive cytokines. While presence of the malignant cell could not be 
demonstrated convincingly at baseline or subsequently in the proliferating culture by 
flow cytometry, it was found that the system supported the growth of CD4+ T cells 
derived from all CHL samples and most control samples derived from FL. There was 
substantially less or no significant CD4+ T cell growth arising from benign lymph nodes. 
Chapter 6 investigated the extended phenotype of the CD4+ T cells at baseline derived 
from the same frozen SCSs as those from which the proliferative cells were derived, 
along with benign and malignant controls. It was shown that the CHL-derived CD4+ T 
cell has a distinctive phenotype, although there was still heterogeneity between cases. 
The distinctive aspects were the absence of markers of chronic immune activation and 
senescence (PD1 and CD57) and an overrepresentation of markers of central memory 
(CCR7, CD62L and CD127). The dominant cytokines produced on stimulation indicated a 
Th1 bias (IFN- and TNF ), likely to a greater extent than seen in benign nodes, and 
similar to that seen in the CD4+ T cell component of the FL-infiltrate. The most potent 
cytokine combination for growth was found to be IL2 and IL4, at concentrations used for 
in vitro Th2 polarising experiments460. However Th2-specific markers were notably 
absent, as demonstrated using IHC in Chapter 4 and in the analysis of the SCS CD4+ T 
cells presented in Chapter 6. Other groups have successfully sustained long-lived T cell 
culture systems using similar methods466, 467. However immunophenotypic and 
functional analysis of the expanding cultures has been limited in these studies to 
confirmation of CD3, CD4 and CD8 expression, along with a demonstration that the cells 
became oligoclonal and develop chromosomal aberrations. Characterising the long lived 
T cell, although an entirely in vitro phenomenon, may identify the originating cell 
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population within the original cell suspension along with molecular mechanisms that 
enable it to persist without TCR stimulation or antigen exposure. The hypothesis that 
the dominant cell in CHL is a central memory or naïve T cell as proposed from the 
results of the immunophenotype demonstrated in Chapters 6 and superior proliferative 
capacity shown in Chapter 5, may be further tested by investigating the functional 
diversity of the expanding progeny of these cells. 
7.2 Aims and Objectives 
The aim of this experiment was to investigate the phenotype of the proliferative T cells 
derived as described in Chapter 5 applying the panel of antibodies used at baseline as 
described in Chapter 6. Hence the change in phenotype of the population over time 
could be determined along with comparisons between CHL, FL and any sufficiently 
expanded benign lymph node-derived sample. 
7.3 Materials and Methods 
7.3.1 Single cell suspensions 
At various time points as the SCS-derived cultures expanded, aliquots of cells were 
frozen down. Ideally, aliquots were taken at days 30, 60, 100, 150 and 200. However, this 
was clearly dependent upon the proliferative capacity of the system. A representative 
selection of 20 frozen samples were chosen as shown in Table 7.1. These were chosen 
based on availability and to ensure adequate controls. 
7.3.2 Freezing methodology 
For consistency, proliferative plates were frozen down as long as >50% of wells were ‘live’ 
as defined in Chapter 5. One 96 well plate was harvested into a 30ml sample tube using a 
multichannel pipette, centrifuged at 2000RPM for 8 minutes, the supernatant removed 
by aspiration and the resultant cell pellet resuspended in 1ml freeze mix comprising 90% 
heat-inactivated human AB serum as used for the culture medium and 10% dimethyl 
sulphoxide (DMSO) and frozen as described in 2.1.2.1 until ready for analysis. At this 
stage the samples were thawed and resuspended as described in 2.1.2.2. 
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Data 
Acquired Source Code Day 
6 CHL 302 0 
6 CHL 304 0 
6 CHL 305 0 
6 FL 603 0 
6 NLPHL 801 0 
6 FL 802 0 
6 TON 804 0 
6 FL 805 0 
6 FH 808 0 
 
Table 7.1: Samples used for the experiment 
described in Chapter 7. The selection was 
made based on availability and in order to 
include sufficient and different time points of 
observation. The internal control (304 Day 0) 
was included to facilitate gating strategy, and 
provide a validation for reproducibility of 
results between batches. The remaining Day 0 
results had been acquired for the experiment 
described in Chapter 6 and as such part of a 
separate experimental batch, with the 
potential problems of batch variation. However, they were included to provide a baseline 
for all samples.  
 
7.3.3 Selection of fluorochromes and antibodies 
The same panel of antibodies was applied in this experiment as had been used in the 
extended phenotyping experiment as described in 6.3.2. 
7.3.4 Flow cytometric analysis, data acquisition, compensation and gating  
This has been described and justified in detail in Materials and Methods 2.3. For the 
purposes of an internal ‘known phenotype’ control, as discussed in 2.3.9.4 an aliquot of 
baseline sample C4/304 was available which provided a sufficiently mixed population of 
cells, with a known phenotype based on the data acquired in Chapter 6, from which a 
gating strategy consistent with the previous experiment could be applied to the new 
experimental samples. This was of particular importance for antigens showing a global 
increase in representation without a clearly discriminant positive population (for 
example CD27, CD28, CD127 and PD-L1). By examining the MFIs derived from this new 
Data 
Acquired Source Code Day 
7 CHL 302 100 
7 CHL 302 60 
7 CHL 302 30 
7 CHL 304 60 
7 CHL 304 30 
7 CHL 304 0 
7 CHL 304 100 
7 CHL 305 30 
7 CHL 305 60 
7 FL 603 60 
7 FL 603 30 
7 NLPHL 801 30 
7 FL 802 30 
7 FL 802 100 
7 TON 804 30 
7 FL 805 30 
7 FL 805 100 
7 FL 805 60 
7 FH 808 100 
7 FH 808 60 
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experimental batch, some consistency between batches could be applied, although the 
limitations of between-batch comparison were taken into consideration in interpreting 
results. 
7.3.5 Statistical Analysis 
Percentage expression of each marker within the CD3+ CD4+ population were analysed 
in a variety of ways given the limited numbers of samples available for each tissue type 
and each time point. First, the hypothesis was tested that the marker concerned would 
be expressed at a significantly different level at various time points compared to 
expression in the baseline sample. Hence data were pooled according to the time point 
at which the sample had been frozen (day zero, 30, 60 or 100) and the assumption was 
made that the proliferating population at each time point was comparable regardless of 
lymph node of origin. Second, the hypothesis was tested that the marker concerned 
would be expressed in the proliferating culture systems at differing levels according to 
the tissue of origin, but disregarding the time point at which the sample was analysed. 
Hence data were pooled according to the tissue of origin, but combining all samples 
across sampling time points (i.e. days 30, 60 and 100: day zero was not included since 
this was not derived from a proliferative culture system). Finally, for CHL and FL only, 
since there were adequate numbers of samples to draw preliminary conclusions on each 
tissue individually, these two factors (age of culture system and tissue of origin) were 
discriminated, and data pooled for each time point and for each tissue. Only those 
samples analysed at subsequent proliferative time points were included for the day zero 
analysis, as described in Table 7.1.  
 
For each distribution of data: by age of culture system, by tissue of origin, and finally by 
age of culture system for each of CHL and FL individually, analysis of variance (ANOVA) 
was performed to determine differences between groups with statistically significant 
difference set at 0.05. Additionally, significance of differences between paired sample 
means were calculated using the method of Mann and Whitney371. Multivariate analysis 
combining the three variables: tissue of origin, time of sampling and expression level of 
marker requires more samples than were available for this experiment in order to be 
adequately powered and as such was not carried out. 
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7.4 Results 
7.4.1 Limitations of Method and Data Interpretation 
In the interpretation of these results, it should be taken into account that changes in 
expression levels of any particular marker may represent either up-regulation or down-
regulation of that marker on cells within the total CD3+CD4+ cell population, or a 
relative enrichment or depletion of subsets of cells expressing that marker at baseline. 
Without tracking individual cells and their progeny these explanations cannot be 
discriminated. In addition any comparisons between the day zero pooled samples and 
those derived from subsequent samples may be subject to batch variation. Additionally, 
inadequate viable cells were available for analysis from the single tonsil-derived sample 
that showed evidence of proliferation at day 30. This was in keeping with poor growth 
observed in all tonsil-derived culture systems. As such the pilot finding reported in 
Chapter 5, that the CD8+ cell dominated in a successful tonsil-derived system in contrast 
to the CD4+ cell in CHL, could not be replicated. All benign control samples available 
were therefore reactive nodes as detailed in table 5.1. 
7.4.2 Individual marker analysis, ANOVA and pairwise comparisons 
For each class of marker described below, composite figures are divided into three. The 
first two columns indicate changing expression of the marker in the proliferating CD4+ T 
cells for each time point sampled. The leftmost column displays results pooled by 
malignant lymph node of origin: either CHL (red) or FL-derived (blue). The middle 
column pools all samples at each time point regardless of node of origin. The final 
column displays the mean expression across all proliferative time points (i.e. excluding 
baseline results) pooled by lymph node of origin to enable comparisons to be made 
between resultant CD4+ cells according to originating tissue.  
 
While most CD4+ T cell markers showed a variation of expression level with time, 
variation in expression levels between samples, regardless of tissue of origin, was far less 
marked (See 7.4.3). Significance of differences between samples by time point or by 
tissue of origin are determined as described in 7.3.5, and levels of significance shown in 
the appropriate figures (Figures 7.1 – 7.12)  
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7.4.2.1 CD4+ CD45RO+ T cells are the dominant cell type in all culture systems. 
Figure 7.1 shows the loss of CD8 expression with time. By day 30 <10% (mean all pooled 
samples) T cells expressed CD8, and by day 60 <2%, with no recovery of cell numbers. 
There was no expression of CD20 in any system by day 30. Hence in all culture systems 
analysed at day 30 the CD4+ T cell was the dominant or exclusive cell type. This is in 
contrast to the single analysis of a tonsil performed in the pilot experiment described in 
Chapter 5 where CD8+ T cells dominated. However, poor growth in the subsequent 
tonsil-derived culture systems prevented any further analysis of proliferative tonsillar T 
cells. 
 
CD45RO was present at high levels in all samples at baseline and persisted with time. 
The CD45RA component was present at widely heterogeneous levels at baseline (see 
Chapter 6) and was lost with time (mean all pooled samples: Day zero: 20%, Day 30: 8%, 
Day 60: 3%, Day 100: 2%). This was most pronounced for CHL (Baseline: 25%, Day 30: 
12%, Day 60: 4%, Day 100: 2%) although this did not reach significance by ANOVA, 
probably reflecting under-powering for the small sample size. 
 
  
   
 
Figure 7.1: Loss of CD8 cells and CD45 isotype change with time. 
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7.4.2.2 TNFRSF and IGSF members (Figures 7.2 and 7.3) 
By day 30 cells in all culture systems universally expressed CD95 (Figure 7.2), having 
been expressed at widely variable levels at day zero (Chapter 6). This persisted at day 
100. 
 
With time there was significant loss of expression of CD27 (means: Day zero vs Day 30 vs 
Day 60 vs Day 100 = 64% vs 18% vs 5% vs 2%) and CD28 (means: 33% vs 23% vs 16% vs 
22%) and ICOS/CD278 (means: 48% vs 32% vs 18% vs 18%). For CD27 this loss was 
significant for both FL-derived and CHL-derived CD4+ T cells. However no difference 
could be found according to node of origin except for CD27, where CHL derived cultures 
expressed the marker at mean level of 12%, compared to 2% in FL, predominantly due to 
persistence of expression at day 30. Most expression had been lost in all cultures by day 
60 (Figure 7.3) 
 
In contrast, there was a significant increase in expression of CD30, CD40-L and RANK-L 
expression with time in all culture systems (Figure 7.2) without any significant difference 
according to node of origin. At baseline, no marker was expressed at appreciable levels. 
However by day 30, CD40-L was expressed in 11% of cells (mean of all pooled samples), 
23% at day 60, and 21% at day 100. RANK-L expression was seen in 11% of all cells at day 
30, persisting at this level until day 100, while CD30 was expressed in 12% at day 30, 23% 
at day 60, and 18% at day 100.  OX40 persisted in all culture systems derived from all 
lymph node types, with no significant variation by tissue type or time point (mean 
expression 30% at day zero, 15% at day 30, 27% at day 60 and 22% at day 100). Data not 
shown in Figures for OX40 or CD40-L; CD30 and RANK-L included for illustration. 
 
  
 
Figure 7.2: Gain of expression of TNFRSF and IGSF members by CD4+ T cells with time in culture 
  
 
Figure 7.3: Loss of expression of TNFRSF and IGSF members by proliferating CD4+ T cells with time in culture 
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7.4.2.3 Cytokine Receptors and Early Activation Marker (Figures 7.4 and 7.5) 
All culture systems analysed were those derived from the IL2 and IL4 stimulated 
conditions, which had demonstrated best proliferation and longest duration of survival. 
Hence expression of these cytokine receptors was of interest. IL2R  was not expressed at 
any time point in the CD4+ T cell compartment. However IL2R  (CGC) was present in all 
systems, persisting at similar levels across all time points, although with greater 
heterogeneity at day zero, than by day 100. The range of expression of CGC had 
narrowed from 17% - 53% at day zero to 29% - 43% by day 100. Mean expression levels 
remained comparable at all time points. IL2R  (CD25), however was expressed by a 
greater proportion of cells as the culture system aged, largely accounted for by a 
substantial increase in FL-derived cultures. At day zero a significantly greater proportion 
of CHL-derived CD4+ T cells expressed CD25 than those derived from FL (6.4.2.3) 
whereas in proliferating CD4+ T cells, levels were similar regardless of nodal source, at 
day 30 and beyond (mean day 30: 28%, by day 100: 36%).  
 
IL4R  was present at low levels in CD4+ T cells of all SCSs at day zero, although its 
presence was confirmed as expected in the CD3- component comprising B cells, 
monocyte and macrophages. In the IL4-rich conditions of in vitro culture, IL4Ra was up-
regulated to a similar extent regardless of tissue of origin (Figure 7.4) which persisted to 
day 100. Mean expression at day zero was 2% and 10% by day 30. However, only a 
minority of CD4+ T cells (never >20%, and <10% in most cases) expressed this receptor, 
of interest since IL4 seems integral to the prolonged survival of the culture system. 
 
The early activation marker CD69 was present at widely heterogeneous levels at 
baseline, with significantly lower expression in CHL-derived cells than control samples 
(6.4.2.3). This heterogeneity persisted with time, however for all pooled samples levels of 
expression were significantly reduced (mean day zero: 59%, day 30: 27%, day 60: 36%, 
day 100: 32%). However, this loss of expression was less marked for CHL with no 
significant change from baseline (mean expression 56% day zero vs 37% day 30, 51% day 
60, 42% day 100), while for FL levels dropped significantly (69% to around 30%). 
Replicate numbers were few and require further validation. However, it appears that 
there is relative loss of this marker from the CD4+ T cell component with prolonged 
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culture except in CHL in which it is retained at a consistent level, having been present at 
a lower level at baseline (Figure 7.5). This gives rise to a significant difference of 
expression by tissue of origin pooling all proliferating samples. 
 
7.4.2.4 Lymph node homing (Figure 7.6) 
CD62L and CCR7 provided two of the best discriminating markers of CHL-derived CD4+ 
T cells compared to all controls at baseline (Chapter 6). However there was loss of 
expression of both markers in CHL-derived cells with time in culture, such that in 
proliferating cells there was no difference in expression of CD62L and CCR7 alone, or in 
combination, by tissue of origin. Expression of CD62L had reduced from mean 60% to 
28% by day 60/100, CCR7 from 28% to 15% and combined expression from 20% to 3%. 
 
  
 
 
Figure 7.4: Variance of expression of IL4Ra and CGC on proliferating CD4+ T cells with time in culture. 
  
 
Figure 7.5: Variance of expression of CD25 and CD69 on proliferating CD4+ T cells with time in culture. 
  
 
Figure 7.6: Variance of expression of lymph node homing molecules on proliferating CD4+ T cells with time in culture. 
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7.4.2.5 Persistence, Senescence and Immunosuppression (Figure 7.7 and 7.8) 
CD57 and PD1, markers of senescence and immunosuppression respectively, provided 
two more of the best discriminating markers of CHL-derived CD4+ T cells compared to 
all controls at baseline (Chapter 6). CD57, as anticipated, was up-regulated with time in 
culture (Figure 7.7). This was most marked for CHL, with a significant increase by day 30 
which persisted until day 100 (around 30%, having been <5% at baseline). This was 
similar to baseline levels for FL, although there were inadequate replicates to draw 
further conclusions regarding FL-derived cells. Overall there was no difference of 
expression levels in proliferating cells by tissue of origin. The main difference arose due 
to increased expression levels in CHL-derived samples. PD1 had a distinctive pattern of 
expression (Figure 7.8) being present at higher levels in FL-derived CD4+ T cells 
compared to CHL (Chapter 6). In contrast to CD57 expression of this marker was lost in 
proliferating cultures (baseline = 40% vs 20% at 30 days, 12% at 60 days and 8% at 100 
days). Mean expression levels of both markers were comparable in proliferating cells 
regardless of tissue of origin. 
 
PD-L1 and CTLA4 are both mediators of immunosuppression and expressed widely on 
activated lymphoid cells. Consistent with this activation-induced expression both 
markers were increased by day 30 (PD-L1 mean 4% at baseline, 22% at day 30, CTLA4 
mean 4% at baseline, 11% by day 30), but subsequently reduced by day 100 (PD-L1: 7%, 
CTLA4: 9%). This was significant for FL-derived CD4+ T cells for both CTLA4 and PD-L1, 
but significant variation of only CTLA4 expression could only be demonstrated for CHL.  
 
As discussed in the introduction, persistence of long-lived memory T cells is IL7 and 
hence IL7-receptor (CD127) dependent. This marker was present in a greater proportion 
of CHL-derived CD4+ T cells at baseline than control samples. With time, expression of 
this marker increased across all samples and persisted (Figure 7.7). Pooled mean 
expression level at baseline was 14%, compared to 23% by day 30 and 18% by day 100. 
Despite all samples showing an increase in CD127 expression with time, the receptor 
remained in a significantly greater proportion of CHL-derived proliferating CD4+ T cells 
compared to all other samples (CHL-derived T cell mean = 26%, pooled controls: 19%, 
FL-derived CD4+ T cells: 18%).  
  
 
 
Figure 7.7: Variance of markers of persistence and senescence on proliferating CD4+ T cells with time in culture. 
  
 
Figure 7.8: Variance of markers of immunosuppression on proliferating CD4+ T cells with time in culture. 
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7.4.2.6 Cytokine expression (Figures 7.9 and 7.10) 
Th1-defining pro-inflammatory cytokines (IFN-  and TNF ) dominated all tissue samples 
at baseline (Chapter 6) with a greater expression in malignant-derived T cells than 
benign controls, although there was no measurable IL2 expression in any sample. In 
contrast little measurable Th2-defining or immunosuppressive IL10 could be detected in 
any SCS, except for some IL4 expression by PTGC-derived cells. 
 
In contrast, proliferating cells showed a diverse cytokine expression repertoire, 
expressing both Th1 and Th2 cytokines simultaneously in some cases. There was no 
significant difference in expression of Th1 cytokines IFN- , TNF  or IL-2 by CD4+ T cells 
according to tissue of origin. IFN-  was expressed at comparable high levels of around 
60% of CD4+ T cells at all time points. TNF  was significantly up-regulated compared to 
baseline in all tissues (baseline mean 12%, at day 30: 52%, day 60: 43%, day 100: 58%) and 
to a similar degree regardless of the origin of the proliferating CD4+ T cell. IL2, not 
detectable at baseline in any CD4+ T cells, was expressed in a substantial proportion of 
cells by day 30, which apparently persisted until day 100, although sample loss for this 
condition limited the number of replicates. Mean expression was similar regardless of 
tissue of origin, although the range of expression varied considerably (4%-30% of all 
CD4+ T cells). 
 
Th2-defining cytokines were expressed in a substantial and increasing proportion of 
CD4+ T cells as time passed. By day 100 a mean of 58% of cells expressed IL4, 22% 
expressed IL13 and 9% expressed IL21. Fewer CHL-derived proliferating CD4+ T cells 
expressed IL4 than those derived from FL or reactive lymph nodes (mean 39% across all 
proliferating cells for CHL, compared to 59% for FL and 78% for reactive nodes), and 
fewer expressed IL13 than those derived from reactive nodes (20% vs 41%). Heterogeneity 
of expression for IL13 was substantial however. IL21 was expressed heterogeneously 
across all samples, with a suggestion of increasing expression with time that was not 
significant. 
 
IL10 was not expressed at baseline or in any proliferating CD4+ T cell. 
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There was no single tube combining antibodies to concurrently detect both Th1 and Th2-
defining cytokines in this experiment, and hence there is no direct evidence for co-
expression of these normally mutually exclusive cytokine systems. However, expression 
of both IFN-  and IL4 in greater than 50% of cells demonstrates that at least a proportion 
of cells co-express both markers. It is possible that some proliferating cells are Th1-like 
IFN-  producing cells and others Th2-like IL4 producing cells, with a proportion of cells 
co-expressing both cytokines and others expressing a wider range of Th1 or Th2-defining 
cytokines (TNF /IL2 and IL13/IL21 respectively). Expression of Th1-defining cytokines 
emerges rapidly and persists, while Th2-defining cytokine expression emerges more 
slowly and is most marked by day 100. 
 
  
 
 
Figure 7.9: Variance of Th1 cytokine expression on proliferating CD4+ T cells with time in culture. 
  
 
Figure 7.10: Variance of Th2 cytokine expression on proliferating CD4+ T cells with time in culture. 
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7.4.2.7 Chemokine Receptor Expression (Figures 7.11 and 7.12) 
CCR4 is highly and heterogeneously expressed at baseline in CD4+ T cells derived from 
all tissues, particularly so for CHL (see Chapter 6). This expression persists with 
proliferation, although significant change with time, or tissue of origin could not be 
shown (Figure 7.11). 
 
Neither CCR6 nor CCR3 (Figure 7.12) were expressed at high levels (<10%), at baseline, or 
in proliferating T cells although there was a significant reduction in CCR3 levels across 
all pooled samples with proliferation, from 2.5% at baseline to 0.8% by day 30, remaining 
below 2% in all samples. This difference was predominantly accounted for by expression 
in 7% of CD4+ T cells in a single case of CHL at baseline, and as such this outlier may be 
questioned as being truly representative, and would require validation in a larger cohort. 
 
The Th1-associated cytokine CCR5 was present at considerable levels at baseline in all 
samples but with no significant difference between samples demonstrated (Chapter 6). 
Expression was significantly lost with time in all samples (Figure 7.10), with mean 
expression across all pooled samples being 18% at baseline, 10% at day 30, 4% at day 60 
and 3% by day 100. This was in spite of the extremely high levels of expression of Th1-
associated cytokines in all samples. In contrast, CXCR3, which was not included in the 
panel for the experiment described in Chapter 6, was expressed in a high proportion of 
CD4+ T cells at day 30, and while there was a reduction in the mean expression across all 
pooled samples at each time point (38% day 30, 30% day 60, 25% day 100) this was not 
significant. There was no difference in mean expression between samples, but overall 
expression levels were highly heterogeneous, ranging from 5% to 80% expression. This 
loss of Th1-defining chemokine receptors is in contrast to the high levels of expression of 
Th1-defining cytokines, highlighting the limitations of surface molecule expression as 
markers of the functional capacity of T cells, as well as the limitations of any 
longstanding in vitro culture system subject to unphysiological alterations of phenotype. 
 
  
 
 
Figure 7.11: Variance of Th1 and Tfh associated chemokine receptors on proliferating CD4+ T cells with time in culture. 
  
 
Figure 7.12: Variance of Th2 and regulatory associated chemokine receptors on proliferating CD4+ T cells with time in culture. 
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7.4.3 Discriminatory markers in proliferating cells 
Combining all results, it is clear that the proliferating CD4+ T cells express a distinct 
repertoire of markers compared to the unstimulated cells of the SCSs. However, the 
resulting proliferative T cells are remarkably similar, regardless of node of origin, despite 
markedly different proliferative properties dependent upon node of origin described in 
Chapter 5, and the distinct phenotypes of the CD4+ compartment at baseline (Chapter 
6). This is apparent in an unsupervised hierarchical cluster analysis using the same 
approach as applied at baseline (6.3.4.2 & 6.4.2.1), which this time fails to discriminate 
samples by tissue of origin or time point of sampling (Figure 7.13). 
 
However, there are six markers whose expression appears discriminatory for CHL. CD69, 
CD27, CCR7 and CD127 remain expressed at higher levels in CHL-derived T cells, 
whereas IL4 and IL13 are expressed at lower levels, compared to control tissues. 
 
 
Figure 7.13: Hierarchical clustering fails to differentiate groups by tissue of origin when 
applied to proliferative CD4+ T cells 
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7.5 Discussion 
7.5.1 Limitations of this experiment 
The limitations of the sources of primary tissue and controls have been addressed in 
6.5.1.3 and remain pertinent to this experiment. The culture systems are entirely artificial 
and the resultant cells unlikely to represent any in vivo phenotypic equivalent. The 
proliferation conditions selected, while avoiding any direct stimulation of the cells 
through TCR specific or super-antigenic stimuli, involved exposure to supraphysiological 
levels of cytokine which in themselves may have provided sufficient stimulation to 
induce antigen and MHC-independent proliferation. 
 
Hence analysis of the resulting proliferating cells phenotype when exposed to such non-
physiological stimulation and stress is unlikely to reveal the ‘dominant’ or ‘founder’ cell’s 
phenotype that went on to populate the system. An increase in the representation of a 
marker in a population of cells as much indicates new expression of that marker by a 
proportion of those cells as it demonstrates proliferation in a specific subset of cells 
which expressed that marker at baseline and goes on to represent a greater proportion of 
the final population. Markers of activation and senescence in general were expressed as 
would be expected for any chronically stimulated system. However, despite these 
substantial limitations a number of conclusions may be drawn. 
7.5.2 Markers of Activation 
First, it appears that any mixed lymph-node derived single cell suspension culture, when 
exposed to IL2 and IL4 at levels capable of sustaining T cell proliferation, will give rise to 
a virtually pure population of CD4+ T cells, with few CD8+ cells and no non-T cells 
surviving beyond 30 days. These cells are exclusively CD95+ and despite this survive 
without undergoing CD95-mediated apoptosis perhaps due to the absence in the system 
of CD95/FAS-ligand. CD45RA expression is lost with ongoing stimulation, representing 
either loss of an unstimulated naïve cell population or TCR-independent stimulation of 
all CD45RA+ naïve cells with consequent expression of CD45RO. 
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The cells are functionally competent in that a high proportion of cells express Th1 and 
Th2-cytokines, and at least some express both concurrently. CD57 is expressed by an 
increasing proportion, as expected under conditions of chronic stimulation.  
 
CD30 and RANK-L, not expressed by the T cells at baseline, are expressed in a minority 
of cells in the ongoing cultures. CD30 expression is induced by IL4 and associated with 
IL4-responsiveness and a Th2-polarised phenotype499, so this finding is consistent with 
chronic IL4 exposure. The functions of CD30 on interacting with CD30-L are numerous, 
with both receptor and ligand found on B cells, T cells and other immune cells, and 
functional data suggesting bidirectional signalling of both suppressive and stimulatory 
nature494. The receptor itself was discovered as a consequence of its characteristic 
expression first in CHL-derived cell lines and then in primary tissue in contrast to other 
B cell-derived malignancies, and in common with the mature T cell malignancy 
anaplastic large cell lymphoma (ALCL). However apart from its representing a distinctive 
marker of these malignancies, and downstream signalling pathways communicating with 
the NF- B proliferative/survival networks suggesting a role in tumour maintenance and 
interaction with the microenvironment, no definitive evidence for the oncogenic or 
obligate role for this receptor have been defined. CD30-targetted monoclonal antibody 
therapy is relatively ineffective in either CHL or ALCL unless conjugated to toxins500, 
suggesting that the mediator of toxicity is neither interference with necessary survival 
signals, nor direction of immune cells towards the malignant cells, but simply tumour 
targeting by its expression of a unique marker. 
 
RANK (receptor-activator of NF- B) and its ligand are expressed by HRS cells119, 501, and 
signalling through this pathway is suggested to be of importance in its survival and 
interaction with the immune microenvironment. The molecule has sequence and 
potential functional homology with CD40, interacts with its own ligand, RANK-L and is 
essential in lymphoid cell development502. Expression on CD4+ T cells was not found at 
baseline (Chapter 6), but it appears to be up-regulated in this in-vitro system for all 
samples including CHL and controls. Persistence of expression over time may reflect 
activation through the cytokine stimuli to which the cells were exposed503. This 
expression pattern is in contrast to the corresponding loss of another similar activation-
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induced molecule, ICOS. Other markers of activation, PD-L1 and CTLA4, these with 
immunosuppressive function, are also found expressed by the expanding T cells. 
However without functional corroboration it is difficult to determine their significance 
except as nonspecific activation markers. CD28 is present at high levels in naïve T cells, 
and lost upon activation and stimulation in this culture system as expected. 
 
7.5.3 The significance of chemokine receptors in the expanding cultures 
As discussed in the Introduction (1.4.3) the expression of chemokine receptors in CHL is 
complex and diverse, and comparisons within the heterogeneity of the disease and 
between diseases rarely performed. Associations with functional CD4+ T cell subsets are 
limited in their applicability and validity. CHL is distinguished by a high expression of 
the chemokines TARC/CCL17 and RANTES/CCL5, which predominantly attract CCR4 
and CCR5-expressing cells respectively. This has been suggested to be a mechanism by 
which the microenvironment of CHL is enriched for T cells of particular function. CCR4 
expression has been associated with Th2 and Tregs, while CCR5 has been described as a 
Th1-expressed receptor, as detailed in the Introduction 1.6.4.3. CXCR3 and CCR3 (ligand 
eotaxin/CCL11) are associated with Th1 and Th2 cells respectively and were also included 
in the phenotyping panel. CXCR3 was not included in the baseline experiment described 
in Chapter 6 for technical reasons, but was available for this experiment. In addition, 
CXCR5 was included which is a marker of germinal centre-associated T cells and B cells. 
There is limited literature to suggest that CCR6 expression is associated with a  
association with a suppressive or memory phenotype.504 
 
Chemokine receptors are an essential component of T cell trafficking, 
compartmentalisation, intercellular communication and intracellular survival signalling. 
The in vitro system used in these experiments contains no survival mechanisms based on 
anatomical compartmentalisation, comprises only CD4+ T cells, and is dominated by the 
presence of excess specific cytokines. Hence the continuous signalling provided by 
supplementary cytokines in vitro subsumes the relative importance of chemokine 
receptors responsible for maintaining survival in vivo. This is most clearly demonstrated 
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by the fact that FAS/CD95, which in vivo indicates a cell destined for apoptosis, is 
universally expressed while the cells continue to survive and proliferate. 
7.5.4 The significance of TH2 cytokines in the expanding culture 
While Th2-specific cytokines are expressed at high levels in this system, the presence of 
IL4 predisposes uncommitted CD4+ T cells towards Th2 polarisation. The ongoing 
presence of a majority of Th1 cytokine-producing cells in spite of IL4 exposure does not 
support a predominance of Th2-determined cells in the initiating culture. Indeed, the 
balance of evidence of IHC (Chapter 4) and SCS flow phenotyping (Chapter 6) argue 
against any significant Th2 presence at baseline. 
7.5.5 The influence of a suppressor/regulatory T cell in the expanding cultures 
The growth of CHL-derived CD4+ cells despite an apparently significant infiltrate of 
Tregs, evidenced by IHC staining for FOXP3 and fluorescence immunostaining for CCR4 
and CTLA4 is in contrast to the findings of Marshall et al detailed in the Introduction 
(1.7.2) describing a hypoproliferative, IL10-secreting, suppressive phenotype for the 
tumour-derived SCSs299. Once again, the large cytokine doses to which the system 
described in this experiment is exposed, in contrast to TCR-bypassing / super-antigen 
stimulus of the system of Marshall et al means that direct comparisons are impossible. 
However, neither system could be deemed more physiological representations of the in 
vivo lymph node microenvironment so these differences are another indicator of the 
problems of in vitro modelling. The experiment described in this chapter did not set out 
to functionally demonstrate the presence of Tregs, so ongoing presence of Tregs in the 
expanding cultures cannot be ruled out, and may be essential in maintaining the 
systems. However an alternative explanation, that the hypoproliferative Tregs are simply 
outcompeted and outgrown by a more proliferative component, is just as feasible.  
7.5.6 Markers of Longevity and Senescence 
CD27 expression may be indicative of cells with a greater capacity for prolonged survival 
and proliferation, with in vitro experiments showing that its expression in association 
with CCR7, the lymph node T cell zone-homing receptor, marks a functional subset with 
longer telomeres, better proliferative capacity and lesser cytokine-producing capacity505. 
In contrast, CD57 is associated with chronically stimulated, terminally differentiated 
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cells. Most functional work on CD57 is derived from models of chronic viral infection 
such as HIV297.  
 
The loss of PD1, another marker of chronic immune stimulation, in spite of the 
emergence of CD57 is of interest and difficult to explain. Its disappearance coincides 
with the loss of CXCR5. Both markers are expressed on Tfh cells (See 1.6.6) and while co-
staining for both markers was not carried out to confirm this, the loss of both these 
markers along with another marker of Tfh cells – ICOS, may indicate that Tfh cells 
within the system are lost.  
 
Cytokine expression, in particular Th1-defining cytokines, is often an indication of 
terminal differentiation of a cell. Activation-induced apoptosis will usually follow once 
the cell has discharged its function in order to maintain immune homeostasis and 
prevent excess, aberrant inflammation – the effector T cell ‘contraction phase’144. While 
these cells may be capable, once committed to cytokine secretion, of further 
proliferation, it is more likely that the system is being sustained by another  
subpopulation of cells with a greater capacity for self renewal and proliferation rather 
than a terminally differentiated cytokine-secreting cell. Hence the longest-lived system 
may be that which possesses the greatest number of, or the most robust progenitor / 
stem cell-like T cells at baseline. These proliferating cells may be relatively multipotent, 
in line with some models of T cell development in which only activation, proliferation 
and exposure to particular inflammatory environments commits the T cell to a 
phenotype (which may eventually itself be relatively plastic) while in the early stages of 
proliferation it remains relatively uncommitted506.  
7.5.7 A distinctive phenotype for the proliferating CHL-derived CD4+ T cell? 
Unlike the immunophenotype of the CD4+ T cell at baseline, few markers in this panel 
distinguish expanded CHL-derived T cells from those derived from non-malignant or FL-
infiltrated nodes. However, there is clearly a difference in functional phenotype 
evidenced by the longevity of malignant cultures over benign cultures, and the greater 
proliferative capacity and longevity of CHL-derived over FL-derived CD4+ T cells. 
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The few distinguishing markers that do exist provide some insight into the nature of this 
population as a whole, and as such the basis for further phenotyping and functional 
work. All findings require validation in a larger cohort of CHL and control node-derived 
SCSs. 
 
CCR7 and CD27 are lost with culture age, but retained to a greater extent in the CHL-
derived system. CD127 is retained, not lost with time, despite the absence of 
supplementary IL7, its ligand, implying either autocrine production of the cytokine, or 
that it is up-regulated in any cell population that has longer survival. CD69, while 
present at lower levels at baseline (indicating perhaps a lesser proportion of CD4+ cells 
in CHL are in an early activated state, or alternatively more are chronically activated 
than in control node-derived cells), is sustained at similar levels through time, in 
comparison to expanding control nodes in which it is lost. The loss of CD62L as a 
distinguishing marker: one of the most discriminant at baseline, may simply reflect the 
loss of importance of the adhesion molecule interaction which is essential to 
transporting a T cell into a lymph node. While the same may be said for CCR7, which 
homes the T cell to the CCL19 and 21-rich paracortical T cell zone, perhaps this again has 
other functions, is being sustained by autocrine production of CCL19 and CCL21 
(although predominantly these are thought to be secreted by stromal cells120) or is 
another non-specific activation marker. 
 
One model explaining all of these findings would be that the CHL-derived node contains 
a CD4+ subpopulation with self-renewal and proliferative capacity capable of generating 
terminally differentiating, functional, cytokine-secreting cells. The progeny of these cells 
are detected by activation markers (e.g. CD69, and other TNFRSF members) and 
probably have a short lifespan, limited proliferative capacity and die off. However, the 
self-renewal capacity of the originating subpopulation sustains the overall expansion of 
the culture system. Such cells resemble the central memory cell phenotype in their 
expression of CD27, CCR7, and CD127505, may be resistant to FAS-mediated apoptosis (or 
in this system perhaps simply not encountering FAS-ligand), remain IL2 and IL4 
dependent, and are capable of producing progeny with both Th1 and Th2-like cytokine 
secretion profiles. In this model, any terminally differentiated cells rapidly die off, 
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including the CXCR5+PD1+CD57+ICOS++ Tfh cells apparently dominant in NLPHL, and 
present to a greater extent in FL and tonsillar tissue, as well as T-BET-expressing effector 
cells, and perhaps hypoproliferative FOXP3 cells. The maintained expression of CCR4, 
from baseline and throughout culture is intriguing, but may represent the replacement 
of native baseline CCR4-expressing Th2 cells and Tregs, with cells expressing CCR4  
induced by IL4 exposure. These cells may or may not have other features of Th2 cells or 
Tregs, and represent two of several phenotypically distinct lineages arising from the 
progenitor central memory-like cell. As these central memory-like cells become 
exhausted, they express CD57 and lose CD27, perhaps a precursor to senescence of the 
culture system as a whole. 
7.6 Summary and Further Work 
Proliferating CD4+ T cells derived from CHL and control nodes are indistinguishable 
using this immunophenotyping panel. They retain effector function in their production 
of Th1- and Th2-defining cytokines throughout. However, the CHL-derived (and to an 
extent FL-derived, more so than benign n0de-derived) culture may contain a greater 
proportion of central memory-like cells expressing CD27, CCR7 and CD127 at higher 
levels and hence capable of sustaining ongoing growth for longer, through self–renewal, 
while continuing to produce Th1 and Th2-determined terminally differentiated effector 
cells. Validation of this model requires a further extension of the central memory cell 
phenotype which would involve combining markers spread across different tubes in this 
panel into a single tube (e.g. CD27, CD127, CD45 isotype as well as CCR7 and CD62L). A 
larger number of replicates are required to increase the robustness of findings, and this 
should include a validation of the long-term cell culture as well as the phenotyping work. 
Cell labelling studies may enable multiple lineages to be followed from individual central 
memory-phenotype progenitors, and provide evidence of self-renewal. Clinical 
translatability of this finding is essential to justify pursuing any further work. This will be 
addressed in Chapter 8. 
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8. Discussion 
This thesis set out to investigate interactions of the tumour-dominating CD4+ T cell with 
the malignant HRS cell in CHL through IHC, flow cytometry and in vitro cell culture and 
as such determine the molecular mechanisms through which these interactions support 
growth and progression of the malignancy. By applying some of these markers to tissue 
microarray, it set out not only to validate prognostic factors already in the literature but 
also to investigate new factors, in order to develop a clinically translatable system to 
identify patients for whom outcome would be poorest and in whom treatment could be 
modified.  
 
This project has provided evidence to set against a well-established yet often 
misrepresented literature on the nature of the microenvironment, arising from over-
interpretation and superficial presentation of data.  
8.1 A model for the CHL pathogenesis based on the CD4+ T cell infiltrate 
The immunophenotyping data presented in Chapter 6 have shown that the CHL-
infiltrating CD4+ T cell appears to have a unique signature, distinguishing it from similar 
cells derived from benign or FL infiltrated lymph nodes. Based on this phenotype, a 
model could be proposed for the T cell infiltrate in CHL. 
 
8.1.1 The CHL microenvironment sequesters naïve and memory T cells from the 
physiological lymphoid pool 
A B cell, which has likely encountered antigen, but not yet engaged its cognate T cell, or 
at least entered a germinal centre reaction, develops a malignant transformation, 
perhaps arising through the genetic instability intrinsic to B cell receptor rearrangement. 
This mechanism of early oncogenesis remains obscure and was not investigated in this 
project. However, while the molecular genetic mechanism of transformation may be 
spontaneous or virally induced, a surrounding infiltrate of supportive cells is required for 
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survival. The malignant HRS cell, or its hypothetical progenitor induces a generalised 
activation state in its lymph node surroundings through cytokine and chemokine 
release. This in turn activates high endothelial vessels of the lymph node, stimulates 
upregulation of adhesion and chemotactic molecules and encourages further lymphoid 
homing to that node, emulating the physiological response to foreign antigen load 
arriving at a draining lymph node. T cells expressing the highest levels of receptors for 
those adhesion molecules and chemotactic stimuli are preferentially recruited from the 
circulation and accumulate within the affected node. A key adhesion molecule initiating 
entry to the lymph node, L-selectin (CD62-L), is essential to this recruitment120. This 
molecule is particularly enriched on naïve and central memory T cells145. The activation 
state of the node leads to inhibition of lymphoid egress and ongoing recruitment of cells 
of the immune response, while other cells are polarised towards a phenotype determined 
by the inflammatory state of the node.  
 
HRS-cells orchestrate this chronic aberrant production of a cytokine and chemokine 
milieu favourable to the survival of these arriving lymphocytes. However the impaired 
recognition of the HRS cell as foreign through poor antigen presentation, and the 
ongoing non-specific recruitment of lymphocytes reduce the opportunity for HRS-
antigen specific interactions to occur. As the malignant cell divides, deriving growth and 
stimulatory stimuli from its own uncoupled intracellular survival and anti-apoptotic 
pathways and from interactions with surrounding immune cells and their secreted 
inflammatory mediators, further recruitment of non-specific lymphocytes occurs. The 
naïve central memory cells thus recruited are arrested in a primed state, with potential 
for proliferation and population of multiple effector compartments, but unable to realise 
this function due to isolation from their cognate antigen and possible suppressive signals 
within the microenvironment. 
 
The cytokine milieu, including IFN-  and TNF  produced by the malignant cell and by 
other cells of the microenvironment polarises many infiltrating lymphocytes towards a 
Th1 phenotype. Some of these cells will have appropriately recognised aberrant 
intracellular antigen presented directly by the HRS cell or by other APCs in the node but 
are unable to mediate a coordinated response in the face of an overwhelming continuing 
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non-specific recruitment of uncommitted naïve and memory T cells, consuming cytokine 
and occupying space. Many of these cells secrete or express B cell helping molecules on 
their cell membrane capable of maintaining malignant cell survival. Other cells, 
including Tregs, Th1-polarised cells and memory cells, are attracted to the infiltrated 
lymph node more non-specifically through secretion of TARC and RANTES and other 
chemokines by malignant cells and the activated microenvironment, interacting with 
receptors such as CCR4 and CCR5. Their influence on the malignant cell, the potency of 
any residual immune response, and on the non-specific infiltrate may influence growth 
of the malignant cells. However, without cognate antigen presentation any anti-tumour 
effect is likely to be non-specific and overwhelmed by pro-tumour non-specific 
interactions. 
8.1.2 The immune infiltrate is an indicator of immunological health of the host 
hence predicting outcome 
The general potency of the immune response reflected by the efficiency of recruitment of 
various T cell subsets to the node, even if ineffective at eradicating the malignancy, may 
be a surrogate marker for overall immune competence and fitness of the host. Once 
treatment is commenced this may be reflected in ability to tolerate toxic therapy, speed 
of regeneration of immunity following immunosuppressive treatment, and efficiency of 
eradication of residual malignant cells once the bulk of disease is removed by treatment. 
This provides one explanation for the positive prognostic impact of expression of FOXP3, 
CD20 and T-BET in the immune infiltrate at baseline on eventual disease outcome. 
8.1.3 Sequestration of the central memory compartment leads to profound cell-
mediated immune defect 
Malignant cells egress initially via normal channels of lymphoid circulation, into 
contiguous nodes, and later disseminate haematogenously leading to widespread 
aberrant recruitment of lymphocytes into the tumour microenvironment. This disturbs 
normal lymphoid circulation. Memory cell pools and lymphoid progenitors would 
initially compensate by proliferating to replace cell loss but eventually the capacity to 
replace sequestered cells would be overwhelmed, or homeostatic feedback from the 
sequestered populations negatively feed back to suppress further production. The 
preferential sequestration of the cells with most potent recall antigen response and 
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proliferative capacity as well as naïve cells would result in a profound functional defect of 
cell mediated immunity. This is well described in CHL42, 507 manifesting  as lymphopenia, 
impaired vaccine response41, predisposition to infection, transfusion-related GVHD508 
and is also consistent with the reported drop in CD4 count in patients with HIV in the 
months preceding development of overt clinical CHL120. 
8.2 Potential Clinical Translation of this work  
Describing a single component of the heterogeneous multi-cellular microenvironment of 
CHL, with its complex, interacting networks and dynamism not apparent in fixed, dead 
tissue, nor convincingly modelled in vitro or in vivo may seem to be an exercise in 
abstract reductionism without any potential for translation to the clinic. However 
selection of the CD4+ T cell as the focus of this thesis was based on its numerical 
dominance in the tumour mass and the biological plausibility of it being most capable of 
providing support, as a T helper cell, to a B cell derived malignancy. This work has 
therefore hence yielded a number of specific and important hypotheses with potential 
for clinical translation. 
8.2.1 A clinically applicable prognostic score may be derived based only on the 
expression of FOXP3 and CD68 at diagnosis. 
Several factors were found in the IHC panel applied to the TMA described in Chapters 3 
and 4, which were associated with clinical outcome. While FOXP3 stood up to the 
greatest extent of statistical analysis, discriminating groups of significantly different 
outcome by test/validation optimal cut-point methodology, as a continuous variable in a 
dose-dependent manner, and in combination with elements of the clinical prognostic 
score in a multivariate analysis, with CD68 being the next most statistically robust, 
confirmation in independent patient datasets is the most important validation exercise 
to be carried out. CD20, PD1 and T-BET also provided prognostic information as single 
variables but were not included in any multivariate analysis. Multivariate analysis is 
often underpowered to detect significant differences between groups. When applying a 
Cox Proportional Hazards model to survival analysis, there must be sufficient numbers 
of events, for which each variable represents a hazard. Mathematical modelling has 
determined that there must be at least ten events for each variable under 
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consideration361. Relatively few patients die of CHL, and even using an outcome measure 
such as freedom from first line treatment failure (FFTF) for which there are more events, 
a very large patient cohort is required for there to be sufficient events to include more 
than a handful of markers as variables in such an analysis.  
8.2.2 CHL can be discriminated from normal and other malignant tissue based 
only on the phenotype of the non-malignant CD4+ cell 
Chapter 6 demonstrated that CD4+ T cells derived from CHL-infiltrated lymph nodes 
could be discriminated from other reactive and malignant nodes by unsupervised 
hierarchical cluster analysis. Post-hoc analysis identified a subset of markers that are 
most discriminatory. While the freeze/thaw process undoubtedly alters cellular 
phenotype it is possible that this finding could be translated into a diagnostic test for 
CHL using a small number of fresh cells aspirated by FNA from a pathological lymph 
node498. This hypothesis remaining to be tested against a blinded sample of cells derived 
from fresh aspirated lymph nodes but a validation study could easily be carried out. 
8.2.3 Appropriate T cell trafficking is essential to anti-CHL-immunity 
The major hypothesis arising from the model of T cell accumulation in CHL described in 
8.1, is that non-specific naïve and central memory cells dominate the CHL 
microenvironment and may provide the cytokine, chemokine and cell membrane 
conveyed signals essential HRS survival. Should the accumulation of such T cells be 
prevented, by blocking key molecular mediators of trafficking to affected lymph nodes, 
then relapsed disease arising from the residual malignant precursor cells surviving 
primary therapy could be prevented. This could take the form of maintenance therapy in 
patients at high risk of relapse, using specific pharmacological blocking agents. Should 
the mediators of T cell trafficking be secreted systemically, as is likely, they may also 
provide early clinical indicators of relapse that may be detected at a stage where early 
therapeutic intervention could alter outcomes, or as an early assessment of treatment 
response at a point where intensification of therapy may be possible, as already explored 
clinically for TARC63. 
 
Bioengineering tumour-specific cytotoxic T cells to encourage trafficking to affected 
nodes has already been proposed in the context of the TARC/CCR4 interaction, where 
Chapter 8: Discussion 
 
306 
anti-CD30-specific cytotoxic T cells have been induced to express CCR4 and hence home 
preferentially to diseased nodes64. The relatively poor graft versus lymphoma response 
seen after most cases of allogeneic stem cell transplant for relapsed CHL509 may be 
explained by failed T cell trafficking although newer approaches using T cell depletion 
and early donor lymphocyte infusion show promise441. Ex vivo expanded therapeutic T 
cells lose expression of CD62L and CCR7510 hence if these markers are key to CHL-
involved lymph node homing and are lost, donor effector T cells will fail to engage with 
their target. However, enhancement of expression of such molecules may come at the 
price of worsened GVHD511. 
8.3 Th2 polarised cells are not an important part of the microenvironment 
The data presented in Chapter 6 failed to demonstrate any Th2-defining cytokine 
expression at baseline and only expression of both Th1 and Th2 defining cytokines once 
cells are activated and proliferated in vitro. This is consistent with the proliferating cells 
arising from a population of Th lineage-uncommitted naïve or memory T cells, which 
only express cytokine at meaningful levels once exposed to an in vitro stimulus. The 
absence of Th2-defining transcription factor expression by IHC demonstrated in Chapter 
4 confirms a wider literature, in contrast to robust data supporting the presence of Th1-
defining T-BET and IFN-γ producing T cells in the microenvironment further supported 
by the experiments in Chapters 3, 6 and 7. Taken together, these data contest the 
hypothesis that the microenvironment is Th2-polarised. Hence this cannot be evoked as 
an explanation for its failure to eradicate the tumour. 
8.4 Hypoproliferation, anergy and senescence are not characteristic of the 
microenvironment CD4+ T cell 
The experiments described in Chapter 5 demonstrated that CHL-derived CD4+ T cells 
proliferate well when exposed to IL2 and IL4 in vitro, better than benign node-derived 
cells, and probably than FL-derived cells, although there is also a highly proliferative 
component arising from the CD4+ T cell microenvironment of FL that warrants similar 
investigation. Increased sample number and possibly culture duration beyond 6 months 
is required to confirm this. Although these findings cannot directly refute the often cited 
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functional demonstration of hypoproliferation and anergy of Marshall et al299 due to 
methodological differences, they certainly do not support it. 
 
FOXP3 and CCR4 are indeed expressed at high levels in the microenvironment of CHL, 
confirmed here through IHC and flow cytometry respectively. However that these 
markers represent Tregs has neither been confirmed here nor in the literature and 
functional experiments using conventional suppressor assays are necessary, although 
other groups have found this technically challenging due to the small numbers of cells 
available377. 
 
PD-L1 is certainly upregulated in the HRS334 and its expression may be important to 
downstream survival pathways, with immunological evidence accumulating that PD1 to 
PD-L1 directional signalling promotes B cell survival283. However, the virtual absence of 
PD1 expression in the microenvironment, including the CD4+ component, argues against 
its importance in failed tumour clearance by mediating immunosuppression through 
PD-L1 to PD1 signalling. 
8.5 Summary 
Overall this work has contributed to the understanding of the role of the CD4+ T cell in 
the CHL microenvironment as a multipotential, central memory-like cell, arrested in 
function in the malignant lymph node yet capable of effector function and proliferation 
in vitro. Much validation work remains to be done, for the clinically translatable 
biomarkers, as well as the phenotyping and proliferation assays with increased sample 
numbers and refined fluorescent marker panels. There remains no satisfactory functional 
ex vivo or animal model of CHL in the context of its microenvironment available for 
pharmacological manipulation outside Phase 1 clinical trials in humans. There may well 
never be such a model, however progress will still be made as long as molecular 
mechanisms and networks of interactions can be measured, described, manipulated and 
interpreted with caution, scepticism and without preconceptions.   
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